the method of claim 16 , wherein the lipase is substantially inactive to arachidonic acid ( aa ) .
a directly compressible tablet which consists essentially of at least one starch which has a tapped density which has been reduced to less than 0.4 g / ml and an active agent .
lactose monohydrate magnesium stearate maize starch meglumine microcrystalline cellulose povidone ( k@@ 25 ) ferric hydroxide ( e172 ) sodium hydroxide sodium starch glycollate ( type a ) sorbitol
tredaptive tablets contain laropiprant in one layer and nicotinic acid in the other layer .
combination according to claim 4 , 5 or 6 , characterized in that the neuro@@ pharmaceutical agent can be administered simultaneously with the infusion of bradykinin or an analogue thereof into the carotid artery .
in patients with renal impairment or in patients undergoing haemodialysis , a dose reduction of pregabalin is required ( see section 4.2 , table 1 ) .
a method according to claim 7 , wherein in the method the region of the packaging film surrounding the front end region of the packaging article is compressed so that a second substantially planar film area area is formed in the region around the packaging article .
composition according to claim 1 or 2 , characterized in that the active ingredient is quinine or a suitable salt or derivative thereof .
electrode unit according to claim 22 , characterized in that the polymer ( s ) forming the polymer binder of the composite electrode has a molar content of 1,2-@@ epoxy@@ propane and / or 1,2-@@ epoxy@@ butane of from 75 to 100 % .
poly@@ alkoxylated tocopherol derivatives of the general formula ( i ) which can be prepared by stepwise base-@@ catalyzed alkoxy@@ lation of vitamin e and exhibit an excellent emulsifying capacity .
a process for the preparation of a light protection agent , characterized in that the p-@@ methoxy cinnamic acid ester of the general formula wherein r is the alcohol residue of d , l-@@ α-tocopherol , pan@@ tol@@ ac@@ tone or panthenol , wherein panthenol may be substituted one- , di- or tri@@ fold in a conventional base .
in one of the study , patients received other medicines .
multiple energy device for x-ray imaging applications
use of phospholipids marine and / or synthetic origin containing a proportion of at least 30 percent ( w / w ) omega-3 fatty acids for the preparation of a nutrient emulsion for parenteral administration , wherein a high level of fatty acid having omega-3 fatty acids compared to tri@@ glyceride oils is achieved a lower triglyceride and cholesterol content of the blood .
patients at higher age should receive a dose selected according to the severity of the infection and the creatinine clearance of the patient .
the element of claim 1 , wherein the film film has two layers and a total thickness of from 0.1 mm to 1 mm .
- if you have diabetic ketoacidosis ( a complication of diabetes causing rapid weight loss , nausea or vomiting ) .
predictive and therapeutic for kidney disease genes and proteins
arrangement according to one of claims 1 to 12 , characterised in that a detector array ( 19 ) is downstream of the beam output coupler ( 9 ) .
use according to any one of claims 1 to 3 , in which the sial@@ yl-@@ lewis antigen is chosen from sial@@ yl-@@ lewis x and sial@@ yl-@@ lewis a .
the assembly of claim 5 , wherein the concave surface is adapted to rotate a surgical instrument attached thereto .
use according to claim 5 , characterized in that the pharmaceutical preparation contains a mixture of ifn-@@ beta and il-2 .
breast-feeding must be discontinued during treatment with sti@@ var@@ ga .
a composition comprising a compound according to claim 1 or 2 in admixture or otherwise in association with an inert carrier .
composition according to claim 1 or 2 , characterized in that the triglycerides with reduced caloric content contain at least 80 % c ₃ ₄ - to c ₄ ₂ triglycerides , 40 to 50 saturated c ₈ to c ₁ ₀ fatty acids and 40 to 60 % of combined stearic acid and beh@@ enic acid .
for details , see section 5.1 pharmacological properties , non-small cell lung cancer .
a polypeptide having the sequence selected from the group consisting of a hematopoietic stem cell proliferation stimulating amount of in@@ pro@@ l in the manufacture of a medicament for treating or joining the fatigue of hematopoietic stem cells , wherein in@@ pro@@ l is selected from the group consisting of the peptide having the sequence : phe-@@ pro-@@ his-@@ phe-@@ asp-@@ leu-@@ ser-@@ his-@@ gly-@@ ser-@@ ala . the method of claim 9 or 11 wherein the hematopoietic stem cells are selected from the group consisting of bone marrow cells , peripheral blood cells , mobili@@ zed peripheral blood cells
angular attachment according to one of claims 1 to 4 , characterised in that the x-ray permeable material consists of reinforced polyoxy@@ methylene ( po@@ m ) .
very poor health data there are no data on the safety and efficacy of oseltamivir in patients who have a history of hospit@@ alisation or unstable medical condition .
the set of claim 1 , wherein the distal end ( 3a ) of the container has a groove ( 10 ) formed around a needle outlet ( 11 ) of the container for receiving the tip of the slan@@ ted needle .
if you have or have ever had difficulty passing urine .
summary of the emea work programme 2006 emea / 6@@ 29@@ 13 / 2006
prevention of dental loss by administration of alendronate or salts thereof
a system for displaying an image stream , the system comprising : an image storage means ( 21 ) for receiving an original image current ; and an image display means ( 300 ) for displaying at least two partial slope image currents , each subset image stream being adapted to be displayed simultaneously on the image display means ( 300 ) simultaneously on the image display means ( 300 ) .
device for resistant to limb movements .
caution should be exercised when administering mycophenolate mofetil teva due to the potential to reduce the efficacy of mycophenolate mofetil teva .
the composition of claim 1 wherein the surfactant is poly@@ oxyl 35 castor oil ( c@@ remo@@ phor el ® ) .
a device according to claim 13 , wherein the container is in a form allowing the biological particles to be difficult to force .
a compound of formula i as claimed in claim 1 wherein q 2 is a monovalent or divalent residue selected from hydroxy , acetoxy , c 1-3 alkoxy and oxo ; or the n-oxide of a piperidine nitrogen designated * or the n-oxide of a piperidine nitrogen designated * or a pharmaceutically acceptable salt thereof or a quaternary ammonium salt thereof , wherein the fourth r 1 is at the nitrogen for c 1-4 alkyl or benzyl , and the associated counterion a is a pharmaceutically acceptable anion .
mechanism of action moxifloxacin has in vitro activity against a broad range of gram-positive and gram-negative pathogens .
some patients may develop osteonecrosis of the bone ( death of bone due to lack of blood supply to the bone ) during treatment with combination antiretroviral therapy .
process according to claim 1 , characterized in that the culture liquid in which the animal cells are suspended is a serum-free culture medium .
the use of claim 7 , wherein said gp@@ i molecule is a plasmodium falciparum gp@@ i inositol@@ glycan domain .
the method of claim 1 , wherein prior to said defining step , said method further comprises the steps of : a ) utilizing said logarith@@ m of a signal representative of said at least one wavelength of electromagnetic energy ; b ) bandpass filters of said first signal whereby a third signal is generated ; c ) normali@@ ses said second signal ; and utilizing a third signal ; and utilizing said derivative of said third signal to produce said data .
the artificially produced three-dimensional mammalian muscle tissue according to claim 1 or 2 , characterized in that the pre-@@ strain is carried out over a period of from 1 to 7 days .
an intervertebral implant having a wedge ( 2 ) , in which two hollow pipes ( 6 a , 6 b ) are arranged opposite each other , which can receive two hollow projections ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b
composition according to any one of the preceding claims , characterized in that the hydrocarbon oil has a chemical structure comprising at least one nonionic radical chosen from -cooh ; -oh ; 4 ; 4 ; nhr ; nr 1 r 2 ; wherein r 1 and r 2 , which may optionally represent a ring , or r 1 &apos; and r 2 &apos; , or where r 1 &apos; and r 2 &apos; are h or a straight or branched alkyl or alkoxy group having 1 to 20 carbon atoms .
use according to claim 4 , wherein the pharmaceutical composition prepared is useful in the treatment of insulin-dependent diabetes mellitus .
a po@@ d@@ logical device according to claim 5 , characterised in that the structure ( 1 ) is a running shoe which comprises the sole ( 1 ₁ ) .
i &apos;ve never seen an adult in an adult .
device according to any one of the preceding claims , characterised in that the scanning function is carried out in a model of soft or spreading material , for example gy@@ ps , and in that the tool device is made entirely or partially of ce@@ mented carbide or ceramic materials or a tool unit for the complete or partial production of bodies ( tool devices ) of hard , soft or lining material .
device and method for isolating cells , bio@@ particles and / or molecules of liquids with the aim of use for animals , biotechnology ( including biological research ) and medical diagnostics
triazolam is contraindicated when co-administered with invirase / ritonavir due to the risk of prolonged or enhanced sedation and respiratory depression ( see section 4.3 ) .
6.6 special precautions for disposal
a device according to any preceding claim , further comprising means for applying electrical current over the body surface .
an infrared clinical thermometer according to claim 1 , wherein the temperature condition estimation means ( 6 ) is a function of the estimation of temperature conditions of the body of the atrial thermometer and / or the environment in which the period of fever is based on a change pattern of the temperature measured with the at least two temperature measurement means ( 2 , 3 ) .
the highest dose ( for mice equivalent to the maximum recommended dose of 10 mg in humans based on mg / m2 ) was close to the maximum dose of mice , but not in rats .
a coating composition comprising a bioactive agent in combination with multiple polymers including a first polymer component comprising at least one aromatic poly ( meth ) acrylate polymer and a second polymer component comprising a poly ( ethylene@@ -co-@@ vinyl acetate ) .
a polynucleotide according to claim 9 which is a dna or rna .
apparatus according to any one of the preceding claims , characterized in that the radiation delivery means further comprises at least one central catheter bore ( 8 ) which is adapted to remain outside the cavity ( 10 ) and a distal end ( 8a ) extending in the longitudinal direction within the longitudinal body of the support probe ( 2 ) .
these symptoms have been reported more frequently when using interferon alpha with sho@@ sa@@ i@@ ko@@ to , a chinese herbal medicine ( see section 4.4 ) .
an electronic endoscope according to claim 1 , characterised in that the shaft ( 1 ) of the endoscope has different tubes ( 12 , 17 and 21 &apos; ) which are displaceable in each other and each of the tubes ( 12 , 17 and 21 &apos; ) which are displaceable with each other , the tube ( 17 &apos; ) having a larger diameter with the distal end ( 27 ) and the tube ( 12 &apos; ) in which the ccd tube ( 21 &apos; ) is held in a longitudinal manner and the tube ( 12
a compound represented by the formula ( i ) : wherein r ¹ is hydrogen or methyl ; r ² and r ³ , which may be the same or different , each is a hydrogen atom or a c ₁ -c ₆ alkyl group , and r ⁴ is a carboxyl group , a c ₁ ₋ ₆ alkyl group , and r ⁴ is a carboxyl group , a morpholino group , a thiomorpholino group , a piperazinyl group , and a 4-c ₁ ₋ ₆ alkyl-@@ 1-@@ piperazinyl group , or a pharmaceutically acceptable salt or ester
your doctor will decide the need for physical examination .
a process for preparing a stable amorphous dispersion in the solid state of mi@@ so@@ prost@@ ol and an excipient selected from ( a ) an excipient in the amorphous state selected from the group consisting of hydroxypropylcellulose , cellulose acetate , carboxymethyl cellulose , cellulose acetate phthalate , cellulose acetate butyrate , hydroxyethyl cellulose , polyacrylic acid polymers and maltodextrin ; or ( b ) an amorphous or semi@@ -crystalline excipient selected from the group consisting of monosaccharides , disaccharides and tri@@ saccharides , comprising spray drying .
respiratory , thoracic and mediastinal disorders general disorders and administration site conditions
in the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products .
polypeptide having increased cy@@ statin c activity , characterized in that it consists of recombinant 3-@@ de@@ hydroxy@@ cy@@ statin c or a modification thereof , wherein one or more amino acids in positions 5-@@ 17 and / or 55-@@ 59 , 83 and 97 have been replaced by other amino acids and / or at the one or more sequences at positions 8-@@ 14 and / or 6@@ 1-@@ 120 .
five percent ( 3 / 56 ) of patients with y@@ md@@ d mutant had worsening liver inflammation compared with pre-treatment values and 13 % ( 11 / 82 ) of patients with y@@ md@@ d mutant .
a composition according to claim 1 , wherein the hydrophilic polymer is an alkyl group represented by the following formula : wherein r ² is an alkyl group having a carbon number of 8 to 20 or a cycloalkyl group having a carbon number of 5 to 7 ; and a structural moiety as defined by the following formula : a composition according to claim 1 , wherein the amphoteric polymer is admixed in an amount of 0.001 to 10 % by weight of the composition .
each arcuate support element ( 2 ) has in its middle part a central section ( 5 ) which has a central portion ( 5 ) whose loop branches ( 4 ) simpli@@ fies in the plane of the arcuate support element ( 2 ) .
blister containing 14 tablets for 15 mg
the compound of claim 16 , wherein r 3 is 2-thienyl , 2-pyridyl , 1-methyl-2-@@ imidazolyl , 2-furyl , or 1-methyl-2-@@ pyrrolyl .
 lopinavir , indinavir , nelfinavir , ritonavir , telaprevir and saquinavir for the treatment of
the increased prevalence of porphy@@ ria cu@@ san@@ rea tar@@ da in hiv infection , the interaction of hiv and uv radiation is discussed as a pre@@ disposition for porphy@@ ria cu@@ ran@@ rea tar@@ da and the photosensitivity for hiv infection .
other sources of information detailed information on this medicine is available on the european medicines agency web site : http : / / www.ema.europa.eu.
if the other ( s ) medicinal products have to be permanently discontinued , capecitabine treatment may be resumed when the requirements are met .
process according to claim 1 , characterized in that the extrudate is a thin film .
also disclosed is a control device for controlling the pressure and the amount of water and the position of the nozzle ( 5 ) .
absorbent article according to claim 19 , characterized in that the transfer layer ( 14 ) is centered substantially along the absorbent layer ( 12 ) to form absorbent sheet extensions ( 50 ) , where the absorbent layer ( 12 ) extends over the transfer layer ( 14 ) .
the tablet of claim 7 having a porosity of 50 to 90 % .
a device according to claim 33 , wherein means for repeating the functional sequence of the means ( a ) to ( e ) are provided at least once .
3 . a method according to claim 1 , characterized in that four layers are applied to the model of the prepared tooth , the first layer being a metal layer of a dental alloy , the second layer being an opaque porcelain layer , the third layer being a dental porcelain layer and the fourth layer is a cutting mass layer .
fertavid should not be administered during breast-feeding .
use according to claim 9 for the manufacture of a medicament which can be administered intravenously , intra@@ peritone@@ ally or intra@@ arteri@@ ally .
use according to claim 19 , characterized in that the selec@@ tion-@@ nucleotide sequence comprises a region which codes for an intracellular protein with tre@@ tre@@ lase activity .
ratiopharm gmbh , gra@@ f-@@ acr@@ o-@@ strasse 3 , d-@@ 890@@ 79 ul@@ m , germany
the apparatus of claim 22 , wherein the light emitter ( 10 ) is further defined as to emit light with a wavelength of substantially 800 nm .
a combination ( 10 , 10a , 10b ) according to claim 4 , characterized in that the generally cylindrical body ( 14 , 14a , 14b ) is flared radially outwardly adjacent the device ( 20 , 20a , 20b ) for mounting the body ( 14 , 14a , 14b ) on a support ( 22 , 22a ) .
always use liprolog mix50 kwikpen exactly as your doctor has told you .
it is also granted by the marketing authorisation .
system according to claim 27 , characterized in that the evaluation and control unit defines the position of a particular point in the endoscope image and selects this point as reference point for the guide system by means of tri@@ ang@@ ulation .
a stabilized dry composition comprising a monoclonal antibody , a carbohydrate as a stabilizer and an inhibitor of the ma@@ ill@@ ard reaction .
a penile prosthesis ( 10 ) for implanting in a patient , wherein the penile prosthesis ( 10 ) has a first part ( 12 , 14 , 18 ) , a second part ( 12 , 14 , 18 ) , and a guide member ( 22 ) , which is connected to the first part ( 12 , 14 , 18 ) and the second part ( 12 , 14 , 18 ) and the second part ( 12 , 14 , 18 ) and the second part ( 12 , 14 , 18 ) and the second
a thro@@ mbe@@ ctomy device for dissolving a thrombus or other closure material in a lumen of a vascular graft or vessel , comprising a flexible sheath ( 20 ) and a wire ( 30 , 30 &apos; ) disposed in the flexible sheath , and a wire ( 30 , 30 &apos; ) disposed in the flexible sheath , and a wire ( 30 , 30 &apos; ) disposed in the flexible sheath , and a wire ( 30 , 30 &apos; ) disposed in the flexible sheath , the wire ( 30 , 30 &apos; ) having a
a device according to any one of the preceding claims , characterised in that a substance which is in contact with gastric juice is at least partially present in a multiparticulate , fast-@@ releasing preparation .
additional monitoring tests , including blood tests , may need to be taken as long as you are taking your medicines .
a pharmaceutical composition comprising an effective amount of at least one compound or a physiologically acceptable salt thereof according to any one of claims 1 to 6 and a physiologically acceptable carrier .
the composition of claim 1 , wherein a portion of the starch molecules substituted with acetate and dicarboxylate residues may be replaced by native or modified starch .
pro@@ qu@@ ad contains live viruses , but they are too weak to induce measles , mumps , rubella or varicella ( chick@@ en@@ pox ) disease in healthy subjects .
it explains how the agency assessed the medicine to recommend its authorisation in the eu and its conditions of use .
general disorders and administration site conditions
a combination of ( a ) a compound of formula ( ia ) or ( ib ) as defined in any one of claims 1 to 29 and ( b ) one or more other anti@@ mycobacterial agents for use as a medicament .
the heart valve prosthesis according to claim 4 , characterized in that an outer surface ( 37 ) of the cage ( 9 ) is slightly concave and connects an angle γ between a straight line which connects the extreme points of the generic atri@@ x of the concave surface ( 37 ) with the dia@@ metrical plane and the central line ( 31 ) of the g@@ cage ( 9 ) with the dia@@ metrical plane and the central line ( 31 ) of the cage ( 9 ) with the dia@@ metrical plane and the central line (
dental material according to claim 5 , characterized in that the crystalline oxide is selected from the group consisting of tio 2 , zro 2 , ba@@ o , where 3 and fe 2 o 3 .
to prevent vomiting , ce@@ ren@@ ia solution for injection should be given at least one hour in advance .
infrared radiator according to one of claims 1 to 15 , characterized in that the heating coil ( 4 ) is made of a carbon fibre material , graphite or graphite paper .
a compound having the formula ( i ) : or a pharmaceutically acceptable salt thereof ; which may be substituted with halogen , c -c alkyl , r and r are independently hydrogen or c -c alkyl ; or r and r are independently substituted with the nitrogen to which they are bonded to the nitrogen atom , or c -c alkyl , or r and r are optionally substituted with the nitrogen , c -c alkyl , c -c alkoxy , mono- or di- ( c -c ) alkyl ; r is c -c alkyl or c -c alkoxy
the method of any one of claims 1 to 10 , wherein the formulation of step ( a ) is a liposome formulation .
a locking mechanism as claimed in claim 7 , wherein the inner surface ( 34 ) is relatively flat , and the outer surface ( 40 ) is curved outwardly or substantially outwardly , relative to the inner surface , relative to the inner surface , the connecting portion ( 14 ) having a bore into which at least a portion of the holding portion ( 12 ) can be inserted .
the protein claimed in claim 4 which is at least 90 % pure by weight .
pp@@ i , h2-@@ receptor antagonists and antacids ) concomitantly with cabozantinib .
a compound according to claim 1 wherein z is a compound according to claim 2 wherein r 12 is - ( ch 2 ) a cor 15 .
the invention further relates to a method for the in-@@ situ formulation of a drug dispersion , whereby the drug dispersion is applied in line .
do not use siklos after the expiry date which is stated on the carton and blister .
a diaper ( 10 ) according to claim 1 , wherein the base structure ( 20 ) has front and rear edges ( 15 , 17 ) defined by respective front and rear attachment lines ( 21 , 22 ) .
anti-@@ hepatitis c virus antibodies and use thereof
 the mah requested 2009 for the introduction of the new applicator for implan@@ on ( implan@@ on n@@ x@@ on )
a process for preparing a composition comprising admixing the compound of any one of claims 1 to 42 and a pharmaceutically acceptable carrier .
the polymer of claim 6 , wherein the polymer is in the form of spherical beads .
use according to any one of claims 1 to 6 , wherein the composition is in the form of an orally consumable food product or food supplement .
eye disorders : cysto@@ id macular oedema , toxic a@@ b@@ y@@ opia .
a method of identifying a patient with breast cancer or breast pre@@ cancer , the method comprising : testing a duc@@ tus fluid sample extracted from a duc@@ tus of a patient &apos;s chest , wherein the liquid is not treated with duc@@ tus of a breast of a patient , wherein the liquid is not infected with duc@@ tus of a patient , wherein the liquid is not treated with duc@@ tus of a breast of a patient , wherein the liquid is not mixed with duc@@ tus of a breast of a patient , the liquid being not
device according to at least one of claims 1 to 12 , characterized in that a supply device ( 17 ) is provided for supplying a nutrient solution , in particular molasses .
consideration should be given to official guidance on the incorporation of medicated pre@@ mixes in feed .
the dna sequence according to claim 7 , wherein the dna sequence has a deletion of 4@@ 84 nucleotides in the 3 &apos; non-@@ coding region of the if@@ n- γ gene and the deletion begins at the r@@ sa i endonuclease recognition site and continues towards the coding region of the if@@ n- γ gene .
a pharmacologically active compound of formula ( i ) of claim 3 wherein a is p@@ glu-@@ his-@@ trp-@@ ser-@@ his-@@ asp-@@ trp-@@ pro-@@ gly-nh 2 , ac@@ -d-@@ trp 1,3 , p-chloro@@ phenyl-@@ d-alanine 2 ( d-@@ c@@ pa 2 ) , d-@@ lys 6 , d-ala 10 -@@ gnrh , d-@@ lys 6 -@@ gnrh lys 5 , d-trp 6 -@@ gnrh , and k , r , u , z , x , y , v and w are as defined in claim 1 , and the salts and complexes of these compounds .
a stent graft ( 12 ) for implanting a proximal insertion site from a distal location in an aorta for an aor@@ ta@@ ta tunnel treatment of an aortic aortic aneurysm ( 11 ) , wherein the stent graft ( 12 ) comprises a stent ( 14 ) having a stent ( 14 ) , the stent graft ( 12 ) , the stent graft ( 12 ) having a stent ( 14 ) having a stent ( 14 ) , the stent graft ( 12 ) , the stent graft ( 12 ) having a stent ( 14 )
a dna strand according to claim 1 , wherein the nucleotide sequence encoding the polypeptide is one corresponding to the portion of a to b of the nucleotide sequence shown in figure 1 or its degenerative isomer .
process for the recombinant production of staphylo@@ kinase polypeptides with plasminogen activator activity as a target polypeptide , characterized in that host cells according to claims 8 to 11 are cultured in a suitable medium and the target polypeptides isolated from the host cells .
apparatus and method for repetitive micro@@ jet drug delivery
products and pharmaceutical formulations as claimed in one or more of claims 1 to 7 , which contain as active ingredient ( a ) camptothecin and as plasma protein fraction ( b ) human serum albumin , human immunoglobulin , glycoprotein , interferon and / or interleukin or another natural or recombinant human plasma protein fraction , wherein the molar ratio of active substance ( a ) to plasma protein fraction ( b ) is 1 : 0.05 to 1 : 100 and preferably 1 : 0.1 to 1 : 50 .
the occlusive dressing of any one of claims 1 to 8 , wherein a strip of release paper ( 72 ) is attached to a corner of the second adhesive layer ( 31 ) and a single sheet separation paper ( 74 ) , and the second adhesive layer ( 31 ) , including the corner strip , is provided , such that a strip which can be gripped by the user , while the individual sheet separation paper is removed , and the dressing is attached to the body .
other medicines and osseor tell your doctor or pharmacist if you are taking , have recently taken or might take any other medicines .
section 5.2 - pharmacokinetic properties
however , the possibility that ne@@ b@@ n may be associated with efavirenz may be more frequent or more severe but cannot be excluded .
the maximum aptt should not exceed twice the baseline value .
the invention relates to a hygienic pulp product , for example a diaper , a nurse or a sanitary napkin , in which at least one layer of the product with partially neutralized citric acid of the composition is impregnated in which me represents a sodium , potassium or ammonium ion .
&#91; the text below should be inserted in this section &#93;
process according to any one of the preceding claims , characterized in that the first and / or second film-forming polymer is dispersed in the appropriate cosmetically acceptable medium in the form of particles .
a method according to any one of the preceding claims wherein the α-amylase is immobilized .
a kit for detecting a target polynucleotide sequence , wherein the kit comprises in packaged combination reagents for performing amplification of the target polynucleotide sequence to produce an amplification of the target polynucleotide sequence , and at least one of consecutive and non-@@ consecutive temperatures , or ( ii ) at non-@@ consecutive sites , and not at the temperature or temperature , and not at the temperature or amplification temperatures , which are relatively low at low temperatures relative to the low temperatures .
an apparatus according to any one of the preceding claims , comprising as part of the first , second , third , and fourth fastening means ( 74 ) mounted on the first housing portion ( 42 ) and a first arm ( 78 ) , which is movable between a locked position , and a first arm ( 78 ) , which is movable between the locked position , and a non-@@ locked position in which it is preferably against the knob ( 58 ) , so that the rotation to remove the device ( 40 ) from the
• withdraw the required amount of soliris from the vial ( s ) into a sterile syringe .
a gene fusion peptide or protein comprising an epitope of an outer class i outer-@@ membrane protein fused to a carrier protein , peptide or epitope thereof , provided that the carrier protein is not β-galactosidase .
the combination as recited in claim 1 , 2 or 3 , characterized in that each extension ( 23 ) further comprises a stop tab ( 30 ) integral with said grasping portion and projects from said handle ( 15 ) so that said stopper ( 15 ) of said tube being retained thereto is prevented from said gripping portions ( 28 ) .
process according to claim 14 , characterized in that in stage d ) the solubilized dihydropyridine derivative is converted to the aqueous gelatin sol prior to association with the aqueous gelatin sol , and the dispersion thus obtained is combined with the aqueous gelatin sol .
transgenic plant with modified physiology , morphology and hormone metabolism of tissue cultures of this plant and process for producing the same .
an apparatus according to claim 2 , wherein the controlled illumination source ( 100 ) generates a pulsed , nitrogen-containing dye laser , which is operable to produce pulses of a first wavelength at a power level that generates pulses of a first wavelength having a power level that generates the first partial group of fluorescence intensity spectra in normal and abnormal tissues with a power level that is driven by an intensified diode array ( 116 ) which is controlled by a multi@@ channel analyser ( 117 ) each synchroni@@ sed to the controllable illumination source ( 100 )
the use of claim 22 , wherein the bacterium is an anaero@@ bes .
in this case the static cyto@@ metry ( microscopic cyto@@ metry ) is inferior to the lower magnitude of flow cyto@@ metry .
day 8 - 17 once the user has no@@ ticed , you should take the last missed tablet of white tablet , even if this means that it is taken at the same time as two tablets .
a composition for use in the treatment , prevention or control of endo- and / or ecto@@ parasitic infections in warm-blooded animals , said composition characterized by a prophylactically , therapeutically or pharmaceutically effective amount of the compound represented by structural formula ( i ) as defined in claim 1 , and the pharmaceutically and pharmacologically acceptable salts thereof in an inert solid or liquid carrier therefor .
the apparatus of claim 16 , wherein the hand piece comprises a spectr@@ ally selective mirror for powering the laser beam .
a non-@@ alcoholic , antibacterial mouthwash consisting essentially of : ( a ) from 0.05 % to 0.2 % by weight sodium benzoate ; ( b ) from 0.01 % to 1.0 % by weight of a weak carboxylic acid selected from the group consisting of :
a process according to any one of claims 1 to 3 wherein the solvent of alkyl cellulose is admixed with the low alkanol optionally water .
neoplasms benign , malignant and un@@ specified ( inc@@ l cysts and polyps )
store in the original package in order to protect from light and moisture .
the ribozyme according to claim 4 , wherein the 2 &apos; -hydroxy@@ modification is a 2 &apos; -deoxy@@ - , a 2 &apos; -o-@@ methyl , a 2 &apos; -@@ fluoro and / or a 2 &apos; -amino group .
si@@ mu@@ lect 10 mg powder and solvent for solution for injection or infusion
exforge 10 mg / 160 mg film-coated tablets amlodipine / valsartan
a compound according to any one of claims 1 to 10 wherein z is s. a compound according to any one of claims 1 to 14 wherein r5 is ( c 2 -c 4 ) alkyl .
the medical device ( 8 ) of claim 4 , wherein the adjacent ends of the first ( 18 ) and second ( 20 ) portions of spring are attached to one another by an epoxy and on the core ( 10 ) .
a method of enhancing the liver and / or the spleen of a human or non-human animal living or non-human animal , comprising the intravascular administration of a medium according to claim 4 prior to imaging to the animal .
the first study compared the combination of emtricitabine and tenofovir disoproxil with the combination of lamivudine and zidovudine ( other antiviral medicines ) .
mechanical locking system for connecting an active implantable medical device , in particular for a heart stimulator , defibrillator and / or cardioverter
it is recommended that the vaccine be administered in accordance with the schedules indicated .
antimicrobial composition according to any one of the preceding claims , characterized in that it acts by neutralising or inhibiting the microbial effect of the microbes , including toxins and / or by preventing the proliferation / propagation of the microbes .
the compound of claim 1 wherein r 2 is a group of the formula - ( ch 2 ) n -ar wherein ar is a phenyl and n is 2 , or a group of the formula wherein one or two of r 3 , r 4 , r 5 and r 6 are oh and the remaining hydrogen atoms are r 7 and r 8 are hydrogen atoms .
the method of claim 1 , wherein the non-@@ bacteriophage sequence is a viral sequence .
the method of claim 7 wherein the polyol is selected from the group consisting of sorbitol , pentaerythritol , neopentyl glycol , propylene glycol , dipropylene glycol and isoprene glycol .
invega should be taken and swallowed whole with water or any other liquid .
in the treatment of nsclc and in the first-line treatment of ovarian cancer , the infusion of paclitaxel carried out over 3 hours in combination with cisplatin resulted in a higher incidence of severe neurotoxicity than with paclitaxel alone and cyclophosphamide , followed by cisplatin .
the method of any one of the preceding claims comprising the steps of : ( a ) operating the x-ray source ( 13 ) to emit x-rays from a first focal point ; ( b ) recovering a projection from a first focal point ; ( b ) recovering a projection while the source ( 13 ) is emitted from the first focal point ; ( b ) recovering a projection while the source ( 13 ) is emitted from the first focal point ; ( b ) recovering a projection from the first focal point ; ( b )
zu@@ tec@@ tra is intended for subcutaneous injection , so for injection under the skin .
the european medicines agency ( ema ) will review any new information that may become available every year and this leaflet will be updated as necessary .
a compound according to claim 2 wherein r is hydrogen .
close supervision of patients should be associated with close monitoring of patients , particularly those at high risk , especially at the beginning of treatment and following dose adjustments .
process according to one of claims 1 , 2 or 3 , characterized in that inhalation powder contains less than 5 % , preferably less than 2 % of active principle .
an adapter according to claim 9 , characterized in that the closure body is a rotatably mounted cylindrical body ( 26 ) closed at one end , open at the other end and is provided with a transverse bore ( 27 ) , the means ( 8 ) for securing the transfer tube to the open end of the closure body .
in a liver transplant , the starting dose is 0.10 to 0.20 mg / kg .
bronchial asthma , history of bronchial asthma or severe chronic obstructive pulmonary disease .
the article of claim 2 in tube or tube form .
medicinal products containing mi@@ an@@ ser@@ ine a member of the european union
a measuring instrument for determining the value of electrical resistance of the human body to the reflex points with a measuring head ( 6 ) , a circuit and a computer ( 4 ) , characterized in that the circuit is provided with a measuring head ( v ) , a circuit and a computer ( 4 ) , characterized in that the circuit ( s w@@ no -s w@@ nn ) , which is connected to the positive pole and the other , in the circuit , that the battery of the analog switches ( s w@@ c1 -s
cellulose-@@ containing product with high compression back@@ ling
the method of claim 1 , wherein said sli@@ me-@@ inhibiting compound is distributed on said device by a method comprising : introducing said medical device prior to insertion or prior to implantation into a solution having a concentration of the sli@@ me-@@ inhibiting compound of between about 1 mm and about 1 ; the drawing of said medical device from said solution ; drying said medical device ; and inserting or implanting said medical device into a mammal .
method and route ( s ) of administration
use according to one of claims 1 to 9 , characterized in that the preparation additionally comprises vasoactive substances , in particular cate@@ cho@@ lamines .
population pharmacokinetic analyses in special populations the pharmacokinetic properties of nintedanib were similar in healthy subjects , cancer patients and patients of the target group .
the inventive peptides can be used in particular for the production of an agent for the treatment of autoimmune diseases , especially for the treatment of uveitis .
a compound according to claim 1 , characterized in that q is 0 or r 0 is halo or methyl ; r 1 is selected from hydrogen , c 1-6 alkyl or carboxy-c 1-6 alkyl ; r 2 is selected from or r 3 is c 1-6 alkyl ; and r 4 is selected from c 1-6 alkyl or c 1-4 alkylene aryl .
a dna expression vector comprising an inserted dna sequence consisting essentially of the dna sequence of claim 4 .
a needleless syringe device according to claim 6 , wherein the shield ( 9 ) comprises a particle outlet opening ( 10 ) which is to be compressed during use to the target so that the particles ( 5 ) can pass through the opening ( 10 ) and the target .
use of an antibody for the manufacture of a medicament for the prevention or treatment of ovarian or colon cancer , wherein the antibody is immuno@@ specific for a polypeptide having the amino acid sequence of seq id no : 2 or seq id no : 4 or a polypeptide encoded by the nucleotide sequence of seq id no : 1 or seq id no : 3 . use of an antibody according to claim 1 wherein the cancer is colon cancer .
a diagnostic reagent comprising mammalian autoantibodies having specificity for at least one epitope of a mammalian cancer-@@ associated marker protein , said cancer marker protein being a modified form of a wild-type protein .
a catheter according to claim 1 , characterised in that said tubular sheath is made of a plastic or polyimide .
a method of analyzing a sample on the presence or absence of a target nucleic acid , said method comprising : ( 1 ) contacting said sample under conditions permitting hybridization with a reagent composition comprising : ( 2 ) detecting the presence or absence of any detectable response .
the method of any one of claims 1 to 11 , wherein the compound is mannose .
hgf mutant and its use as anti-cancer agent
cisapride ( used to treat certain stomach problems ) .
metal medical implant with surface and method for producing the surface
the pharmaceutical composition of claim 60 , wherein the vehicle or carrier is a saccharide selected from the group consisting of lactose , sucrose , mannitol , and sorbitol .
the medical device of claim 16 , characterized in that the transducer ( 6@@ 76 , 6@@ 86 ) is adapted to generate the swelling signal and the echo signal receives and the tip ( 6@@ 72 , 6@@ 84 ) and the transducer are movable relative to each other .
an antibody protein comprising an amino acid sequence according to seq id no : 2 . the antibody protein of claim 44 . a method of producing an antibody protein according to any one of claims 44 to 46 , the method comprising the steps of : ( a ) culturing the host cell of claim 48 under conditions in which the antibody protein is expressed by the host cell , and ( b ) isolating the po@@ one .
a ) 5.@@ 6.@@ 1998 b ) 27.@@ 11.@@ 1998 c ) oj l 320 , 18.@@ 11.@@ 1998
pharmaceutical preparation according to claim 1 , characterised in that it contains alkanols , in particular polyols and carbohydrates , hydrophilic polymers , in particular polyvinylpyrrolidone , polyvinyl alcohol , nonionic surfactants , especially polyalkylene glycols and polyoxyethylene fatty acid esters and / or proteins , especially albumin , especially human serum albumin , as stabilizers .
the system of claim 4 , wherein the diagnostic means comprises means ( 74 ) for determining changes in the relationship of heart rate and q t interval for the patient over a range of heart frequencies .
4-substituted 3-hydroxy@@ -3-@@ pyrrolin@@ e-@@ 2,5-di@@ one compounds , process for their preparation and pharmaceutical compositions containing them .
if treatment is stopped : patients who develop acute liver injury who develop acute liver injury and when the product is withdrawn , an increased risk of liver injury may have an increased risk of liver injury when tasmar is restarted .
novel strain of the yeast candida sa@@ ke ( sa@@ it@@ o and o@@ ta ) van u@@ des and bu@@ ck@@ ley and its use in the control of fungal diseases in harvested fruits
the dry powder inhalation system for transp@@ ulmonary administration according to claim 1 , wherein the freeze-dried mixture contains a synthetic low molecular weight medicament as the active ingredient .
use of il-@@ 4r or of a derivative thereof according to claim 1 , characterized in that the derivatives are parts , mutants or variants of il-@@ 4r .
active substance preparation for oral administration , in particular to ruminants according to any one of the preceding claims , characterized in that the coating comprises from 1.5 to 30 % by weight , based on the weight of the active substance core , from 1 to 20 % by weight of a cellulose ether , and from 0.5 to 10 % by weight of at least one filler selected from the group consisting of metal carbonates and 0.5 to 10 % by weight of at least one filler , the inner core close layer , from 0.2 to 8
oral contraceptives , norethisterone and / or ethinyl estradiol the concomitant use of pregabalin and oral norethisterone and / or ethinyl estradiol containing contraceptives has no effect on the steady state of these substances .
the total neutrophil count should be monitored closely , particularly during the first weeks of filgrastim therapy .
women of childbearing potential or their male partners have to use effective contraception during treatment and for the ribavirin smpc .
a compound according to any one of claims 1 or 2 wherein r ² and r ³ are both hydroxy .
counting device ( 2 ) according to claim 1 , 2 or 3 , characterised in that the latching tongues ( 25 , 30 ) are arranged on the counting wheel ( 8 ) and the control wheel ( 9 ) for the springs in the radial direction .
a composition according to claim 2 , wherein said monoclonal antibodies are reactive with different serotypes of the same bacterial species .
biocompatible substance specific reagents for the treatment of physiological fluids .
a pharmaceutical composition comprising an agent as defined in claims 13 or 14 together with a pharmaceutically acceptable carrier or diluent .
the hybridoma cell line of claim 4 having the accession number ferm bp-@@ 48@@ 75 ( km 10@@ 54 ) .
two weeks later ( day 29 ) will continue treatment with a 40 mg dose every week .
the assembly of claim 9 , wherein the inner fastening member ( 354 ) of the shell member ( 212 ) and the outer fastening member ( 350 ) of the mounting member ( 340 ) includes complementary tapered mounting surfaces for interlocking in response to a mating surface engagement of the complementary tapered flat .
a guide wire having a distal end piece and a longitudinal shaft extending longitudinally from a proximal end to the distal end piece and with a single helically wound wire extending from a position at the distal end portion , characterized in that the single helically wound wire is ribbon@@ -shaped and has a pitch angle in the range 35 ° to 76 ° .
method according to claim 17 , characterized in that the orientation of a magnetic field is detected by means of two magnetic field detecting elements ( 13 ) .
since be@@ cap@@ ler@@ min promotes cell proliferation , it should be used with caution in patients with malignancies .
dispersion according to claim 1 or 3 , characterized in that the fluorocarbons have a degree of substitution of from 10 to 90 and preferably from 20 to 80 % .
use of a pharmaceutically effective amount of an arg@@ y@@ ro@@ lo@@ bium rose@@ um extract comprising a flavonoid glycoside compound for the manufacture of a medicament for the treatment of an animal suffering from hyperglycaemia and non-@@ insulin-dependent diabetes mellitus .
agent for treating cardiac disease with map kinase tn@@ ni@@ 3@@ k
selective cytokine inhibitory drugs for the treatment of myelodysplastic syndrome
the article of claim 2 wherein said backing is a liquid permeable film with apertures .
process for the preparation of probiotic cheese
the polymer of claim 1 , wherein each formula d has no homo@@ polymeric sub@@ block having more than 10 oxyalkylene units .
the method of claim 7 , wherein step ( b3 ) of joining a first portion ( 10@@ 2a ) of the cover material ( 102 ) with a second portion ( 10@@ 2b ) of the cover material ( 102 ) comprises the bonding by ultrasound .
the system of any one of claims 1 to 4 , wherein the typical feature is the first negative peak value ( n1 ) of the electrical voltage signals .
a texa@@ phyrin metal complex of the formula : r ( iii ) , r ( iii ) , c ( iii ) , t ( iii ) , c ( iii ) , c ( iii ) , t ( iii ) , ( iii ) , c ( iii ) , t ( iii ) , ( iii ) , c ( iii ) , t ( iii ) , ( iii ) , c ( iii ) , t ( iii ) , ( iii ) , c ( iii ) , t ( iii ) ,
use according to claim 7 for imparting she@@ en during production .
the method of claim 16 , wherein the cell or tissue sample comprises vascular smooth muscle cells .
the analysis of the deman@@ ding and semen results from an independent expert team has been shown to be the best criterion .
the compound of claim 34 wherein r 1 is methoxy .
18.@@ 1 ; 2@@ 0.3 ) in patients on placebo / dexamethasone .
clinically relevant ctc toxicities that were reported in &lt; 1 % of patients who were randomly assigned to pemetrexed include : allergic reactions / hypersensitivity , erythema multiforme , supraventricular arrhythmia and pulmonary embolism .
the flow support system of any one of the preceding claims , wherein said tube means ( 34 , 316 ) includes : ( a ) an outer tubular sleeve ( 34 , 346 ) connected to said opening with said cover means and having a proximal end ( 36 , 348 ) , a body ( 38 , 348 ) and a sheath passage ( 347 ) extending through said sleeve passage and proximal and distal ends ( 360 , 364 ) and a conduit channel ( 366 ) extending between said lead ends .
the use according to any one of the preceding claims , wherein the dosage units containing the competitive progesterone antagonists contain at least one compound selected from the group consisting of 11β- ( ( 4-n , n-dimethylamino ) -@@ hydroxy-@@ methyl-@@ -17α-@@ propy@@ yl-@@ 4,9 ( 10 ) -@@ est@@ radi@@ ene@@ -3-one ( e@@ -3@@ 84@@ 86 ) -@@ estr-1,3,5 ( ( e@@ -3@@ 84@@ 86 ) -@@ estr-1,3,5 ( ( e@@ -3@@ 84@@ 86 ) -@@ estr-1,3,5 &#93; -@@ 11 ( 3&apos;@@ h ) -@@ furan &#93; -@@ estr-1,3,5 ) -@@ 11 ( 3&apos;@@ h ) -@@ furan
drill guide and method of use
the apparatus of claim 16 , wherein the laser is a poly@@ chromatic or monochromatic light source from 220 to about 2@@ 400 nm .
an automatic blood pressure monitor according to claim 1 , wherein : said monitoring means is oscil@@ metric ; said cuff pressures ( cp ( i ) are reduced in predetermined cuff pressure levels ; said complex tips ( cp ( i ) are reduced in predetermined cuff pressure levels ; said complex tips of said cuff are reduced and said associated cuff pressure levels are reduced in predetermined cuff pressure levels ; said complex tips of said cuff are reduced ; said complex tips of said cuff are reduced and said associated cuff pressure levels ; said complex tips
one dose of hepatitis b immunoglobulin immediately after birth ( within the first 24 hours ) .
a process according to claim 1 or 2 , wherein the erythritol generating microorganisms are au@@ re@@ ob@@ asi@@ dium , sp .
monoclonal antibody according to claim 1 , characterized in that the ability to bind human glu-@@ plasminogen and human lys-@@ plasminogen is substantially not inhibited by ε@@ -amino@@ caproic acid .
how can the progressive type of geno@@ type correlation for the development of gene therapy ?
immune system disorders metabolism and nutrition disorders nervous system disorders metabolism and nutrition disorders nervous system disorders metabolism and nutrition disorders cardiac disorders metabolism and nutrition disorders cardiac disorders cardiac disorders metabolism and nutrition disorders cardiac disorders metabolism and nutrition disorders cardiac disorders metabolism and nutrition disorders cardiac disorders metabolism and nutrition disorders nervous system disorders metabolism and nutrition disorders cardiac disorders metabolism and nutrition disorders cardiac disorders metabolism and nutrition disorders cardiac disorders metabolism and nutrition disorders cardiac disorders metabolism and nutrition disorders cardiac disorders metabolism and nutrition disorders cardiac disorders general disorders and administration site conditions
method according to one of claims 7 to 12 , characterized in that the relaxation course is predicted by the support points with the aid of a mathematical model of the tube .
use of alkyl@@ salicylic acid esters as perfuming ingredient .
( ai@@ v@@ losin 4@@ 2.5 mg / g - 20 kg ) ( ai@@ v@@ losin 4@@ 2.5 mg / g - 5 kg ) ( ai@@ v@@ losin 8.5 mg / g - 20 kg ) ( ai@@ v@@ losin 8.5 mg / g - 5 kg )
a compound having the structure : wherein a ) x is selected from the group consisting of o , s , so or so ; b ) each y is independently hydrogen or a straight or branched , substituted or unsubstituted , substituted or unsubstituted , substituted or unsubstituted , substituted or unsubstituted , and wherein the cyclic hydrocarbon chain is mono- or a straight and monocyclic and a monocyclic combination , or r is a substituted or unsubstituted aryl , wherein r 1 to 15 of others has different atoms .
therefore , no dose recommendations can be made for very young children ( children &lt; 2 years ) , and telzir with ritonavir is not recommended in this population ( see section 4.2 ) .
a process according to claim 4 wherein said compound is r ₁ isopropyl ; r ₂ is hydrogen or methyl ; r ₃ is methyl and r ₄ is methyl and wherein said compound r ₁ is isopropyl ; r ₂ is hydrogen ; r ₃ is methyl and r ₄ is methyl .
compositions according to claim 1 , characterized in that the active principle protected from the r@@ lumen is chosen from vitamins , amino acids and medicaments .
a sustained release preparation of a biologically active protein comprising an effective amount of the protein in a mixture of 95 to 5 % by weight of ε-caprolactone homopolymer in a molecular weight range from 15,000 to 100,000 and 5 to 95 % by weight of a crystallization modifier selected from the group consisting of crystalline fatty acids and crystalline fatty acid esters having saturated c 12 -c 18 fatty acid ester of polyhydric alcohols .
what are exelon and prometax ?
no dosage recommendations for amlodipine are available for patients with mild to moderate hepatic impairment .
in a pre- and postnatal study in rats , the maternal exposure to the mother was performed with
in the first study , evicel was compared with manual compression ( direct pressure in the hand ) with regard to the reduction in bleeding in vascular surgery .
stelara 45 mg solution for injection in pre-filled syringe each syringe contains 45 mg ustekinumab in 0.5 ml .
the solution should be administered slowly , at a rate that is comfortable to the patient and is max@@ min@@ x 10 ml / minute .
a prosthesis according to claim 1 , characterised in that the total included taper angle of the locking outer and internal tapers ( 26 , 28 ) is between about six and about 17 degrees .
the nucleic acid of claim 5 which is dna .
latvija glaxosmithkline latvia sia tel : + 371 67@@ 3@@ 12@@ 6@@ 87 l@@ v-@@ e@@ pa@@ sts @ gsk. com
discharge device according to one of the preceding claims , characterized in that a metering gas flow channel ( 18 ) is provided for the medium , which is preferably provided with a metering chamber ( 26 ) which is movable between a filling and a emptying system ( 27 , 28 ) , and in particular a metering chamber ( 26 ) , which is displaceable in the bottom of the medium chamber ( 4 ) , and in particular , a pressure gas flow channel ( 18 ) which is movable in the cross-section of the medium chamber
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
the full epar for sono@@ vu@@ e can be found here .
apparatus having an adjustable ap@@ plan@@ tation template for the cornea
method for determining blood pressure and blood pressure measuring apparatus
a compound having a structural formula : wherein x is selected from the group consisting of oxygen , nitrogen and sulfur ; y is nitrogen , and n is 1 ; r 1 is alkyl , alkenyl , alkynyl , -ch 2 co 2 h or -ch 2 co 2 me , wherein y is substituted with r 6 wherein r 6 is substituted with r 6 wherein r 6 is selected from the group consisting of hydrogen and methyl .
close monitoring is recommended when this medicinal product is administered with ep@@ clu@@ sa ( see sections 4.4 and 4.8 ) .
an immunoglobulin molecule according to claim 1 , wherein at least a portion of the cdr is replaced by a pep@@ di@@ t@@ mimetic which is a thrombopoietin ( tpo ) mimetic , and wherein the cdr is selected from the group consisting of cdr1 of a heavy chain and cdr1 of a light chain .
the composition of claim 8 , wherein : said non-ionic emulsifying agent comprises a substantially linear c -c alcohol ethoxylate having an average 7.2 mol of ethylene oxide in the condensate , a molecular weight of 6@@ 19 , a number of hydroxy groups of 108 , an hlb point of 50 ° c , a fluidized point of 21 ° c , a point point of 177 ° c , and a specific gravity of 0.9@@ 67 .
36 annex iii labelling and package leaflet 37 a. labelling 38 particulars to appear on the outer packaging carton 1 .
use according to any one of claims 1 to 5 , which is a cosmetic use .
a method according to claim 5 , wherein the active agent is composed of a carrier and an agent .
no dose adjustment of cellcept appears necessary .
&#91; the current approved wording of this section should be deleted and replaced by the following &#93;
animal behavioural studies with olanzapine indicated 5ht , dopamine , and cholinergic antagonism , consistent with the receptor-@@ binding profile .
process according to claims 11 and / or 12 , characterized in that as auxiliaries and additives are used as auxiliaries and additives selected from the group consisting of polyols , emulsifiers , fibres , dyes , perfume oils , flavouring agents , cosmetic agents , pharmaceutical agents and food additives .
the method of claim 23 , wherein the sintering step is carried out before the bone conducting assembly is provided in the interconnecting spaces .
process for the preparation of the compounds of formula ( i ) according to claim 1 , in which r represents a chain ( b ) in which r &apos; is a hydrogen atom , characterized in that a derivative r 1 so 2 ch 2 r 2 ( ii ) , in which r 1 and r 2 are as defined in claim 1 , is reacted with an azetidin@@ one of the formula : in which r 3 and r 4 have the meanings given in claim 1 , the product being isolated and optionally converted to a
method of treating bacterial infections that are not caused by streptococci .
use of a compound according to claim 1 in the manufacture of a pharmaceutical composition for the treatment of rheumatoid arthritis , cancer , multiple sclerosis , guil@@ lan@@ -@@ bar@@ r@@ é syndrome or psoriasis in mammals , including humans .
an intramedullary nail as claimed in claim 3 , characterised in that the passage for the pin is threaded and that the pin is a screw .
bio@@ degradation of an organic compound and method for environmental enhancement by removal of said compound
composition according to any one of claims 1 to 13 , characterized in that the solvent medium suitable for dyeing is aqueous and its ph is from 8 to 11 .
if nespo is switched to nespo , haemoglobin should be monitored every one or two weeks and the same route of administration is recommended .
the drive assembly according to claim 2 , wherein the cylinder further includes a locking strip to prevent rotation of the cylinder about the barrel axis , and wherein the locking hub includes a flange ( 70 ) , the flange being adapted to displace the locking strip thereby allowing the barrel to rotate .
the apparatus of claim 1 , wherein the fingerprint memory and the recognition circuit are below the sensor circuit .
polyclonal or monoclonal antibody against an interleukin-4 protein , the interleukin-4 protein characterized in that it has the effect of a b-cell growth factor ( bc@@ gf ) on human cells and the effect of a t-cell growth factor ( tc@@ gf ) on human cells .
the method of claim 14 , wherein said mixture further comprises at least one enzyme that is suitable for removing at least one kind of residue from a contact lens which is disposed in liquid aqueous medium containing said hydrogen peroxide , said at least one coated object including said at least one enzyme .
the method of claim 16 , wherein the phyto@@ sterols are selected from the group consisting of sterols , sterol esters , stan@@ ols , stanol esters and mixtures thereof .
novartis pharma gmbh ro@@ on@@ straße 25 d-@@ 90@@ 4@@ 29 nu@@ re@@ mbe@@ rg germany
this can be operated by means of a rotating actuating member ( 31 ) , which is arranged at the end of a rod ( 30 ) guided along the shaft ( 1 ) near the sleep ( 3 ) so that the tool can be held in a comfortable position and can be removed away from the operating field .
a method for identifying compounds which inhibit binding of β@@ 3-@@ donor short to β@@ 3 integrin , as active ingredients for treating arteriosclerosis , resulting unstable plaques , acute coronary thrombosis , myocardial infarction , stroke , peripheral arterial injury , chronic venous ulcer and restenosis processes , characterized by the following steps : ( a ) incubating a mixture containing ( b ) detecting the inhibition of a binding of the component ( a1 ) to the component ( a2 ) in the presence of the compound ( a3 ) as compared to the absence of the compound
• after dilution , k@@ io@@ vig should be used immediately .
a metal complex of a piperazine non@@ oate derivative according to any one of claims 1 to 8 for use as a medicament .
endo@@ lumen@@ al device ( 1 ) according to one of the preceding claims , in which the elongated body ( 2 ) comprises radio-opaque markers ( 30 , 31 ) for identifying the position along the body of a distal and / or proximal end of the expansion device ( 5 ) .
list of the names , pharmaceutical form , strengths of the medicinal products , route of administration , marketing authorisation holders in the member states
the most common adverse reactions ( ≥ 25 % ) in either alk@@ -@@ positive or ros@@ 1-@@ positive nsclc were visual disturbances , nausea , diarrhoea , vomiting , oedema , constipation , transaminases increased , fatigue , decreased appetite , dizziness and neuropathy .
process for the preparation of sustained release pharmaceutical compositions .
cell culture systems and methods for organ support devices
the method of claim 1 comprising : ( a ) forming an emulsion including a hydrophilic , monomeric , continuous phase and a discontinuous oil phase , the emulsion comprising : wherein the discontinuous oil phase comprises 70 to 99 % of the emulsion and is substantially all of the polymerization initiator in the continuous aqueous phase of the emulsion ; and ( b ) polymerizing the emulsion .
your doctor will work out your dose of temodal .
treatment of invasive candidiasis prophylaxis of candida infections
the monoclonal antibody and derivatives thereof according to claim 23 , characterized in that they are of each of the hybridoma cell lines 20@@ 8.@@ 25 d.@@ 2 / 94 c.@@ n.@@ c.@@ m.@@ i-@@ 4@@ 86 , 20@@ 8.@@ 25 a.@@ i-@@ 4@@ 25 / 135 c.@@ n.@@ c.@@ m. i-@@ n.@@ c.@@ m.@@ i-@@ 4@@ 51 , 20@@ 7,@@ 25 a.@@ 4.4 / 45 c.@@ n.@@ c.@@ m. i-@@ 4@@ 52 , 20@@ 8.@@ 25 .
a composition comprising an effective amount of a compound of formula ( 1 ) according to any one of claims 1 to 4 .
the method of claim 4 , wherein the light beam is a laser beam .
a vaccine according to claim 12 comprising a glyco@@ conjugate antigen specific for vibrio cholerae .
the fusion protein of claim 5 , wherein the linker domain comprises five - ( gly ) 4 ser-@@ linker modules .
use according to claim 6 , wherein the anti-@@ il-6 receptor antibody is a reshaped human antibody of an antibody obtainable from the hybridoma having the accession number ferm bp-@@ 29@@ 98 .
the cpmp has recommended the maintenance of the marketing authorisations for the medicinal products listed in annex i containing the combination of loratadine and pseudoephedrine , including the amendments in accordance with the summary of product characteristics set out in annex iii .
use of a mixture of homologous lauryl polyglycol ethers according to claim 1 as a local anaesthetic agent for the preparation of therapeutic preparations for the treatment of the human body .
an instrument according to claims 4 and 10 and claim 11 or 12 , characterised in that the operating element ( 40 ) is supported by the second position in the third position directly or indirectly against a second spring ( 76 ) .
1 . a support structure for preventing the movements of powder material to be used as a bone implant ( powder ) to be used , wherein the support structure is formed into contact with bone tissue , which support structure is made of an at least partially absorbable polymers , copolymers or polymer mixture , and having an open porosity , and in that the surrounding tissue is produced by the support structure , which is made up of an at least partially absorbable polymer , copolymers or polymer mixture , and in that the surrounding tissue is produced
a process according to claim 12 wherein a 3 is h and a 2 and a 6 is oh .
use according to any one of the preceding claims , characterized in that z represents a number which can vary from 75 to 95 .
a process for producing a phosphoric acid diester of the formula wherein x is a hydrogen atom or a halogen atom , or a salt thereof , which comprises reacting α-tocopherol with a halogenated phosphorylating reagent and further either having uridine , its 2 &apos; and 3 &apos; hydroxyl groups , or with a 5-@@ halogeno@@ substituted derivative thereof , and removing the protecting groups of the resulting compound .
this includes any possible side effects not listed in this leaflet .
process according to one of claims 14 to 20 , characterized in that the cell is chosen from strains of e. coli .
wound dressing according to claim 1 , characterized in that the composition is in the form of a gel .
the method of claim 7 , wherein the drug is alfa@@ x@@ alone .
metabolism and nutrition disorders common uncommon rare
auto@@ kinin mobility factors in the diagnosis and treatment of cancer .
studies in which healthy volunteers received a single dose and multiple oral doses of type 2 diabetes showed significant absorption of glimepiride within 1 h and cmax after approximately 2.5 h .
b. van war@@ red bo@@ t the rapporteur on the rapporteur of dr and the emea / cvmp / cvmp / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she / she will have the rapporteur of dr .
the assembly of any one of the preceding claims , wherein at least a portion of the coil ( 52 ) is made of a radiopaque material .
a c 1-8 alkyl optionally substituted on a terminal carbon atom having a substituent selected from the group consisting of cycloalkyl , heterocyclyl , aryl , heteroaryl , amino ( with two substituents independently selected from the group consisting of hydrogen and c 1-8 alkyl ) , ( halo ) , ( halo ) , and the cycloalkyl , heterocyclyl , aryl and heteroaryl parts of the aa ) .
relistor was used every 3.2 days ( median dosing interval with a range of 1 to 39 days ) .
shelf life after dilution according to directions : 10 hours .
it is available as a spot-on solution in applicators containing five different strengths for use in dogs .
a sanitary panty according to claim 1 , wherein the length ( c2 ) of the liner fastening o@@ we@@ n between the front side portion ( 23 ) and the rear side portion ( 24 ) is assuming that the free length ( c1 ) of the crotch portion ( c1 ) is in the range of 110 to 150 .
in 1.8 % of patients receiving zu@@ ramp@@ ic 200 mg , 6.7 % of patients receiving 400 mg of le@@ sinu@@ rad and 0 % of patients with placebo experienced serum creatinine at least 2-fold compared to baseline .
nucleic acids exhibiting different expression in hepato@@ blastoma and normal liver
the process according to claim 1 , wherein the bifunctional ligand is derived from diethylenetri@@ aminepentaacetic acid or 1,4,@@ 7,10-tetraazacyclododecane-1,4,@@ 7,10-tetra@@ acetic acid .
apparatus as claimed in any one of the preceding claims , further for determining a patency of the airway , the data processing means ( 54 , 134 , 136 ) further comprising detection means ( 132 , 134 , 136 ) adapted to detect the presence of cardio@@ genic components in the airflow to determine that the airway is continuous .
the system of claim 2 , wherein the plurality of ventilator support parameters also comprise at least one of the arterial blood gas pac@@ o2 levels of the patient ; the arterial blood gas pac@@ o2 level of the patient ; and the arterial blood gas ph level of the patient .
tissue graft from gastric submucosa for repairing neurological tissue
inflatable electrode for temporary stimulation
the defibrillator of claim 3 , wherein the user commands ( 271 ; 272 ; 274 ) for the second mode are push buttons .
supplement according to one of claims 9 - 11 , characterized in that it is derived from d-glucose .
device according to one of claims 1 to 9 , characterized in that the drive element ( 10 ) is part of a vibration bridge ( 18 ; 42 ; 60 ) .
process according to claims 1 to 7 , characterized in that the eucaryotic polypeptide analogue has the sequence met-@@ phe pro at its n-terminus .
a permanent waving agent comprising 0.01 to 1 % by weight , calculated to the total composition , as a hydrogen peroxide of an oxidizing agent , characterized in that it contains a catalase free peroxidase in spatially separate composition thereof .
a retractor for use in endoscopic surgery , with a shaft ( 1 ) , at its proximal end , a handpiece ( 2 ) having a distal end thereof and whose distal end is made from a stretched straight starting position , the distal end of which is arranged in a stretched straight position , the distal end of which is arranged in a fixed straight position , the distal end of which is arranged in a fixed straight position , the distal end of which is arranged in a stretched straight position , the distal end of which
a microwave apparatus for heating a fluid flowing in a fluid line ( 12 ) , comprising : a means ( 16 ) for providing a microwave heating space ( 10 ) ; a microwave heating chamber ( 10 ) ; a microwave heating chamber ( 10 ) ; a microwave heating means ( 14 ) ; a microwave heating means ( 14 ) ; a microwave heating means ( 14 ) ; a microwave heating means ( 14 ) ; a microwave temperature sensing means ( 20 , 22 , 45 , 22 , 45 ) having a noninvasive
the composition of any one of claims 1 to 5 , wherein the additional polymer is a copolymer of glycolide and lactide .
an inhalation device according to claim 10 , characterised in that the control means is provided as electronic circuit with at least one microchip .
official , national and regional antimicrobial polic@@ ies should be taken into account when administering the veterinary medicinal product .
the ratio rates of per@@ -@@ proto@@ pool regression analysis and the non-@@ significant sensitivity to po@@ is@@ son@@ -@@ regression analysis were 0.@@ 81 ( 95 % ci : 0.@@ 69 to 0.@@ 94 ) and 0.@@ 89 ( 95 % ci : 0.@@ 77 to 1.@@ 02 ) .
a compound according to claim 3 &apos; - ( cyclopent@@ ylidene amino ) -2- &#91; &#91; 5- ( trifluoromethyl ) -2-@@ benzothiazolyl &#93; methyl &#93; spiro@@ - &#91; isoquinoline-@@ 4 ( 1h ) , 3 &apos; -pyrrolidine &#93; -1.@@ 2 &apos; , 3,5 &apos; ( 2h ) tetralin .
medical device for supplying or withdrawing liquids by injection , infusion or transfusion comprising a housing ( 1 ) with a supply ( 1 ) with a supply or withdrawal port ( 4 ) and a closing element ( 5 ) for the connection piece ( 4 ) , characterized in that a radial gap ( 15 ) is provided between the stub ( 4 ) and the pin ( 12 ) when the closure element ( 5 ) is sealed by means of the closure element ( 5 ) and the pin ( 12 ) by means of the
walking aid according to claim 1 , characterized in that each of the rods on the first side part and the second side part are dimensioned so that the bars on the first side part are fitted into a cavity of the rods on the second side part , thereby allowing mutual movement of the bars in accordance with a telescope principle .
multipack comprising 168 ( 4 x 42 ) ampoules with consumer materials for the bree@@ lib nebuliser ( contains 1 mouthpiece and 1 nebuliser chamber ) .
a method of producing copies of at least part of a nucleic acid strand present at least one of a nucleic acid strand present in a sample , the method comprising steps of ( i ) providing a solid support system , which method comprises steps of ( i ) providing the steps of ( i ) the steps of ( i ) providing the steps of ( i ) the steps of ( i ) providing the steps of ( i ) the steps of ( i ) providing the steps of ( i ) the steps of (
use according to any one of the preceding claims of a compound selected from the group consisting of : wherein r = ( digit@@ oxo@@ sis ) 3 -d-@@ glucose + acetyl , ( digit@@ oxo@@ sis ) 3 -d-@@ glucose , ( digit@@ oxo@@ sis ) 3 + acetyl or ( digit@@ oxo@@ sis ) 3 ; wherein r = l-@@ rhamnose ; and wherein r = l-@@ rhamnose or l-@@ rhamnose d-glucose , for the manufacture of a medicament for inhibiting the ex@@ por@@ ted signal sequence free protein , comprising treating cells with the compound .
a system according to claim 1 , characterized in that the system comprises means for measuring the resistance of the patient &apos;s respiratory tract , which includes compliance of the patient &apos;s respiratory tract and the size of the control signal .
the article of any preceding claim wherein the acquisition layer ( 22 ) is a fiber-@@ containing web containing between about 50 to 95 weight percent wood pulp and about 5 to 50 weight percent of non-@@ cellulosic synthetic fibers .
a method according to any one of claims 18 to 21 , wherein the step of generating sensor data is processed one or more echo signals to generate intensity data for a scan line with a known orientation relative to the scanning means ( 12 ) , and the combining step is a two-dimensional image of the article .
a process according to claim 16 wherein the carrier is lactose .
re@@ ven@@ ue from the sale of publications of any type , including cur@@ the@@ berry right .
pregnancy the effect on pregnancy and lactation has not been studied in humans .
if the product has been dissolved in the supplied water for injection , it should be clear .
polypeptides derived from human apo@@ lipoproteins a@@ iv , their preparation and their use .
a measuring valve according to any one of claims 3 to 5 , wherein the inner surface has a surface of the valve shaft .
a micro@@ spherical composition according to claim 1 for parenteral administration and slow delivery , further characterized by a pharmaceutically and pharmacologically acceptable liquid vehicle in which the microspheres are dispersed .
the signal difference is preferably determined in a measuring device ( 5 ) provided on the hose ( 1 ) and transmitted tele@@ metrically .
hypersensitivity to penicillins may cause cross-@@ allergy to cephalosporins and vice versa .
nervous system disorders common headache dizziness uncommon taste disturbance odour
device for amplifying electromagnetic oscillations for influencing a biological system
the use of claim 4 , wherein at least one of the modified live bv@@ dv is derived from a cyto@@ pathogenic virus .
use of a chimeric dna / rna ham@@ mer@@ head ribozyme in the manufacture of a medicament for treating a proliferative disease of the eye , wherein the ribozyme is directed to the sequence of any one of seq id nos : 1-@@ 261 , 27@@ 1-@@ 280 , wherein said sequences are directed within the p@@ rna gene .
a retractable intravenous needle device ( 10 ) according to claim 2 characterised in that the manual actuating means has an inclined ramp ( 20 ) formed on the hub and normally is located outside the passage ( 32 ) of the housing , near its second end and a finger pressure directed away from the second end ( 30 ) by a user so that the hub ( 14 ) moves from outside the stop means ( 34 ) towards the locking means ( 36 , 38 , 40 ) .
a composition according to any preceding claim , further comprising an agent for buffering .
the apparatus of claim 1 , wherein the catheter outlet ( 16 ) includes a tubular member that extends tangentially from the base ( 14 ) and a hollow interior ( 66 ) extending coaxially with the passageway ( 26 ) in the tubular member to be opened in the socket ( 58 ) of the flexible insertion catheter member ( 54 ) .
austria france france france netherlands united kingdom tel : + 44 ( 0 ) 1 4@@ 89 ( 0 ) 1 ) spain france france the netherlands united kingdom • the netherlands • the netherlands • the netherlands • the netherlands • the netherlands • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
the apparatus of any one of claims 1 or 2 , wherein each first , second , third and fourth conduit means ( 44 , 50 , 56 , 60 ; 128 , 130 , 152 , 154 ) comprises an electrically conductive coil coil ( 90 , 94 ; 132 , 136 ; 15@@ 2@@ a-c , 15@@ 4@@ a-c ) received in a dielectric jacket ( 92 , 96 ; 134 , 138 ; 156 ) .
pulmonary and cardiac reactions including death due to bronchospasm in asthma patients and rare death associated with heart failure , have been reported following administration of timolol maleate .
composition according to any one of the preceding claims , characterized in that the aqueous phase contains at least one gelling agent chosen from polyacrylamides .
if a dose of doribax has been missed if you have a concern that you may have missed a dose of doribax , talk to your doctor , pharmacist or nurse immediately .
a vector comprising a recombinant dna molecule according to claim 15 .
for a full list of excipients , see section 6.1 .
a dispenser as claimed in any one of claims 1 to 3 , characterised in that the longitudinally slotted clip ( 60 ) has a closure body ( 62 ) for the one end of the tube ( 111 ) in parallel with a closure body ( 62 ) for the one end of the tube ( 111 ) , and a longitudinal slotted clip ( 55 ) formed at the insertion piece ( 50 ) , the tube ( 111 ) engages the tube ( 111 ) in a region between its ends .
the medicine can only be obtained with a prescription .
if repeated or severe low blood sugar levels occur , please inform your doctor or hospital and take the need for reduction or interruption of insulin infusion .
the use of claim 11 , wherein the allergic inflammatory disorder of the airways is selected from the group consisting of idiopathic pulmonary fibrosis and autoimmune lung disease .
the method of claim 15 wherein the heat shrink tube ( 80 ) is heated to the elevated temperature with hot air .
an apparatus according to claim 1 , wherein the flow restriction means ( 16 ; 170 ; 230 ) includes at least one arm ( 16 ; 170 ) between the first position in which the at least one arm ( 16 ; 170 ) fits the tube ( 86 ; 142 ) to prevent flow and a second position in which the at least one arm ( 16 ; 170 ) does not exceed the tubing ( 86 ; 142 ) .
the electrosurgical instrument of claims 6 , 7 or 10-@@ 17 , wherein the head includes an electrode ( 34 , 9@@ 30,@@ 10@@ 30,@@ 17@@ 30,@@ 2@@ 130 ) and the electrode comprises the electrically conductive surface .
process according to claim 6 , characterized in that the denatu@@ rant is formamide , heat or a denaturing ph or combinations thereof .
acylated 4-@@ amidin@@ o- and 4-@@ guanidino@@ benz@@ ylamines for inhibiting plasma kallikrein
compounds of formula i according to claims 1 to 4 , wherein r1 is f@@ and r2 h or r1 h and r2 r and r2 are f ; r3 is oh ; a is h ; r3 is oh ; ( c 1 -c 4 ) alkyl ; ( c = o ) - ( c 1 -c 4 ) -alkoxy ; -ch 2 ch 2 -o- ; -ch = ch-ch = ch- -o- ( ch 2 ) p -o- ; p = 1 or 2 ; and r7 methyl , ethyl , ome , f , cl ,
conditions or restrictions with regard to the safe and effective use of the medicinal product
a use according to claim 4 or 5 , characterized in that ( - ) nor@@ cisapride is to be administered 1 to 4 times per day .
talk to your doctor if you have stopped or stopping your treatment .
patients who test positive for hepatitis b infection should continue with a doctor who has exper@@ tise to treat hepatitis b.
the invention relates to a novel flavonoid derivative , an extract containing the flavonoid derivative , the cosmetic and pharmaceutical use thereof , preparations containing the flavonoid derivative or the extract , and a method for producing the flavonoid derivative or the extract .
calcium channel blockers felodipine , nifedipine , nicardipine , diltiazem , ni@@ modi@@ pine , verapamil , amlodipine , n@@ iso@@ l@@ dipine , iso@@ radi@@ pin ( saquinavir / ritonavir )
- swollen and mostly itchy patches on skin or mucous membranes ( urticaria ) ,
a method of detecting or quantifying an analyte in a subcutaneous fluid of a mammal , the method comprising : ( a ) permitting a subcutaneously injected or implanted sensor for detecting or quantitative measurement of an analyte in the subcutaneous fluid , wherein the sensor is capable of detecting the output signal of the assay using an optical device ; and ( c ) reading the output signal of the assay using an optical device ; and ( c ) the measurement of the measurement obtained in step ( b ) with the concentration of the analyte .
a drilling device ( 1 ) according to any one of the preceding claims , characterized in that said penetrating means ( 2 ) comprises a central conductive member ( 15 ) and an outer conductive member ( 16 ) , said central ( 15 ) and said outer ( 16 ) portion being separated by a cylindrical insulation means ( 12 ) , said outer member ( 15 ) and said outer ( 16 ) portion being separated by a cylindrical insulation means ( 12 ) , wherein said two parts ( 16 ) and said outer ( 16
the import , sale , supply and / or use of rabi@@ gen sag@@ 2 may be pro@@ hibited in certain member states on the whole or part of their territory pursuant to national animal health policy .
the method of claim 1 , wherein the vir@@ ally infected eukaryotic cells are retro@@ vir@@ ally infected , eukaryotic cells .
method according to claim 22 , characterized in that the electric current reaches a current density of up to 120 a / cm 2 , preferably 80 a / cm 2 .
the individually packaged absorbent article of claim 2 wherein said releasable sheath ( 34 ) has an inwardly facing surface facing the outwardly facing surface of said backsheet ( 24 ) and an opposing outwardly facing surface and having an opposing outwardly facing surface and wherein said absorbent article ( 20 ) and said releasable sheath ( 34 ) and said release sheath ( 34 ) are folded about two transverse axes , said said absorbent article ( 20 ) and said detachable sheath ( 34 ) being folded about said second triple section ( 51 ) to form said
material according to any one of claims 4 to 6 , characterized in that it comprises up to 50 % by weight , and preferably up to 20 % by weight of one or more component ( s ) , in addition to the above-mentioned composition based on the methylidene malon@@ ate , the above-mentioned composition being selected from the group consisting of : poly@@ cyano@@ acrylates , preferably polyalkyl@@ cyano@@ acrylates , polyalkyl@@ methacrylates ; bio-compatible polyurethanes ; polyoxy@@ alkyl@@ enes ; poly@@ aminoacids ; polylac@@ ta@@ tes ; polylac@@ tate -co-@@ glyco@@ lates ; polyvinyl alcohols .
musculoskeletal and connective tissue disorders uncommon :
implantable device for monitoring intracranial and cerebrospinal fluid pressure
the osmotic device of claims 1 or 2 , wherein the delivery of the first active agent is delayed with respect to the delivery of the second active agent .
an intraocular device as claimed in claim 1 , characterised in that the end portion ( 28 ) includes an angle in such a way that upon removal of the device in the capsular sac of the bent end portion substantially tangentially a circle having a diameter of between 9 and 10 mm , according to the inner dimensions of the capsule bag .
the method of claim 14 , wherein seph@@ acryl s-@@ 200 or sepharose cl-@@ 6b for gel filtration chromatography are used .
it is not known whether pemetrexed is excreted in human milk and undesirable effects in the breast-@@ fed infant cannot be excluded .
the method of claim 28 , wherein the second silica transfer particle comprises at least one anion exchange group covalently bonded thereto and the first silica magnetic particle comprises a silica oxide coating .
almost all of these patients had received medicines known as azathioprine or 6-mercaptopurine in addition to tnf-@@ blockers .
a process according to any one of claims 6 to 10 , wherein said microorganism is a strain of a fungus of the species which also belongs to the strain san@@ k 114@@ 86 ( no . ferm bp-@@ 25@@ 98 ) as strain .
use in patients with chronic heart failure ( nyha class iii or iv ) is contraindicated ( see section 4.3 ) .
a drug delivery system according to claim 13 , characterized in that the spherical , microporous polymer network comprises microspheres having a diameter of between 0.5 and 150 µm ( microns ) .
the machining of the socket bearing can be improved by means of an operating robot to obtain better surface con@@ formity .
pri@@ alt treatment should only be carried out by a doctor who has experience in the intrathecal dosing of medicines .
human antibodies which bind il-12 and process for producing the same
the device of claim 1 , further comprising a syringe ( 12 ) connected to the tubular member ( 14 ) for supplying the fibrous material ( f ) into the lumen of the tubular member ( 14 ) .
for the full list of all side effects reported with su@@ vaxyn cir@@ co + m@@ h r@@ tu , see the package leaflet .
process for removal of meth@@ ylamines .
the compound of claim 1 wherein each of r 1 and r 2 is hydrogen and r 3 is hydroxy .
aranesp 15 µg darbepoetin alfa iv / sc
a method according to any one of claims 1 to 28 , wherein the ph is maintained constant during the time of reaction between ph 7.3 and 8.2 .
there is no clinical experience with tesavel in patients with severe hepatic impairment ( child-pugh score &gt; 9 ) .
the device of claim 1 , wherein the biasing element comprises an elastic material .
a process according to any one of claims 4 to 6 , wherein the isolated high meth@@ oxyl pectin is obtained from at least one representative of citrus fruit husk , apple juice , apple wine , apple po@@ ma@@ de , sugar beet , sunflower species , vege@@ tables , waste products of plants selected from at least one representative of app@@ les , sugar beet , sunflower and citrus fruits .
however , diagnosis in clin@@ ics in which not the entire spectrum of the therapeutic possi@@ bilities can be lost , a very much stra@@ ssi@@ e and on the surgical therapy can be separated .
subcutaneous injection into the abdominal wall results in more rapid absorption compared to other injection sites .
the mixer of claim 1 , wherein said delivery means comprises a needle connector ( 34 ) or needle-@@ penetrable material ( 38 ) .
a compound according to claim 8 wherein r 2 is r 11 .
compounds of formula i according to claim 1 wherein m is a central moiety of the following formula : n is 1 or 2 , u@@ 1 and u@@ 2 are the same or different and are the same or different and are the same or different and is methylene &#91; -ch - &#93; or isopropylidene &#91; -c ( ch ) - &#93; , and is methylene &#91; -ch - &#93; or isopropylidene &#91; -c ( ch ) - &#93; , and is the same or different and are the same or different and are the same or different and
the method according to one or more of claims 1 to 12 , wherein the cell is a c. ele@@ gan@@ s cell .
a method according to any one of the preceding claims , wherein the host microorganism is modified to display the ligand or receptor via a bacterial pathogen vector .
an ultrasonic endoscope according to claim 3 , wherein each of the discontinuous sections of the flexible circuit board is constructed such that at least one plurality of small holes or a plurality of slices in ( i ) are formed a transition section from the large-@@ diameter portion to the stepped section and ( ii ) a transition section from the stepped section to the small diameter portion .
a topical composition according to claim 2 wherein the plasticizer is carboxymethylcellulose .
the agency wants to stimulate a de@@ b@@ link with all sta@@ ke@@ holders , which will be discussed whether the introduction of such a concept in the european union ( eu ) is useful and which is suitable to support the development of new medicinal products .
3 observed for fasting normal levels at baseline ( &lt; 5.@@ 17 mmol / l ) which increased to high ( ≥ 6.2 mmol / l ) .
what were the main concerns of the chmp ?
treatment with introna in combination with ribavirin has been reported in combination with ribavirin .
finally , the invention also relates to the use of bat@@ 3 cdna for in vivo and / or ex vivo introduction of bat@@ 3 in tumor cells resulting in improved recognition by nk cells , for the immunotherapy of malignant diseases .
a container according to claim 16 , wherein in the resting position for the tray ( 16 ) , it is inclined towards the interior of the vessel ( 11 ) so as to facilitate a sharp object deposited thereon and the pivoting of the shell from its rest position into a disposal position .
electro-@@ therapy apparatus according to any one of the preceding claims , comprising a housing ( 36 in fig . 8 ) for electrical components , wherein the feed electrodes are contact electrodes located on the outer surface of the housing .
use of the graft polymers prepared according to one of the methods of claims 1 to 6 as absorbents for water and aqueous solutions .
this syndrome may be associated with some features of tumour lysis syndrome such as hyperuri@@ caemia , hyperkalaemia , hypocalcaemia , hyper@@ phosphat@@ aemia , acute renal failure , elevated lactic dehydrogenase ( ld@@ h ) values , and possibly associated with acute respiratory failure and death .
the use of claim 26 , wherein the compound is thr-@@ pro-@@ gln-@@ gln-@@ lys or a pharmaceutically acceptable salt thereof .
compounds of general formula ( i ) according to claim 1 , wherein the radical r 1 -a at position 3 of the thio@@ chromen@@ one ring is , r 1 is phenyl or 5- to 6-membered heteroaryl , wherein phenyl and heteroaryl are optionally substituted or different from the group consisting of halo , cyano , ( c 1 -c 3 ) alkyl , optionally substituted by residues selected from the group consisting of halogen , cyano , ( c 1 -c 3 ) alkyl , and is optionally substituted or different from the group consisting of halo or
thiazolidine@@ carboxamides as modulators of prostaglandin f receptor
use of a nucleic acid encoding a functionally active portion of a notch protein for the manufacture of a medicament for preventing or treating a malignancy in a patient .
the needle cap of the pre-filled syringe contains dry natural rubber ( a derivative of latex ) .
the module of any one of claims 1 to 3 , wherein the ligand is a poly@@ anion .
braf v@@ 600 mutations were reported in 13 % of the study population .
radical formation can be carried out after por@@ fi@@ mer sodium has absorbed light to produce a porphyrin molecule in the affected state .
compounds according to claim 2 , characterized in that the radicals r denote methyl , ethyl , propyl , n-butyl , n-octyl or 2-ethylhexyl radicals .
the bioreactor of claim 1 , wherein the bioreactor further comprises microorganisms distributed in each module .
haemoglobin levels should not exceed 12 g / dl .
ted before you start to start , and believe me , i h@@ ate that to consult ... would you do a little bit outside the work ?
the histamine h1 antagonist effect of mirtazapine is associated with its sedative properties .
arrangement according to claim 6 , characterised in that the switching means ( 12 , 13 ) jointly can be switched together and the atrial probe ( 10 ) is associated therewith .
the pharmaceutical composition of claim 4 , further comprising a chemotherapeutic agent effective to treat the malignant disease or condition of the mammal .
a sustained acting agent for parenteral administration comprising interferon as an active ingredient in admixture with a pharmaceutically acceptable biodegradable protein as a carrier , said agent being in the form of powder particles or as a shaped body , with the proviso that it is neither needle or stick r@@ ö@@ mite .
severe hypoglycaemia may lead to un@@ consciousness and / or seizures .
use according to claim 1 or 2 , wherein the cosmetic contains at least one other kind of organopolysiloxane as the formula ( 1 ) .
use according to any one of the preceding claims , characterized in that the second peptide sequence of formula ( b ) is a sequence selected from the group consisting of seq id no : 1 and seq id no : 3 .
orthopaedic fixation screw , particularly with a longitudinally continuous bore , with a concentric hexagonal socket in the region of the head ( 4 ) , in the region of the head ( 4 ) , a further hexagonal socket ( 7 ) which is smaller than the first hexagonal channel ( 6 ) and is connected in the longitudinal direction to the first hexagonal cannula in the longitudinal direction relative to the screw .
device for external fixation of bone fractures with at least one re@@ position chuck ( 1 ) and a longitudinal support , the device also comprising at least one of the connecting pins ( 11 ) of the re@@ position forceps ( 1 ) and the at least one longitudinal support ( 18 ) and the clamping element ( 19 ) which can be connected to each other .
elderly patients should be treated only in the presence of psoriasis associated with disability and renal function should be closely monitored .
check with your doctor or pharmacist if you are not sure .
use according to claim 7 , characterized in that the active intracellular catalase is that of living microorganisms .
surface structure according to one of claims 1 to 6 , characterized in that the depressions ( 18 ) have a round shape and are preferably circular or el@@ ip@@ -shaped .
♦ common ( these may occur with up to 1 in 10 doses of vaccine ) : • heat , itching or bruising at the injection site • increased sweating , chills , flu-like symptoms • lymph node swelling , underarm or groin
this medicine should not be given to children or adolescents .
a compound according to claim 2 which is ( 2e , 4e ) -3-methyl-@@ 5- &#91; 2- ( 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro@@ -naphthalen@@ -2-yl ) -cyclohex@@ -1-enyl &#93; -@@ penta-2,4-dienoic acid .
in com@@ mit , the rate of non@@ cerebral major bleeding or cerebral bleeding was low and similar in both groups .
a method according to any one of the preceding claims , wherein the active agent is poorly soluble in water .
the use according to any one of claims 1 to 8 , wherein the bpi protein product is for topical administration in a unit dose of between 1 µg / ml to 1 gm / ml .
recombinant adenoviral vectors expressing chimeric fiber proteins for cell-specific infection and genomic integration
an n-vinyl pyrrolidone polymer according to any one of claims 1 to 6 , on which a pharmaceutically acceptable drug or enzyme has been grafted .
the effect of posaconazole on fosamprenavir levels is not known when fosamprenavir is administered with ritonavir .
however , the increase in 5-fu exposure ten@@ ded to increase more than proportional to the increase in te@@ ga@@ fur dose .
for more information , see the package leaflet .
a process according to claim 1 or claim 2 wherein r ¹ represents a hydrogen atom or a methyl group .
a blood collection device comprising : ( a ) a blood collection assembly ( 12 ) , comprising : ( c ) a second transfer device ( 18 ) , a blood collection receptacle ( 16 ) , a blood component separation ( 16 ) , a second transfer device ( 14 ) , a blood component separation ( 16 ) having a second transfer path ( 20c ) , ( c ) having a second transfer path ( 20c ) , ( c ) having a second transfer path ( 20c ) , ( c ) , a second
the composite wound dressing ( 10 ) of claim 1 , wherein the contact component ( 14 ) comprises : a first outer layer ( 22a ) , an intermediate layer ( 22b ) and a second outer layer ( 22c ) , the layers ( 22a , 22b , 22c ) being each made of a permeable , non-@@ adherent mesh , wherein the layers ( 22a , 22b , 22c ) are each made of a permeable , non-@@ adherent mesh , wherein the layers ( 22a , 22b , 22c ) are each made of a permeable
exercise tolerance xo@@ ter@@ na breezhaler reduced the first dose of xo@@ ter@@ na breezhaler from the first dose to dynamic hyper@@ inflation and extended the time to maintain stress .
dose delay and adjustment : tri@@ sen@@ ox treatment should be withheld , adjusted or early discontinued if there is a toxic response to grade 3 or higher following the general toxicity criteria ( common toxicity criteria ) of the national cancer institute , and a compound for tri@@ sen@@ ox therapy is considered to be possible .
a pharmaceutical substance of peptidic nature which resto@@ res the function of the myocardium containing the active peptide gene and a pharmaceutically acceptable carrier and which is characterized by the fact that it contains an effective amount of the tetrapeptide ala-@@ glu-@@ asp-@@ arg &#91; seq id no : 1 &#93; as an active peptide gene .
claims for the following contracting states : de , se emulsified composition having an average particle size of 0.0@@ 10 to 0.0@@ 70 µm and having at least the following components ( a ) , ( b ) and ( c ) ; wherein the weight ratio of ( a ) / ( c ) is 0.5 / 1 to 5 / 1 .
composition according to claim 18 , characterized in that the water-soluble alcohols are chosen from c 1-6 alcohols , such as ethanol , isopropanol , t-@@ butanol and n-butanol , and polyols such as alkylene glycols , for example propylene glycol , glycerol and polyalkylene glycols ; and glycol ethers .
a compound according to claim 1 wherein z is sulfur .
an apparatus according to claim 9 , characterized in that the focal distance of the infrared tonometer ( 14 ) is such that there is no interaction with the atomi@@ sation of the dry egg and the precise temperature measurement is adjusted when the device ( 1 ) is positioned in a distance appropriate for the intended application .
the invention relates to compounds of the general formula in which a , b , l , r1 , r2 , r@@ 3a and r@@ 3b are as defined in claim 1 , in particular their physiologically compatible salts with inorganic or organic acids or bases , in particular their physiologically compatible salts with inorganic or organic acids or bases having valuable properties , in particular an anti-@@ thrombotic effect and a factor xa inhibiting effect .
rue de l ’ institut 89 b-1@@ 330 ri@@ xen@@ s@@ art belgium
the composition of claim 8 , wherein the amount is 0.1 - 300 mg / kg / day .
the assembly of any one of claims 1 to 7 , wherein said securing means ( 46 ) comprises an annular member projecting from said abutment post ( s ) and said ball ( 52 ) has an internal thread ( 52 ) engaging in an external thread ( 32 ) on said support member .
the platform assembly of claim 25 , further comprising a memory connected to the control unit and a plurality of templates for triggering selected controlled movements of the movable member for performing different types of a predetermined movement of the platform , the input device being operable to operate under the plurality of templates .
the oxygenator of claim 8 further comprising a manifold ( 26 ) abutting and configured to deliver gas from said hollow fiber membrane ends to said member ( 14 ) .
each tablet contains sitagliptin phosphate monohydrate equivalent to 25 mg sitagliptin .
a compound according to claim 1 of formula i , characterized in that r is cho , r 1 , r 2 and r 3 are h , r 4 is n ( ch 3 ) 2 , lines - - and ....@@ . for a double bond , and the line stands for a single bond .
each vial contains 10 mg of the active substance .
the device of any one of claims 1 to 4 , wherein the housing comprises a one-piece plastic structure .
a compound according to claim 1 wherein a and b are independently phenyl , naphthyl or a 5- or 6-membered heterocycle or condensed heterocycle having 1 to 4 heteroatoms independently selected from an oxygen atom or sulfur atom or 1 to 4 nitrogen atoms .
the use of claim 7 , wherein the electrophilic leaving groups are selected from a halide group , an epoxy group , a tosylate group or a mesylate group .
the expression vehicle of claim 28 , wherein the virus vector is an adenovirus vector .
a process according to claim 1 , wherein the acid is hx of step ( a1 ) - ( s ) - ( + ) -@@ mandelic acid .
the method of claim 2 , further comprising generating an antibody against the protein .
the invention relates to a method for producing a circular , annularly closed , minimally hypnotic expression construct from a dna double strand , as well as the expression construct produced by this method and the use thereof .
process according to one or more of claims 1 to 4 , characterized in that d represents imino , oxy or methylene .
a vaccine precursor in a flexible form produced by the process of claim 1 . the method of claim 1 , wherein the human rotavirus is selected from the group consisting of human rotavirus strain , serotype 1 , dsm@@ -1 strain , serotype 2 , p strain , serotype 3 , and the st@@ 4 strain , serotype 4 .
acute neuron@@ al-@@ induced ligands of the calcium binding protein -1
poration pack for silver powder for the preparation of dental am@@ alga@@ m .
a plaster dressing according to claim 11 , characterized in that the plaster dressing comprises two edge cover layers ( 6 , 8 ) covering opposite edges of the dressing and a central cover layer ( 7 ) extending between the edge cover layers .
the use according to any one of claims 1 to 8 , wherein the fuc@@ an is for administration as a pharmaceutical composition in a form comprising at least one of cream , paste , injectable carrier and polymer .
the device of claim 1 , wherein the magnification ( 11 ) is a thickening .
the use of this gas is described in the literature for investigating respiratory function and pneumatic retinitis .
the chmp decided that relistor ’ s benefits are greater than its risks and recommended that it be given marketing authorisation .
cosmetic and dermatological cleaning preparations containing : a ) one or more pregelatinized , cross-linked starch derivatives , b ) one or more ethoxylated oils .
the recommended starting dose is 5 mg for patients with pre@@ disposing factors for myopathy ( see section 4.4 special warnings and special precautions for use ) .
the monitor ( 10 ) of claim 2 , further comprising a dc drive selection circuit ( 42 ) for applying the electrode selected from the reference conduit circuit than the new reference electrode , with a dc clock control signal from the dc signal generating circuit .
19 . the imaging system according to claim 4 , characterized in that it comprises a polari@@ ser ( p ) arranged on the path of the light beam of the source ( fs ) and which bundle comprises linearly polarised .
explan@@ ation of the tur@@ bo@@ pin and its work .
it is also important that patients should not shake the inhaler before use , not to breathe through the spiromax and do not cover the air inlets if they are pre@@ pping to the step ‘ breathe ’ .
in neutropenic mice , the auc / mic ratio to reach the bacterio@@ stasis was at least 16 times the ratio observed in immuno@@ competent animals ( see section 4.4 ) .
medical check valve according to one of claims 1 to 16 , characterized in that the housing ( 10 ) has inlet and outlet openings which are formed on staggered sides of the body of the body and that the piston ( 66 ) is movable from the closed position into a second position in which the sealing lip is located below the two axes .
a device according to claim 17 or 18 , characterised in that the material is selected from the group consisting of n@@ br foams ( natural butadi@@ enes ) , the s@@ br foams ( synthetic butadi@@ enes ) , the elastomer foam materials , in particular from polyether block amide , of polyurethane , wool , cellulose , wood , ter@@ ra@@ ko@@ tt@@ a , gy@@ ps , ceramic materials .
a plant tissue comprising plant cells according to claim 13 or 14 . a transgenic plant comprising plant cells according to claim 13 or 14 . a transgenic plant comprising a plant cell according to claim 13 or 14 . the use of a dna molecule according to claim 13 or 14 . the use of a dna molecule comprising a dna sequence as defined in any one of claims 1 to 3 or a vector according to any one of claims 5 to 7 for the production of transgenic plants , plant cells and / or tissue .
a pharmaceutical formulation containing formoterol fumarate dihydrate having a particle size of less than 10 µm and an additive which emits heat less than 0.5 j / g of heat on the exposure of water-containing vapor .
a transformation method which comprises inoculating and co@@ cultivation of a target tissue from a target plant with an agrobacterium at a time to which the target tissue is in its natural plant environment , and subsequently generating a transgenic plant by de@@ differentiation and regeneration of the target tissue , wherein the inoculation is carried out by injecting agrobacterium into said tissue so as to be injected into said tissue so as to be damaged as a little as possible .
a method for producing a detergent composition comprising liposomes and liposomes dissolving anionic surfactants , the method comprising the steps of : ( i ) preparing a stabilized aqueous liposomal suspension , comprising the steps of : ( i ) preparing a stabilized aqueous liposomal suspension , at least one of 1 to 4 % by weight , based on the total weight of the stabilized aqueous liposome suspension , at least one of from 1 to 4 % by weight of the total detergent suspension , of step ( i ) in an amount of 0.1 to 35 %
the composition of claim 20 , further comprising a plasticizer .
the method of claim 14 , wherein the viral antigen is fused to the interleukin-2 by means of a linker .
the method of claim 7 , wherein the foreign protein is a heterologous protein derived from the group consisting of therapeutic polypeptides and pathogenic agents .
all patients who did not have disease progression should receive chemo@@ radiotherapy ( cr@@ t ) according to protocol ( t@@ pf / cr@@ t ) .
use according to claim 1 for the treatment of central nervous system disorders .
a bone fixation system according to any preceding claim , wherein said elongate plate ( 31 ) has a rounded edge ( 36 ) extending between said top and bottom surfaces .
the use according to claim 9 or 10 , wherein the immune response modifier or regulator contains α in admixture or in combination with a pharmaceutically or veterinarily acceptable carrier .
the use of a compound of the formula i and / or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 6 , alone or in combination with other drugs or active substances , for the preparation of a medicament for the treatment or prophylaxis of diseases associated with n@@ ri@@ es .
the sterilizer ( 1 ) according to claim 10 , characterized in that a cryogenic plasma is produced in the vacuum housing .
patients should be advised not to drive or operate complex machinery , do not drive or operate any other potentially hazardous activities until this medicinal product affects these activities .
use according to claim 46 , characterized in that a is phenyl , phenyl substituted with one or more alkyl , haloalkyl or alkoxy , aralkyl , aralkyl or n-@@ containing heteroaryl or heteroaryl containing heteroaryl in the aryl and / or alkyl unit .
process for the preparation of physiologically acceptable salts of 1,4-di@@ substituted piperidine compounds according to claims 1 to 15 , characterized in that at least one compound of the general formula ( i ) is reacted with at least one acid , preferably an inorganic or organic acid , preferably in the presence of a suitable reaction medium .
a cleaner according to any one of the preceding claims , characterised in that the ends of the hair ( 3 ) are substantially on the surface of a rotational body which is provided with two conical surfaces .
a method according to claim 1 or 2 , wherein the amylin agonist is cgrp .
aortic and mitral valve stenosis , obstructive hypertrophic cardiomyopathy
use according to any one of claims 1 to 4 , characterized in that the duty ratio of sulfite is between 0.001 % and 10 % by weight .
a method of attaching a closure member to a heat and pressure sensitive polyolefin layer of a disposable diaper or a similar disposable absorbent article , in which a preformed laminate ( 40 ) is formed from a single layer ( 44 ) of a disposable absorbent or disposable absorbent article , in which a preformed laminate ( 40 ) is formed from a single layer ( 44 ) which is bonded to the second surface ( 44 ) of a disposable absorbent article , and the bonding layer ( 46 ) is formed with an anti-@@ stick layer (
the agency ’ s committee for medicinal products for veterinary use ( cvmp ) concluded that the benefits of clo@@ sa@@ mectin pour-on solution for pour-on and associated names continue to outweigh the risks , subject to the variation of the marketing authorisations in the form of new adverse reactions and precautions , as well as in the form of conditions for risk minimisation and monitoring .
store in the original package in order to protect from light .
a method according to claim 12 , wherein the step of providing a coil core further comprises providing a first cutting liner ( 15 ) attached to the first end of the coil core ( 10 ) and a second cutting liner ( 15 ) attached to the second end of the coil core ( 10 ) .
the effects of rebif on fertility have not been studied .
the invention relates to chewing gum compositions containing ( a ) a water-insoluble base fraction , ( b ) a water-soluble proportion , and ( c ) physiologically active ingredients are selected from the group consisting of ( c1 ) sterols and / or sterol esters , ( c2 ) polyunsaturated fatty acids , their esters or glycerides and ( c3 ) ho@@ dio@@ a extracts or the active steroid glycosides obtained therefrom , and mixtures thereof .
a cyclodextrin inclusion complex obtainable by the process of claim 1 . the cyclodextrin inclusion complex of claim 12 comprising a solids enhancing agent and one or more active ingredient ( s ) in an amount of 1 to 20 % by weight of the complex .
a composition as claimed in claim 4 or 5 , wherein the carrier is hydrophilic and nonionic .
the use of claim 2 wherein the compound of formula ia comprises an amino group or pharmaceutically acceptable ammonium salts thereof , wherein n , y is selected from the group consisting of : isobutyl , cyclopropylmethyl , and benzyl , wherein r 1 is selected from the group consisting of isobutyl , cyclopropylmethyl , and benzyl , wherein r 1 is selected from the group consisting of isobutyl , cyclopropylmethyl , and benzyl , wherein r 1 is selected from the group consisting of isobutyl , cyclopropylmethyl , and benzyl , wherein r 1 is selected from the group
for instructions on use with the pre-filled pen , see section 6.6 and package leaflet .
the catheter of claim 6 , wherein the rotatable member has an axial lumen ( 8@@ 16 ) allowing passage of a guidewire therethrough .
jaw implant according to claims 8 and 9 , characterized in that buccal and lingual beve@@ ls ( 31 ) in the interface region of the implant body ( 30 ) have an angle α which is greater than an angle α &apos; between corresponding buc@@ cal@@ side and lingual beve@@ ls ( 32 ) in the interface region of the implant end ( 34 ) and that the angle α is in the region of the implant insertion section and the angle α is increased under the pressure of the screw ( 35 ) and at the angle α
the plasmid shuttle vector of claim 1 or 2 further characterized in that the restriction endonuclease cleavage sites are selected from sal i and s@@ fi i sites .
29@@ 0-3 or bacillus circul@@ ans which are produced in the conversion of starch or starch similar substrates to cyclodextrin ( cd ) in an increased extent γ@@ -c@@ d , characterized in that its protein sequence in the region between amino acid position 180 and amino acid position 240 has the amino acid sequence asn leu xaa asp ( seq .
a compound of the formula : wherein r ₁ and r ₂ are each independently h , ( c ₁ -c ₄ ) alkyl , ( c ₂ -c ₆ ) alkynyl or ( c ₂ -c ₆ ) alkynyl ; r ₃ , r ₄ and r ₅ are each independently h , ( c ₁ -c ₆ ) alkenyl , ( c ₂ -c ₆ ) alkenyl , ( c ₂ -c ₆ ) alkenyl , ( c ₂ -c ₆ ) alkenyl , ( c ₂ -c ₆ ) alkenyl , ( c ₂ -c ₆ )
after crosslinking , the medical instruments made from the polymer material ( 6 ) have a high transparency , are kin@@ k-@@ proof and flexible .
17 . a composition as claimed in any one of the preceding claims in which the cationic organic material contains between 0.1 and 20 % by weight of the total weight and the composition contains between 0.5 and 1000 ni@@ h units ( national institute of propen@@ tic units ) of thrombin per gram of the composition .
if a patient tole@@ tioned the infusion , the dose may be increased to achieve the therapeutic dose of 1 mg / kg and the infusion rate may be increased by slow titration , depending on the tolerability .
the method of any one of claims 1 to 3 , wherein the antibody for the enzyme does not substantially inhibit the ability of the 1st s@@ bp@@ m of the conjugate to bind to a second specific binding pair member ( 2. s@@ bp@@ m ) .
the method of claim 16 , wherein the enzyme is bovine chymosin , bovine pro@@ chymosin , aspergillus niger glucoamylase , humicola griseo@@ sa glucoamylase or mucor me@@ he@@ he@@ i carboxyl protease .
reception arrangement according to one of claims 11 to 23 , characterised in that it is associated with a transmitter ( 13 ) connected via a distributor element with the antenna elements ( 2 ) and that a transmitter signal emitted by the transmitter ( 13 ) is fed onto the antenna elements ( 2 ) in such a way that a magnetic resonance excitation signal is fed into the reception volume .
process according to claim 1 , characterized in that the microorganisms are altered by means of microorganisms .
compounds of formula ( i ) according to any one of claims 1 and 5 , characterized in that r 1 represents an isobutyl group , their isomers and addition salts thereof with a pharmaceutically acceptable acid or base .
the apparatus of claim 1 , wherein the main control program further generates a power potential value by detecting a maximum power value from the set of deriving power values and multiplying the anaerobic capacitance value with the maximum power level , the performance potential parameter corresponding to the product .
circuit arrangement according to claim 3 , in which the output signal is increased continuously or in stages in the presence of a warning signal .
use according to any one of claims 1 to 9 , wherein the contact lens care composition is a daily lens contact lens composition .
5 . the oscillator of claim 4 , wherein the stop surface is discontinuous and is formed by a crown ring .
a process for preparing a compound according to claim 1 which is 4- &#91; 1-@@ cyano-@@ 7-hydroxy-@@ 6- ( 3-hydroxy@@ -1-@@ octenyl ) -2-@@ azabicyclo &#91; 3.3.0 &#93; oct@@ -2-en-3-yl &#93; thio@@ butanoic acid or a salt or ester thereof .
the method of claim 14 , wherein the peptide has an amino acid sequence selected from the group consisting of : ( a ) a r l i ; ( b ) h a r l ; ( c ) f a r l ; ( d ) f a r l ; ( d ) a r l ; and ( e ) a r l c ; wherein said peptide comprises at least one and up to 25 additional amino acids that flank either the n- or c-terminal end of said peptide .
medicinal product no longer authorised with regard to the safe and effective use of the medicinal product
renal excretion of unchanged be@@ da@@ qu@@ iline is negligible ( &lt; 0.001 % ) .
a pump according to any preceding claim , wherein said pressure increasing device is capable of developing a pressure of at least 8.@@ 26 x 10 ⁵ n / m ² ( 120 p@@ sig ) .
process according to claim 6 , characterized in that the mixture comprises at least two starch acetates with different substitution levels .
a compound according to claim 11 or 12 , characterized by a differential alkali metal meta@@ metric curve at a heat rate of 5 ° c / min in a closed cruc@@ ible with a hole having an integrated temperature of about 94 ° c , a peak temperature of about 109 ° c , a peak temperature of about 109 ° c , a peak temperature of about 109 ° c , a peak temperature of about 109 ° c and an associated heat of about 171 degrees c , a peak temperature of about 109 ° c and
if the pandemic situation occurs , immunisation should be delayed in patients with severe febrile illness or acute infections .
check the number of vials and prepare the material in the vial : • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
vaccine for the immunization of cats against toxopla@@ sms without the spread of the oocysts .
on average , there are six weeks , but the cells can also be frozen and kept up up to two years until you and your surgeon have agreed a matching operation .
the stent of claim 6 , wherein the stent is thin-walled .
use of the imaging agent of claims 1 to 17 for the intravascular detection of atherosclerosis .
monoclonal antibody specifically directed against a novel epitope of lfa@@ -1 antigen from human t lymphocyte .
this included the limitation of the duration of treatment in certain conditions , the contraindication of the medicinal product in patients with pre-existing fibrosis or with other medicinal products , the output of a referral for healthcare professionals ( d@@ hp@@ c ) , in which the risk is num@@ ved , a che@@ ck-@@ list for prescribers and a pharmacological in vitro studies for the affinity of the 5-ht receptors for the medicinal product .
poly@@ nitrogen derivatives according to any of claims 1 to 3 , according to the following formula : ( w@@ -a ) x1 x-@@ b- ( c-@@ z ) x2 ( ia ) , in which w , a , x , b , y , c , z , b , y , c , z , x ₁ and x ₂ have the meanings given in claim 1 , wherein x ₁ = x ₂ = 1 , which corresponds to the following formula : w a-@@ x-@@ b-@@ y@@ -c-@@ z ( ib ) .
use of a moisture sensitive active pharmaceutical ingredient in the manufacture of a pharmaceutical composition for the treatment of hypertension , wherein the moisture sensitive active pharmaceutical component is wet granulated with a solution of co@@ povidone .
pyrimidine based cd@@ k inhibitors for the treatment of pain
in germany , 400@@ 0-@@ 5000 h@@ k@@ b-@@ rupture ( without regard to a number of dark@@ dity ) can be taken into account after the meal itself in germany , involving 400@@ 0-@@ 5000 h@@ k@@ b ru@@ de@@ n ( without consideration of any patient ’ s clinical course ) . • this is because it is not known whether this medicine can be taken into account in patients with a history of severe allergic reactions ( such as a sudden number of seizures ) , which can be taken into account in germany .
use according to claim 1 , wherein the neurological disorder or disease is caused by the action of substances that cause neurodegenerative diseases .
an electrical connection is achieved in a simple and reliable manner that within the further cone-@@ shaped sealing surface ( 11 ; 12 ) , at least one electrical contact ( 18 , 20 ) is provided in each coupling half ( 1 , 2 ) .
composition according to any one of the preceding claims , characterized in that the composition also comprises at least one active agent chosen from the group consisting of proteins or protein hydrolysates , amino acids , polyols , urea , sugars and sugar derivatives , vitamins , starch , plant extracts , ceramides , essential oils and antiseptic agents .
a prosthesis according to claim 26 , wherein the liquid is a physiologically acceptable oil .
the prion deactivation method according to any one of preceding claims 1 to 20 , further characterized in that said detergent has an alkali metal content of at least 500 ppm .
probes for detecting and identifying helicobacter pylori
seeds according to claims 1-3 , wherein the oleic acid content is from 55 to 75 % by weight .
eesti österreich norge pfizer animal health tel : + 370 5 269 17 96
no . : 1 &#93; , sequences comprising sequences substantially complementary to the cdna sequence &#91; seq .
an increased incidence and greater severity of renal tubular basophils / hy@@ al@@ ini@@ sation , dilation and bladder formation and interstitial lympho@@ cytic inflammation and medial arterio@@ lar hypertrophy were observed at 8 to 13@@ fold ( valsartan ) and 7 to 8@@ fold ( amlodipine ) exposure of a clinical dose of 160 mg and 10 mg amlodipine .
web for absorbent articles with textured carrier contact surface
section 4.6 – fertility , pregnancy and lactation
an aerosol formulation as claimed in claim 11 or 12 wherein the adjuvant comprises magnesium stearate .
a protein or peptide for use in modulating malignant cell growth in a mammal , wherein the protein or peptide is : ( a ) a mammalian ribonucleotide reductase r1 ; or ( b ) a biologically active analog or derivative of ribonucleotide reductase r1 of ( a ) .
the device of claim 16 , wherein the grid is located along the top surface of the base .
the bio@@ data interfacing device according to claim 7 , wherein the camera unit ( 68 ) is pivotally formed with respect to its attachment area on the outer surface of the operating console ( 1 ) .
a pharmaceutical composition comprising bmp@@ -2 , ε@@ -amino@@ caproic acid , autologous blood and a pl@@ ga matrix .
an artificial joint device ( 2 , 2a , 2b , 2c ) according to claim 11 , which is used in an artificial leg ( 1 ) and / or an artificial arm ( 40 ) , and further comprising an operating belt detecting means ( 24 ) for detecting an operating cu@@ ft of a user to detect the artificial leg ( 1 ) and / or the artificial arm ( 40 ) , and wherein the control / regulating means ( 21 ) controls the actuators ( 13@@ d , 17@@ d ) according to the scanned
the combination of o@@ bin@@ u@@ tuzumab with chlorambuc@@ il or ben@@ dam@@ u@@ stine may increase the incidence of neutropenia ( see section 4.4 ) .
a process according to either of claims 7 and 8 , wherein an agent for accelerating lipase activity has been introduced into the solution prior to lyophilization .
massage device according to any one of the preceding claims , characterized in that the further massage device ( 4 ) can be placed on a different massage device ( 7 ) and can be connected to the latter .
eme@@ da@@ stine 0.5 mg / ml as di@@ fumarate .
a substrate as claimed in claims 1 to 16 used in agricultural substrates .
upon repeated administration of peginterferon beta-1a to sexually mature female monkeys , effects on menstrual cycle and progesterone levels were observed .
process according to one of claims 1 to 18 , characterized in that the second reagent is sodium azide .
treatment as rivastigmine has a plasma half-life of approximately 3.4 hours and inhibits acetylcholinesterase over a period of approximately 9 hours , an asymptomatic overdose is recommended , all existing exelon transdermal patches , and no other transdermal patch should be applied for the next 24 hours .
skin disorders : nail disorders , itching , excessive sebaceous production , skin discolouration , skin ulceration , face oedema , sweating , patches of skin ;
severe allergic reactions to insulin may occur which may be life-threatening .
a process for the preparation according to claim 16 , wherein the antigen has a molecular weight of 84 kda , which corresponds to a transient marker of the chronic phase of toxopla@@ smosis .
a vector comprising a dna encoding a nuclear cell targeting sequence operably linked to a dna encoding a recombination promoting enzyme from the group e. coli rec@@ ca proteins , modified e. coli rec@@ ca proteins having atpase activity and enzymatically active parts thereof , at least one selection marker , and wherein the desired characteristic is selected from the group consisting of the expression of an additional protein , the desired property of which is selected from the group consisting of the expression of an additional protein , and the plant cell is selected from the group consisting of
the use of claim 1 , wherein the germ is staphylococcus aureus or staphylococcus epidermis .
a syringe according to any one of claims 5 to 9 , wherein the liquid-absorbent material comprises a water holding and fluid absorbing accelerator and an antibacteri@@ ally active agent .
use according to any one of the preceding claims 1 to 4 , characterized in that the product contains at least one adjuvant selected from the group comprising emollients , re@@ fre@@ shing agents , perfumes , colouring agents , ampho@@ lyte , sodium chloride , sugar , glycerol , glycols , solvents and thickeners .
a pharmaceutical preparation according to claim 14 , wherein sa or sa in combination with epa is present in an amount greater than 20 % by weight of the total unsaturated fatty acids present .
a compound according to claim 3 or 6 , wherein l is s ( cr 2 2 ) m , -nr 1 so 2 ( cr 2 2 ) m , so 2 ( cr 2 2 ) m , so 2 ( cr 2 2 ) m , so 2 r 1 , r 2 , r 2 , r 2 , r 2 , r 2 , and no 2 , wherein each r is independently h or alkyl ( 1-4c ) ; and r 2 is as defined in claim 9 .
a process for the preparation of a compound of the structure according to formula ( a ) wherein the compound of formula ( i ) is : ( 1 ) a n , or c ( r ) ; ( r ) r &#93; -3- &#91; &#91; &#91; 4- ( 3-carboxy@@ methyl-4-@@ methyl-2-oxo-@@ 7-@@ quinolinyl &#93; &#93; -3- &#91; &#91; &#91; 4- ( 3-carboxy@@ methyl-4-@@ 6,8-difluoro@@ 7-@@ quinolinyl ) &#93; -3- &#91; &#91; &#91; 4- ( 3-carboxy@@ methyl-4-@@ 6,8-difluoro@@ 7-@@ quinolinyl &#93; - &#93; -3- &#91; &#91; &#91; 4- ( 3-carboxy@@ methyl-4-@@ 6,8-difluoro@@ 7-@@ quinolinyl ) &#93; -3- &#91; &#91;
a compound according to claim 1 which is 4- ( 3-cyclopent@@ yloxy@@ -4-methoxy@@ benzyl ) -1- ( 1-methyl@@ imidazole@@ -4-@@ yl-@@ carbonyl ) piperidine .
method and route ( s ) of administration
oxidation dyeing composition for keratinous fibres comprising glycerol and another polyol as glycerol at predetermined ratio
an apparatus comprising : a central support ( 7 ) ; a pair of side supports ( 6 ) on respective sides of the central support ( 7 ) ; attaching means ( 8 , 9 ) to each side of the central support ( 7 ) for moving the sliding means in relation to the surface of the central support ( 7 ) for movement of the sliding means in relation to the surface of the central support ( 7 ) to the surface of the central support ( 7 ) for movement of the driver .
the pharmaceutical composition of claim 12 consisting of one or more nucleic acid molecules having a nucleotide sequence encoding a protein selected from a protein antigen that is expressed from a hyperproliferative cell and a protein antigen characteristic of an autoimmune disease , and one or more hydroxylated lower alkylene .
surgical instrument according to one of claims 1 to 3 , characterized in that the arrangement of auxiliary markings has a regular spacing of auxiliary gradu@@ ations which extend from an origin which corresponds to the distal end of the catheter .
a tampon according to claim 1 , characterized in that the tampon has an insertion end comprising the vertex of the contracted matrix and a withdrawal end comprising the crimped edges of the contracted matrix .
the duple@@ x@@ ed parvovirus particle of any of claims 1-@@ 28 , wherein said duple@@ x@@ ed parvovirus particle is a hybrid parvovirus particle .
common injection site reactions : transient pain , redness , hardness .
use according to claim 1 , wherein the composition is prepared using rb 1 or r@@ g 1 together with a metabolic precursor for acetylcholine .
process for the industrial production of phosphatidyl@@ ser@@ ines
a pair of protein bound membrane-@@ bound , chimeric receptors , wherein one of the receptors comprises : ( a ) an extracellular portion and ( b ) an intracellular or transmembrane moiety derived from a t cell receptor cd3 , zeta or et@@ a polypeptide , a b cell receptor of cd4 or a functional hiv envelo@@ le-@@ binding derivative thereof , and ( b ) an intracellular moiety derived from cd28 .
the method of claim 6 , wherein the catalase is present at a concentration of 50 to 50,000 iu / ml .
an arrangement according to any one of the preceding claims , characterised in that the switches ( s ₁ , s ₂ , s ₃ , s ₄ , s ₅ ) are sealed or uni@@ closed by disposable current flow devices ( d ₁ , d ₂ , d ₃ , d ₄ , d ₅ ) .
pregnancy talk to your doctor if you become pregnant ( or plan to become pregnant ) while taking thymanax .
a compound according to claim 1 wherein the ( acid group ) is -co 2 h. a compound according to claim 1 wherein r 5 is oxygen .
a hardenable composition according to any one of claims 1 to 21 in the form of a film material .
use in patients with renal transplant there is no experience with the administration of ze@@ stril in patients with recent kidney transplantation .
intraocular pressure recording system according to one of the preceding claims 1 to 4 , further comprising a passive strain gauge ( 5 ) . intraocular pressure recording system according to claim 5 , wherein the passive strain gauge ( 5 ) has a generally circular shape of a continuous meri@@ dian element placed in such a way that several of its sections ( 7 ) are arranged radially .
the recess ( 6 ) , the central axis ( 8 ) of which is displaced relative to the ( 9 ) of the tibia part ( 1 ) for the equation to the anatomy , permits an un@@ disturbed course of the cross-@@ bands ( 7 ) .
the caregi@@ ver should be instructed to measure the pulse if the child does not feel well , and the treating physician should be informed of a very rapid or very slow heart rate .
an elastic protective material for a safety glove , which is at least for medical purposes , comprising at least two partial materials , the first part ( 1 ) being adapted to penetrate the first sub@@ material , the first part ( 1 ) being adapted to penetrate the first sub@@ material , wherein the first part ( 1 ) is provided , the first part ( 1 ) being adapted to penetrate the first sub@@ material , the first part ( 1 ) being adapted to penetrate the first sub@@ material , the first part ( 1 )
will i read the boo@@ k today ?
the present invention relates to the production of classical fo@@ wl@@ pe@@ viruses of the strain a / f@@ pv / ro / 34 ( h@@ 7@@ n1 ) by means of a reverse gene@@ tics and the production of mutants of said virus strain whose genome is largely consistent with the wild type strain .
a compound according to any one of claims 1 , 2 or 3 for use in medical therapy .
caution should be exercised when using this medicine with clonidine .
an amylin antagonist as claimed in any one of claims 1 to 12 for use in the treatment of type ii diabetes mellitus . the amylin antagonist of any one of claims 1 to 12 for use in the treatment of a patient with insulin resistance .
a device ( 3 ) for accommodating the substance to be introduced is provided via the electrodes ( 2 ) .
composition according to claim 8 , characterized in that the polar monomers ( b ) are chosen from acrylic acid , n , n-dimethyl@@ acrylamide , dimethylaminoethyl methacrylate , quaternized dimethylaminoethyl methacrylate , vinylpyrrolidone and their mixtures .
tekturna has negligible influence on the ability to drive and use machines .
the device of claim 7 , wherein the proximal portion ( 16 ) is made of a material selected from the group consisting of stainless steel , nickel titanium alloys .
you know , the whole thing with &quot; you are so a pig , right ?
if the dog is also to be washed with shampoo , it is better to do this before the application of the veterinary medicinal product .
you have ever experienced hypersensitivity reactions to other antifungals such as ketoconazole , fluconazole , itraconazole or voriconazole .
the o@@ cc cell lines were cultivated on collagen-@@ i matrix with and without entrapped fibro@@ - / myo@@ fibroblasts ( cultured from no@@ d@@ re pal@@ mar@@ fibro@@ matosis ) .
the valve prosthesis of claims 1 to 7 , wherein the reinforcement extends along a portion of the reinforced free co@@ ap@@ tation edge .
if the animals are exposed to blue@@ tongue virus , the immune system will be able to produce antibodies more quickly .
a hybridoma cell line , characterized in that it is formed by cell fusion of a mouse myeloma cell and a mouse spleen cell which has been immunized with the c-@@ reactive protein and a monoclonal antibody which reacts specifically with the side surface of a c-@@ reactive subunit of a c-@@ reactive protein .
use of a compound of formula i as defined in any one of claims 1 to 7 in the manufacture of a medicament for reducing dopamine synthesis and delivery in a patient suffering from hyperactivity of the dopaminergic system .
keppra contains sodium the maximum single dose of keppra concentrate contains 2.5 mmol ( or 57 mg ) sodium ( 0.8 mmol &#91; or 19 mg &#93; sodium per vial ) .
a compound according to claim 1 which is ( 3@@ as@@ -cis ) -1,2,3,3a , 8,@@ 8a-@@ hexahydro-@@ -1,@@ 3a , 8-@@ trimethyl@@ pyrrolo &#91; 2,3-b &#93; indol-5-yl , ( 7-hydroxy@@ -1-methyl-@@ 1,2,3,4-tetrahydro@@ isoquinolinyl ) carbamate or the ( 3@@ ar@@ -cis ) isomer thereof , or a mixture of the two isomers .
pharmaceutical composition , characterized in that it contains a imidazo- &#91; 4,5-b &#93; pyridine compound according to claim 1 .
the system of claim 8 , wherein the modifier gas is nitrogen .
the angioplasty device of claim 9 , wherein said actuator ( 4 ) is a balloon , a cutting motor , a fiber mesh , or a laser .
a process for preparing a compound according to claim 1 , characterized in that a ) a benzo@@ thieno &#91; 3,2-c &#93; pyridine derivative of formula ( ii ) , in which w 1 represents a suitable reactive leaving group , and optionally in the presence of a catalyst with an alkylating reagent , and optionally in the presence of a catalyst with an alkylating reagent , and in the presence of a catalyst with a therapeutically active non-toxic acid addition salt , or vice versa the acid addition salt form by treatment with acid and , if desired ,
the use according to claim 8 , wherein the medicament is for administration in an antibody dose of from 20 mg / m 2 to 250 mg / m 2 .
he &apos;s now on the dead : &quot; we &apos;ll do slowly and learn us . &quot;
hair dyeing composition containing at least one tri@@ amino@@ hydroxy@@ pyrimidine in admixture with 1,4-di@@ aminobenzene and / or 1-methyl-@@ 2,5-di@@ aminobenzene and at least one coupler selected from the group resorcinol , 2-methyl resorcinol , 2-chloro@@ resorcinol and / or α-@@ naphthol .
such effects are usually reversible .
the use of claim 6 , wherein the disease is depression .
a product comprising : ( a ) a recombinant retrovirus as defined in any one of claims 17 to 29 ; and ( b ) a compound having little or no cytotoxicity encoded by the enzyme encoded by the vector construct of the recombinant retrovirus into a cytotoxic compound for use in a method of treatment of the human grain .
risk factors for bp@@ f were the right pneumo@@ one@@ ctomy ( p = 0.03 ) and lumbar trauma in post-operative ventilation ( p = 0.003 ) . other risk factors such as : age , preoperative radio@@ therapy , suture technique , diabetes mellitus , corticosteroid therapy did not reach statistical significance .
a method of making a wound dressing according to any one of claims 1 to 15 , comprising the steps of : ( a ) providing one of the wound facing sheet ( 14 ) with a back surface and one of the wound facing surface ; ( b ) providing a support sheet ( 12 ) ; ( c ) providing a support sheet ( 12 ) ; ( c ) providing the absorbent sheet ( 12 ) to the wound facing sheet ( 14 ) along a network of bond lines , forming the absorbent material within the
a starting dose of 80 mg peg@@ vi@@ som@@ ant should be administered subcutaneously under medical supervision .
use of a composition according to one or more of claims 1 to 9 , characterized in that the weight ratio of components b ) to c ) is from about 4 : 1 to 1 : 2 .
the exact mode of action of lacosamide is not yet understood , but it appears to inhibit the activity of sodium channels ( pores on the surface of nerve cells ) that allow the transmission of electrical impulses between nerve cells .
a formulation according to claim 5 , wherein the tonicity modifier is mannitol .
the method of claim 7 , wherein two or more of the core wires ( 34 ) are coated , subsequently onto the outer surfaces of the core wires , a layer ( 38 ) of insulating material and the plurality of wires are crimped to a multi-@@ wire coil .
the sterilisation container ( 1 ) for accommodating instruments , especially endoscopes or parts thereof , consists of a lower part ( 2 ) and consists of a base ( 2 ) which can be detachably mounted on the latter ( 3 ) .
a process according to claim 14 comprising the preparation of a compound of formula ( i ) , or a stereoisomeric or non-toxic pharmaceutically acceptable acid addition salt thereof , wherein r 4 and r 5 are together form a bond or = o and r 6 and r 4 are h and r 6 and r 4 are h ; or r 3 , r 4 , r 5 and r 6 , r 4 , r 5 and r 6 are h ; and r 1 and r 2 have the meaning given in said claim .
an implantable atrial defibrillator ( 30 ) according to claim 8 further characterized in that the second detector includes second recognition circuit ( 62 ) for detecting the depolarization activation wave and a second output circuit ( 76 ) coupled to the second recognition circuit ( 62 ) to generate the second trigger signal in response to the second recognition circuit ( 62 ) .
microgranules according to claim 1 , wherein the amount of copolymer is between 4 and 10 % with respect to the amount of ur@@ so@@ deoxycholic acid .
the article of claim 5 wherein the fiber density of the hydrophilic fiber aggregates is between 1.5 x and 3 times the fiber density of the region of the fibrous sheet not containing the aggregates .
an artificial kidney according to any one of claims 1 to 5 , characterised in that a source ( 11 ) for sterile liquid is connectable to the extracorporeal blood circuit ( 5 , 7 ) either upstream or downstream of the exchanger ( 1 ) .
a process according to claim 7 wherein the preparation is heated about 1 to 3 hours at a temperature of about 50 ° c. the method of claim 8 wherein the ph is about 4.@@ 24 to 4.@@ 42 .
cis bio international , paris , france
as aripiprazole mylan is a generic medicine , the company presented the results of studies in volunteers to show that the 10 mg tablet and the 10 mg orodispersible tablet of aripiprazole mylan are bioequivalent to the corresponding tablets of the reference medicine , abilify .
the requirements on submission of periodic periodic safety update reports for this medicinal product are presented in the article 107 c ( 7 ) of directive 2001 / 83 / ec and in the european internet portal for medicinal products published in the union ( eu@@ d list ) and any future updates of updates .
in the event of effentora , it is given as a buccal tablet , so that fentanyl is absorbed via the mouth mucosa .
the high@@ ly-@@ efficient ultrasonic transfer member of claim 4 , wherein the wire has a free end surface which is flat at least at one surface thereof radially inward from its outer periphery .
3 . the laminate material of claim 1 wherein the adhesive layer has an aperture density of at least about 1 % .
cosmetic or pharmaceutical preparations containing a sunscreen agent according to claim 7 , characterized in that r 3 is hydrogen , r 1 and r 2 are the same or different and denote -coor 5 , -cor 5 or -cn , wherein r 5 represents an aliphatic or optionally substituted aromatic radical containing up to 18 carbon atoms .
synthetic genes for enhanced expression
the coupling site of claim 6 , wherein the tubular housing ( 214 ) includes a substantially cylindrical outer wall ( 221 ) and a flange ( 229 ) extending radially inwardly from the outer wall toward the opening ( 236 ) over a portion of the first end of the valve member , the flange having a radially outwardly directed surface of a male luer connecting cone in sealing frictional engagement when an end of the male luer connector cone is inserted into the cavity by the membrane .
highly concentrated aqueous dispersions containing hydrophilic micro@@ fine metal oxide particles and dispersant
a lifting and walking aid according to claim 9 , wherein the bent ends of the parallel side tube elements ( 2d , 2e ) in the upper horizontal frame are bent at a smaller angle than 90 ° so that the front portion of the upper horizontal frame ( 2@@ d-@@ 2f ) is slightly raised .
the white needle guard is now visible .
process according to claim 5 or 6 , characterized in that cell suspensions of the genotype dsm 6@@ 009 are used .
the microscope of claim 4 , further characterized in that the scanning means is operable to move the light beam transmitted from the third optical fiber means to the light focusing means .
she said me , i shoul@@ dn &apos;t look .
elevations to &gt; 8 x uln were observed in 2.4 % of patients treated with bosentan .
these patients may be at increased risk of hypersensitivity reactions and should not be given pomalidomide .
voriconazole / emtricitabine voriconazole / tenofovir disoproxil fumarate anticonvulsants
7 . filter according to one of claims 1 to 6 , characterised in that the first and second loops ( e1 , e2 ) are convex and of a first free extremity ( m1 ) after a second free extremity ( m2 ) of the filter in the same direction of rotation about the centre ( o ) .
process according to one of claims 1 to 7 , characterized in that , in step b ) , a substrate containing inorganic compounds and / or organic compounds is used .
in order to secure the article after use , for the purpose of disposal in a rolled or folded configuration , the article is designed such that the article ( 44 ) facing the body facing the body facing the body is in the range of 35 to 50 dynes / cm in the region of between 35 and 50 dynes / cm , thereby causing a stronger adherence of the first fastening means ( 72 ) to untreated areas of the film .
use of a composition according to any one of claims 1-10 for the manufacture of a pharmaceutical preparation for the therapy or prophylaxis of immuno@@ regulatory anomalies .
process for the preparation of a pharmaceutical composition according to claim 1 , characterized in that the composition is a nasal cream .
an air cleaning device according to claims 1 and 11 to 12 , characterized in that the respective filter holder ( 52 , 12 ) formed essentially from an inner clamping tap ( 43 ) and a web ( 45 ) formed with the clamping tap ( 43 ) extends through the respective longitudinal groove ( 40 ) and is connected to its outer end with an approximately u-shaped tension member ( 44 ) and engages with its free external ends and engages on the outside surfaces of the inner wall ( 37 ) .
surgical instrument according to claim 14 , characterized in that the latch ( 57 ) is guided in a recess ( 58 ) of the actuatable handle ( 19 ) .
an insertion assembly according to claim 16 , characterised in that two such positions of the resilient arms are provided for movement in different directions .
this is usually achieved by a incorporation rate of 100 - 200 ppm ti@@ amulin hydrogen fumarate in the finished feed provided that feed intake is not restricted .
ask your doctor for advice .
a yeast cell culture according to claim 1 or a method according to claim 2 , wherein the protein of the yeast phero@@ mone system is an abc transporter involved in membrane transport of the yeast phero@@ mone and the surrogate is also an abc transporter .
an aromatic camptothecin ester having the formula ( i ) : wherein r 1 is h , no 2 , nh 2 , n 3 , a c 1 -c 16 -alkylene group , a c 1 -c 16 alkyl group , a c 1 -c 16 -alkylene group , a c 1 -c 4 alkyl group , a c 1 -c 16 -alkylene group , a c 1 -c 8 alkyl group , a c 1-8 alkyl group , a c 1 -c 8 alkyl group , a c 1 -c 6 alkyl group , a c 1 -c
a hair treatment composition according to claim 1 , which comprises a direct dye .
a hydrophilic adhesive composition according to any one of claims 1 to 5 , wherein water is present in a proportion of 1 to 85 % by weight .
a compound according to any one of claims 1 to 5 wherein z is c or n and r 20 is methyl , ethyl , isopropyl , cyclopropylmethyl or hydroxy@@ ethylene .
a process for the preparation of gem@@ -di@@ phosphonic acid-@@ a@@ meth@@ op@@ terin ( meth@@ 0-@@ ox@@ yla@@ te- ) and de@@ aza@@ -n-@@ 10-@@ a@@ meth@@ op@@ terin compounds , the ge@@ ale diphosphonic acid moiety of which is linked via a peptide bond to the pteridin@@ yl@@ glutamic acid moiety , the geminal diphosphonic acid moiety of which is linked via a peptide bond to the pteridin@@ yl@@ glutamic acid moiety , the geminal diphosphonic acid moiety of which is connected to the p@@ tero@@ yl glutamic acid moiety , the geminal diphosphonic acid moiety of which
the invention relates to novel dihydro@@ thien@@ opyrimidin@@ es of formula 1 , as well as pharmacologically acceptable salts , diastereomers , enantiomers , racemates , hydrates or solvates thereof , ( i ) which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases , inflammatory diseases of the joints , skin or the eyes , diseases of the peripheral or central nervous system or cancers , and pharmaceutical compositions containing these compounds .
a head according to claim 11 or claim 12 , wherein the spring element ( 158 , 170 , 192 ) is supported on a side wall ( 164 ) of the head .
the pharmaceutical composition of claim 3 , further comprising a pharmaceutically acceptable diluent or carrier .
a nucleic acid construct or set of genetic elements according to any one of claims 28 or 29 , wherein the single-stranded nucleic acid molecule is an inhibitory nucleic acid molecule .
an electrical muscle stimulator according to claim 1 , characterized in that it includes a cp@@ u ( 3 ) , said means ( 10 ) for restoring the pulse generation after proper re@@ positioning of the electrode by the cp@@ u .
use according to any one of the preceding claims , wherein the first clearing composition comprises an antibody which is anti-idiotypic for the first antibody or antibody fragment .
the invention relates to a device for the contact of at least one electronic component ( 24 ) mounted in a housing ( 4 ) , in particular a power semiconductor ( 24 ) , on a cooling surface ( 26 ) and a spring element ( 2 ) which can be attached in the housing ( 4 ) and which presses the component ( 24 ) against the cooling surface ( 26 ) in a pressure position of the spring element ( 2 ) .
pharmaceutical dosage form according to claim 14 , characterized in that it comprises the form of a tablet , a multilayer tablet , a multiple coated tablet or a capsule .
morning , next week , next month , next year ?
thromboembolic disorders including deep vein thrombosis , thrombo@@ phlebitis and pulmonary embolism have been reported ( see also section 4.4 ) .
each tablet contains 40 mg telmisartan and 12.5 mg hydrochlorothiazide .
a recombinant nucleic acid construct according to claim 9 , wherein the coding nucleic acid comprises a codon for a hydrophobic amino acid residue inserted between thr + 163 and val + 164 .
process according to claim 2 , characterized in that said base is potassium tert-@@ but@@ oxide .
adalimumab also affects biological reactions that are induced or controlled by tnf , including changes in the levels of adhesion molecules responsible for leukocyte migration ( ela@@ m-1 , v@@ cam@@ -1 and icam-1 with an ic50 of 0.@@ 1- 0.2 nm ) .
process according to one of claims 1 to 4 , characterized in that the ab@@ asic site is produced by the action of an aqueous acidic medium .
a dental prosthesis as claimed in any one of the preceding claims , characterised in that at the adjacent surface between a crown or bridge and a removable tooth replacement piece , the attachment is carried out as a square block ( 16 ) in a vertically extending manner to the crown or bridge , and the removable replacement part is carried out as a square block ( 16 ) , and the removable replacement part ( 16 ) is provided with a corresponding recess ( 17 ) , and in that vertical grooves ( 6 , 7 ) are
this may suggest a disease of the heart muscle ( cardiomyopathy ) which has been reported rarely in patients receiving betaferon .
do not store above 30 ° c.
an oligonucleotide of the formula vii according to claim 35 , characterized in that it corresponds to formula viia in which b , y and n have the meanings given in claim 35 .
composite nonwoven fabric , process for its preparation and its use in all absorbent hygiene articles
this medicine is usually used together with other anti-hiv medicines to help control the control of hiv infection .
use according to claim 8 , wherein the oligosaccharide fragment consists of mono@@ phosphoryl manno@@ penta@@ ose fragment , 6-@@ phospho@@ -@@ manno@@ se-@@ α ( 1-3 ) - { manno@@ se-@@ α- ( 1-3 ) } ₂ -@@ manno@@ se-@@ α ( 1-2 ) -@@ mannose .
are you doing your heart ?
selective labeling of the glycans of immunoglobulins
use of a combination of : ( 1 ) a compound according to any one of claims 1 to 5 ; and ( 2 ) an immunosuppressant at a sub-@@ therapeutic dose ; for the manufacture of one or more medicaments for use in prolonging the time of the acceptance by a recipient host of a graft from an mh@@ c-@@ un@@ matched donor host , compared to the period resulting from the administration of the immunosuppressant at the sub@@ therapeutic dose in the absence of the peptide .
a compound according to any one of claims 17 to 20 , wherein the o-@@ acyl derivative is an aliphatic o-@@ acyl derivative .
agent according to claim 3 , characterized in that it contains as active substance a compound of formula i , wherein the active substance is a compound of formula i in which r ₁ is hydrogen and a composition according to claim 1 , characterized in that it contains as active substance a compound of formula i in which r ₂ is methyl and the remaining substituents are as defined in any one of claims 1 to 7 .
compounds according to claim 2 , in which r ² represents a hydrogen atom , a straight-chain or branched chain alkyl group having from 1 to 6 carbon atoms , an aralkyl group or a protecting group which makes the protected carboxy carboxy in the living body easily into a free carboxyl group .
x-ray diagnostic device according to one of claims 1 to 3 , characterised in that the detector ( 14 ) consists of a matrix of photosensitive surfaces ( 23 ) which can be connected individually or in groups to a measurement amplifier .
the plant of any one of claims 26 or 28 to 31 , wherein said plant is a maize plant .
official batch release : in accordance with article 114 of directive 2001 / 83 / ec as amended , the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose .
administration of a drug using a phase converting formulation
the method of claim 2 , wherein the polymeric surface is silicone , the surface of the article or the device is initially pre-treated by applying a solution of poly ( methyl ( vinyl ether / maleic anhydride ) and then treated to a warm / dry cycling , and subsequently treated by applying a combined solution of pvp and ps@@ 0@@ 76 in isopropanol and then subjected to a further warm / dry exchange circuit .
the company presented the results of studies looking at the effectiveness of vera@@ flo@@ x against various bacterial infections in cats and dogs .
use according to claim 1 , wherein the medicament is for the treatment of nasal obstruction .
i wanted to give you the site .
the method of claim 16 , wherein the opioid analgesic is an opioid analgesic selected from the group consisting of al@@ fentanil , allyl@@ pro@@ tidine , alpha-@@ pro@@ lamine , ani@@ ri@@ ri@@ dine , benzyl@@ morphine , be@@ zi@@ tidine , ani@@ ri@@ ri@@ dine , benz@@ or@@ ph@@ ol , clon@@ amide , buprenorphine , bu@@ ro@@ ph@@ ine , clon@@ it@@ az@@ ol , pi@@ ver@@ ro@@ mine , di@@ azo@@ ph@@ ine , bi@@ heptan@@ ol , p@@ imino@@ dine , penta@@ midine , pro@@ heptan@@ ine , pro@@ morph , pro@@ peri@@ dine ,
use according to any one of claims 1 to 7 , wherein the medicament is suitable for administration of the antibody at a dosage in the range of 0.01 to 4 mg of antibody .
the committee recommended that agenerase be given marketing authorisation .
a method according to any one of claims 2 to 5 , wherein the time series is classified as the first time series of time when the significance ( s ) has a value greater than a predeterminable barrier .
toothbrush ( a1 ; a2 ; a3 ; 100 ) according to claim 1 , wherein the head ( 2 ; 114 ) has a substantially l-shaped cross-section , the bristle assembly ( 3 / 3a ; 116 ) being attached to the inner side of a ( 21 , 120 ) of wings ( 21 , 22 ; 120 , 122 ) of the head , and wherein the bristles ( 41 , 146 ) of the bristle assembly extend towards an angular plane of the l-shaped head .
radiotherapy apparatus according to claim 8 , wherein the head-@@ pivoting mechanism ( 131 , 132 ) pivots the radiation irradiation head ( 10 ) about both of the two axes ( s1 , s2 ) which are orthogonal to each other .
use of a compound for the manufacture of a medicament for the inhibition of tumor necrosis factor alpha or for the treatment of septic shock , wherein the compound is ( ± ) -3,4-di@@ 2-@@ aden@@ e@@ yl-@@ endo-@@ 6-hydroxy@@ bicyclo &#91; 3.3.0 &#93; octane dihydrochloride &#91; 3.3.0 &#93; -furan@@ -3-ol &#91; 3,2-b &#93; -furan@@ -3-ol or &#91; 3r , 6r &#93; -6- ( 6-amino-@@ purin-9-yl ) -@@ estr-1,3,5 &#91; 3,2-b &#93; -furan@@ -3-@@ ol dihydrochloride .
a device according to claim 4 , which is to apply a pressure to an arm , the length of the cylinder being in the range from 3 cm to 200 cm , the base surfaces of the fingers being distributed over a generally cylindrical surface having a diameter in the range of 7.5 cm to 75 cm and the tips of the fingers are distributed over a generally cylindrical surface having a diameter in the range from 2 cm to 25 cm .
catheter system according to claim 12 , characterized in that the adhesive forming the compound is a polyurethane .
the mean change in diastolic blood pressure was - 0.1 mmhg for lumiracoxib and + 0.5 mmhg for nsaids ( p &lt; 0.0001 ) .
2 . process according to claim 1 , characterized in that the particle size of the gy@@ rase inhibitors is 0.5-@@ 150 µm , preferably 4 to 40 µm .
biocompatible , implantable micro drive for hearing aid
a scalpel according to claim 1 , wherein the handle ( 50 ) is releasably attached to the blade holder ( 20 ) by a projecting member disposed on the handle ( 50 ) , releasably connected to a slot formed on the blade holder ( 20 ) .
name and address of the manufacturer responsible for batch release
factor x analogue according to claim 5 , characterized in that it has a deletion of the factor x β peptide .
montelukast is not recommended as monotherapy in patients with moderate persistent asthma .
the apparatus of claim 1 , wherein the sensing means is an ultrasound sensor and the second means comprises a microprocessor .
a surgical device for treating a patient comprising : at least one needle ( 60 ) having an insertion end ( 58 ) ; at least one dilator ( 54 ) , and a loop ( 42 ) having a length sufficient to connect the dilator to the insertion end , and wherein the dilator has a second end portion ( 56 ) with an insertion end ( 58 ) , and a loop ( 42 ) having a length of the dilator with the insertion end , the dilator having a second end portion ( 56 ) having a
a compound according to claim 3 , wherein r 8 is h or substituted or unsubstituted ( c 1 -c 6 ) alkyl ; or a pharmaceutically acceptable salt thereof .
an injector according to one or more of the preceding claims , characterized in that the guide member ( 67 ) is connected to the adjusting member ( 15 ) , but axially im@@ movably .
tabulated list of adverse reactions adverse reactions reported in patients with melanoma are listed below by system organ class , frequency and severity .
limited data from patients receiving higher than recommended zin@@ for@@ o doses show similar adverse reactions observed in patients receiving the recommended doses .
a kit according to claim 51 , wherein the gaseous phase comprises an osmotic gas having a water solubility of not more than 0.5 mm at 25 ° c and an atmosphere .
use of n-@@ aryl@@ methylene ethylenediamine@@ tri@@ acetates , n-@@ aryl@@ methylene@@ di@@ acetates or n , n &apos; -di@@ aryl@@ methylene@@ di@@ acetates as no donors
device according to claim 7 , characterized in that the drive means ( 19 ) can be operated from the rear end ( 6 ) of the anchoring element ( 3.@@ j ) .
ted@@ dy told me i &apos;m supposed to make a big list of surgeries .
binding molecules and computer-@@ assisted methods for increasing their binding affinity
the device of claim 3 , wherein the tapered support comprises a cannula tube ( 215 ) .
an apparatus according to any one of the preceding claims , wherein the image sensor ( 34 , 36 ) is arranged to produce image data , wherein areas without reflective markings ( 14 ) are identified as a black and with the reflective markings ( 14 ) as bright locations .
medicament for the prevention and treatment of diseases of the circuits containing spiro@@ 3-@@ hetero@@ azolidin@@ es .
the use of claim 6 , wherein the compound comprises at least one compound selected from the group consisting of 2-hydroxy@@ cyclo@@ eicos@@ one , 2-hydroxy@@ 10@@ -cyclo@@ eicos@@ ene , 2-hydroxy@@ cyclo@@ toremifene , and 2-hydroxy@@ 12-@@ cyclo@@ toremifene .
retinoids for the treatment of psychotic disorders
device according to claim 26 , characterized in that the ratio of d / 2 to x is between 0.5 and 1.0 .
the powder is dissolved in water before it is injected by a doctor or nurse .
the nucleic acid molecule according to claim 1 or claim 2 , wherein said molecule encodes at least 200 , preferably at least 300 contiguous amino acids of the amino acid sequence shown in seq id no : 3 or seq id no : 4 .
ibaf@@ lin 3 % oral gel : 30 mg ibaf@@ loxacin / g gel ( equivalent to 3@@ 0.9 mg / ml )
the composition of claim 17 , wherein the fatty acid alkyl ester is selected from the group consisting of alkyl laurate , alkyl palmitate and stearic alkyl myristate .
conditioning cream for hair dyeing with good color application properties
a composition according to claim 6 or claim 7 wherein r 1 is hepta@@ dec@@ -8-@@ enyl , undecyl , undecyl , tridecyl , penta@@ decyl or hepta@@ decyl , and r 2 is methyl , ethyl or hydroxyethyl .
method according to claim 4 , characterised in that a computer-@@ controlled piezo@@ electric proportional valve is used as valve , which operates proportional to the control and whose flow rate and cross section are adjustable .
the expiry date refers to the last day of that month .
a device for illuminating tissue of a patient to measure the light absorption of the tissue by means of a measuring system ( 2 ) , which comprises : at least two light sources ( ld , 416 ) for applying at least two light beams to the patient ; and a means ( 524 , 332 ) for applying the at least two light beams to the tissue , the probe means ( 1 ) further comprising : a connecting means ( 82 ) with : a probe means ( 1 ) having a probe means ( 1 )
a two-@@ chamber pre-filled syringe with an outer barrel ( 1 ) having a bypass line groove ( 3 ) , which is substantially at its center on the inner wall ( 2 ) , a sealing plug ( 6a , 6b ) which is in the longitudinal direction of the outer cylinder ( 2 ) in a direction perpendicular to the outer cylinder opening ( 4 ) in a direction perpendicular to the outer cylinder opening ( 4 ) in a direction perpendicular to a direction near the outer cylinder opening ( 4 ) in a direction perpendicular to
a device according to any one of claims 7 to 9 , characterised in that the box@@ -shaped part permits a slight penetration in the crown of the crown .
c@@ 1d gene for use as a medicament for inducing apoptosis in cells by overexpression of the c@@ 1d gene .
soluble , encapsulated polypeptide of no@@ g@@ o-@@ a protein
a composition according to claim 15 , wherein the tips , g , j , l and m with the nitrogen atom of the ring form a ring selected from the pyridine and pyrimidine rings .
plant containing plant cells according to one or more of claims 8 and 11 to 13 . plant according to claim 14 , which is a crop plant .
a mixture according to any one of claims 1 to 7 , characterised in that it contains an extract of lamin@@ aria flex@@ cau@@ tilis and an avian extract , in particular of avian of sor@@ bus au@@ cu@@ par@@ ia .
use of the composition of any one of claims 1 to 21 , wherein budesonide or a prodrug or derivative thereof which contains polyunsaturated fatty acid which contains one or more of omega-3 , omega@@ -6 and omega@@ 9 or a derivative thereof , and the antioxidant is administered simultaneously .
the catheter of claim 1 or 2 , wherein the guide wire ( 10 ) comprises a proximal segment ( 11 ) formed from an elongate flexible tube , an intermediate segment ( 16 ) formed from a relatively short tube formed at the distal end of the proximal segment ( 11 ) and extending distally from the distal end of the intermediate segment ( 11 ) and extending distally from the distal end of the intermediate segment ( 16 ) and extending distally therefrom , the core wire ( 20 ) being tapered distally .
a method according to any one of the preceding claims , characterized in that the aqueous solution further contains an additional monomer selected from the group consisting of ( a ) methacrylic acid , itaconic acid , 2-acrylamido-2-methylpropane@@ sulfonic acid , 2-acrylamido-2-methylpropane@@ sulfonic acid , and the salts thereof , ( b ) an alkyl or alkoxyalkyl ester of a dicarboxylic acid selected from itaconic acid , maleic acid and fumaric acid , ( c ) vinyl sulfonic acid , ( d ) methyl acrylate and ethyl acrylate , ( meth ) acrylate and ( f ) polyethylene glycol mono
use according to claim 8 , characterized in that the anticonvulsant substance is a benzodiazepine selected from clon@@ azepam , clo@@ baz@@ am , diazepam and pro@@ diazepam .
use of an animal cell according to any one of claims 1 to 4 for evaluating an agonist activity or antagonist activity of a chemical substance via the transcrip@@ tion-@@ promoting ability of a ligand-@@ controlled transcriptional control factor in a reporter test by measuring the amount of a reporter gene under the transcriptional control of the ligand-@@ controlled transcriptional control factor .
the needle assembly of claim 4 , wherein the removable vented plug ( 37 ) further comprises a pierceable partition ( 39 ) such that a blood sample can be removed from the backflow chamber ( 44 ) without removal of the plug ( 37 ) .
a pedicle screw assembly ( 1 ) comprising a screw threaded shaft ( 2 ) having a partially spherical head ( 3 ) having a partially spherical head ( 3 ) at one end , a hollow cylindrical connecting member ( 6 ) having a seat for the head and an opening , through which the shaft ( 2 ) is formed at an end , a hollow cylindrical connecting member ( 6 ) , a hollow cylindrical connecting member ( 6 ) , a hollow cylindrical connecting member ( 6 ) having a seat for the head and an
cab@@ az@@ it@@ axel inhibits the transport of p-glycoprotein ( pgp ) ( digoxin , vinblastine ) , breast cancer resistance protein ( b@@ ck@@ -c@@ an@@ r-@@ resist@@ t protein , bcrp ) ( methotrexate ) ( methotrexate ) and organic anion transporting polypeptide oatp1@@ b3 ( c@@ ck@@ 8 ) at concentrations of at least 15 times the concentration observed with exposure to oatp1b1 ( est@@ radi@@ ol-@@ 17β-@@ glucuronide ) , while the concentration of oatp1b1 ( est@@ radi@@ ol-@@ 17β-@@ glucuronide ) is at least 5 times the concentration observed under clinical conditions .
composition according to claim 9 , characterized in that the oxidizing agent is chosen from hydrogen peroxide , urea peroxide , alkali metal bro@@ mates , alkali metal ferri@@ cyan@@ ides , per@@ salts , redox enzymes , optionally in combination with their donor or corresponding cofactor .
a multifocal intraocular lens according to claim 18 , wherein light passes through the annular zone ( 22 ) and focu@@ ses to approximately 20 % of the first distance behind the retina of the eye in pathogenic illumination conditions .
device for administering an injectable product
an aerosol dosing product according to any one of the preceding claims , wherein the outlet channel ( 40 ) is formed by drilling . an aerosol dosage product according to any one of the preceding claims , wherein the side opening ( 34 ) is formed by drilling .
after reconstitution , a clear colourless solution is obtained in less than 3 minutes . − cloudy solutions or solutions with precipitate should not be used . − any unused solution should be discarded . − for injection , only polypropylene syringes should be used . − the product should be used immediately .
method of administration this medicinal product is for oral use .
a compound of the formula : or a pharmaceutically acceptable salt thereof , wherein r is h , c -c alkanoyl , c -c alkyl , c -c alkenyl , c -c alkynyl , c -c cycloalkyl , ( c -c cycloalkyl ) - ( c -c alkyl ) , ( c -c ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c
• - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
in addition , the legs ( 10 ) of the inner ( 1 ) and outer basket ( 8 ) are aligned so that a continuous lateral opening and the inner cage ( 1 ) and the outer cage can be fixed relative to each other in a predetermined end position .
set according to one of claims 1 to 7 , characterised by a bearing shells ( 113 ) which can be displaced relative to the probe tube ( 12 ) , which are assembled in a longitudinally displaceable , lockable handle ( 116 ) , by screwing connections or the like .
tanning module according to claim 16 , characterized in that a flange ( 6 ) is attached to the at least one air suction opening ( 5 ) .
using other medicines please tell your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
the method of claim 1 or 2 , wherein the host organism is escherichia coli .
three of 14 isolates had protease resistance mutations .
a method of producing a substantially purified protein or polypeptide , which method comprises : a ) introducing into a host cell a nucleic acid encoding a fusion protein or polypeptide comprising a fusion protein or polypeptide encoding a fusion protein or polypeptide comprising : d ) cleaving the substantially purified fusion protein or polypeptide with a proteolytic enzyme or polypeptide having a proteolytic enzyme or polypeptide ; and d ) purifying the protein or polypeptide of interest ; and d ) purifying the protein or polypeptide of interest , thereby recovering a substantially purified protein or polypeptide .
in children , this medicine can be prescribed to treat the following types of fungal infections : - -
since some reports of pharmacovigilance surveillance have been reported , a potential interaction with warfarin was included in the summary of product characteristics .
&#91; product name &#93; may be used in certain circumstances in addition to other medicinal products &#91; statins &#93; , if the levels of blood fats cannot be controlled with a statin alone .
nucleic acid sequences for proteins involved in tocopherol biosynthesis
in the review , the chmp considered the measures to minimize the risks identified using these medicines , but the chmp considered that limitations and additional guidance for dental physicians would not reduce the risks to an acceptable level .
a process according to claim 6 or 7 wherein the stabilizing agent is polyvinylpyrrolidone .
it has been shown that no treatment with ace inhibitors should be made in dogs with unstable kidney disease at stage 4 due to the risk of decreased glomerular filtration rate or increasing azo@@ ta@@ emia .
the method of claim 2 , wherein said amylase alpha-amylase is bacillus licheniformis .
composition according to any one of claims 12 to 14 , characterized in that it also comprises at least one antagonist chosen from the group consisting of cgrp , histamine , interleukin-1 and / or tnf-α and antagonist p , no yttrium salts or neodymium salts .
a quinazoline derivative of the formula ii according to claim 1 , wherein : m is 1 and the group r 1 is at 7 position and is selected from 3- ( 1,2,3-@@ triazol-1-yl ) propoxy , 2-@@ pyrid@@ -4-yl@@ ethoxy , 3-@@ pyrrolidin@@ yl@@ propoxy , 3-morpholino@@ propoxy , 3- ( 1,1-@@ diox@@ tetrahydro@@ hydro-@@ 4h-@@ 1,4-@@ thiazolo , 3- ( 4-methylpiperazin-1-yl ) propoxy , 4-@@ morpholino@@ -4@@ ylethyl , 3- ( 4-methylpiperazin-1-yl ) propoxy , and is selected from the group consisting of fluorine , chlorine , bromine and trifluoromethyl , with the proviso that at least one
the marketing authorisation holders are provided for the next five years in all member states in which methylphenidate is used , all available retrospective data on the review should be submitted annu@@ ally to verify changes in use in use in time .
there were no other changes in foetal external , visceral or skeletal morphology .
vaso@@ vist is a solution for injection with the active substance gado@@ fos@@ ve@@ set trisodium salt .
as criteria for distinguishing between benign and malignant lung , the total diameter and the density of the lesion , the total diameter and the density of the lesion , the total diameter and the density of the lesion , is the same in the peripheral area , the presence of spi@@ cu@@ ae , and also the spi@@ ru@@ tic changes in the edge area , the pleural effusion itself , the pleural effusion and the pleural effusion .
for final concentrations of at most 20 mg / ml , a volume equivalent to 15 mg / kg body weight ( maximum 1 g per day ) is transferred into a sachet containing 9 mg / ml ( 0.9 % ) sodium chloride solution ; or for a solvent vial :
the antibody of claim 1 , wherein said antibody has an affinity of more than 10 -9 he@@ t .
a computer tomography apparatus comprising : a patient support for supporting a selected portion of a patient in an examination zone ( 24 ) ; an x-ray tube as claimed in any one of claims 1 to 5 ; a mounting device ( ii ) which has undergone the x-ray tube ( 20 ) and an image reconstructing means ( 164 ) for reconstructing signals from the radiation detector ring ( 160 ) in image representations .
use of a vector according to one or more of claims 1 to 17 in malignant b cells for vaccination of patients with malignant b-cell diseases .
the detection of coronary cold with the e@@ bt must be considered as the currently most non-invasive marker for the presence of coronary athero@@ matosis , including their early shapes .
a method according to claim 5 , wherein the amylase is a liquefied amylase or an iso@@ amylase .
a formulation according to claim 36 which is the fine binder particles in an amount up to 15 % by weight based on the total weight of the formulation .
a scaffold according to claim 10 or 11 , wherein the scaffold comprises interconnected pores , oriented fibers , laminar structures , or a combination thereof .
the invention relates to compounds of formula ( i ) , wherein the radicals have the cited meanings , to the physiologically compatible salts thereof , and to a method for the production thereof .
a cardiac pacemaker according to any one of claims 1 to 8 , characterised in that the mean stimulation interval duration is controlled in such a manner that it increases when the difference between the residual gradient gradient and the target value decreases and decreases a negative threshold value when the difference exceeds a positive threshold value .
1.@@ 83 e-@@ 01 3.@@ 79 e-@@ 01 1.@@ 74 e-@@ 02 3.@@ 53 e + 00 1.@@ 91 e + 00 6.@@ 34 e-@@ 01 4.@@ 99 e-@@ 01
a pharmaceutical composition comprising at least one compound of formula ( i ) according to any one of claims 1 to 7 , together with a pharmaceutically acceptable diluent or carrier .
a dialysis machine according to claim 2 , comprising means for determining the connection ( 22 , 23 ) with the contact screen ( 16 ) in a desired , rotated position on the arm ( 19 ) .
the method of claim 18 , wherein each of the plurality of oligonucleotide 5 &apos; -@@ mono@@ phosphates has an identical length .
in this way , a safe position and position correction of guide probes can be carried out under ecg control .
if viread 163 mg film-coated tablets are co-@@ infected in patients co-infected with hiv and hepatitis b virus ( hbv ) , these patients should be closely monitored for signs of exacerbation of hepatitis ( see section 4.4 ) .
transgenic mouse expressing green fluorescent protein in astro@@ cytes
device according to one of claims 1 to 4 , characterized in that the electrode unit ( 1 ) and the key ( 3 ) each have mechanical coupling means ( 13 , 13 , 19 , 19 , 19 ) which cooperate with mechanical means ( 14 1 , 14 2 ) of the module to ensure temporary coupling with this module .
the use of an echin@@ acea composition in the manufacture of a medicament for enhancing immune tolerance in a mammal , wherein the echin@@ acea composition is formulated to provide a daily dose of caffe@@ ic acid from 40 µg / kg body weight to 2000 µg / kg body weight , and in echin@@ acea polysaccharides of 1 mg / kg body weight to 200 µg / kg body weight and in echin@@ acea polysaccharides of 1 mg / kg body weight to 50 mg / kg of body weight .
composition according to any one of claims 7 to 9 , characterized in that at least one active substance is gentamicin , neomycin , bac@@ it@@ rac@@ in , clindamycin , erythromycin , aciclovir , vid@@ ar@@ abine , dex@@ panthenol , allan@@ toin or hirudin .
apparatus according to claim 33 , characterized by a control circuit ( 52 ) for ensuring the contact between the distal end ( 22 ) of the catheter ( 20 ; 45 ; 64 ; 78 ) and the location of the heart wall ( 76 ) .
the wound dressing of claim 4 , further comprising calcium ions .
the method of claim 13 , wherein said chelating agent comprises a water soluble zinc salt , said salt being added in an amount of from 0.05 mg to 50 mg per 100 ml of solution .
trudexa should be administered in combination with glucocorticoids during induction treatment .
topotecan has also been studied in children ; however , limited efficacy and safety data are available .
right here to guide my little girl before trauma .
a system according to any one of claims 23 to 27 , wherein the measuring cell comprises an operating electrode ( 13 ) , an electrolyte chamber ( 16 ) and a reference electrode ( 15 ) and connected to a associated flow element ( 8 ) comprising an inlet and an outlet for perfusion fluid which can be separated from the measuring cell by an oxygen gas permeable membrane ( 22 ) .
a composition according to claim 4 , characterized in that the further compound is selected from the group consisting of n- ( 2-hydroxyethyl ) -n-@@ ethyl , 2-chloro@@ -p-phenylenediamine , n , n-bis ( 2-hydroxyethyl ) -p-phenylenediamine , 4-aminophenol , para-phenylenediamine , 2- ( 2,5-di@@ aminophenyl ) ethanol , 2,5-di@@ amino@@ toluene , 3,4-methylenedioxyphenyl , 2-amino-4- ( 2-hydroxy@@ ethylamino ) anisole , 2- ( 2,4-diaminophenoxy ) -@@ ethanol , dl-@@ 3- ( 2-hydroxyethyl ) pyrazole , 5,6-dihydroxyindole and 5,6-dihydroxy@@ indoline , β-@@ alanine , l-proline , l-lysine , dl-@@ tyrosine , and each of the physiologically acceptable salts of these
• pull off the inner needle cap and dispose of it .
3-@@ de@@ methoxy@@ i@@ stam@@ yc@@ ine b and its 2 &apos; -n-@@ form@@ mido@@ ylated derivative .
liquid perfluoro@@ polymers and medical applications using the same
urinary outflow obstruction of the urinary canal must be ensured .
- methotrexate ( used to treat rheumatoid arthritis , psoriasis and leukaemia )
a method according to claim 12 , wherein said folding of the outer portion of at least one of said third and fourth layers of fabric occurs prior to said dividing along said second serpentine line .
the system of any one of claims 17 to 21 or 23 to 30 , further comprising a salt of salicylic acid in conjunction with said antiperspirant .
a process according to claim 1 or 13 , wherein 3-aminopropyl ( 2-ethoxyethyl ) phosphinic acid or a salt thereof is prepared .
a container ( 30 ) according to claim 1 , characterized in that the container has a projecting edge ( 32 ) disposed on the inner side thereof and which is arranged in the vicinity of the primary opening .
if your child is at the same time as hexavac or other vaccines , please contact your doctor for details of information on this medicine . • if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
a process for producing 2-keto-l-gulonic acid from l-sorbo@@ sone , which comprises contacting l-sorbo@@ sone with purified aldehyde dehydrogenase according to claim 1 in the presence of an electron acceptor and the resulting 2-keto-l-gulonic acid is isolated from the reaction mixture .
herbal pharmaceutical preparation for the treatment of migraine according to any one of the preceding claims , characterized by the combination of tan@@ ace@@ um par@@ th@@ en@@ um with zin@@ gi@@ ber officin@@ ale .
a method according to claim 14 , characterized in that the display is in the form of a ber@@ ny which can be printed .
a dna base sequence wherein one of the strands has bases arranged in the following order : wherein a , t , g and c are adenine , thymine , guanine , or cytosine .
( every 3 to 4 days ) , a new ken@@ tera patch , according to the instructions for use , should be administered twice weekly ( every 3 to 4 days ) .
a device for fixing a knee joint in certain positions and for the position control of instruments for replacement of the knee joint of a patient by a prosthesis , wherein the device is connectable to an operating table ( 1 ) , the device being connected to an operating table ( 1 ) , the device being connected to an operating table ( 1 ) , the device being connected to an operating table ( 1 ) , the device being connected to an operating table ( 1 ) , the device having an operating table ( 1 )
a method for transferring nucleic acids in cells , characterized in that it comprises the steps of : ( 1 ) contacting the nucleic acid with a transfer agent as defined in claims 1 to 10 to form a nucleic acid / transfer agent complex ; ( 2 ) contacting the cells with the complex formed under ( 1 ) in vitro .
intraocular lens with a support element for a telescope
do not take a sun baths , extensive hot baths or sa@@ un@@ le baths or hot whirlpool baths .
the pre-filled syringe of humira is a glass syringe with needle@@ guard and contains a solution of adalimumab .
erythropoietin is a growth factor that primarily stimulates red blood cell production .
pumping apparatus according to claim 24 , characterized in that the detection means ( d2 ) which displays the beginning of a cycle of the force means and a circuit which compares an output signal of the display means ( d2 ) and the rise time of said output signal from the pressure sensor ( 28 ) .
a third &#91; 18 f &#93; -@@ labelled intermediate which is obtained by steps a to i of the method as claimed in claim 7 or 8 .
the system of claim 1 , wherein the system comprises program control means ( 58 ) controlling the computer means and allowing the control signals produced by the computer into a visible displayed surface contour .
the method of claim 38 , wherein the sialyltransferase polypeptide has an amino acid sequence as shown in seq id no : 3 .
condom coated with acidic polysaccharides .
a composition for use in veterinary medicine comprising an effective amount of at least one compound of claim 1 together with one or more carriers and / or excipients .
the safety of tenofovir disoproxil fumarate has not been confirmed in the field of ledipasvir / sofosbuvir and a pharmacokinetic enhancer .
use of an active agent which inhibits cyclin g1 protein , wherein the active ingredient comprises : i ) antisense oligonucleotides or polynucleotides or fragments thereof , or sequences complementary to at least a portion of a polynucleotide encoding the cyclin g1 protein and which bind to a polynucleotide encoding the cyclin g1 protein , and which bind to a polynucleotide encoding the cyclin g1 protein , in order to produce the fragments or derivatives thereof with the cyclin g1 protein , the fragments or derivatives of the antibody having deletions and / or substitutions of amino acid residues with
these active substances include f@@ lec@@ ain@@ ide and propa@@ fen@@ one .
the use of claim 95 , wherein the organism is human .
the surgical system of claim 1 , wherein the control mechanism comprises means for controlled ablating of the skin ( epidermis ) along the course of a skin / dermal interface .
the method of claim 2 , wherein the active substance is a toxin .
the use according to claim 1 , wherein the polysaccharide is hyaluronic acid or a pharmaceutically acceptable salt thereof .
composition according to any one of the preceding claims , characterized in that the allyl ether unit defined in claim 1 is chosen from the allyl ether unit having a fatty chain of the anionic amphiphilic polymer of the following formula ( i ) ch 2 = cr &apos;@@ ch 2 whether n r represents r 2 = cr &apos;@@ ch 2 whether n is r r is equal to or ch 3 , b represents ethylenic oxy , n is 0 or -ch 3 , b is selected from the group consisting of : r &apos; is -h or
method for stabilizing active components using polyol / polymeric microcapsule , and cosmetic composition containing the microcapsule
use of the products of formula ( i ) as defined in claim 1 for the preparation of pharmaceutical compositions intended for the treatment of diseases resulting from an abnormal stimulation of the receptors of endothelin .
the other ingredients are α , α-@@ trehalose dihydrate , histidine hydrochloride monohydrate , histidine , polysorbate 20 , water for injections .
reproductive system and breast disorders
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the method of claim 19 , further comprising : providing a second , as a spare , a replacement sheet film which is contained within the cavity of the container ( 50 ) ; and transferring the second , as a replacement of the container ( 50 ) from the container ( 50 ) through the transfer port ( 80 ) in the first pore barrier film ( 40 ) and the container barrier film ( 60 ) , and into the isolated space ( 22 ) .
curved ribs were associated with increased incidence in association with reduced maternal body weight parameters ; the no-@@ effect dose was 75 mg / kg ( 10 times the human exposure ) .
the plant of claim 36 which is homozygous for said recombinant dna .
method for treating schizophrenia and means for use in this method
a method for producing an aqueous injectable liquid drug delivery composition for injection into a body in a state in a state in which a pharmacological treatment or diagnosis requires the composition of claim 13 , and an effective concentration of a drug selected from the group consisting of antibacterial agents , anti-@@ glaucoma and anti-@@ infla@@ matory agents , anti-inflammatory agents , or a diagnosis , comprising the composition of claim 13 , and an effective concentration of a drug , an anti-@@ inflammatories , an anti-@@ glaucoma agent , an anti@@ parasi@@ sive agent , a composition of
gas plasma treated , porous medium and separation method using the medium .
process according to one or more of the preceding claims , characterized in that the polyhydric alcohol is at least one member selected from ethylene glycol , diethylene glycol , triethylene glycol , polyethylene glycol , diethanolamine , triethanolamine , glycerol , trimethylo@@ l propane , 1,3-propanediol , 2,3-@@ propanediol , pentaerythritol , sorbitol or polyglycerol .
claims for the following contracting states : es , gr a process for the preparation of compounds of the formula : wherein r ¹ is a group of the formula r h , nh ₂ , -nh@@ co@@ o-c ₁ ₋ ₄ alkyl , -nh-@@ z or -nhcoch ₂ n ( y ) -ch ₂ ch ₂ nh ₂ or guanidino group , or a protected amino , amidino or guanidino group , and optionally a compound of the formula i in a physiologically acceptable salt , or a salt of a compound of formula i in the free acid
a process according to claim 2 , wherein the concentrated sulfuric acid is used in an amount of 2 to 3 equivalents per equivalent hn@@ o 3 .
&apos;@@ cause i think god kno@@ ws that ... ~ ~ ~ i need to drink something .
a process for producing the antibiotic ll-e@@ 19@@ 0@@ 20@@ α and ll-e@@ 19@@ 0@@ 20@@ β , as defined in claim 1 , which comprises cultivating a liquid medium which has assimilable sources of carbon , nitrogen and inorganic salts , the medium being vaccinated with viable culture of the organism streptomyces ly@@ di@@ cus s@@ . tan@@ z@@ ani@@ us nrrl 180@@ 36 or mutant thereof for a period of from about 90 to 200 hours at a temperature of from 25 to 32 ° c which is ma@@ re@@ harvested and extracted the antibiotics .
the use of claim 16 , wherein the heparin is present at a concentration in the range of about 1@@ µg / ml to 100@@ µg / ml .
the full epar for taxotere can be found here .
process according to one of claims 1 to 3 , characterized in that the pharmaceutical composition contains from 50 to 400 mg of s- ( carboxymethyl ) -l-@@ cysteine and / or n-acetyl cysteine and has a diameter of 5 to 12 mm .
this medicine is not a cure for hiv infection .
the substantially pure plasminogen activator inhibitor of claim 11 , wherein said inhibitor is a fusion polypeptide exhibiting an apparent relative molecular mass of about 180 kilodaltons in the sds-page analysis .
the use of an active agent combination according to any one of claims 1 to 8 for the preparation of a medicament form for drug addic@@ tive or noise therapy , in particular the therapy of alcoholism .
4 . a polymer according to claim 3 , characterised in that the polymer contains two to ten h@@ sod units .
16 . a method of coating a submerged surface for preventing the growth of microbes or plants or the adhesion thereof , said method comprising the step of applying to said surface a composition prepared according to claim 3 .
• induction chemotherapy followed by radiotherapy ( ta@@ x 323 )
novel substituted thiophen@@ carboxamides , their preparation and their use as medicaments
therefore , orgalutran use is contraindicated in patients with hepatic impairment ( see section 4.3 ) .
a system according to claim 1 , wherein the weight ratio of the pores forming the pores to the coating material of the pellet is of the order of 1 : 300 .
the method for producing a biological material chip as claimed in claim 10 , wherein the avi@@ dins are avidin , streptavidin or their altered bodies which can form a stable complex with biotin .
an adhesive bandage , wound dressing , or surgical drape as claimed in any one of claims 1 to 4 , wherein the flexible elastomer base is in the form of a parallelogram comprising a first four-@@ grade second four@@ th-@@ four since and a third four-@@ point , wherein the adhesive is bonded to the intermediate layer and the intervening four is free of adhesive .
driving device according to claims 1 or 2 , characterized in that the deflection mechanism ( t ) is the drive actuator ( a ) .
a device according to any one of the preceding claims , wherein the amount of the solid support containing the volatile substance at the beginning of the lifetime of the device is 3 to 30 g .
nucleic acid sequence encoding a peptide according to any one of claims 1 to 10 .
if you have been told by your doctor that you have an intolerance to some sugars , contact your doctor before taking this medicine .
taking karvezide with food and drink karvezide may be taken with or without food .
novomix 30 is an insulin analogue for the treatment of diabetes .
as a precautionary measure , concomitant use of strong or moderate cyp2c19 inhibitors should be dis@@ cou@@ ra@@ ged ( see sections 4.4 and 5.2 ) .
eu / 1 / 01 / 183 / 026 1 pre-filled syringe eu / 1 / 01 / 183 / 027 10 pre-filled syringes
pharmacovigilance system the mah must ensure that the system of pharmacovigilance , as described in version 4.0 presented in module 1.8.1. of the marketing authorisation application , is in place and functioning before and whilst the product is on the market .
some@@ body is closed with a charge of wa@@ y ... from the drug delivery ... ko@@ your , morphine , de@@ tol .
infections and infestations blood and lymphatic system disorders
a coating , adhesive , ma@@ stic@@ x , ste@@ m or binder composition comprising a core / shell particle prepared according to any one of claims 1 to 7 , wherein the coating , adhesive , ma@@ stic@@ x , ste@@ m or binder composition contains a reactive crosslinkable resin and the target material is selected from cross-linking agents for the reactive crosslinkable resin .
pharmaceutical composition containing at least one medicament according to one of claims 10 to 13 , and optionally excipients and / or adjuvants and optionally other active ingredients .
the composition of claim 8 , wherein the enhanced hepato@@ protective activity is 75 % for galacto@@ samin@@ e-@@ induced hepatotoxicity in mammals .
a compound according to any one of claims 1 to 7 for pharmaceutical use .
what are the risks associated with onivyde ?
the dosage unit according to any one of claims 18 to 31 , wherein said inflammatory disease is rheumatoid arthritis .
• testing of lumiracoxib containing medicinal products useful in the treatment of osteoarthritis
a process according to claim 1 , wherein the edible oil is a fat-soluble vitamin .
aptivus should only be used in these patients unless the potential benefit outweighs the potential risk and with increased monitoring of clinical and laboratory parameters .
gol@@ d-@@ free alloys for the firing of ceramic materials .
quixidar 5 mg / 0.4 ml solution for injection quixidar 7.5 mg / 0.6 ml solution for injection quixidar 10 mg / 0.8 ml solution for injection
a fine white deposit with a clear colourless supernatant may be observed upon storage of the vial .
a method of identifying a substance which modulates m@@ c-@@ r@@ 1b receptor activity , comprising : ( a ) combining a test compound in the presence and absence of an m@@ c-@@ r@@ 1b receptor protein , wherein the m@@ c-@@ r@@ 1b receptor protein comprises the amino acid sequence selected from the group consisting of seq id no : 2 , seq id no .
system according to any one of the preceding claims , characterized in that , in the tooth-cleaning agent , the humectant is at least sorbitol , glycerol or xylitol or any mixture of these substances .
the composition of claim 1 , wherein the hydrophobic@@ ally-@@ modified clay is present in the composition in an amount of from 0.05 % to 5.0 % .
enhancement of electro@@ electrophoresis separation of single dna strand by a@@ sy@@ metric field reversal .
a method according to any one of claims 1 to 9 in which the suspension is whole blood , the first particles ( 104 ) are red blood cells and the second particles ( 108 ) are white blood cells and the pores ( 102 ) of the membrane ( 100 ) are sized to allow the passage of substantially un@@ deformed red blood cells through the pores ( 102 ) during the passage of un@@ deformed white blood cells .
the kit of claim 13 , wherein said antibody is a monoclonal antibody or a polyclonal antibody , and preferably is a monoclonal antibody .
a pharmaceutical composition comprising an il-2 transcriptional inhibitor and 40@@ -o- ( 2-hydroxyethyl ) -@@ rapamycin in combination or association with a pharmaceutically acceptable diluent or carrier , with the proviso that cyclosporin a is excluded as the il-2 transcription inhibitor .
the device of claim 1 , wherein the support comprises an absorbent material such as a fibrous synthetic material or filter paper .
the stent of claim 1 , wherein each connecting strut ( 90 ) of the first connecting strut column ( 32 ) has a mid-@@ section having a substantially frustoconical conical configuration .
the laminated tissue construct of claim 6 , wherein the plasticizer is selected from the group consisting of glycerol , diethylene glycol , polyethylene glycol , or a substitute thereof , palmitate , sorbitan , oleate , ricinoleate , laurate , sorbitan monolaurate , sorbitan monooleate , poly ( oxyethylene ) - ( 20 ) sorbitan monolaurate , butyl@@ acetyl ricinoleate , glycerol tri@@ capro@@ ate , glycerol tri@@ butyrate , chlorinated paraffin , polymer ester , glycerol tri@@ butyrate , chlorinated paraffin , polymer ester , glycerol tri@@ butyrate , chlorinated paraffin , polymer ester , glycerol tri@@ butyrate
the method of claim 4 or 5 , wherein the specific absorbent components are reduced haemoglobin hb and oxy@@ hemoglobin hb@@ o and the calculating step comprises calculating a degree of oxygen saturation of hemoglobin y .
device for sterilisation of suction bottles
use according to claim 1 , characterized in that the electro@@ kinetic index &quot; i &quot; of the semi-permeable membrane is on polyacrylonitrile base which is a carrier of solid , negative charges and contains a neutral or cationic polymer , with no greater than or equal to 0.7 .
the orthopedic casting article of claims 12-@@ 16 , wherein said viscous curable resin further comprises a sufficient amount of a second reactive monomer or oligomer , such that after polymerization of said second reactive monomer or oligomer , said mixture of said resin and said polymerized second reactive monomer or oligomer at 1.0 rad / s has an tan δ of less than 10 .
dose adjustment of pioglitazone within the dose recommendation or change in diabetic treatment should be considered ( see section 4.5 ) .
device according to one of claims 1 to 16 , characterised in that , in order to form the active substance storage container ( 4 ) , the chip ( 15 ) is provided in particular between an outer chip ( 14 ) and an adjacent , particularly the chip ( 15 ) , which is adjacent to the container space , a sealing spacer ( 17 , 23 ) which surrounds the container space .
the prosthesis of claim 1 , wherein the valve prosthesis ( 10 , 100 ) is adapted to replace the aortic valve .
hold the viraferon , solution for injection , multidose pen with the needle tip pointing upwards .
process for the preparation of optically active glyci@@ dic esters .
if you take more myfenax than you should :
patients treated with memantine showed a statistically significantly better outcome in the primary endpoints : assessment of cognitive function ( alzheimer disease assessment scale ) ( p = 0.003 ) and ci@@ bi@@ c-@@ plus ( p = 0.004 ) and ci@@ bi@@ c-@@ plus ( p = 0.004 ) at week 24 , compared with the last for the end of treatment ( last observation carried out for each patient ) .
the apparatus of claim 1 , wherein the second flow is tangential to the first flow .
osmotic non-@@ fermented laxative for treatment and prevention of colorectal cancer
device and method for treating vari@@ ences
what is pan@@ ac@@ ur aqua@@ sol used for ?
the catheter of claim 1 , wherein the lumen ( 70 ) is tubular and has a circular cross-section , the longitudinal axis of the lumen is offset and is parallel to the longitudinal axis of the catheter to define a portion ( 76 ) of reduced thickness in the wall ( 74 ) of the catheter .
a peptide having 5 or 6 residues which inhibits the enzymatic activity of a phospholipase a 2 , said peptide having an amino acid sequence corresponding to a sequence selected from the region of residues 69 -@@ 75 of phospholipase a 2 .
plant cell , characterized in that it contains a nucleic acid sequence according to claim 12 or a chimeric gene according to one of claims 13 to 16 .
the approximately active substance impermeable polyester film can be removed before use .
the method of claim 5 , wherein the second solution is a non-aqueous solution .
side effects may occur at least up to four months after the last injection of humira .
an arylalk@@ yl-@@ 1,2-di@@ amine according to claims 1 and 2 , characterized in that it is represented by the formula ( iii ) : aryl@@ alkyl-@@ 1,2-di@@ amine according to claims 1 and 2 , characterized in that it is represented by formula ( v ) : a process for the preparation of the arylalk@@ yl-@@ 1,2-di@@ amine of claims 1 and 2 , wherein x represents the following steps : a ) the compound of formula ( vii ) : in which : b ) an aryl@@ sulphonyl group is selectively introduced at one of their amine functions
empagliflozin improves glycaemic control in patients with type 2 diabetes by reduction of renal glucose re@@ absorption .
the invention relates to a method for the controlled iontophoretic application of active substances and devices suitable therefor .
4.7 effects on ability to drive and use machines
a non-therapeutic method of inhibiting an increase in the amount of triglycerides in humans comprising administering to said method an effective amount of a peptide according to claim 1 .
the ultrasound catheter of any preceding claim , wherein the proximal portion ( 112 , 212 ) is attached to the ultrasound transmission member ( 24 ) with a clamping connection ( 230 ) .
a third study compared for@@ xi@@ ga with a sulphonylurea ( glipizide ) , both medicines were given in combination with metformin in 8@@ 14 patients .
a separation device or packaging material according to claim 1 , wherein the surface roughness ( r a ) is formed by means of a embossing .
wheelchair according to claim 9 , characterized in that the flap arrangement ( 16 ) comprises pivotally mounted spacer rods ( 60 , 61 , 62 , 63 ) whose opposite outer ends are fixed to a corresponding strut ( 41 ) .
the printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch .
the device ( 10 ) can be placed on a counter-@@ surface via a contact surface ( 20 ) .
sphygmomanometer according to one of the preceding claims , characterized in that the sensor elements ( 23 , 49 , 42 ) cooperate free of return forces .
a compound which is &#91; 2-methoxy@@ 5- ( 5-trifluoromethyl-@@ tetrazol@@ -1-yl ) -benzyl &#93; - ( 2@@ s-@@ phenyl@@ piperidine@@ -2@@ yl ) -amine , or a pharmaceutically acceptable salt or solvate thereof .
a tablet according to any one of the preceding claims , wherein the colloidal silica is present in an amount of 0.1 to 0.5 % w / w .
the method of claim 13 , wherein the reporter or effector group comprises a che@@ lated metal and the method comprises the further step of reacting the crosslinked antibody fragment conjugate with a metal salt to introduce the metal .
a device for mixing an orthopaedic cement , comprising a mixing chamber ( 1 ) and a dispensing chamber ( 2 ) , wherein the mixing chamber ( 1 ) comprises an inlet opening ( 17 ) , the inlet chamber ( 1 ) having an inlet opening ( 17 ) , the inlet means and the outlet opening being provided in cement flow communication , and wherein the closure comprises a ball or ball ( 15@@ t ) having a hole extending therethrough , which is disposed between the mixing chamber and the dispensing chamber .
it must be protected from light and must not be frozen .
uses of hm@@ gb , hm@@ g@@ n , hm@@ ga proteins
corynebacterium glutamicum genes encoding stress , resistance and tolerance proteins
hydrochlorothiazide may cause or exacerb@@ ate hypovola@@ emia which may lead to electrolyte imbalance ( see section 4.4 ) .
the conjugate of claim 1 , wherein the lipid has a functional group which is an amino group , a carboxyl group , a thiol group , or an aldehyde group .
the method of claim 11 , wherein the water alcohol solution is water and ethanol .
device according to one of the preceding claims , characterised in that the disc or ring ( 13 ) is incorporated in the toothed wheel gear of the drive device ( 2 ) .
van@@ to@@ bra 170 mg nebuliser solution tobramycin
the concentrate of proteolytic enzymes enriched from bro@@ mela@@ in is absorbed into the systemic circulation from the wound surfaces ( see section 5.2 ) .
lansoprazole inhibits the activity of this enzyme via a reaction with the sulfhydryl group of the enzyme h + / k + atpase .
method for producing a selectively crosslinked medical prosthesis made of polyethylene and a prosthesis produced thereby
the use of claim 1 , wherein the cc chemokine mutant is an active variant of the cc chemokine mutant in which one or more amino acids have been deleted , deleted or conservative .
a compound according to any one of claims 1 to 9 for use as a medicament .
a vaccine composition according to any one of claims 11 to 14 which is capable of stimulating an interferon-@@ γ production on the antigen or antigenic composition in a mammal .
he &apos;s also a doctor , so you know it .
an ear@@ cup according to any one of claims 1 to 3 , characterised in that the first element has a uniform thickness .
in patients with hyper@@ gam@@ maglo@@ bul@@ in@@ aemia , normalisation of igg levels was observed in 49 % of ben@@ ly@@ sta and 20 % of placebo-treated patients at week 52 .
use according to any one of claims 26 to 28 , characterized in that the preparation is provided in a dose corresponding to that of the non-@@ nitro@@ sa@@ ted protein .
a sugar-@@ based polymer as claimed in claim 7 , wherein the non-reducing sugar is sucrose .
plant according to any one of claims 1 to 9 , characterized in that it is a vigabatrin or au@@ ber@@ in species .
a compound according to claim 1 wherein r 4 is phenyl .
use of an aliphatic diol or an aliphatic polyol as an additive to a culture of a ph@@ a-@@ producing microorganism for producing a composition from a hydroxy@@ terminated pha having a number average molecular weight of greater than about 20,000 and a number average molecular weight of greater than about 20,000 mole % , wherein : ( a ) the aliphatic diol is ethylene glycol , diethylene glycol , propylene glycol or neopentyl glycol , and ( b ) is the aliphatic polyol pentaerythritol .
a multiple lumen access system according to claim 19 , further comprising a luer connector ( 526 ) on the device lumen valve ( 528 ) and an infusion syringe having a complementary luer connector .
carton ( containing 8 transdermal patches )
use of micro@@ proteins as tryp@@ tase inhibitors
manufacturer ( s ) of the biological active substance ( s ) and manufacturer ( s ) responsible for batch release
ventricular tachycardia / fibrillation , sudden death ( see section 4.4 ) 11
6 . a process according to any one of claims 1-5 , characterized in that the components are used in powder form . 6 .
claims for the following contracting state : es a process for producing the antibiotic ce@@ fe@@ pimozide dihydrochloride hydrate which comprises less than 5 % of the anti-@@ isomer and the δ 2 isomer , which comprises reacting the anhydrous hydrochloride salt of 2- ( 2-aminothiazol-4-yl ) -2-methoxy@@ imino@@ acetic acid with a mixture containing less than 5 % of the anti-@@ isomer and the δ 2 isomer , the syn isomer of 2- ( 2-aminothiazol-4-yl ) -2-methoxy@@ imino@@ acetic acid being reacted at a ph of 5.0 to 7.5 in an aqueous organic solvent at a ph of 5.0
contents of the pack and other information
human monoclonal antibodies to epidermal growth factor receptor
infusion-related reactions external clinical trials include reports of pyrexia , chills , rigors and vomiting , mostly mild to moderate in intensity .
these are called impulse control disorders and may be associated with behaviour such as gam@@ bling , excessive eating or mon@@ e@@ od , abnormally high sexual drive or an increase in sexual thoughts and feelings .
a decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis .
an absorbent article according to the preceding claims , wherein said adhesive is a hot-melt adhesive having a residual tack of less than 16 grams per inch peel strength .
in patients with pre-existing cardiac , renal or liver disease , oedema may lead to oedema ( with or without congestive heart failure ) as serious complication following high doses of testosterone or other an@@ abolic steroids .
use of a first composition comprising an estrogen compound having a daily dose equivalent to the estrogenic activity of 17-@@ alpha-@@ ethinyl estradiol in a range from 0.01 to 0.04 mg , and a subsequent composition comprising a contraceptive daily dose of a progestin for the manufacture of a two-@@ step contraceptive dose for the manufacture of a two-@@ step contraceptive composition for the manufacture of a two-@@ step contraceptive composition , for the preparation of a two-@@ step contraceptive composition , for the preparation of a two-@@ step contraceptive composition , for the manufacture of a two-@@ step contraceptive
the ratchet ( 10 ) of any one of the preceding claims , wherein the handle ( 12 ) is a t-@@ rod ( 138 ) .
yt@@ trig@@ a with food and drink no special precautions should be taken with regard to the safe and effective use of yt@@ trig@@ a .
the use of arthro@@ scopy is for joint diagnosis and , if appropriate , for the sanitizing of meniscus lesions .
if you have liver or kidneys problems or if you are elderly , speak to your doctor as you may need a lower dose .
the method of claim 30 , wherein the amount of impurities contained in the precipitate is at least 50 % lower than the amount of impurities contained in the acetone mixture .
the invention relates to the use of active substance combinations containing phenolic active substances and fungicidal agents for preserving animal skins and lea@@ ther .
section 4.4 - special warnings and precautions for use
a composition for delivering an agent to cells , said composition comprising : a transport vector comprising an avidin residue selected from avidin tetra@@ mer , avidin monomer subunit , avidin dimer subunit and non-@@ glycosylated derivatives thereof ; at least one mono@@ biotinylated agent thereof , in order to provide an avidin bio@@ tin-@@ agent complex according to claim 1 , further comprising a pharmaceutically acceptable carrier for the avidin bio@@ tin-@@ agent complex .
use according to any one of claims 1-3 and 9-12 , wherein the retroviral infection is an hiv infection .
what is in this leaflet
the invention relates to a method for the synthesis and amplification of nucleic acids by means of an enzyme@@ -cataly@@ zed reaction , whereby a nucleic acid is co@@ pied from a single-stranded initiator nucleic acid without allowing hybridization of the initiator nucleic acid to the nucleic acid to be co@@ pying .
the apparatus ( 10 ) of claim 4 , wherein a polarization change is about one-half degrees , and wherein the reference value indicates a gas bubble in the stro@@ a ( 34 ) having a diameter of about 15 microns .
s@@ ze@@ go@@ w@@ ska 3 0@@ 5-@@ 850 s@@ ze@@ ig@@ i poland
enantiomeric compounds for the treatment of cardiac arrhythmias and methods of use thereof
there are no data on the excretion of rosuvastatin in human breast milk .
a balloon catheter apparatus according to claim 4 , characterized in that the polymer comprises a polyurethane , polyethylene , nylon or p@@ ba@@ x .
kr@@ ó@@ lo@@ we@@ j mar@@ y@@ sie@@ c ki 11 / 4 pl@@ -@@ 0@@ 2-@@ 9@@ 54 war@@ s@@ za@@ wa tel : + 48-@@ 22 8@@ 42 71 00
composition according to any one of claims 5 to 7 , characterized in that the phosphor@@ us-@@ containing polycationic dendrimer is in non-@@ covalent manner with the nucleic acid .
the brachytherapy source of claim 1 , wherein the radioactive material ( 10@@ 12 ) is selected from the group consisting of iodin@@ e-@@ 125 and palla@@ di@@ um-@@ 103 .
if you stop taking champix
a process according to claim 6 wherein the inhibin is human inhibin and the activin is human activin .
a piperidine derivative or a pharmacologically acceptable salt according to claim 1 , wherein n is 2 .
the vaccine is available as a suspension for injection .
composition according to any one of the preceding claims , characterized in that the oligomer or polymer derived from a polyolefin is formed in the reaction of a polyolefin derivative and at least one acid chosen from maleic acid ; maleic anhydride ; fumaric acid ; itaconic acid ; citro@@ conic acid ; me@@ sa@@ conic acid ; ac@@ coni@@ tic acid ; its derivatives and mixtures .
the nmr probe of claim 2 , wherein two shiel@@ ds ( 77 ) are attached to the probe in which one of the shiel@@ ds between the planar coils ( 70 , 72 ; 90 , 92 ) is positioned near the first side of the sample space and the other shield is positioned between the planar coils ( 71 , 73 ; 91 , 93 ) proximate the second side of the sample space .
composition , characterized in that it consists essentially of 1- &#91; 3,5-bis ( 1,1-dimethylethyl ) -4-hydroxyphenyl &#93; -5-@@ hex@@ ne@@ ne@@ -1-one ( te@@ bu@@ fa@@ fe@@ lone ) in a concentration of at least 15 % , preferably from 15 % to 30 % , and in that it has the following properties : ( a ) at 20 ° c and in that it has the following properties : ( d ) in water at 20 ° c and at concentrations of 10 % or below and in that it has the following properties : ( d )
- if your kid doesn &apos;t feel well .
the pharmaceutical dosage form of claim 2 , wherein the outer layer further comprises a binder which constitutes from about 5 % to about 20 % by weight of the dosage form .
1 vial + 1 pre-filled syringe
if you forget to take irbesartan bms : if you accidentally forget to take the daily dose , you should continue treatment as prescribed .
the pant of any one of the preceding claims , wherein said baffle layer ( 16 ) is smaller in dimensions than said absorbent body ( 18 ) .
a method for producing a recombinant dna molecule containing a nucleotide sequence encoding a surface-@@ exposed protein of haemophilus influenzae or related haemophilus species , said protein having an apparent molecular weight of 42 000 , a human l@@ gd binding ability and the amino acid sequence depicted in fig . 9 , or for an immunogenic or ig@@ d-@@ binding portion of said protein or variants , wherein said nucleotide sequence is fused to another gene , said method comprising a conventional production step .
a compound of formula i : or a stereoisomeric mixture thereof , a diastereomer enriched , a diastereomer , enriched , diastereoisomer , enantiomerically enriched , or an enantiomer thereof , or a prodrug thereof , or a prodrug thereof , which is a compound selected from the group consisting of : ( c -c ) - ( c -c ) - ( c -c ) - ( c -c ) - ( c -c ) - ( c -c ) - ( c -c ) alkyl ; r is ( cr r ) - ( c -c ) alkyl
in a study in 10,@@ 101 postmenopausal women with pre-existing coronary artery disease or an increased risk of coronary events ( ru@@ h study ) , vasodilation ( hot flushes ) occurred in 7.8 % of ral@@ oxi@@ fen@@ -treated and 4.7 % of placebo-treated patients .
a binding protein for growth hormone having a specific activity of at least about 10,000 pmol / mg , comprising an amino acid sequence selected from the sequence at the n-terminal end of the growth hormone receptor sequence of from 190 to 250 amino acid residues of figure 8a or 8b or from substitution , insertion and deletion variants thereof , wherein the variants have the ability to bind selectively to growth hormone .
the water-soluble luminescent semiconductor quantum dot of claim 1 , wherein the core of the quantum dot is selected from the group consisting of ii@@ b-@@ vi@@ b semi@@ conductors , ii@@ b-@@ vb semi@@ conductors , and ivb ivb is semi@@ conductors and the size of the core is from about 1 nm to about 10 nm .
this is an increased risk of the risk that the treatment is insufficient and that mild resistance is developed ( see section 4.5 ) .
however , the role of this bio@@ marker ( pd-@@ l1 expression ) has not been fully elucid@@ ated .
composition according to either of claims 1 and 2 , characterized in that a part of the monomeric units of the sequestering agent is replaced with the exception , such as : malic acid units according to the formula wherein r is as defined above ; maleic acid and fumaric acid units according to the formula preparation according to claim 3 , characterized in that up to 10 monomeric units per polymeric molecule may be replaced by one of the malic , maleic or fumaric radicals as defined in claim 3 .
the endoscopic bipolar forceps according to any one of claims 1 to 11 , wherein the abutment is secured to the jaw by means of an adhesive .
a muscle stapler according to claim 3 , wherein each projection comprises : an upper portion ( 26a ) having an acute cone angle ; a central portion ( 26b ) having a cylindrical shape ; and a lower portion ( 2@@ 6c ) having an obtuse cone angle .
symptoms after administration of a large amount of em@@ la are listed below .
the poly@@ oxyl 35 hydrogenated castor oil of claim 19 which is c@@ remo@@ phor el or c@@ remo@@ phor el-@@ p .
a method of manufacturing according to claim 6 , further comprising the step of uniformly heating said cap ( 21 ) with a diffuse controlled heat source to heat said gas pocket ( 28 ) to a predetermined temperature before said cap ( 21 ) is fused to said surface of said fiber .
high sensitivity detection of biomolecules using phage display
a medicated feed that is not consumed within 24 hours should be replaced .
the co-administration of prevenar 13 and 23-@@ valent pneumococcal polysaccharide vaccine has not been studied .
a composition according to any one of the preceding claims , further comprising compounds selected from the group consisting of buffering agents , antioxidants , preservatives , coloring agents , fragrances , lubricants , humectants , sunscreens or dry agents .
method for producing a dental prosthesis and a curable system
when co-administered with prezista co-administered with 100 mg ritonavir , no dose adjustment of indinavir of 800 mg twice daily is warranted based on 600 mg b.@@ i.d.
after extraction of the mic@@ cro@@ bi@@ lle biomass with a water content up to 92 mass parts in % with a ketone and the mechanical separation of the la@@ c@@ ella is the removal of the lipophilic cell ingredients from the ketone - ketone - lipophilic cell contents system by addition of an alkali metal salt solution .
a composition according to claim 9 in sublingual tablet form further comprising a cyclodextrin .
if you cannot swallow the tablets , you can drink it in a glass of water without any carbonic acid or apple juice :                                                                           
in a study where the injections were less administered ( within the first three months and subsequently every three months ) , the vision of the patients who received lucentis remained better than those receiving sham injections .
a compound as claimed in any one of claims 1 to 4 for use as a medicine .
an aerosol delivery device comprising : at least one aerosol source ( 20 , 220 , 320 , 120 ) ; and at least one ionization electrode ( 70 , 224 , 370 , 170 ) for generating an ion flow thereof in a direction along a path for capturing and moving the aerosol from the aerosol source in the direction along the web , the direction extending away from the aerosol source .
composition in an aerosol container containing aluminium oxide nanoparticles
a cosmetic composition according to claim 16 , comprising a use selected from the group consisting of ma@@ ke@@ d@@ ling , sun@@ care , skin care and hair care .
the educational material for valdoxan / thymanax is inhaled separately to the prescribing physician :
use of a conjugate vaccine according to any one of the preceding claims , wherein the medicament is prepared in a form for subcutaneous administration .
this may cause serious side effects , which may require urgent medical attention . • if you have any further questions on the use of this medicine , ask your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription , ask your doctor or pharmacist . − this medicine has been prescribed for you and you should tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
a device according to any preceding claim , wherein the defibrillator is an implanted defibrillator .
a recombinant marek &apos;s disease ( md@@ v ) disease of serotype 1 , 2 or 3 , ( i ) in which the gd gene of the md@@ v virus is placed under the control of a promoter that is other than the natural promoter of the md@@ v virus under the control of a promoter , which is other than the natural promoter of this gene and the expression of the gd gene in cell culture in cell culture , and its expression in the genome of the virus in cell culture , which is not essential for
determination of diure@@ tic effect of candidate drugs .
a method according to claim 13 or 14 , wherein the enzyme is micro@@ peroxidase .
the subsequent follow-up was done for up to 35 weeks .
the delivery system of claim 1 or 2 , wherein the active material is attached to the rna sequence via a spacer .
in patients whose blood pressure was not controlled with 80 / 12.5 mg tablets , diastolic blood pressure was more effective than the change to the 80 / 25 mg tablet at the 80 / 25 mg dose as compared to further administration of the lower dose .
the system of claim 17 , wherein the at least one rib is annular .
of these patients , 66 did not show any progression of structural damage as t@@ ss change of zero or less .
this change results in a decrease in the total plasma concentration of the active substance in plasma , the amount of unbound amprenavir representing the active moiety is likely to be unchanged .
the use of this medicine can be used either .
a method according to claims 13 to 15 , wherein the foam is brought into contact with the foam by wea@@ ving , tu@@ kes , spraying , casting or fla@@ ff@@ ings . the method of claims 13 to 15 wherein the foam is placed on a surface of the foam . the method of claims 13 to 15 wherein the foam is placed on a surface of the foam by wea@@ ving , wea@@ ving , spraying , casting or sp@@ rat@@ ling .
use according to claim 11 , wherein r 2 is a group of formula y 1 y 2 .
powder and solvent for solution for injection .
the insulin will work more quickly when injected in the abdominal wall .
the pacemaker as described in claim 1 , wherein said modulating means ( 224 ) further comprises means for deriving stimulation intervals based on directly preceding heart beat intervals that are decre@@ mented to provide said desired stimulation interval to said desired stimulation interval .
a device according to any one of claims 4 to 7 , wherein the reservoir ( i ) comprises from 1 to 15 % by weight of a pharmaceutically acceptable pergo@@ lide salt , ( ii ) 10 to 70 % by weight permeation enhancers comprising 1 to 35 % by weight of glycerol monolaurate and 1 to 35 % by weight methyl laurate and ( iii ) 35 to 85 % by weight ethylene vinyl acetate copolymer .
use according to claim 8 , wherein the reporter moiety is an iodinated organic compound .
the use of a compound i as claimed in claim 1 for the manufacture of a medicament for the treatment or prophylaxis of angina pectoris .
an absorbent composite fabric ( 1 , 6 ) according to any one of the preceding claims , wherein the first layer ( 2 , 8 ) of the textile composite is at least partially hydrophobic , deposited on the fibers of the first layer ( 2 , 8 ) of fibrous material , absorbent composite fabric ( 1 , 6 ) according to any one of the preceding claims , wherein the fibrous second layer comprises antiseptic and / or moisturizing agent .
fibrinogen is converted to fibrin by cleavage of fibrinogen to fibrin monomers and fibrino@@ peptides .
a compound as defined in any one of claims 1 to 21 , or a physiologically acceptable salt thereof , for use in therapy .
devices for delivery of molecular sieve materials to form blood clots
a dried product according to claim 7 comprising an enzyme , serum complement , antibody or antigen ( either free or coupled to a carrier ) , a fluoresc@@ ence-@@ labeled protein , a vaccine component or a polysaccharide .
potassium-sparing diuretics , potassium supplements , salt substitutes containing potassium and other agents that may increase potassium levels if a medicinal product that affects potassium levels is prescribed in combination with valsartan , monitoring of potassium plasma levels is indicated .
the vector of claim 14 , wherein the promoter of the ta@@ ka amylase promoter is aspergillus oryzae .
immunocompromised patients in a 12-week prophylaxis study in 4@@ 75 immunocompromised patients , including 18 children aged 1 to 12 years and older , the safety profile in the 238 patients receiving oseltamivir was consistent with that observed in prior clinical trials with tamiflu for prophylaxis .
use according to claim 17 , characterized in that the mineral water or thermal water is chosen from the following water : water from the v@@ ich , water from the v@@ ich basin , water from uridine , water on la roche po@@ y , water from the la b@@ our@@ -@@ bo@@ le , water from the lu@@ in@@ ci@@ è@@ res , water from the group consisting of :
the fluid management device ( 15 ) controls the fluid delivery devices ( 10 ) as a function of the image acquisition result .
a gel according to claim 5 , wherein the m@@ q resin has a vinyl unsaturation content of from 1.0 to 2.0 % by weight , which is present in an amount of from 15 to 20 % by weight ; the si@@ h-@@ cross linking agent is a polyorganosiloxane with dimethyl@@ dimeth@@ oxy@@ - and hydrogeno@@ methyl@@ sil@@ oxy repeating units having a si@@ x-@@ bound hydrogen and hydrogen methyleth@@ oxy repeating units having a si@@ x-@@ bound hydrogen and a hydrogen@@ -@@ bonded hydrogen ion content of 0.1 to 1.0 % by weight , said cross-linking agent being
use of compounds according to claim 1 and / or of physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-ht 2a receptor-@@ antagonistic action .
an endoscope suitable for insertion into the coronary arteries of a patient , comprising as an image transmitting element an optical fiber cable of a multi-@@ filament type , having a circular or substantially circular cross section having 50 to 20,000 light transmitting fibers , each having 50 to 20,000 light transmitting fibers , each having 50 to 20,000 light transmitting fibers , each having a core diameter of the optical fiber cable , an object lens placed at one end of the imaging element , and an image transmitting image pickup element located at the other end of the
- the committee concluded that concerns with regard to the safety of
composition for the oxidation dyeing of keratin fibres , and in particular human keratin fibres , such as the hair , which comprises , in a medium suitable for dyeing , at least one precursor of an oxidation dye and at least one oxidation dye of the formula ( ii ) with an acid , with the proviso that the composition for dyeing does not contain an additional oxidation dye chosen from 3-methyl-@@ para-aminophenol , 2-methyl-@@ para-aminophenol and 2-hydroxymethyl-@@ p-aminophenol when in formula ( i ) m is zero and the group r 1 represents β-hydroxyethyl .
azopt has not been studied in patients who wear contact lenses .
vaccine composition according to claim 3 , characterized in that the w / o emulsion is a first phase and the live ca@@ v immunogen is a second phase of the vaccine composition .
concomitant use with st. john ’ s wort ( see section 4.5 ) .
on 1 october 2015 , the united kingdom triggered a referral under article 13 ( 2 ) of commission regulation ( ec ) no 12@@ 34 / 2008 .
a compound of formula ii or its pharmaceutically acceptable salt .
adults and adolescents 12 years and older
compound of formula ( i ) according to claim 1 , in which r 3 represents methyl , ethyl or n-propyl and r 7 represents hydrogen , -c 1-6 -alkyl , -c 1-6 or -coch 3 .
the protein of claim 1 , wherein the linker sequence is an amino acid or is a plurality of amino acids selected from the group consisting of glycine , asparagine , serine , threonine and alanine .
a method of applying a protective coating to the skin , the method comprising applying to the skin a sterile polymeric formulation according to any one of claims 1 to 3 to the skin in a thin layer and allowing the organic liquid solvent to evapo@@ rate .
the method of claim 15 , wherein the step of responding to an emergency condition of the patient further comprises the step of : exchanging speech message to the patient from the medical support note .
the method of claim 29 , wherein the lar@@ vic@@ idal agent is adapted for systemic administration to plants .
prolongation of the qt interval in 9.9 % of patients receiving dela@@ man@@ id 100 mg twice daily , qt prolongation in the ecg was reported ( frequency category &quot; ) , compared with 3.8 % of patients receiving placebo + ob@@ r .
- if you are taking lopinavir / ritonavir as prescribed , it is as good as possible so that the virus does not respond to this medicine ( development of resistance ) .
meta-analysis of overall survival data produced a hazard ratio of 1.08 in favour of controls ( 95 % ci :
a composition according to claim 3 wherein the absorp@@ tion-@@ promoting agent is lauroyl choline chloride .
between injections , a minimum interval of 1 month should be observed : for example 2 , 3 and 4 months ; 2 , 4 and 6 months ; 3 and 5 months .
the method of claim 13 , wherein the added stabilizer is methionine .
70 % of patients were treated for more than 48 weeks .
eur@@ arte@@ si@@ m is used to treat uncomplicated malaria caused by the parasite plasmodium falciparum .
a thrombin receptor antagonist according to any one of claims 1 to 5 wherein r 2 is selected from phenyl , t-butyl , isopropyl , isobutyl , cyclohexylmethyl , benzyl , 4-hydroxybenzyl , 2-naphthylmethyl , 1-@@ napth@@ ylmethyl , 2-thienylmethyl , methyl@@ thioethyl , indol@@ ylmethyl and substituted benzyl , and r 4 is cyclohexylmethyl .
a formulation according to claim 12 , wherein the monoesters are selected from the group comprising isopropyl myristate and ethyl oleate .
the support ( 10 ) of any one of the preceding claims , wherein the upper portion of the metal member forms a shoulder ( 20a ) for engagement with the head ( 38 ) of the screw ( 36 ) .
a glass ionomer cement comprising a glass according to claim 13 , a poly@@ alk@@ enoic acid or a precursor of said and water .
claims for the following contracting states : at , be , ch , de , fr , gb , it , li , lu , nl , se a thio@@ formamide derivative of the general formula : wherein : r is a straight or branched alkyl group having 1 to 4 carbon atoms ( s ) : r is a straight or branched alkyl group having 1 to 4 carbon atoms ( s ) ; r is a straight or branched alkyl group having 1 to 4 carbon atoms ( s ) ; r is a straight or branched alkyl
button and continuous loop fixation loop
a fluid pump according to claim 3 , wherein the means ( 46 ) supplying fluid from the circumference of the impeller to the flow wheel is provided by means of flow leakage forces , from conduits extending from the pump chamber outlet port ( 28 ) and each in an arrangement which forms three or more flow nozzle ports ( 52 ) within the pump chamber inlet opening ( 26 ) near the axially extending neck portion ( 42 ) of the impeller ( 16 ) .
a system as claimed in claim 1 in which the second polymer is insoluble in the solution of the first polymer or the solvent therefor .
what clopidogrel 1a pharma is and what it is used for 2 .
a process according to claim 1 or 2 , characterized in that the layer retaining the active ingredient further comprises an absorbent and a surfactant .
warfarin ( used to prevent blood clots ) , oral contraceptives , phenytoin ( for seizure inhibition in epilepsy ) and antacids ( aluminium or magnesium medicines for stomach upset ) .
a method for producing high density arrays of target substances , comprising the step of decomposing a bundle of target strands , wherein the target strands comprise the target substances , characterized in that the decomposition leads to an array of high density with a thickness greater than 50 µm .
a method for providing droplets for delivery to the upper and lower respiratory tract , comprising : applying liquid to first and second outlets ; applying a first electro@@ hydrodynamic nebulizer ( 23 ; 35a ) to an electrical potential , to provide an electrical potential and to cause the liquid to be atomi@@ sed , to form an atomi@@ sation with opposite polarity , so as to form a substantial mixture of the two accele@@ rations of opposite polarity .
in patients receiving g-csf after allogeneic bone marrow transplantation .
due to adverse events in this study , 12.@@ 9 % of fab@@ ly@@ n patients and 12.@@ 3 % of placebo-treated patients discontinued therapy .
for the review of the contraindication in pregnancy , data from post-marketing surveillance and from the published literature are used , which are considered to be related to the risk of spontaneous abortion , mis@@ carriage , full-@@ birth , immature and low birth weight in women susceptible to measles , mumps , rubella and / or varicella ( varicella ) , and the risk of malformations and rubella disease in children and the risk of congenital varicella syndrome .
mouth rinse according to claim 1 , characterized in that as the buffer salts in the second component ( b ) the salts of complexing acids are contained from the group of hydroxy or amino@@ polycarboxylic acids , organo@@ phosphonic acids or condensed oligo@@ phosphoric acids .
a process for the preparation of 4- ( 2- ( 1,4,5,6-tetrahydro@@ pyrimidin@@ -2-yl@@ carbamoyl ) ethyl ) benzoic acid ( compound of formula xv ) or a salt thereof , comprising hydrogenation of benzyl-@@ 4- ( 2- ( pyrimidin@@ ylcarbamoyl ) -vinyl ) benzoate ( compound of formula xiii ) or a salt thereof .
agent according to claim 11 or 12 , characterized in that it is mixed with water in a weight ratio of from 1 : 0.5 to 1 : 20 before use .
device and method for ultrasonic sealing disposable diapers .
the gel of claim 48 , wherein the biologically active agent is covalently linked to the hydrolytically degradable polymer .
and mr@@ s. ma@@ y , believe me , i understand your fru@@ stration .
a gra@@ b bite object according to any one of the preceding claims , characterised in that the above-mentioned layer ( 5 ) is a mineral material . the gra@@ b cylinder object according to any one of the preceding claims , characterized in that the above-mentioned layer ( 5 ) is a printed cover paper .
a pharmaceutical composition according to claim 6 for use in the treatment of infertility .
a method of attaching a housing ( 100 ; 200 ; ... ) for a mechanical or electrical device to an aerosol container ( 120 ; 220 ; ) with the following successive steps : placing a skirt ( 125 ; 225 ; .... ) of the housing around the neck ( 121 ; 221 ; .... ) of the container ; placing a sleeve ( 102 ; 202 ; ... ) of the housing around the enclosure ; and connecting the collar to the sleeve .
peptide conjugate according to claim 17 , characterized in that , in the general formula i , r can stand for : a monounsaturated radical of cis or trans configuration with the general formula in which r represents a linear or branched alkyl radical , which comprises at least 6 carbon atoms , preferably from 6 to 16 carbon atoms , and the derivatives of the formula , dihydro@@ lipoic acid , and the derivatives thereof , the α-@@ monounsaturated unsaturated fatty acid and the derivatives thereof , the α-@@ monounsaturated unsaturated fatty acids and the derivatives thereof , the
the grounds for the referral were different versions of member states on the use of the medicinal product in adolescents and children ( over 6 years of age ) .
the product of claim 10 wherein the foam stabilizing and emulsifying surfactant is in the form of a polyoxyethylene sorbitan ester .
alcon cu@@ s@@ í s a cam@@ il fab@@ ra 58 08@@ 320 el mas@@ no@@ u ( barcelona ) spain
the graft ( 10 ) of claim 2 wherein the amplitude ( a ) of the pleats in the middle portion ( 20 ) is from about 3 to about 20 % of the internal diameter of the pleats .
a process according to claim 1 or 2 , wherein the microorganism belonging to the genus al@@ tero@@ monas is alter@@ ro@@ monas pu@@ tre@@ faciens sub@@ species sa@@ ga@@ ami@@ faciens sc@@ c@@ c-@@ 1@@ 162 ( fer@@ m-@@ bp@@ -16@@ 26 ) , al@@ tero@@ monas pu@@ tre@@ faciens s@@ cr@@ c-@@ 28@@ 71 ( fer@@ m-@@ bp@@ -16@@ 24 ) , age@@ monas pu@@ tre@@ faciens i@@ x@@ 15@@ 10 , and i@@ am 124@@ 25 , i@@ x@@ 12@@ 6@@ 41 .
if you notice any serious effects or other effects not mentioned in this leaflet , please inform your doctor .
the laparoscopic bipolar electrosurgical instrument of any preceding claim , wherein the closure force is in the range of about 7 kg / cm 2 to about 13 kg / cm 2 .
method according to claim 7 , characterized in that at least one of the rollers is a hard cast roll .
a composition according to any one of the preceding claims , wherein a dosage unit of the composition comprises from 1 to 32 mg of the nsaid substance .
zoledronic acid is not metabolised but is excreted unchanged via the kidney .
the variant of claim 2 comprising at least one amino acid substitution selected from the group consisting of : l@@ 45@@ k , l@@ 4@@ 5r , v@@ 48@@ k , v@@ 48@@ r , g@@ 49@@ r , g@@ 49@@ y , g@@ 49@@ i , g@@ 49@@ r , g@@ 49@@ y , g@@ 49@@ i , g@@ 4@@ 2n , l@@ 114@@ , a@@ 14@@ 2@@ k , a@@ 68@@ n : p@@ 70@@ t , e@@ 69@@ t , y@@ 68@@ n : p@@ 67@@ t : e@@ 69@@ t , y@@ 65@@ n : v@@
medicaments containing at least one combination according to claims 13 to 19 and optionally other pharmaceutical active ingredients .
a surgical clip according to claim 1 , wherein : the clip ( 10 ) consists of two to ten partial clips ( 12 ) .
biological process for the preparation of alpha-@@ adrenoceptor and alpha-@@ hydroxy acid .
absorbent article having a multi-@@ ply absorbent structure
a sic@@ k-@@ bed according to claim 19 or 20 , characterised in that the actuating pin ( 80 ) engages the sleeve-shaped housing lug ( 65 ) and is provided in the longitudinal region ( l ) orthogonal to its longitudinal axis with a groove in the longitudinal region ( l ) , with a transverse opening ( 71 ) extending through a half-@@ circle ( 72 ) and the transverse opening ( 71 ) passing through straight walls ( 71 , 74 ) through which the actuating bolt ( 80 ) passes through the blocking pin ( 80
cosmetic and dermatological washing preparations containing one or more pregelatinized , cross-linked starch derivatives and one or more ethoxylated oils
n- ( 5-@@ thioxo-@@ l-@@ propyl ) -l-@@ cysteine and derivatives , their preparation and pharmaceutical compositions containing them .
benzodiazepines , medicaments for the treatment of psy@@ ch@@ ic
an ultraviolet radiation measuring apparatus according to claim 4 , further comprising a reference table of degrees of skin inflammation that is expected to be produced when light is received with the accumulated value of said ultraviolet band in conjunction with skin types and accumulated values of said ultraviolet band , and wherein information about a degree of skin inflammation is obtained from the reference table based on the accumulated value of the light intensity and a skin type of a measurement person displayed by the display means ( 60 ) .
the use of claim 13 , wherein the peptide is an opioid peptide .
he needs to go into a hospital .
the applicator ( 12 ) of claim 1 , wherein the rotor ( 38 ) has a d-@@ shape approximately cross sectional profile and is adapted to receive coil of the plurality of attachment members ( 10 ) .
agent according to at least one of claims 1 to 4 , characterized in that the fluorine-containing components e ) are compounds of the formula ( ii ) , r 1 -y@@ -c r h 2r c s f .@@ 2s cf 3 , wherein r is a polymerizable function selected from the group consisting of vinyl unsaturated compounds , preferably a vinyl@@ - ( c -c ) - and -o- ( &#91; ch-ch -o &#93; - ( ch ) - and -o- ( &#91; ch-ch -o &#93; - ( ch ) - and -o- ( &#91; ch-ch -o &#93;
process according to one of claims 11 to 13 , characterized in that the aqueous phase contains an amount of ethanol which is between 100 µl and 1000 µl , preferably between 200 µl and 500 µl per millilitre of aqueous phase .
b ) represents one or more water soluble or non-@@ water-soluble polymers which are compatible with a ) .
injection device according to claim 11 , characterized in that each rear locking tongue ( 27 ) is arranged in an intermediate position on the length of the jaw ( 26 ) .
the use of claim 1 , wherein x is nor 6 and r 6 is selected from the group consisting of h , c 1 -c 6 alkyl , c 2 -c 6 alkenyl , c 2 -c 6 alkynyl , acyl , aryl , heteroaryl , saturated or unsaturated 3-@@ membered cycloalkyl , c 1 -c 6 , c 1 -c 6 alkyl , wherein the cycloalkyl or aryl or heteroaryl groups having 1 to 2 further cycloalkyl or aryl or heteroaryl groups may be condensed .
after administration of this product , a period of 3 months should elap@@ se before vaccination with live viral vaccines .
stomach pain , digestive disorder decreased blood calcium levels feeling weak
the use of claim 43 , wherein the metabolic disorder is obesity .
the pharmaceutical composition of claim 25 , wherein the agent is il-2 , il-4 , or an agent that stimulates a t-cell by a cd2 , cd28 , cd40 or ctla4 surface receptor .
a process according to any one of the preceding claims , wherein fermentation is carried out by means of a mixture of moderate thermophilic bacillus species and other lactic acid-@@ producing microorganisms .
an acid , salt or ester according to claim 3 , wherein r ⁶ is a hydrogen atom , a c ₁ -c ₁ ₀ alkyl group or an aralkyl group having a carbocyclic c ₆ -c ₁ ₀ aryl group as an aryl moiety and a c ₁ -c ₆ alkyl group as an alkyl part .
a compound according to claim 1 , which is n- ( 2-hydroxy@@ -5-@@ chlorophenyl ) -3- ( trifluoromethyl ) phenyl acetamide , n- ( 3- ( trifluoromethoxy ) phenyl ) -n &apos; - ( 2-hydroxy-5-@@ chlorophenyl ) urea , n- ( 3- ( trifluoromethyl ) phenyl ) -n &apos; - ( 2-hydroxyphenyl ) urea ; n- ( 3- ( trifluoromethyl ) phenyl ; n- ( 3- ( 4-hydroxy-phenyl ) urea ; n- ( 3- ( trifluoromethyl ) urea ; n- ( 3- ( trifluoromethyl ) urea ; n- ( 3- ( trifluoromethyl ) urea ; n- ( 3- ( trifluoromethyl
the device or combination of claim 22 , wherein the measuring device is for measuring the flow rate and / or turbulence and / or pressure .
a method for the production of polypeptides in a prokaryotic cell , characterized in that ( i ) provides a cell comprising ( a ) at least one gene coding for a heterologous polypeptide in operative association with a regulatable expression control sequence which is repres@@ sible by a tetracycline repressor protein , and ( b ) the cell of ( i ) which lead to expression of the gene coding for the heterologous polypeptide , and ( iii ) the heterologous polypeptide is isolated from the cell or the medium .
no@@ bi@@ vac my@@ x@@ o-@@ rhd lyophilisate and solvent for suspension for injection for rabbits
- treatment or prevention of duodenal or gastric ulcer in patients who
it is expected that the medicines work in the same way as with diabetic peripheral poly@@ neuropathy .
adults with relapsed or refractory ph + all as monotherapy .
a stone according to claim 1 , characterised in that the foam material contains mineral fibres .
solid compositions containing chitosan powder and process for producing the same
a gingival former according to claim 1 , characterised in that the through-@@ bore ( 14 ) is located in the upper end region ( 16 ) of the head part ( 2 ) , especially in the upper half , preferably in the upper third , to the free end face ( 20 ) of the head part ( 2 ) .
dr. ke@@ p@@ ner , do we get her ?
a process for the preparation of a medicament for the treatment of hyper@@ li@@ pe@@ mic conditions and decreasing the concentration of cholesterol and triglycerides in the blood of mammals , wherein a non-@@ β-@@ oxidizable fatty acid analog compound of the general formula ( i ) : alkyl-@@ x@@ ch ₂ is contacted with a pharmaceutically acceptable carrier or diluent , wherein alkyl is a saturated or unsaturated hydrocarbon group having 8 to 22 carbon atoms , x for o , s , so or so ₂ and r is hydrogen or c ₁ -c ₄ alkyl .
compositions according to any one of the preceding claims , characterized in that the poly-@@ α-ole@@ fins are of the optionally hydrogenated poly@@ butene type or of optionally hydrogenated poly@@ dec@@ ene type .
serious side effects mediated by the immune system related to a sulphonamide group include : rash , allergic reaction and serious haematological disorders including aplastic anaemia , which may very rarely be fatal ( see section 4.4 ) .
the active substance in imbruvica , i@@ bru@@ tinib , blocks an enzyme called bri@@ b@@ on tyrosine kinase ( b@@ bc ) , which is predominantly found in b lymphocytes .
it exhibits low uptake of dopamine without significant affinity for hist@@ amin@@ ine@@ rgic , dopaminergic , cholinergic and adrenergic receptors .
a coupling according to any one of claims 1 to 10 , characterised in that the slider ( 44 ) is part of a transversely displaceable housing ( 42 ) .
mechanical sche@@ er stress &quot; or the release of pro@@ inflammatory cytokines .
a bone fracture setting apparatus as claimed in any one of the preceding claims , wherein the rotatable load support ( 240 ) has a substantially c-shaped member ( 241 ) having two arms disposed on opposite sides of the bone ( 1 ) , the load support ( 240 ) being fixed to the bone ( 1 ) by means of an elongate member ( 243 ) permitting the c-shaped element ( 241 ) to recipro@@ cate the c-shaped element ( 241 ) to allow rotation of the bone ( 1 ) to one of the axes .
take special care with champix
an apparatus according to claim 1 or 6 , comprising a downstream conduit attached to the outlet ( 20 ) and having a distal end adapted to attach to an intravenous catheter .
for practical information about using i@@ bli@@ as , patients should read the package leaflet or contact their doctor or pharmacist .
method for examining the movement system of the eye .
after oral administration , elimination is limited by the rate of absorption .
a compound according to claim 2 , wherein the compound has the following features : ( i ) z is oxygen ; ( ii ) r 1 is hydrogen , -r , -ch 2 y , -ch 2 sr or -ch 2 y ; ( iii ) r 2 is a monocyclic , bicyclic or tricyclic heterocyclic or heteroaryl ring system , wherein each ring of the system has 5 to 7 ring atoms .
a be@@ tide of the formula : x is n , -x 1 -x 2 -x 3 -x m -x 4 -x 5 -x 6 -x c , wherein x@@ n is an acyl or other n-terminal or a peptide having up to 50 amino acids , and wherein x is an acyl or a substituted or unsubstituted amino acid and r 3 is an acyl group , an isocyanate group , a thio@@ isocyanate group or a sulphonyl group , and provided that additional residues of be@@ ti@@ d@@ onic acid are optionally comprised of x n , x
the in vitro method of claim 1 , wherein said cell expresses lt@@ β@@ r and said composition contains a homo@@ tri@@ meric p@@ 30 polypeptide having an apparent molecular weight of about 30 kda , said homo@@ tri@@ meric polypeptide having an apparent molecular weight of about 30 kda , wherein said homo@@ tri@@ meric polypeptide binds under physiological conditions to a herpes virus entry mediator ( h@@ v ) polypeptide or a lympho@@ toxin-@@ beta receptor ( lt@@ β@@ r ) polypeptide or a lympho@@ toxin-@@ beta receptor ( lt@@ β@@ r ) polypeptide or a lympho@@ toxin-@@
the invention also relates to these cleaning tools .
now you can select the required dose • turn the cap in the direction of the arrow ( diagram f ) to adjust the correct dose .
a device for the production of granules , in particular pharmaceutical granules , the device comprising a drum ( 4 ) , which comprises circumferential openings ( 25 ) and an organ ( 30 ) for supplying the drum with a substance for coating the drum , characterized in that the drum ( 4 ) has mutually parallel profiles ( 22 ) which define the openings ( 25 ) .
see section 4.2 for dose reduction of myocet due to hepatic impairment .
a boronic acid adduct according to claim 1 , wherein y is α-@@ fur@@ yl@@ di@@ oxime .
6.6 special precautions for the disposal of unused veterinary medicinal product or waste
a kit for diagnosing or detecting the presence of a ps@@ ma comprising : ( a ) at least one compound according to any one of claims 1 to 28 ; ( b ) an instruction .
a compound , salt or prodrug according to claim 20 , wherein the compound is 8a ( r , s ) , 1 ( r ) -@@ diastereomeric mixture , the 8a ( r ) , 1 ( r ) -@@ diastereoisomer or the 8a ( s ) , 1 ( r ) -@@ diastereoisomer or the 8a ( s ) , 1 ( r ) -@@ diastereoisomer or the 8a ( s ) , 1 ( r ) -@@ diastereomer &#91; 8@@ a- ( 4-fluorobenzyl ) -8-@@ methoxy-@@ 6-oxo-@@ - &#93; -2-methyl@@ propionamide &#91; 8@@ a- ( 4-fluorobenzyl )
process according to any one of the preceding claims , characterized in that the sweetening agent contained in the sweetener mixture is xylose , ribo@@ tulose , glucose , mannose , galactose , fructose , maltose , tetra sugar , hydrogenated and non-@@ hydrogenated starch hydrolysate , sorbitol , xylitol , lactitol , mannit@@ m ( 1-o-@@ α-d-glucopyranos@@ yl-d-@@ mannitol ) , 1,1-@@ gps ( 1-o-@@ α-d-glucopyranos@@ yl-d-@@ sorbitol ) , 1,6-@@ gps ( 6-o-@@ α-d-glucopyranos@@ yl-d-@@ sorbitol ) , 1,6-@@ gps ( 6-o-@@ α-d-glucopyranos@@ yl-d-@@ sorbitol ) , 1,6-@@ gps ( 6-o-@@ α-d-glucopyranos@@ yl-d-@@ sorbitol ) , 1,6-@@ gps
the use of claim 21 , wherein the surgery is cardiac surgery .
use according to claims 1 to 3 , characterized in that the natural substance is the seed oil of the plant th@@ un@@ be@@ gia al@@ ata .
a method according to any one of claims 1 to 10 , further comprising separating circular nucleic acid molecules in a sample , said method comprising : introducing a label at one end of said linear nucleic acid molecules , said label being a protein capable of being immobilized on a matrix by direct interaction with said matrix and contacting said sample with a matrix which binds selectively to said matrix , said labeled linear nucleic acid molecules being immobilized on said matrix .
however , this has not been investigated in vivo and the clinical significance of these results is uncertain .
a mixture of substances containing reduced glutathione and at least one antho@@ cyano@@ compound from the group pe@@ lar@@ gon@@ idine on@@ on@@ idine cyan@@ idin mal@@ vi@@ din@@ idine , del@@ ph@@ in@@ idine , for the therapeutic treatment of the human or animal body .
the device of claim 15 , wherein the retractor assembly comprises a plurality of overlapping leaf members ( 614 , 616 , 6@@ 18 ) .
kit consisting of body compress and releasably attachable thermal device
an immunologically active polypeptide having no or reduced toxicity useful for the preparation of an anti@@ pertussis vaccine , wherein the polypeptide comprises the s1 subunit of the pertussis toxin , modified by the substitution of an amino acid through a others capable of destroying or reducing the toxicity of s1 without altering its immunological properties , wherein at least glutamic acid ( 129 ) is substituted by another amino acid .
crosslinked polymer / clay alloy composite composite material
device according to claim 1 , characterized in that the regulating means ( 27 ) comprises means for alternately and repeatedly opening and closing the second connection ( 29 ) or the third connection ( 22 ) .
use of the water-soluble carboxy@@ polysaccharide-@@ magnetic iron oxide complex of small particle diameter according to claim 1 as contrast medium for mri evaluation of lymph nodes , bone marrow or blood vessels , or as mri contrast medium for examination of the intravascular flow rate .
a device according to any one of claims 11 or 12 in combination with a fusion promoting substance .
device and method for the transdermal delivery of agents to erythropoietin
an injectable biocompatible compound for tissue multiplication comprising : a plurality of discrete particles in a carrier , wherein said particles have an average diameter dimension of between 100 and 1000 microns , and the carrier is a biocompatible medium with sufficient liquid to carry and dispense the particles , characterized in that the particles of one of the substrate formed from alumina and carbon are with a carbon coating .
the heating device ( 14 ) according to claims 8 to 10 , characterized in that the temperature-@@ conducting element ( 18 ) is in thermal connection with the at least one window ( 12 ) .
orodispersible tablets according to claim 1 , wherein the proportion of disintegrating agent is from 3 to 15 % by weight and the proportion of soluble diluent is 30 to 90 % by weight , the percentages being based on the weight of the tablet .
each hard capsule contains 0.5 mg anagrelide ( as anagrelide hydrochloride ) .
device according to claims 1 , 2 and 4 , characterized in that the narrowing of the inner circular channel is formed by the presence of helical vanes ( 30 ) .
alternatively , the mask base body can be designed in such a way that the breathing tube can be connected to at least two connection sites , and the connecting port is closed with a closing element .
the use of any one of claims 11 to 15 , further defined as use of an irreversible inactivated reverse transcriptase according to any one of claims 1 to 6 for the manufacture of a medicament for an hiv-@@ positive animal .
a corticoid derivative of the general formula : wherein r is hydrogen , hydroxy , methyl or methylene ; including the acylation product thereof , wherein the 17-@@ position of the steroid backbone is hydroxy and the ketone form thereof , wherein r is hydroxy , or a physiologically acceptable salt thereof .
medical instrument according to claim 2 , characterized in that endoscope ( 44 ) and camera module ( 46 ) can be introduced individually via the openings ( 19 and 30 ) and can be coupled together in the instrument ( 10 ) .
the particle according to claim 5 or 6 , characterized in that the therapeutic effect of the particle is further supported by a modification of its surface with one or more effector molecules other than cyto@@ statics , toxins , enzymes , heavy metals , the bio@@ compatibility active substances and substances facilitating transport of the particle through vessel walls and vascular tissue .
5 . a process according to any one of claims 1 to 4 in which in the compound of structure ( i ) , r ² to r ⁴ are hydrogen and r ¹ is hydrogen or c ₁ ₋ ₄ alkoxy .
the aim of this study was the evaluation of data on the time of the plasma bu@@ pivacaine level , the 1-@@ glyco@@ protein@@ ic acid and albumin concentrations in children with continuous peri@@ dural anaesthesia in the postoperative phase .
a wound dressing comprising a wound treatment composition ( 1 ) having at least one absorbent or adsorbent compound in the form of silica gel contained in a shell which is contained in a shell having a functional inner wall ( 5 ) , and a functional outer wall ( 6 ) , wherein the wound dressing is characterised in that the wound dressing is characterised in that collagen is admixed with the silica gel collagen .
do not take zomarist if you are pregnant or breast-feeding ( see also “ do not take zomarist ” ) .
use of a multi@@ channel probe according to one of claims 1 to 13 as part of an apparatus for invasive operations on the human kidney .
the use of the medicinal product is not recommended in these patients unless the potential benefit outweighs the risk .
the method of claim 10 , wherein the monoclonal antibody is bound to a solid phase .
in addition , a bypass valve member ( 5 ) is provided by inhaled respiratory air ( 3 ) which can be inhaled in the closed valve valve ( 3 ) , the two said switching points of the valve flap ( 3 ) being pre@@ settable between the sealed and the free lumen ( 4 ) of the valve housing ( 2 ) .
the pharmaceutical composition of claim 5 , further comprising an agonist of r@@ ar@@ β2 .
composition according to claim 3 , characterized in that the silicone gums are poly@@ di@@ organopolysiloxanes having a number-average molecular weight ranging from 200,000 to 1,000,000 , which are used as such or with a solvent .
a pharmaceutical composition comprising a peptide compound according to any one of claims 1 to 7 together with a pharmaceutical carrier or excipient .
9 . a compound as defined in claims 1-5 for use as a gastrointestinal secretion inhibitor .
efficacy results ( patients with breast cancer or multiple myeloma )
a dental tube assembly according to claim 1 , wherein the inner tubes ( 11 , 12 , 13 , 14 ) comprise an air supply tube ( 11 ) , an air suction tube ( 12 ) , a water supply tube ( 13 ) and an evacuation air supply tube ( 14 ) .
inhibition of factor xa disrup@@ ts the intrinsic and ex@@ trin@@ sic pathway of the coagulation cascade , both the formation of thrombin and blood clots being inhibited .
allergic rhinitis adults , adolescents ( 12 years of age and over ) and children over 6 years of age : the recommended starting dose is a total of 8 pu@@ ffs of budesonide nasal spray 32 µg / dose per day ( 256 micrograms ) .
if no improvement is detected after this improvement , sandimmun therapy should be discontinued .
the carrier catheter of claim 6 , wherein the introducer further comprises a composite piece at a proximal end .
the potenti@@ ation of serotonergic neurotransmission is specifically mediated by 5-ht@@ 1 receptors as 5-ht@@ 2- and 5-ht@@ 3 receptors are blocked by mirtazapine .
identification of se@@ t-1 from c. ele@@ gan@@ s and its use
a process for producing purified anthocyan@@ idin ru@@ tino@@ side according to claim 3 , wherein the β-@@ glucosidase selectively soluble the β-@@ glucoside linkage of anthocyan@@ idin glucoside without dissolving the β-@@ glucoside linkage of anthocyan@@ idin ru@@ min@@ side .
a process according to any one of claims 1 to 6 in which the oxo@@ acid derivatized solid support contains a sulfo@@ propyl , sulfate , sulphonate , phosphonate or phosphate residue .
method for eliminating oxygen by fermentation of carbon dioxide depletion in anaerobic fermentation
aerosol lacquer according to claim 3 or 4 , characterized in that the solvent is present in a proportion of less than 50 % by weight , preferably in a range between 5 % and 30 % by weight relative to the total weight of the composition .
an apparatus for performing the method of claim 1 , comprising means ( 13 ) for detecting an increase in the internal pressure of an inlet portion of the secondary filter ( 8 ) to an upper limit , means ( 13 ) for detecting the decrease in the internal pressure of the inner chamber ( 8a ) to a lower limit , means ( 14a ) for detecting the internal pressure of the inner chamber ( 8a ) to a lower limit , means ( 14a ) for detecting the internal pressure of the inner chamber ( 8a )
the vaccine induced the gut in 70-@@ 100 % of subjects in the vaccinated subjects .
bed frame , in particular for hospital bed , comprising a support device associated with a rack part .
process according to claim 30 , characterized in that the first , second and third organic solvents are ethanol .
a compound according to claim 12 wherein r 1 is amino or -nr 3 co ( c 1 -c 10 ) alkyl .
these symptoms differ from every@@ day stress and associated loads .
no allergic reactions , including anaphylaxis , have been observed in clinical trials , and the immunogenicity of i. e. administered ziconotide is low .
very common very common common common
the method of claim 14 , further comprising detecting the presence of cntf receptor protein having the amino acid sequence of figure 2 ( seq id no : 1 ) by : ( i ) incubating the cell with an antibody of claim 13 under conditions permitting an immuno@@ specific binding ; ( ii ) detecting binding of the antibody to the cell .
studies in animals have shown reproductive toxicity ( see section 5.3 ) .
the normal release by a sachet ( q@@ p ) should apply to all products that are released in accordance with the eu conditions of the eu marketing authorisations .
the system of claim 1 , wherein the container ( 10 ) contains a concentrate in powder form having a particle size greater than 100 microns .
a method for holding a device ( 10 or 70 ) as defined in claim 1 or claim 2 , comprising the steps of : detaching the sensor carrier ( 26 or 86 ) from the measuring surface of the coolant container ( 12 or 72 ) ; attaching the sensor carrier ( 26 or 86 ) to the sensor carrier ( 26 or 86 ) ; attaching the sensor carrier ( 26 or 86 ) to the sensor carrier ( 26 or 86 ) ; and releasably attaching the sensor carrier ( 26 or 86 ) to which the
a spring ( 17 ) can act on the upper part ( 9 ) which can be adjusted by means of a spindle ( 8 ) , for the connection of the weight of the vertically adjustable parts .
various regimens of treatment were assessed during amprenavir / fosamprenavir development programs and with no additional ritonavir supplementation .
in addition , you have the adverse reactions reported in the post-marketing setting of patients taking cialis as needed .
the dsrna of claim 1 , wherein the lipophilic group has a log@@ k o@@ w exceeding 2 .
the use of claim 11 , wherein the ifn-γ is des@@ cyst@@ y@@ cys-@@ human-@@ ifn-γ .
based on this plan , safety information has been included in the summary of product characteristics and the package leaflet for v@@ on@@ cen@@ to , including the appropriate precautions to be followed by healthcare professionals and patients .
a chimeric peptide according to any one of the preceding claims , wherein the transportable peptide is insulin .
if you stop taking tasigna do not stop taking tasigna unless your doctor tells you otherwise .
please read the question below 5 under frequently asked questions in section 4 of this user manual . • read the package leaflet before use : read the package leaflet before use : • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
‘ stable ’ coronary artery disease : • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
the joint prosthesis ( 100 ) of any one of the preceding claims , wherein the negative surface feature comprises inner structural features with which a portion of the bioabsorbable component ( 120 ) fits in a mechanically locked configuration .
antigen fragments associated with stress-@@ induced proteins and their use as vaccine
an implant ( 2 ) according to any one of the preceding claims , wherein each tapered side ( 13 ) , ( 14 ) of the projection ( 11 ) tapers at an angle in the range of about one degree to about two degrees .
the method of claim 2 , wherein the number of target nucleotides removed from the target dna is less than the number of mutation nucleotides added to the target dna due to addition of one or more mutation nucleotides to the target dna when the modified dna is formed .
special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products , if appropriate
trans@@ vascular hemodynamic ultrasound catheter and method .
an arrangement according to claim 1 , wherein - the image data having a high repetition rate is tomo@@ synthesis data ; - each of the radiation sources ( 1 ) ; and - the line detectors ( 1 ) are diver@@ mented in each of the radiation detectors ( 6 ) , and - the line detectors in each of the radiation detectors ( 6 ) are directed in each of the radiation detectors ( 6 ) and , in each case , the line detectors in each of the radiation detectors ( 6 ) , in order to
the use of claim 1 , wherein each administration contains about 1 to 5 mg of the anti@@ progestin daily .
arrangement according to one of the claims 1 to 5 , characterised by the shaft ( 112 ) of the pin ( 11 ) , the second disc ( 22 ) moved to the shaft of the pin , in the direction of the head ( 111 ) of the post ( 11 ) , the second disc ( 22 ) moved back to the head ( 111 ) of the pin ( 11 ) .
the device ( 100 ) of claim 1 , wherein the second portion of the adhesive member ( 106 ) includes a tab ( 312 ) having a non-adhesive surface remaining from the skin surface when the attachment surface ( 714 ) of the attachment member ( 106 ) is engaged with the skin surface ( 300 ) and the non-adhesive surface is generally coplanar to an adhesive surface ( 714 ) .
( 44-20 ) 74 18 84 00 fax ( 44-20 ) 74 18 84 47 e-mail : mail @ emea. europa. eu http : / / www. emea. europa. eu © emea 2007
a compound according to any one of claims 1-3 wherein r 5 is chloro or methyl .
the composite material according to claim 8 , characterized in that the diameter of the resorbable polymeric reinforcing element is between 4 µm and 800 µm .
date of first authorisation : 23 february 2004 date of latest renewal : 20 february 2009
cosmetic composition according to claim 22 or 23 , characterized in that the agent contains further uv light protection filters in the form of soluble compounds or other pigments .
the majority of adverse reactions occurred in the first month of treatment , except in cases of urinary retention or residual urinary volume following bladder emptying of more than 200 ml , which could occur after prolonged treatment in men as compared to women .
in a distribution device for gases , in particular air distributor for a bubble device with at least one air inlet ( 5 ) and at least two air passages ( 13 , 14 ) is provided for opening and closing the air flow ( 13 , 14 ) at least one wi@@ ir@@ -shaped actuating element ( 7 ) .
sanitary bath apparatus , in particular bath ( 10 ) , with a device according to one of claims 1 to 7 , characterised in that the device is in a groove which fits in the bottom ( 12 ) and / or the wall of the bath device .
1 pre-filled syringe with 5.0 ml water for injections with separate plunger rod .
an instrument according to claim 7 , wherein each projection engages a corresponding recess in an adjacent tooth with gam@@ e so that the cutting teeth jointly describe a helical path with its outline .
use according to claim 2 , characterized in that the degree of sulph@@ ation of hyaluronic acid in a solution for injection is in the range of 0.1 to 2 .
carrier for analyte determination method and method for producing the carrier
the pump of claim 5 , wherein said body ( b ) further comprises an outlet port ( 32 ) in flow communication with said exit chamber lumen ( 28 ) .
the mah provided extensive data on support of intravenous augmentin administration , including studies and con@@ views , which confirm efficacy of both intravenous augmentin therapy and intravenous augmentin therapy followed by oral augmentin therapy in the treatment of lower respiratory tract infections .
as compared to 1996 , there was a some other image for the centralised procedure in 1997 .
doxorubicin hydrochloride has been available since the 19@@ 60@@ s .
exp ( month / year ) use immediately after reconstitution .
you or your child are sexually ill , or if the flu symptoms become worse , or if the fever persists , or if the fever persists , or lasts the fever .
use of a formoterol active substance concentrate according to any one of the preceding claims 1 to 14 and 18 in inhalers for inhalation therapy .
storage must be the national regulations for radioactive substances .
a compound according to claim 2 which is 1- ( 2-methoxy@@ imino@@ cyano@@ acetyl ) -3- ( 2-@@ tetrafluoro@@ ethoxyethyl ) urea .
the main results of the toxicology studies in rats and monkeys were consistent with the pharmacological activity of pali@@ fer@@ min , especially in the proliferation of the epithelial tissue .
compositions for the systemic control of warm-blooded animals , comprising an effective amount of 1- &#91; 3-chloro-4- ( 1,@@ 1,2-@@ trifluoro@@ methyl-2-@@ trifluoro@@ methoxy@@ ethoxy ) phenyl &#93; -3- ( 2,6-di@@ fluoro@@ benzoyl ) urea of formula ( i ) and a pharmaceutically acceptable carrier .
non-@@ fo@@ sto@@ stic production of genetic vaccines and enzymes
the composition of claim 17 , wherein said composition is a slow release formulation .
in the treatment of hyper@@ thyroidism , there are no major risk problems in the treatment of hyper@@ thyroidism and are associated with less than 1 % frequency ; postoperative hypo@@ cal@@ ci@@ emia or hypo@@ parathyroidism is especially distinguished in patients with mor@@ bus bas@@ se@@ do@@ w disease in approximately 2 % of all our patients .
injection device according to claim 6 or 7 , characterized in that the tooth height of the teeth of the teeth ( 17 ) corresponds to the push rod ( 4 ) of a step height of the sta@@ ir member ( 13 ) .
the concentrate is a clear viscous , yellow to bro@@ wn-@@ yellow solution .
dental treatment chair according to claim 11 , characterized in that the slip coupling ( 52 ) has an elastically compressed coupling ring ( 54 ) between two friction surfaces .
in case of impaired white blood cells , you may experience fever or infections .
the method of claim 15 , wherein said antibody is for the manufacture of a medicament for administration to an animal .
the composition of claim 5 wherein the poly ( ortho ester ) is the reaction product of a ke@@ ene@@ acetal and a polyol .
a method as in claim 7 , wherein the active tgf-β is selectively eluted from the hydrophobic interaction matrix in step ( f ) by applying an elution gradient with increasing alcohol concentration .
the use of claim 27 , wherein the neurodegenerative disease is alzheimer &apos;s disease .
a compound according to claim 3 which is 17β- ( cyclopropylamino ) -4,4-di@@ fluoro@@ androst@@ -4-en-3-one .
9 . a solution according to claim 6 wherein the surfactant is ar@@ la@@ so@@ ve 200 ® .
the structure ( 1 ) of claim 1 comprising individual cores of a width in the range of 20 to 2000 mm .
limited experience is available in combination with byetta and thiazolidin@@ edi@@ ones ( see section 5.1 ) .
method according to at least one of the preceding claims , characterized in that the temperature of the second calen@@ der rolling pair ( 6.@@ 1.@@ 6.2 ) is held at room temperature , i.e. between 18 and 25 ° c. a method according to at least one of the preceding claims , characterised in that a ( first ) calen@@ der rolling pair ( 4.1 , 4.2 ) is used as the pre-@@ sealing tool .
a method as described in claim 25 or claim 26 , comprising laminating the tendon to the fas@@ cial envelope in the same direction as the orientation of the collagen .
you shoul@@ dn &apos;t have to do it .
intervertebral implant according to claim 1 , characterised in that the joint surfaces ( 14 , 15 ) are formed in one piece with the support plates ( 4 ; 6 ) .
diclofenac interaction studies in healthy adults showed no pharmacokinetic interactions between sodium oxybate and diclofenac .
official batch release : in accordance with article 114 of directive 2001 / 83 / ec , the official batch release will be undertaken by an official drug control laboratory or a laboratory designated for that purpose .
use according to any one of claims 1 to 8 , characterized in that the composition also comprises at least one hydrophilic or lipophilic complementary sunscreen agent active in the uva and / or uvb region and optionally having a sulphonic acid group .
do not receive key@@ tru@@ da if you are pregnant unless your doctor tells you to .
a formulation according to claim 2 , wherein the ratio of tri@@ propylene glycol methyl ether : alcohol is 80 : 20 .
an implant and delivery device according to claim 14 , wherein the one or more flow control filaments substantially fill the tube passage to prevent flow through the tube passage .
3,@@ 5.3 &apos; -tri@@ iodo@@ thyronine sulfate as thyro@@ mimetic agent and pharmaceutical formulation thereof
an endoluminal graft system according to any preceding claim , wherein the side branch graft ( 2 ) is made of ptfe , polytetrafluoroethylene .
the method of claim 13 , wherein the antibiotic is ce@@ fe@@ pimozide dihydrochloride monohydrate .
the method of claim 53 , wherein the tissue type is muscle .
uncommon : ec@@ chymo@@ sis , bullous e@@ rup@@ tions , exfoliative dermatitis , erythema multiforme , steven@@ s- johnson syndrome , toxic epidermal necrolysis , angioedema
- examples of signs of a lack of sugar in the brain : headache , hot dog , feeling sick , vomiting , tiredness , drowsiness , difficulty sleeping , restlessness , aggres@@ siveness , difficulty concentrating , impaired reaction , loss of appetite , loss of appetite , feeling abnormal ( paraesthesia ) , numbness and tingling in the mouth , dizziness , loss of self-@@ control , aids , seizures , loss of consciousness .
a pouch according to claim 3 , characterised in that the pivot pin part has a reinforced end ( 36 ) to prevent out an out@@ cur@@ ring of the pivot pin part from the bore .
use according to claim 8 , wherein said protein carrier is one selected from the group consisting of albumin and proteo@@ glycans .
in comparison to mammography and sono@@ graphy , mri revealed 6 oc@@ cul@@ t carcinomas and occurred in 19 / 63 carcinomas ( 3@@ 0.2 % ) .
the oligonucleotide according to one or more of claims 1 to 10 , wherein one or more groups of at least 1 to 4 linked to each other are not modified .
use according to any preceding claim , wherein the hydrogel comprises at least 75 % by weight of pyro@@ gen-free water .
in brain infar@@ ctions , micro@@ angio@@ pathic lesions and very poor colla@@ teral vascular occlu@@ sions were found to be differences in the normal individuals in the mr perfusion images .
first genital herpes : 250 mg three times a day for five days .
a pneumococcal polysaccharide-@@ immunogenic protein conjugate produced by the method : ( a ) culturing a pneumococcal and isolation of crude pneumococcal polysaccharide or solubilization of pneumococcal polysaccharide powder or solubilization of pneumococcal polysaccharide powder or solubilization of pneumococcal polysaccharide powder or solubilization of pneumococcal polysaccharide powder or solubilization of pneumococcal polysaccharide powder , ( b ) of the polysaccharide of step ( a ) from step ( a ) to an end-@@ point , which is predicted by the process of step ( a ) to an end point of a pneumococcal polysaccharide or solubilization of pneumococcal polysaccharide powder
use according to any one of the preceding claims wherein the weight ratio of 40@@ -o- ( 2-hydroxyethyl ) -@@ rapamycin to cyclosporin a is about 1 : 16 .
membrane according to claim 1 , characterized in that the preferred concentration of the diamine component ( b ) is 15 to 50 mol % , the diamine component ( c ) is 20 to 75 mol % and the diamine component ( d ) is 10 to 40 mol % , based on 100 mol % , based on 100 mol % .
the method of claim 33 , wherein the hydrochloric acid is present in an amount of from about 0.1 to about 6 mole equivalents of the amount of 4-hydroxy@@ acetophenone .
aerosol suspension preparation according to claim 1 , characterized in that it comprises a surfactant .
device ( 2 ) according to claim 3 , in which the display means ( 26 ) is a display screen ( 30 ) and / or a pressure device ( 32 ) for hard@@ copy .
process for the preparation of optically active glycol derivatives .
each viread film-coated tablet contains 163 mg tenofovir disoproxil ( as fumarate ) .
absorption of tipranavir in combination with low dose ritonavir is reduced in the presence of antacids ( see section 4.5 ) .
a patch for the following contracting states : es , gr 1 . a process for the preparation of a compound of the formula : wherein ph is substituted or different , r ₁ is amino and / or cyano substituted phenyl , trifluoromethyl and / or cyano , r ₁ is amino and / or cyano , r ₁ is amino ( c ₃ -c ₈ -cycloalkyl-c ₁ -c ₇ alkyl ) amino , n- ( c ₃ -c ₈ -cycloalkyl-c ₁ -c ₇ alkyl ) amino , n- ( c ₃ -c ₈ alkylcarbonyloxy ) c ₁ -c
the method of claim 31 , wherein the transformant is selected in a medium containing an antibiotic produced by a lactic acid bacterium .
abilify can be taken with or without food .
11 . device according to claim 9 or 10 , characterized in that it also comprises a handle ( 50 ) slidable on the rod ( 11 ) , which slides in at least one of the grooves ( 24a , 24b ) in which one of the rotor ( 30a , 30b ) slides and slides into the desired position .
a pharmaceutical composition according to any one of claims 1 to 8 in which the remainder of the agent is formulated as a lotion , cream , ointment , gel or solution .
the chemical stability of vistide mixed with saline solution has been demonstrated in glass bottles , in infusion bags of polyvinyl chloride ( pvc ) compounds or ethylene / propylene copolymer and in pvc based vented intravenous administration sets .
a compound as claimed in any one of claims 1 to 4 in which r 1 is optionally substituted phenyl .
neutropenia and anaemia ( both occasionally severe ) , thrombocytopenia very rare :
substituted furan and pyrrole derivatives and use as lipoxygenase enzyme inhibitors , especially 5-lipoxygenase inhibitors .
the tablet may be crushed and mixed with water or apple sa@@ uc@@ e immediately before intake .
the garment of claim 5 wherein said closure means comprises hook straps ( 13 ) .
process according to claim 11 , characterized in that a sterol is added to the preparation of step d ) .
use of a xylanase according to claim 1 or 2 for feed .
ellipta part of a multipack , can ’ t be sold separately .
what liprolog mix25 100 u / ml suspension for injection in cartridge contains
kinzalkomb has been studied in five main studies involving a total of 2,@@ 9@@ 85 patients with mild to moderate hypertension .
a compound of formula i as claimed in claim 1 for use in alleviating the symptoms of estrogen depri@@ vation .
use according to any one of the preceding claims , wherein the salt is sodium bicarbonate .
zoledronic acid teva generics is supplied in multipacks containing 5 or 10 sachets .
oral administration , once daily 15 mg ibaf@@ loxacin / kg body weight
the system of claim 1 , wherein the conditioning event is a particular pattern of activation times of different regions of the heart detected by multiple electrodes .
the dose may be increased as required with consistent effects and tolerability .
as therapy with the combination of nevirapine plus efavirenz does not show any additional efficacy and more adverse events than separate use with each medicinal product , these therapy is not recommended .
a compound according to any one of claims 1 to 17 wherein x 1 is selected from a chemical bond , -s- , -o- , -nh- or -n ( c 1 -c 3 alkyl ) .
memantine accord 20 mg film-coated tablets memantine hydrochloride
use only clear , colourless solutions .
use of a h@@ vegf antagonist in the manufacture of a medicament for treating age-related macular degeneration , wherein the h@@ vegf antagonist disrup@@ ts binding of h@@ vegf to the fl@@ t receptor and / or flk@@ -1 receptor and wherein the h@@ vegf antagonist is an anti-@@ vegf antibody or fragment thereof .
a medical prosthesis according to any one of claims 1 to 4 , wherein the ratio of equivalents of a chain extender to equivalents of polycarbonate glycol is between 0.75 to 1 and 12 to 1 .
the method of claim 4 , wherein the antibody immunoreactive with a peptide having a specified sequence of 10 to 18 amino acids from the a protein is a polyclonal antibody with a bound detection marker .
compound of formula ( i ) according to any one of the preceding claims , in which r 4 is chosen from c 1-6 -alkyl , halogen , cyano and aminosulfonyl .
a urine sampling apparatus according to any one of claims 8 to 37 , further comprising a downwardly open washing chamber ( 162 ) disposed inward and adjacent to the inner periphery of the front portion of the edge of the bowl assembly , and a cleaning device is disposed in the washing chamber , wherein the urine sampling vessel is introduced into the washing chamber and washed with water , and washed with water , the used water being washed into the bowl .
pack according to one of claims 1 to 7 , characterized in that the planar reinforcing element ( 22 , 23 ) comprises a ring .
stretcher ( 1 ) according to claim 1 or 2 , characterised in that the hinges ( 21 ; 22 ) each are arranged on a different element ( 10 ; 11 ) on different joint axes and each is arranged at a joint ( 21 ; 22 ) of the part-@@ elements ( 10 , 11 ) on the same hinge axis .
1 ml sterile solution contains 1.@@ 850 g@@ b@@ q ( 90y ) chloride corresponding to 92 ng y@@ t on date of calibration .
chroman derivatives of the formula i in which r and r are each methyl , r is oh or o@@ ac , r and r are h , r and r are h or methyl , r is unsubstituted or mono-substituted by methyl , ethyl or isopropyl substituted by methyl , ethyl or isopropyl substituted by methyl , ethyl or isopropyl substituted by methyl , ethyl or isopropyl substituted oxo@@ dihydro@@ pyridyl or oxo@@ dihydro@@ pyridinyl ; r ) trans@@ -3,4-dihydro-@@ 4- ( 1,6-dihydro-@@ 1-methyl-@@ 6-oxo-@@ 3-@@ pyridazin@@ ylamino ) -2,4,@@ 7-di@@ methyl-4- ; b ) trans@@ -3,4-dihydro-@@ 4- (
a cosmetic composition according to claim 1 , wherein the beh@@ yl@@ lact@@ ylate is present in an amount of 15 to 30 % by weight .
a pharmaceutical composition according to claims 8 , 9 or 10 which is in a form suitable for oral administration .
co-administration of effentora with strong cyp3a4 inhibitors ( e. g .
circular , hair needle-@@ shaped , circular / hard needle-@@ shaped , le@@ fe@@ f@@ led , and hairpin e@@ rup@@ tions of the ham@@ mer@@ head &quot; ham@@ mer@@ head &quot; ribozymes
device according to one of the preceding claims , wherein a third chamber is located in the selectively opening passage region ( 3 ) between the first ( 5 ) and the second chamber ( 6 ) .
a system according to any one of the above claims , characterized in that the sound filtered and reinforced are reinforced .
a pacemaker system ( 25 ) comprising pulse generating devices ( 26 , 28 ) for generating and delivering pacing pulses ( mp@@ i ) to the heart chamber of a patient , a detecting device ( 30 ) for detecting the pulse generation of a patient , and a delivery device ( 31 ) for detecting the pulse generation of a patient , and a delivery device ( 42 ) for detecting an escape interval of a heart chamber , and a triggering device ( 31 ) for detecting an escape interval of a heart chamber , and a
14 observed for fasting normal levels at baseline ( &lt; 1,@@ 16 mmol / l ) which increased to high ( ≥ 1.@@ 4@@ 67 mmol / l ) and increased changes in fasting triglycerides from borderline at baseline ( ≥ 1.@@ 16 mmol / l &lt; 1.@@ 4@@ 67 mmol / l ) to high ( ≥ 1.@@ 4@@ 67 mmol / l ) .
the method of claim 12 wherein the molar ratio of arginine to ibuprofen is less than 0.@@ 97 : 1 .
a humanized antibody that specifically binds to v@@ t2 and / or a v@@ t2 variant , said humanized antibody comprising at least one cdr from a non-human antibody in a human variable region framework .
how much to take the recommended dose is one tablet ( 10 mg ) once a day .
device according to claim 1 , characterized in that it comprises a charge calibration element ( 36 ) which supplies electric energy to the electrodes ( 32 , 34 ) .
an ion selective electrode with i. a reference electrode in physical contact with angiotensin ii a reference composition which is in physical contact with one side of ii@@ i of an ion-@@ selective membrane comprising the composition of any one of claims 1-5 .
milk , yo@@ g@@ urt ) , or with mineral enriched drinks ( e.g. , calcium for@@ tified orange juice ) ( see section 4.5 ) . • the other ingredients are : • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
the method of claim 22 , wherein the shell or soft animal is selected from the group consisting of gar@@ ne@@ ses , hu@@ ds , flow cancers , cra@@ ving , ven@@ u@@ sc@@ s , oy@@ sters , and mi@@ s@@ sa@@ ps .
a process according to any one of claims 9-@@ 17 , wherein the single crosslinking agent is the polymerization mixture ( i ) .
11 c@@ cp direc@@ tor s@@ park , cor@@ p a2 , eto@@ a@@ j 5 0@@ 13@@ 7@@ 14 buc@@ ure@@ ş@@ ti tel : + 40 21 207 18 00
a purified biologically active tnf-@@ r protein according to claim 9 , comprising the sequence of amino acid residues 1-2@@ 35 of figure 2a .
process according to claim 10 , characterized in that one or more pi@@ li selected from the group consisting of k@@ 88@@ ab , k@@ 88@@ ac , k@@ 9@@ 9- and 98@@ 7@@ p-@@ pi@@ li are used .
you should check with your doctor or pharmacist if you are not sure .
if you use an insulin pump
a forearm walking support in one of the positions n ° 1 , n ° 10 and n ° 13 me the following characteristic of the elbow cuff : the lower part of the elbow cuff has been designed to provide one of the following characteristics : the lower part of the elbow cuff , and to the segments ( ab , cd ) of the elbow and to the segments ( ab , cd ) in a plurality of flanking positions against a panel , especially in the three-@@ quar@@ ters of the lower arm support .
a method according to claim 14 , wherein the hydrogen bonds are formed between the ligands on the first strand and the ligand on the second strand .
high stability porous zirconium oxide beads .
syringe device according to one of claims 9 and 12 to 16 , characterised in that the guide elements ( 14 , 14 &apos; ) have a projection section ( 51 , 154 ) suitable for protecting the fingers with respect to the needle when the guide elements holding the guide elements .
apparatus according to claim 1 , further comprising an energy source ( 3 ) for the control device ( 4 ) .
a hair treatment composition according to any one of claims 1 to 4 , wherein the non-reducing organic chelating compound is present in an amount of 0.1 to 10.0 % by weight .
alteration of fine chemicals in organisms by genetic modification of the shi@@ k@@ im@@ ate pathway
hair conditioning compositions comprising imidazol@@ ines and amino functional silicones or dimethi@@ cones
the overall incidence of mortality was 19 % , only patients with heart failure died .
votubia with other medicines votubia may affect the way some other medicines work .
method according to claim 22 , characterized in that the timer is fed by the fuzzy controller ( 24 ) after a certain number of cardiac beats , and the heart beat frequency is determined as an arithmetic mean of several measurement values .
the suction pad has a round suction disc ( 10 ) which is provided with an adhesive point ( 16 ) on one side .
do not use kogenate bayer 500 iu if you notice any particles or the solution is cloudy .
process according to one of claims 6 to 10 , characterized in that the pulverulent partially stabilized zirconium oxide is sprayed into the form of a distinc@@ tly spherical agglomerates to obtain a distinc@@ tly spherical agglome@@ rate .
treatment with zomarist should not be restarted after discontinuation of treatment with zomarist and normalisation of liver function tests .
in these cases , it is recommended to receive contact with a specialised specialised centre .
a method according to any one of claims 21 to 23 , wherein the housing is separated from the container .
a homeo@@ pathic kit comprising a first , second , third and fourth homeo@@ pathic composition , wherein : the first composition has a homeo@@ pathic dilution of an insulin-like growth factor 1 , the second composition has a homeo@@ pathic dilution of a transforming growth factor beta@@ -1 , the third composition having a homeo@@ pathic dilution of a growth factor derived from b@@ b-@@ platelet , and the fourth composition has a homeo@@ pathic dilution of a granulocyte macrophage colony stimulating factor .
electrical device for transdermal administration of medicaments with an opposing product and method therefor .
a compound which is 1- &#91; 1- &#91; 4- ( cyclohexyl@@ methoxy ) phenyl &#93; -2- ( 4-methylpiperazin-1-yl ) ethyl &#93; cyclohexanol or 1- { 2- &#91; 4- ( 1,3-benzodioxol@@ -1-yl ) piperazin-1-yl &#93; -1- &#91; 4- ( trifluoromethoxy ) phenyl &#93; ethyl } cyclohexanol or a pharmaceutically acceptable salt thereof .
isolated cases of either accidental or visual overdose of tol@@ cap@@ one tablets have been reported .
the dna construct of claim 3 , further comprising a dna sequence encoding a cellulose binding domain ( cb@@ d ) , wherein the cellulose .
microcrystalline cellulose , povidone , silica colloidal anhydrous , talc , titanium dioxide ( e171 ) , red iron oxide ( e172 ) , red iron oxide ( e172 ) .
use of a compound according to any one of claims 1 to 11 for the manufacture of a medicament for inhibiting phosphodiesterase ( pde ) type iv or tumor necrosis factor ( tnf ) in a mammal .
the dosage should be determined by the physician according to the requirement of the patient .
the administration of the product should be clinically supervised in patients with liver disease , in neonates , in neonates or in patients with increased risk of thrombosis or disseminated intravascular coagulation , in view of the potential risk of thrombotic complications in the context of the potential risk of thrombotic or consu@@ al-@@ coag@@ ulo@@ pathy .
animal studies with daclatasvir have shown embryo@@ toxic and teratogenic effects ( see section 5.3 ) .
before the application of ra@@ pli@@ xa , the surface of the tissue should be dried by appropriate standard techniques ( e.g.
the apparatus of claim 1 , wherein the reservoir ( 42 ) includes between about 4 and about 18 liters of the infusate .
the suture of claim 11 , further comprising a tissue piercing needle mounted to extend from the first end portion of the member in longitudinal direction , the needle extending from the sheath .
a compound of formula ( i ) , ( ia ) , ( ib ) or ( ic ) according to any one of claims 1 to 11 , or a pharmaceutically acceptable salt or solvate thereof , for use in medical therapy .
use according to claim 1 , wherein r 1 is h. the use according to claim 1 , wherein r 1 is halogen .
the method of any one of claims 32 to 36 , wherein the graft ( 134 , 166 , 376 , 9@@ 95 , 392 ) additionally comprises a radio opaque marker within the tubular member .
apparatus according to any one of the preceding claims , wherein the exten@@ so@@ meter means ( 4 ) comprise a resistive semiconductor or piezoelectric exten@@ so@@ meter .
use of a product according to claim 1 or 2 for the manufacture of a medicament for treating congestive heart failure in a mammalian patient in need of such treatment .
an isotonic tc@@ f preparation having an approximately neutral ph , comprising : at least 5 mg / ml tcf ; a basic amino acid or a salt of a basic amino acid .
use of a composition according to any one of claims 1 to 16 for the cosmetic treatment of hair .
the median time to onset of severe neutropenia was 9 days , the median duration of time was 7 days .
chymo@@ papain according to any one of claims 8 to 13 for use in chemi@@ mon@@ ucleo@@ lysis .
sche@@ ring españ@@ a , s. a. c / men@@ de@@ z al@@ var@@ o , 55
the method of claim 51 , wherein the second source is a first source of different inorganic complex .
 breast enlargement in man  chest pain , feeling sick ( general feeling unwell ) , fever  unusual tiredness or weakness   • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
process according to claim 1 , characterized in that the colon@@ ized base@@ ment membrane ( 1 ) remains approximately 72 hours in the nutrient solution .
thiazides should be used with caution in patients with impaired hepatic function or advanced liver disease , as it should be used with caution in patients with hepatic impairment or with advanced liver disease .
outer carton for cozaar comp 100 mg / 12.5 mg film-coated tablets blister
a compound according to any one of claims 1 to 25 wherein all of r 17 , r 18 and r 19 are hydrogen .
active ingredient combinations of 3-@@ iodin@@ e-2-@@ propynyl butyl@@ carbamate and phenoxyethanol and preparations containing such combinations of active agents
the invention relates to a high-@@ throughput method for examining the effect of non-@@ membrane permeable and a gene containing a gene on predetermined target cells with the following steps : ( a ) preparing a compound containing the compound and a cap@@ so@@ id , ( b ) providing the construct into the target cells , ( d ) , the construct of the construct into the target cells , ( d ) essentially simultaneously detecting a reaction generated by the connection to a reaction means contained in the target cell in the containers .
the inhibitor compound or salt of claim 9 , wherein r 1 is phenyl substituted with r 11 at the 4-position and r 11 is substituted from the group consisting of phenoxy , thiocarbamate , benzamido , phenyla@@ zo and phenyl , wherein the phenoxy , thiocarbamate , benzamido , phenyla@@ zo or phenyl is substituted in the meta or para position or both with a single atom or a substituent containing a longest chain of up to 5 atoms except hydrogen .
if you accidentally take too many tablets / capsules , contact your doctor , pharmacist or hospital immediately .
an accommodating lens ( 32 ) according to claim 1 , wherein constriction of the ciliary muscle ( 28 ) causes movement of the lens optic ( 34 , 1@@ 202 ) within the capsule bag ( 20 ) toward the iris to secure the vision in the near region .
29 . a complementary polypeptide obtainable by the method of any one of claims 18-@@ 23 , which is complementary to ( a ) sequence position for sequence position to an original polypeptide , which is oriented with respect to the original peptide or protein , either from the amino terminus to carboxy terminus or from the amino terminus to the amino terminus ; ( b ) is oriented by a nucleotide strand oriented in relation to the original peptide or protein ; ( b ) is oriented by a nucleotide strand oriented to the amino terminus , ( b
composition according to claim 1 , characterized in that the compounds of formula ( i ) are chosen from 5,6-dihydroxyindole , 2-methyl-@@ 5,6-dihydroxyindole , 5-methoxy@@ -6-hydroxy@@ indole , ( 5 or 6 ) -@@ acetoxy ( 6- or 5- ) hydroxy@@ indole , 2-carboxy@@ -@@ 5,6-dihydroxyindole , 3-methyl-@@ 5,6-dihydroxyindole , 2,3-dimethyl-@@ 5,6-dihydroxyindole and their salts .
process according to claim 14 , characterized in that the active substances are chosen from anionic , nonionic , cationic and / or amphoteric or zwitterionic surfactants , cationic and / or nonionic textile softening agents , foam inhibitors , perfume oils , dyes , preservatives , di@@ dou@@ le-@@ dissolving polymers , anti@@ static agents and / or anti-@@ friction aids .
a method of producing an absorbent macro@@ structure having a ever@@ ted volume of not less than 10 mm 3 , the method comprising steps of a ) providing at least a plurality of absorbent polymer particles ( app ) ; b ) providing a carrier ; c ) applying the particles to the app in at least one of the regions in the first and second regions by forming one or more of the steps in the first and second regions by forming one or more of the steps in the first and second regions by forming a different
glass ceramic according to any one of the preceding claims , wherein the weight ratio of mgo to sio 2 is in the range of 32 : 68 to 38 : 62 .
the device of claim 1 , wherein the plug ( 26 ) carries a fluid-tight membrane extending proximally from the proximal end surface of the plug .
a composition for reducing bitter taste , comprising a microorganism according to any one of claims 1 to 3 .
a method as claimed in any one of the preceding claims , wherein the emitted acoustic de@@ formations comprise the harvested statement in a volume that carries information about the medical device in a volume which is too low to be used for patient and / or medical care , and wherein the method is for the patient and / or medical care@@ rs , and wherein the method further comprises the steps of monitoring for patient and / or medical care , and wherein the method further comprises the steps of monitoring a step of the implantable medical device
the use according to claim 1 , wherein the anti-@@ vla-4 antibody composition is administered intravenously .
the use according to any one of claims 2 to 10 , wherein the rar agonist is to be contacted in a therapeutic amount in the range of about 50 to 150 µg .
an article according to any one of claims 9 to 14 , wherein the flavor generating medium comprises tobacco and an aerosol generating material and is formed by heating the flavouring medium which contains tobacco components .
a method of purifying hair which comprises applying to the hair a hair care preparation according to claim 8 or 9 .
the method according to claim 1 , characterized in that when the probes have no tracer markings , the size and amount of the released probes is recorded by mass spectrometry .
fabri@@ k gmbh . , ba@@ d@@ ner straße 23 , a-@@ 25@@ 14 tra@@ is@@ kir@@ chen , austria
use of compounds of the formula i according to claim 1 for the production of medicaments for the treatment of respiratory diseases .
the method of claim 1 , wherein the growth modulating amount provides a mean disease resistance of about 70 % or greater .
a magnetic field generator according to claim 3 or 4 comprising : a temperature exceeding detection means ( 154 , 158 ) for detecting a temperature of said yoke exceeding a predetermined threshold of said yoke ; and a temperature lowering means for decreasing temperature of said yoke based on said temperature exceeding detection means ( 154 , 158 ) .
method for removing transmis@@ sible spongi@@ forming spongi@@ form encephalo@@ phores from protein solutions
an elastomeric glove comprising : a base material comprising an elastomeric polymer ; and a polymeric layer on a surface of the base substance , wherein the polymeric layer comprises a coating polymer , the polymeric coating comprising a polymer of poly@@ amine-@@ epichlorohydrin , the elastomeric polymer of claim 22 wherein the coating polymer comprises a hydrogel epichlorohydrin of claim 22 , wherein the coating polymer comprises a hydroxyethyl methacrylate .
the drug delivery system of any one of claims 1 to 9 , wherein each bead further comprises a non-@@ enteric moisture barrier having water-insoluble , semi-permeable polymeric membranes .
virus according to claim 4 , characterized in that the le@@ po@@ pi@@ pox virus is a my@@ xo@@ ma virus .
the method of any one of claims 1 to 9 , further comprising : - receiving an emergency out@@ signal from a user to the monitoring unit ; and transmitting a signal from the monitoring unit by means of wireless telemetry to the implantable medical device to change the mode of operation of the implantable medical device in response to receiving the signal .
manufacturer ( s ) of the biological active substance ( s ) and manufacturing authorisation holder ( s ) responsible for batch release
the compound of claim 22 , wherein r 1 is n-propyl , y is ethylene and r is isopropyl , namely n 2 phenylethyl n 6 - ( 2-@@ propanoyl ) -8- ( pyrazol-1-yl ) -9- ( prop-1-yl ) -9h-@@ pur@@ ine@@ -2,6-di@@ amine .
o take a lot of liquid between meals to help prevent fluid loss .
the fastener according to claim 1 , wherein said means for promoting adhesion includes a reservoir for containing a therapeutic agent .
in another study ( v@@ 59@@ p@@ 6 ) conducted in 524 adolescents , the immunogenicity of men@@ ve@@ o was compared with that of meningococcal polysaccharide 4 vaccines ( ac@@ w@@ y-@@ ps ) .
an apparatus according to claim 31 , wherein the reservoir forms a liquid chamber having a variable volume and the operation device is adapted to dispense fluid from the chamber to the adjustment device and to remove liquid from the adjustment device by expansion of the volume of the chamber .
caution should be exercised when alogliptin is used in combination with metformin and a thiazolidinedione as there is an increased risk of hypoglycaemia in these triple therapy ( see section 4.4 ) .
the pharmaceutical composition of claim 50 , wherein the compound is as 2 o 3 , na@@ as@@ so 2 or sb 2 o 3 .
2 . process according to claim 1 , characterized in that the average concentration of the non@@ fermentable substance in the fermenter ( fi ) is maintained above 22 % by weight ds .
the transdermal therapeutic system according to any one of the preceding claims , wherein the material of the backing layer is non-@@ biodegradable to more than 90 % , preferably more than 99 % .
a method according to any one of claims 1 to 3 , characterised in that the amount of fluid flowing through a timer ( 25 ) is determined by pressuri@@ sing fluid from the fluid source ( 47 ) by feeding fluid from the fluid source ( 47 ) , and the pressure drop with the time to the ratio of the fluid ( 25 ) flowing in a time unit is set through the channel ( 25 ) .
a method according to claim 15 , further comprising coating the coated carrier material prepared in step ( d ) by sing@@ le- or repeatedly applying a coating process according to claim 15 to the coated carrier material , the solid or semi-solid material used in the initial coating process during each coating process , or another .
the invention relates to a device and a method for the administration of xenon and / or a medium containing xenon , especially a xenon containing gas mixture , to a patient , the patient being connected to an inhalation circuit and a cardio@@ pulmonary bypass circuit ( cp@@ b circuit ) .
a compound according to claim 1 which is 5- ( 2-ethyl-@@ 2,3-dihydro-1h-@@ inden-2-yl ) 1- -propyl-@@ oxadiazole or a non-toxic , pharmaceutically acceptable salt thereof .
signs of chest pain may include pain in the neck and shoulder area and in the left arm of the child .
this medicinal product is authorised in the member states of the eea under the following names :
0.25 mm x 8 mm ) .
treatment with hypo@@ kala@@ emic medicinal products concomitant treatment with methyl@@ xanthine derivatives , steroids or non-@@ potassium-sparing diuretics may potentiate a possible hypo@@ kala@@ emic effect of β@@ 2-@@ adrenoceptor agonists .
the wireless eeg system for a sound-@@ induced response according to claim 1 , wherein the electrode array ( 12 ) provides a difference input to the transmission means ( 18 ) .
method of reducing gastrointestinal damage
ossi@@ cular prosthesis with an adjustable rate of sound conduction in the middle ear
a compound according to claim 16 which is 5- &#91; 4- ( n , n-diisopropylcarboxamide ) benzyl &#93; imidazo &#91; 4,5-c &#93; pyridine .
instrument according to one of claims 1 to 24 , characterized in that the shaft ( 12 ; 68 ) is straight .
the method according to any one of claims 1-5 , wherein the peptide de@@ form@@ ylase contains the sequences ( i ) hex@@ x@@ h , ( ii ) eg@@ cl@@ s and ( iii ) g@@ x@@ g@@ xa@@ ax@@ q .
a method for producing crystals of human growth hormone and histidine or a derivative of histidine selected from the group consisting of amides and esters of histidine , such as the methyl or ethyl ester , dipeptides such as his-@@ gly , his-@@ ala , his-@@ leu , his-@@ lys , his-@@ ala , his-@@ leu , his-@@ lys , his-@@ ala , his-@@ leu , and optionally setting the solution at a temperature of from about 0 ° c to about 30 ° c and d ) isolating the solution at a temperature of about 0 ° c to
eu / 1 / 07 / 4@@ 19 / 004 eu / 1 / 07 / 4@@ 19 / 005 eu / 1 / 07 / 4@@ 19 / 006 eu / 1 / 07 / 4@@ 19 / 007 eu / 1 / 07 / 4@@ 19 / 008 eu / 1 / 07 / 4@@ 19 / 009
insulatard innolet 100 iu / ml suspension for injection in a pre-filled pen insulin human ( rdna )
this veterinary medicinal product should not be used in cats as it is not suitable for this species .
toothbrush according to one of claims 1 to 4 , characterized in that the brush head ( 3 ) can be detached from the handle .
centrifugal separation device and method for separating fluid components
a foil cover cover according to any one of the preceding claims , characterised in that the first end ( 14 ) of the foil tube ( 1 ) is connected to the tubular sleeve ( 2 ) by manually releasable fastening means ( 15 ) .
excipient with known effect each hard capsule contains 16@@ 3.@@ 4@@ 41 mg lactose .
ge healthcare as ny@@ co@@ ve@@ i@@ en 1-2 p. o.
therefore , it is important to permanently discontinue the hla-b * 57@@ 01 allele because of the risk of serious or life-threatening reaction abacavir , and patients not re-@@ treated with abacavir if a hypersensitivity reaction cannot be excluded .
the method of claim 18 wherein the hydroxypropyl methylcellulose is present in the suspension in an amount of 3 % by weight .
a purified and isolated dna molecule for use in ensuring the expression of a protein or polypeptide product having epitopes of gp@@ 75 , wherein the gp@@ 75 is from amino acid 22 to amino acid 6@@ 53 of the c-@@ erbb@@ -2 protein , in a prokaryotic and preferably eukaryotic host cell , wherein the dna is selected from : ( a ) dna molecules which are complementary to the dna molecules of ( a ) ; and ( c ) dna molecules which are complementary to the dna molecules of ( a ) ; and ( c )
a method of identifying nucleic acids differentially represented in two populations of nucleic acids , which are labelled with an individual from a clone derived from a clone , wherein one of rna and another is represented by dna , comprising the steps of : a ) annealing rna and dna sequences ; b ) treatment with rna@@ se@@ h and dna sequences ; b ) co@@ pying and amplifying residual rna molecules by polymerase reaction reaction , the sequences located outside the specific rna sequence , the sequences located outside the specific rna sequence as a primer .
the method of claim 31 , wherein the sulfhydryl tag is phosphoramidite .
during titration , if adequate analgesia is not achieved within 30 minutes after initiation of a single tablet , a second effentora tablet of the same strength may be used .
use according to any one of claims 1 to 7 , characterized in that the radicals r 3 and r 4 are hydrogen .
this results in passive protection against tetanus for at least 21 days following concurrent vaccination .
( 4@@ 9-@@ 221 ) 97 66 80 fax ( 4@@ 9-@@ 221 ) 97 66 82 78 e-mail :
a cosmetic composition comprising : a ) 0.01 to 50 weight percent vitamin b compound ; b ) 0 to 90 % by weight of a emollient component ; c ) 0.01 % to 40 % by weight of a polar emollient ; c ) 0.01 % to 40 % by weight of a composition , wherein the vitamin b 3 compound is added to the composition in a manner that the vitamin b 3 compound concentration exceeds the saturation solubility of the vitamin b 3 compound in the polar solvent .
3 ml solution in a 3 ml pre-filled syringe ( type i glass ) with a plunger stopper ( with fluorocarbon polymer coated bromobutyl ) .
an isolated polypeptide selected from the group consisting of : ( a ) a polypeptide comprising the sequence of seq id no : 7 ; ( b ) a polypeptide comprising the sequence of seq id no : 8 ; ( c ) a polypeptide comprising amino acids 43 to 66 of seq id no : 1 ; ( c ) a polypeptide comprising amino acids 43 to 66 of seq id no : 1 ; ( f ) a polypeptide comprising amino acids 43 to 66 of seq id no : 1 ; ( d ) a polypeptide comprising
in most cases , grade 1 or 2 diarrhoea and did not lead to discontinuation of lapatinib treatment .
the electrode system ( 10 ) of claim 10 , wherein the flexible mesh ( 50 ) has a non-conductive material having an intermediate means for supporting the electrically conductive gel means ( 16 ) thereon .
the applicant also decided to provide further comparative data on the inhalers provided with their respective inha@@ lations to obtain reliable information on the particle size distribution .
compounds having agoni@@ stic activity at the beta@@ 2-@@ adrenergic receptor and the muscarinic receptor
the clinical remission rate at week 6 was 10 % ( difference to placebo 2 % , 95 % ci : -6 , 10 ) when administered without corticosteroids , compared with 20 % ( difference to placebo 14 % , 95 % ci : -1 , 29 ) when co-administered with corticosteroids .
method for screening compounds for preventing infection or patho@@ genicity
method for altering the nutrient composition of milk secreted by milk donating animals
33 particulars to appear on the outer packaging
the medical suture holding member according to claim 1 , wherein said synthetic high molecular material is a copolymer containing at least 30 mole percent or more poly-@@ ε-caprolactone .
adverse reactions in adult clinical trials and in post-marketing experience and suspected ( at least possibly ) related to treatment are listed in table 2 by body system organ class and frequency .
the combination composition of claim 21 , wherein the immunosuppressant is selected from azathioprine , cyclophosphamide , methotrexate , bre@@ quin@@ ar sodium , deoxy@@ sper@@ gu@@ alin , mi@@ z@@ ori@@ bine , 2-morpholino@@ ethyl@@ mycophenolate , cyclosporin , rapamycin , tacrolimus hydrate , leflunomide , ok@@ t-3 , anti-@@ tnf-@@ α antibody , anti-@@ il-6 antibody , and f@@ ty@@ 720 .
pharmaceutical preparation according to one of claims 1 to 4 , characterised in that it has polyethylene glycol with an average molecular weight of 400 to 6000 .
other serious medical complications , such as severe deterioration of renal function , disease related hospit@@ alization and progression of disease to end-stage renal failure , occurred in these patients .
paediatric population the safety and efficacy of lu@@ rasi@@ done in children and adolescents below 18 years have not been established .
swelling in the area of use is very common ( more than 1 in 10 people ) . • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
however , serious systemic allergic reactions ( anaphylactic reactions ) have occurred in patients during aldurazyme infusion or up to 3 hours thereafter .
an antibody according to any one of claims 1 to 3 which has no substantial binding activity against other indoles or glucuron@@ ides present in human samples .
if you forget to take isentress  
the stent of claim 41 , wherein the balloon is curved in an expanded state and extends from a proximal end and a distal end .
thrombus filter with separable grasp@@ er
the method of claim 3 , wherein the thermostable dna polymerase is taq polymerase .
compound according to claim 1 or 2 , characterized in that r 2 is constituted by the group consisting of ethyl , ethenyl , ethynyl , propyl , 1-@@ propenyl , 1-@@ propynyl , 1,2-@@ prop@@ dienyl and cyclopropyl .
a pharmaceutical composition according to claim 6 in dry form .
driving a car or operating machinery ) .
the particle of claim 1 wherein the phospholipid is a synthetic phospholipid or a modified natural phospholipid . the particle of claim 1 wherein the phospholipid is selected from the group consisting of phosphatidyl@@ chol@@ ines , phosphatidyleth@@ ano@@ lamines , phosphatidyl@@ ser@@ ines , phosphatidyl@@ inosi@@ t@@ ols and mixtures thereof , as claimed in claim 1 , wherein the phospholipid : titanium dioxide based ratio is in the range of 0.1 : 100 to 15 : 100 .
the protective device according to any of claims 18-@@ 25 , wherein the viewing tube comprises at least one working channel and wherein the protector comprises at least one tubular extension which can be aligned with the channel .
a method according to claim 4 , characterized in that the result of the erythrocyte sedimentation test is determined by the formula : wherein : the diagnostic coefficient alpha α indicates a tumor when α ≥ 1.5 , a e@@ sr index of the test test , b 1 and b 2 e@@ sr index of the control tests , x maximum value of the es@@ r in test a or the mean value of b 1 and b 2 .
a pharmaceutical composition comprising an effective amount of a compound of claim 1 and an effective amount of a h 1 receptor antagonist and a pharmaceutically active carrier .
the locking of the rib members ( 17 ) is carried out by a pin ( 32a ) which can be inserted into a bore ( 22 ) after the type of a split connection .
claims for the following contracting states : at , be , ch , de , dk , fr , gb , it , li , lu , nl , se a compound of the formula or a pharmaceutically acceptable salt or solvate thereof , wherein g is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar
a drive mechanism according to claim 1 or claim 2 , characterised in that the piston means ( 180 ) comprises a threaded screw .
an inhalation device according to any one of claims 1 to 3 , wherein the mouthpiece actuator and the mouthpiece are directly coupled .
a method of releasing genetic material from a solid medium which binds genetic material , said method comprising : a .
apparatus for automatic control of spontaneous respiratory support .
the lead system according to claim 24 , wherein the tip engaging region ( 100 ) is electrically conductive .
device according to claim 10 , characterized in that the markings are formed by metallic coating , preferably platinum coatings attached to the jacket ( 17 ) of the catheter ( 1 ) .
&#91; invented name &#93; should not be taken by children .
a compound according to any one of the preceding claims wherein a 2 represents a single bond , a c 1-4 alkylene group or a c 2-5 alkenylene group .
the garment of claim 7 , wherein said first body panel ( 4 ) comprises a first pair of side panels , and wherein said second body panel ( 6 ) comprises a second pair of side panels , each of said side panels ( 6 ) having a second pair of side panels , each of said side panels ( 6 ) having a second pair of side panels , wherein each of said side panels ( 6 ) has a second pair of side panels , each of said side panels ( 6 ) having a second pair
a method for producing an immunotoxin suitable for use in humans or animals comprising a toxin fused to an antibody capable of recognizing diseased or disease-@@ causing cells wherein the toxin is a modified exotoxin according to claim 1 , wherein the modified exotoxin gene comprises domains ib , ii and iii of the exotoxin .
a prosthesis according to claim 1 , characterised in that the angle of inclination of the planar surfaces has a value lying between 1 ° and 10 ° .
no specific treatment is available for triumeq overdose .
thermoplastic material device and two-@@ stage casting method
and you don &apos;t have any fri@@ ends . ~ ~ ~ no fri@@ ends , even your bro@@ ther .
use according to any one of claims 1 to 15 and 17 , characterized in that r 3 is a linear or branched alkyl group containing 1 to 6 carbon atoms , preferably a c 1 -c 4 alkyl .
the seroprotection rate for varicella virus ( ≥ 5 gp@@ elisa units / ml ) was 9@@ 0.9 % ( between 8@@ 0.8 % and 9@@ 4.5 % ) ; this antibody concentration correlates with long-term protection against varicella .
other medicines and eucreas tell your doctor or pharmacist if you are taking , have recently taken or might take any other medicines .
introduction of eudra@@ sa@@ fe ii in january 2003 major bandwidth implemented introduction of eudra@@ work@@ space in june 2003 introduction of the pk@@ i infra@@ structure to december 2003 introduction of the ip / vp@@ n infra@@ structure to december 2003
agent according to one of claims 1 to 7 , characterized in that the aqueous medium contains a tonicity control agent in an isotonic state corresponding to the production of a blood plasma .
a process according to any one of claims 4 to 9 , characterized in that the temperature is 25 to 50 ° c. a process according to any one of claims 4 to 10 , characterised in that the molar ratio of 1-@@ c ₃ to c ₁ ₂ alkyl@@ glucoside to the fatty acid ranges from 0.001 to 5 to 1 .
microparticles according to claim 26 , characterized in that the substance is chosen from gink@@ go@@ lides and their derivatives .
summary of the safety profile in clinical trials in several indications including allergic rhinitis and chronic idiopathic urticaria , at the recommended dose of 5 mg daily , more adverse reactions were reported in patients with neoclarityn than in patients treated with placebo .
primary hypercholesterolaemia and mixed hypercholesterolaemia in the efficacy and safety of simvastatin in patients with hypercholesterolaemia , treatment with 10 mg , 20 mg , 40 mg and 80 mg simvastatin per day resulted in a 30 % , 38 % , 41 % and 47 % mean reductions in ldl cholesterol .
a compound of formula i as claimed in claim 1 , wherein x is cr 7 = ch , wherein r 7 is hydrogen or alkyl of 1 to 3 carbon atoms .
consideration should be given to determination of serum lipids and blood glucose in the fasting patient .
dna according to any one of claims 1 to 8 , characterized in that the regions coding for the complete repeats at position + 26 to + 92 , position + 98 to + 164 , position + 182 to + 249 and position + 258 to + 324 are superimposed in fig . 7 .
surgical instrument according to one of claims 10 or 11 , characterized in that the at least one axial stop ( 50 ) is located adjacent or in the region of the at least one first coupling member ( 52 ) .
as a matter , the prac recommended the amendment of the marketing authorisations for the substances acting on the ras .
a method according to claim 5 or claim 6 , in which the modified cells are disrupted , followed by collecting the plasma membrane fragments .
a method for screening compositions for identifying agonists , antagonists or modulators of acid-@@ sensitive ion channels , comprising contacting cells encoding acid controlled channels with the composition to be analyzed in the presence of phe-@@ met@@ arg-@@ phe-@@ amide ( f@@ mr@@ f@@ amide ) and a sufficient acidic extracellular ph to thereby amplify the acid controlled channel currents ; and determining whether the composition enhances or inhibits the opening of the acid susceptible ion channels of the deg / en@@ ac channel family .
a pharmaceutical composition comprising a compound according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier .
the supportive endoluminal graft of any one of the preceding claims , wherein the trun@@ vering component ( 101 ) has a rupture liner ( 122 , 123 ) having a resilient wall of substantially inert , biocompatible material , wherein the rubber liner is mounted on the internal surface of the frusto-conical component and the compliant wall has a diameter size which is expanded with the constriction component .
it is recommended that all women of childbearing potential use effective contraception during treatment .
there is a significant change in the duration of the d@@ ad@@ -@@ co@@ g and a negative change in the d@@ ad@@ -@@ co@@ g in the setting of a co@@ vari@@ ation of the status of the d@@ ad@@ -@@ co@@ g in the setting of the patient in the treatment of patients with a history of myocardial infarction . • a negative change in d@@ ad@@ -@@ co@@ g has been shown to be an improvement in the duration of observation of the patient ’ s ability to drive and to use machines .
process according to claim 1 , 2 or 3 , characterized in that it contains 5 to 15 % by weight of acetylsalicylic acid and / or benzyl alcohol . the stable solution of acetylsalicylic acid according to any one of claims 1 to 4 , characterized in that it contains 5 to 15 % by weight of acetylsalicylic acid , 10 - 40 % by weight of dimethyl isosorbide monoethyl ether and from 0.005 to 2 % by weight of saccharin and / or cyclooxygenase and / or from 1 to 40 % by weight of saccharin and /
a removable and sterilizable , or preferably disposable suction cannulas formed from transparent material , characterized in that they are suitable , in particular in its insertion region , to form a hollow body to form an instrument according to any one of claims 1 to 3 .
the use of a gamma@@ -amino@@ butyric acid agonist , but not diazepam , for the manufacture of ophthalmic medicament intended for topical application for the treatment of ocular excess pressure , for example for the treatment of glaucoma .
multi-@@ punch balloon catheter for reducing damage to coated expandable medical implants
the apparatus of claim 4 , wherein a portion of the swe@@ dish switch ( 110 ) is also disposed on one of the first and second side surfaces of the control unit .
the recombinant vaccinia virus of claim 3 , wherein the immunodeficiency virus is monkey immunodeficiency virus .
the method of claim 7 , wherein the water-soluble polymer has a molecular weight greater than 5000 and less than 100,000 , in particular of one of about 18@@ 500 .
use according to any one of the preceding claims , characterized in that the medicament for the treatment of tumour diseases has an anti@@ mitotic effect in mammals .
a method according to claim 1 , in order to obtain specific gene sequences and their expression products in target cells present in cell environ@@ ments which differ or absent from their origin .
4.2 posology and method of administration
a compound of formula ( i ) as claimed in claim 1 , or a pharmaceutically acceptable salt thereof , for use as a tyrosine kinase inhibitor .
when zal@@ mox@@ is is used , this reaction may be treated with ganciclovir or val@@ ganciclovir .
because the number of patients with adreno@@ cortical carcinoma is low , the disease is considered ‘ rare ’ , and lyso@@ dren was given on 12 march 2007 .
the system of claim 2 , wherein the plurality of back@@ reflective markers ( 406 ) comprises : an elevated reflective surface ( 702 ) , and a flat surface ( 704 ) disposed on the basis of the raised reflective surface .
store in the outer carton in order to protect them from light .
the hybrid plasmid according to claim 2 , further comprising a transcription terminator of the alkaline protease of bacillus licheniformis atcc 5@@ 39@@ 26 operably linked to the mature region coding for the proteolytic enzyme of bacillus len@@ tus dsm 54@@ 83 according to claim 1 .
a method according to claim 11 or 12 comprising : ( a ) exposing the photo@@ polymerizable composition to a first reaction temperature of the first dose of actinic radiation for initiating the polymerization of the free radical functional group after a limited induction period t ; and ( b ) subjecting the photo@@ polymerizable composition to a second dose reaction temperature of a second dose of actinic radiation to initiate polymerization of the cationically active functional group after a limited induction period .
this is up to 1.@@ 58 g ethanol per vial , equivalent to 40 ml beer or 17 ml wine .
the invention also relates to a method for producing the peptides and to the pharmaceutical use thereof .
a cavit@@ y-@@ retaining tool for surgery according to claim 18 , wherein said connecting means ( 246 ) is adapted to be passed through a hole in said foil member ( 233 , 312 , 382 ) by a needle segment ( 241 ) which penetrates said film member ( 233 , 312 , 382 ) .
an implantable orthopaedic hip joint prosthesis according to claim 1 , wherein the projection of the insert is deformed when the insert is inserted into the tray and the protrusion in the un@@ deformed state returns when the projection is positioned in the roof of the shell .
choose a flat , clean and well-@@ lit work surface .
the following pack sizes are available : outer cartons containing 1 bottle containing 30 film-coated tablets and cartons containing 90 ( 3 bottles of 30 ) film-coated tablets .
system according to claim 6 , characterized in that the care device ( 2 ) is designed so as to send a predetermined alarm division by means of wireless communication using the mobile station to the data processing system ( 14 - 20 ) after a second predetermined time is elapsed , and in response to an indication of the detection means ( 10 ) , the at least one product ( 8 ) has not been removed .
 loss of appetite , headache , constipation ( difficulty passing stools ) , feeling sick ( nausea ) , vomiting , rash , hair loss , tiredness .
agent according to one of claims 10 and 11 , characterized in that , with the amphiphilic non-ionic lipid ( lipids ) , at least one additive is associated to modify the permeability or surface charge of the vesicles and which is capable of modifying the permeability or the surface charge of the vesicles and which is selected from the group consisting of a long-chain alcohol and the corresponding sodium salts thereof , long-chain alcohols and their salts , long-chain amino alcohol esters and their salts and quaternary ammonium derivatives , alkyl sulphates and ionic sterol derivatives .
the method of claim 1 , wherein the therapeutic gene is the dystro@@ phin gene .
a support structure as claimed in claim 1 , characterised in that each cam ( 190 ) is offset from the preceding and subsequent cam ( 190 ) such that the elements ( 30 ) , one after the other or a group after the other , after the other , according to a predetermined sequence from the normal position are moved downwards and returned back to the normal position .
use of pox@@ en@@ tants from combinations of multiple pox or para@@ pox virus strains for the preparation of medicaments for pre@@ finite tumor therapy to reduce pain and optimi@@ sation of the patient &apos;s well@@ ness .
a composition according to any one of claims 1 to 17 , wherein the ifn-β is maintained in a solution at a ph of 3.5 to 9.5 for a period of 24 hours at 4 ° c. the composition of claim 18 , wherein the ph is a neutral ph .
a spherical biocatalyst according to claim 1 or 2 , characterized in that the enzymatically active material contains an oxidoreductase or is an oxidoreductase .
a lifting means according to any one of the preceding claims , characterised in that the flow valve ( 12 ) is provided with a setting means , such that during the inflating and / or deflation of the inflatable seat , the relative pressures of the fluid have the relative pressures of the fluid in the compartments ( 14 ) of the inflatable seat to adjust the proportion of the fluid , which is supplied to each of the compartments ( 14 ) and / or extending them , depending on the pressure differences of the fluid in the
the pharmaceutical composition according to any one of claims 1 to 3 , wherein the heparin derivative has a molecular weight between 2500 and 6@@ 500 daltons .
the artificial sub@@ retinal implant device of claim 2 , wherein individual micro@@ photo@@ diodes ( 10 ) are embedded in said mes@@ h-@@ like mesh consisting of an inert substance .
however , many therapeutic principles in these arrhythmia are also based on empi@@ ric concep@@ ts and not confirmed in clinical trials , and not supported in clinical studies .
expression of a fusion polypeptide transported without leader sequence from the cytoplasm
a method for producing locally limited x-ray radiation , the device being capable of being inserted into a body of a subject to be treated , the method comprising : providing a ge@@ tter having the steps of : providing a ge@@ tter , which method comprises : providing a ge@@ tter that comprises the steps of : providing a ge@@ tter that comprises the steps of : providing a ge@@ tter that is less than the activation temperature ; placing the cathode within a vacuum housing ; placing the cathode within a vacuum housing ; and increasing the temperature
co-administration of amprenavir and rifabutin resulted in an increase in rifabutin plasma concentrations by 193 % and thus increases in the dose of rifabutin associated with rifabutin .
stelara concentrate for solution for infusion should be used only for the intravenous induction dose .
i need someone who gets this .
process for producing a disposable absorbent pad .
the magnet assembly of any preceding claim , wherein the first material is a metal alloy and the second material is a reinforced epoxy .
pharmaceutical compositions comprising tumor necrosis factor and 2-methoxy@@ st@@ one@@ one@@ -3-@@ sulf@@ amate as estrone sulph@@ atase inhibitors
the method of claim 5 , wherein step ( vii ) comprises reducing the percentage by a predetermined amount prior to the repeat of steps ( v ) and ( vi ) .
the enhanced absorption pharmaceutical composition of claim 40 , wherein the macrogol fatty acid ester is selected from the group consisting of ge@@ luci@@ re 50 / 13 , ge@@ luci@@ re 44 / 14 and any combinations thereof .
plant according to one of claims 1-6 , characterized in that it is formed by a first pocket ( 61 ) with a flexible wall ( 63 ) , which includes a second dense pocket ( 2 ) with double wall ( 5 , 82 ) , and in that the first pocket ( 61 ) is formed with a double wall ( 5 , 82 ) , and in that the first pocket ( 61 ) is formed either the first chamber or the second chamber , while the second bag ( 2 ) determines the respective other chamber
peelable perforated blisters contain 14@@ x1 , 28@@ x1 , 30@@ x1 , 50@@ x1 , 84@@ x1 , 90@@ x1 or 100@@ x1 film-coated tablets .
rejection reduction dex 10 mg / m2 oral , days 6-@@ 7 , 13-@@ 16 ;
a cannula according to any preceding claim , wherein the at least one liquid inlet comprises a first fluid inlet immediately adjacent to the distal end and a second liquid inlet located proximally of the first inlet .
the dna of claim 16 which encodes the amino acid sequence from the 57 th amino acid serine to the c-terminal of the amino acid sequence shown in seq id no .
this is only a long term precursor .
reproductive studies in animal models indicated that recombinant interferon alfa-2b in rats was
an assembly as claimed in any one of the preceding claims , further comprising one or more blister packs with individually opening blisters that are only made of aluminum blisters , the order is such that the one or more blister blisters must be opened after the at least one blister pack .
the method of claim 1 , wherein at least a first of the species of oligonucleotide probes includes means for detecting the oligonucleotide probe .
a method for producing the polypeptide of claim 1 comprising ( a ) culturing a homologous recombinant cell having incorporated therein a novel transcription unit incorporated therein , comprising a regulatory sequence , an exon and / or a compound donor site operatively linked to a second exon of an endogenous nucleic acid sequence encoding said polypeptide under production of said polypeptide , and ( b ) recovering said polypeptide .
the method of claim 71 , wherein said non-human animal is a transgenic mouse comprising a human antibody library .
a retroviral vector producing packaging cells for use in medicine according to claim 8 , wherein the gene product is thymidine kinase and the chemical treatment is treatment with ganciclovir .
composition according to claim 7 , characterized in that it contains sorbic acid .
use according to claim 1 of the compounds of general formula ( i ) as defined in any one of claims 1 to 8 , in which r 1 or r 2 which are the same represent a methyl or ethyl group , as well as their addition salts with pharmaceutically acceptable acids .
a pharmaceutical composition according to any one of the preceding claims which comprises at least 25 mg of the non-steroidal anti-inflammatory drug .
the chmp concluded that privi@@ gen ’ s benefits are greater than its risks and recommended that it be given marketing authorisation .
pectin@@ ase , pectins , low-molecular pectin and food and drink containing low molecular weight pectin .
a host cell transformed with ( i ) dna sequence according to any one of claims 1 to 15 or ( ii ) a cloning or expression vector according to claim 16 .
the kit of claim 20 , wherein the solid phase is coated with streptavidin and the probe is biotinylated .
a method according to claim 2 , wherein the at least three intensity values i &#91; ρ i , λ j &#93; comprise the values i &#91; ρ 1 , λ 1 &#93; , i &#91; ρ 1 , λ 1 &#93; , i &#91; ρ 1 , λ 2 &#93; , i &#91; ρ 1 , λ 2 &#93; ) and i &#91; ρ 2 , λ 2 &#93; ) and i &#91; ρ 2 , λ 2 &#93; ) and i &#91; ρ 2 , λ 2 &#93; ) and i &#91; ρ 2 , λ 2 &#93;
table 7 shows sv@@ r12 rates in treatment-naïve subjects with genotype 1 infection with ex@@ vi@@ era and ombitasvir / paritaprevir / ritonavir in combination with ribavirin for 12 weeks in study sap@@ phi@@ re-@@ i.
the intravascular multi@@ anchor stent ( 10 , 110 , 130 ) of claim 1 and 2 , wherein each spine ( 20 , 120 , 140 , 142 ) align@@ s after the common longitudinal axis ( a ) when the multi@@ anchor stent ( 10 , 110 , 130 ) is in an un@@ extended state .
use according to any one of the preceding claims , characterized in that no in the medicament is present in an amount of from 1 to 100,000 nmol / min the use according to any one of the preceding claims , characterised in that the concentration of the no in the range of 1 - 180 ppm , preferably 1 - 80 ppm , in particular 1 - 40 ppm , is present , the no in a carrier gas or gas mixture .
the method of any one of claims 1 to 10 , comprising storing the calibration factors in a memory associated with a field emitting coil coil .
a flow indicator according to claim 7 , wherein the spring ( 8 ) has a predetermined spring rate adapted to the optimal inhalation strength for a given user .
system according to claim 15 , characterized in that a locking circuit ( 80 ) is provided which alternately enables the high-frequency current supply to the electrode ( 16 ) and the position detection by means of the position sensor ( 42 , 62 ) by means of two direct electrical electrode leads ( 82 , 84 ) .
a pharmaceutical composition for parenteral injection , intravenous injection , subcutaneous injection , intra-@@ ocular administration , nasal administration , pulmonary administration and osmotic pump administration comprising a glycosylated leptin protein according to any one of claims 1 to 12 in a pharmaceutically acceptable carrier .
6 . agent according to one of claims 4 and 5 , characterized in that the thickener is xanthan gum , an algae or carrageenan derivative , an alginate , a cellulose derivative , a clay of mont@@ mo@@ ril@@ lon@@ ite type or an acrylic copolymer in the form of the sodium salt .
1 and no@@ te for guidance modified release oral and transdermal dosage forms &#91; recommendation for the oral and transdermal dosage forms &#93; , 1999 ema / cpmp / e@@ wp / 280 / 96 cor@@ r * ) conducted in the studies in which the studies were conducted ( 2009 to 2010 ) .
expression vector for fusion genes and method for producing immobilized enzyme
a method according to claim 3 , wherein the microorganism further has a resistance to α-@@ amino-@@ β-hydroxy@@ valeric acid and l-@@ ion@@ ine ; and an auxo@@ troph@@ y which includes the permeable type for l-isoleucine and in the growth of l-leucine .
device for assisting the blood circuit ( 1 ) according to claim 15 , characterized in that the device comprises two opposing plates ( 25 , 26 ) which can be placed on both sides of the blood line ( 20 ) .
the method of claim 4 , wherein said tax@@ oid extraction agent is received from said first column , said first column being comprised of tax@@ oids and said tax@@ oid releases said tax@@ oids in critical or supercritical fluid / cosolvent mixtures , and said first tax@@ oid preparation is de@@ ases , said first tax@@ oid preparation being de@@ ases to produce tax@@ oids and a critical or supercritical fluid / cosolvent mixture .
more than 80 % of patients in the documented clinical trials were also treated with stimulant agents .
the method of claim 6 , including the step of flow cyto@@ metric cell sorting of apoptotic cells bound to the conjugated monoclonal antibody .
do not try to inject yourself unless you have received this training .
a process according to claims 1 to 4 , wherein the denatured protein containing aqueous composition is spray dried with a jet spray dri@@ er or nebulizer and optionally mixed before spray drying with a carbohydrate .
claims for the following contracting states : at , be , ch , de , dk , fr , gb , it , li , lu , nl , se a compound of the formula and the pharmaceutically acceptable salts thereof .
a diagnostic garment according to any one of the preceding claims , further comprising a thermistor ( 44 ) located on the glove or tube for measuring the skin temperature .
summary of the emea work programme 2007 emea / mb / 44@@ 20@@ 95 / 2006
2,5-@@ bis@@ -di@@ methylamine ¬ 1,4 benz@@ quinone derivatives for the treatment of alzheimer &apos;s disease , a method for the production thereof , and intermediates therefor
a process according to any one of claims 1 to 16 , wherein sequence b1 and sequence b2 are directly joined together or separated by a number of nucleobases or by a linker or spacer .
pharmaceutical compositions according to the preceding claims for the preparative treatment for surgical procedures on the colon and / or for the supportive treatment in the treatment of mon@@ e@@ mias or hypera@@ mon@@ e@@ mias .
a method of producing a metal oxide cluster in a single step , said method comprising the steps of : reacting a metal alkoxide with a sub@@ stoichiometric amount of an acid in the presence of an oxide particle growth suppressor and a solubilizing agent and in the absence of water at a temperature and for a period of time sufficient to form a metal oxide cluster gel capable of forming a fine powder when all volatile materials are removed .
a dna according to claim 1 having the nucleotide sequence seq id no : 2 or homologous naturally occurring nucleotide sequence of another mammalian species hybridizable thereto and encodes a crf binding protein according to claim 1 .
preparation of pure stereoisomers of tri@@ cyclo- &#91; 5.@@ 2.@@ 1.0 ( 2.6 ) &#93; dec@@ -1@@ 9-@@ yl-@@ xantho@@ genate and their use as medicaments
composition according to claim 43 , in which the additional inorganic filters are nanopigments of amorphous or crystalline titanium oxide , in the form of ru@@ tile and / or an@@ atase , iron oxide , zinc oxide , zirconium oxide or cerium oxide .
the active substance in nplate , romiplostim , stimulates the formation of platelets .
fenofibrate has a potential to decrease uric acid levels by approximately 25 % .
an emulsion according to any one of the preceding claims wherein the emulsion further comprises at least one compound selected from the group consisting of on@@ biotic agents , osmotic pressure controlling agents , serum stres@@ fiers , and antioxidants .
pregnancy should be avoided for one month after vaccination .
a device according to any preceding claim , characterised in that the balloon ( 24 ) has a length which is between about 3 and 4 cm in length .
container according to claim 12 , characterized in that the part ( 17 ) has an enlarged rear end region of the sheath ( 15 ) .
device for detecting an endoscope shape
the apparatus of claim 7 , wherein the slots ( 180 , 182 ) are substantially perpendicular to a plane formed by the first and second attachment rods ( 186 , 184 ) when the first and second plates ( 170 , 172 ) are in the closed position .
the peptide of claim 1 wherein x is deleted and a1 is lys , a2 is aib and a3 is the pen ; and the peptide is d-phe-@@ cys-@@ tyr-d-trp-lys-@@ leu-@@ pent@@ en@@ thr-nh 2 ( seq id no : 8 ) .
people over 65 years of age or with impaired kidney function ( see section 4.4 ) . • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
a composition comprising a compound according to any one of the preceding claims in combination with a pharmaceutically acceptable carrier .
the incidence of patients with hypoglycaemia was significantly lower in the sitagliptin group ( 4.9 % ) than in the glipizide group ( 3@@ 2.0 % ) .
an immunogenic fragment according to claim 1 , wherein the isolated polypeptide comprises the amino acid sequence of seq id no : 2 .
the method of claim 37 , further comprising the step of heating the construct .
powder containing low molecular weight dextran and process for producing the same
apparatus according to claim 1 , characterised in that the device ( 4 ) is a rotationally driven roller at a lower speed than that of the motor ( 5 ) which is the front part ( 3 ) which is located forward .
composition according to either of claims 4 and 5 , characterized in that the acidic compound is tartaric acid , succinic acid , citric acid or one of its partial salts such as monosodium citrate .
the frequencies listed are defined as follows : very common ( ≥ 1 / 10 ) , common ( ≥ 1 / 100 , &lt; 1 / 10 ) , metabolism and nutrition disorders very common :
the use of homo- or copolymers based on quaternized 1-@@ vin@@ ylimid@@ imidazoles according to claim 1 or 2 , wherein the copolymer is composed of 1-@@ vinylpyrrolidone , 2-hydroxyethyl acrylate , 2-hydroxyethyl methacrylate , 2-hydroxy@@ propyl acrylate , 3-hydroxy@@ propyl acrylate or a mixture thereof as component b. the use of a homo- or copolymers as claimed in the claims 1 to 4 , wherein the polymer is composed of a component a alone or from 10 to 98 % by weight of component a in quaternized form and 2 to 90 weight percent of component b .
treatment should be carried out under the supervision of a physician experienced in the treatment of haemophilia .
genotype 2 / 3 : the recommended duration of treatment is 24 weeks .
an air freshener according to claim 1 , characterised in that when the container ( 2 ) has been inserted with the wick ( 5 ) into the housing ( 1 ) , the cover cap ( 9 ) can be moved and removed over the wick ( 5 ) .
the inventive dental implant consists preferably of plastic , ceramic or hybrid materials .
do not attempt to give yourself an injection until you are sure that you understand the preparation and administration of an injection .
a device according to any preceding claim , wherein the electrode attachment comprises a plurality of active electrodes held in an electrode support .
an assay method , wherein atp is measured using luci@@ fer@@ in and luciferase for light generation , the amount of light being related to the amount of atp , characterized in that the luciferase is a protein according to any one of claims 1 to 10 .
cosmetic and / or dermatological and / or pharmaceutical composition for topical application comprising at least one compound which is an inhibitor of the enzyme 3-@@ beta-@@ h@@ sd
3 . a growth promo@@ tant according to claim 2 , wherein the gel matrix comprises k@@ -c@@ carrageenan , gelatin , alginates , cellulose or their derivatives , or gel forming synthetic polymers .
the european commission granted a marketing authorisation valid throughout the european union for roche to glaxosmithkline biologicals s. a. on 4 march 2011 .
a taxane derivative according to claim 17 , wherein x 10 is t-@@ butoxy , r 9a is β-@@ hydroxy , r 10 is hydrogen and r 10a is hydroxy .
your doctor may prescribe a different dose .
use of an o-@@ glycan for the manufacture of a medicament for the treatment of rheumatoid arthritis , wherein the o-@@ glycan is selected from the group consisting of a di@@ sial@@ ylated , mono@@ fucos@@ ylated glycan : and a mono@@ sial@@ ylated , tri@@ fucos@@ ylated glycan having a polylac@@ to@@ samine backbone : wherein r1 is h , a sugar or an aglycone , and wherein r2 is h , oh , a sugar or an aglycone .
a compound according to claim 14 or claim 15 wherein n is the integer 1 and alk 1 is an optionally substituted c 1-6 alkylene chain .
conditions or restrictions with regard to the safe and effective use of the medicinal product
the probe of claim 10 , wherein the at least one actuating member ( 82 , 142 or 176 ) comprises a plurality of electrodes spaced apart .
do you think i &apos;ll die ?
a compound according to claim 1 , wherein r is 2-amino-4-thiazolyl and r is carboxymethyl , 1-carboxy@@ -1-methylethyl , 1-carboxy@@ -1-@@ ethyl , or a radical of the formula wherein s is 1 , 2 , or 3 .
• the prac considered the procedure under article 31 of directive 2001 / 83 / ec , as amended .
in studies of the individual active substances , both alogliptin and metformin occurred in the milk of lactating rats .
instrument according to claim 9 , characterized in that the at least one element ( 62 ) covers the distal side and / or proximal side face ( 66 , 68 ) of the neutral electrode ( 56 ) .
the kit of claim 17 for use in detecting nucleotide variation in codon 12 of the k@@ ras gene , wherein the detection step primer comprises the sequence 5 &apos; -@@ act ggt ggt ag@@ t tg@@ g ag@@ c tg .
32 . a method according to claim 31 , wherein the membrane has a pore size which is not above 0.45 µm .
composition according to any one of the preceding claims , characterized in that it also comprises pearlescent pigments , pigments or nanopigments of metal oxides coated or uncoated .
the method of claim 4 , further comprising the step of measuring the polarization degree associated with the hyperpolarized gas in the second vessel , prior to administration to a desired subject at the end use site .
a method of randomisation of polynucleotides at specific sites comprising the steps of : ( a ) providing polynucleotides that differ at one or more sites , said one or more site ( s ) defining the sites at which one or more sites ( s ) produced by means of an agent produced in step ( c ) from the polynucleotide hetero@@ duplex starting from the polynucleotide hetero@@ duplex starting at step ( c ) , filling one or more of the strand fracture ( s ) produced by the polynucleotide hetero@@ duplex starting in step ( c )
process according to claim 8 , characterized in that in step a ) the treatment is carried out by lowering the ph by means of acetic acid to the vicinity of 4 and that the precipitated ribo@@ somes are collected .
synergistic compositions of n-acyl homoserine lactones and 4-@@ quinolin@@ ones
a method for coating the surfaces of medical implants with living cells by means of a nutri@@ tive physiological liquid , wherein the implants are introduced and fixed in a receiving container , which is introduced into a receptacle and which is moved to the cells at least one axis , and , independently , the receptacle is moved at the same time , independently of each other , by two rotation axes extending perpendicular to each other .
penta@@ midine salts and their use for the treatment and prophylaxis of pneumocystis carinii pneumonia .
therefore , drinks containing plant extracts , including herbal te@@ it , should not be taken with rasilez hct .
agent for dyeing keratin-containing fibres , in particular human hair , comprising as dye component a combination of aromatic aldehydes .
selection of resistance to lopinavir in patients after protease inhibitor therapy was characterised by studies of long-term isolates of 19 with protease inhibitors experienced in 2 phase ii and one phase iii study .
use of a biocompatible implant for the manufacture of a medicament for inducing an immune response in an immunologically immature animal according to claim 1 , wherein the immunologically immature animal is one day old animal .
the use according to any one of claims 1 to 5 , wherein the medicament further comprises a biologically compatible carrier , for example selected from dimethylsulfoxide , polyoxyethylene sorbitan monooleate , polyols , aqueous dextrose solution , ringer &apos;s solution , saline solution , or a combination thereof , and / or an adjuvant selected for example selected from anti-inflammatory agents , biological reaction modifiers , or a combination thereof .
u@@ li@@ pri@@ stal acetate is excreted in human milk .
method according to claim 29 , characterized in that the second insecticidal protein is selected from the group consisting of bt δ-@@ endotoxins , protease inhibitors , lectins , α-@@ amylases and peroxid@@ ases .
cosmetic and / or pharmaceutical preparations containing ( a ) fatty acid@@ -n@@ -alkyl polyhydroxy@@ alkyla@@ mides and ( b1 ) oligo@@ glycerine and / or ( b2 ) oligo@@ glycerol fatty acid ester .
if the rate of infusion is not increased beyond the initial rate of 12 ml / h due to the initial rate of 12 ml / h , the infusion of 12 ml / h should be re@@ initiated at the start of infusion .
failure to respond to erythropoietin should prompt immediately after causative factors .
a kit comprising in a therapeutically effective dose or multiple dose amount of glp-2 or an analogue thereof and at least one other peptide hormone selected from the group consisting of igf-1 , igf-@@ 2 , gh , egf , hgf and kgf .
allow the refrigerated solution to reach room temperature before administration .
the blood pressure measurement system of claim 10 , wherein the arrhythmia correction circuit ( 114 ) is the amplitude of a detected oscillometric pressure pulse wave produced by an arrhythmia using the relationship corrected o@@ sm@@ -1 ( c ) = sm 1 ( a ) &#91; δ@@ v f ( n ) / δ@@ v f ( a ) &#93; , and δ@@ v f ( a ) the amplitude of the instantaneous pulse wave sensed by the second pulse wave detecting means , and δ@@ v f ( a ) is the amplitude of the instantaneous pulse
dry eyes , swollen eyes , eye pain , restlessness , aqueous eyes , eye irritation .
medicinal product groups may be influenced by concomitant treatment with lansoprazol-@@ ct
a radially expandable supporting structure according to claim 1 , characterised in that the connected ends of a pair of members ( 1 ) with the connected ends of a pair of members ( 1 ) adjacent in the longitudinal direction of the tubular body are connected to the end only one of the two adjacent slots ( 2 ) of an adjacent ring ( 3 ) via an elongate member ( 4 ) .
an endoscopic tool comprising : ( a ) a hollow tube ( 15 ) comprising a plurality of discrete units of hemostatic agent ( 18 ) , said hollow tube ( 15 ) having proximal and distal ends ( 38 , 39 ) having an opening in said distal end ( 38 ) of said hollow tube ( 15 ) , said valve allowing said blood killing means ( 18 ) to prevent said blood killing means ( 25 ) in said distal end ( 38 ) of said hollow tube ( 15 ) , but said valve allowing said
endoscopic probe according to claim 3 , characterized in that the concave lens ( 81 , 91 ) is made of polymethylmethacrylate or epoxy material .
the blood collection set of any one of claims 1 to 4 , wherein said waste liquid bag ( 26 ) has a valve ( 33 ) in its interior to prevent counter@@ flow .
1-@@ aryl-@@ erg@@ in@@ yl-@@ urea derivatives , process for their preparation and their use as medicaments .
the agency ’ s committee for medicinal products for human use ( chmp ) decided that stribild ’ s benefits are greater than its risks and recommended that it be approved for use in the eu .
a process according to claim 10 or 11 , wherein the oxidizing agent is aqueous iodine , n-@@ chloro@@ succinimide , n-@@ bromo@@ succinimide or a salt of per@@ iodo@@ tic acid .
if your doctor has switched you from one type or brand of insulin to another , i must
meddra system organ class blood and lymphatic system disorders gastrointestinal disorders
the infusion pump ( 10 ) of claim 1 or 2 , wherein the means for automatically loading the tubing segment into the pump includes means ( 514 , 528 ) for holding the tubing segment and pulling it into the pump .
the internal surfaces ( 6a , 6b ) of the o.@@ g. opening ( 6 ) of the female element ( 2 ) are made of a special material which is made from a plastic paste and a glass material which makes it possible to have a high power to form the envelope of the capsule ( 5 ) to cut the cover of the capsule ( 5 ) by rotating the cutting element ( 2 ) than@@ k of the support ( 7 ) .
a kit ( 2 ) according to claim 1 further including : a drug ( 32 ) which is suitable for systematic distribution which is effective to treat the diseased site ( 26 ) and locally fixed to the site ( 26 ) by prior distribution of the local setting agent ( 14 ) .
process for the preparation of chiral succinic acid derivatives
a dry powder inhaler pharmaceutical composition comprising a mixture of a pharmaceutically active agent and a particulate roller dried anhydrous β-@@ lactose .
claims for the following contracting states : at , be , ch , de , fr , gb , it , li , lu , nl , se the pyrro@@ les of the general formula wherein one of x and y is o and the other is o , s , ( h , oh ) or ( h , h ) and the other o , s , ( h , oh ) or ( h , h ) is a heterocyclic aromatic group of the formula : and one of x and y is a heterocyclic aromatic group
a method for producing a controlled release solid oral dosage form comprising oxycodone hydrochloride , wherein the oxycodone hydrochloride is incorporated into a controlled release matrix , wherein the oxycodone hydrochloride is incorporated in a controlled release matrix , with ( b ) mixing the granules having a water soluble hydroxyalkyl@@ cellulose , ( b ) , between 25 % and 75 % by weight of oxycodone hydrochloride and between 55 % and 85 % by weight of oxycodone hydrochloride and between 55 % and 85 % by weight of oxycodone hydrochloride after 6 hours .
the use of claim 14 , wherein the antiviral agent is selected from the group consisting of nucleoside reverse transcriptase inhibitors , non-nucleoside reverse transcriptase inhibitors and protease inhibitors .
adults and adolescents over 12 years of age 10 mg once daily as 1 tablet
secondary endpoints were histological response , alt normalisation , and different parameters of antiviral efficacy .
arrangement according to claim 1 or 2 , characterized in that each whole body tanning device ( 1 , 2 , 5@@ 6-@@ 59 , 80 , 92 ) comprises a support element ( 11 ; 21 ) and at least one wall element ( 12 , 13 ; 22 , 23 ) and a ceiling element ( 14 , 13 ; 25 , 26 ) arranged parallel to the support element ( 11 ; 21 ) and that the at least one reinforcing element ( 15 ; 16 ; 25 ; 26 ) is arranged between the support element
universal virus-@@ inactivated plasma plasma derived plasma derived plasma derived from parts of plasma not derived from white blood cells
an expression plasmid for producing a heterologous protein in . the plasmid comprising : an expression plasmid according to claim 8 , comprising a translation stop codon in the same reading frame as the structural gene of the heterologous protein dna sequence , wherein the codon is located prior to the ds@@ re dal@@ gar@@ no sequence .
- if you have recently had a severe injury , - if you have recently undergone surgery ( including dental
suction pump according to claim 1 , characterized in that the pump parts ( 1 , 10 , 18 , 6 , 8 ) which are detachably connected together are arranged on a common base plate ( 2 ) .
a compound according to claim 1 selected from the following : ( ± ) - -7-@@ hydroxy@@ -3-phenyl-@@ 4- { 4- { 2- ( pyrrolidin-1-yl ) ethoxy } phenyl } chroman , ( ± ) - -7- ( 4-fluorophenyl ) -4- ( 4- ( 2-@@ pyrrolidino@@ ethoxy ) phenyl &#93; -3-phenyl-@@ chroman ( ± ( trifluoromethyl ) phenyl &#93; -3-phenyl-@@ chroman ( ± ( trifluoromethyl ) phenyl &#93; -3-phenyl-@@ chroman ( 4- ( trifluoromethyl ) phenyl &#93; -3-phenyl-@@ chroman ( 4- ( trifluoromethyl ) phenyl &#93; -3-phenyl-@@ chroman ( 4- ( trifluoromethyl ) phenyl &#93; -3-phenyl-@@ chroman ( 4- (
device for postoperative fixation of a lateral colo@@ stomy .
the method of claim 7 , wherein the polymeric solutions or emulsions are either natural or synthetic .
the mouth rinse solution contains , besides usual additives such as alcohol , sorbitol , detergents , sweeteners , flav@@ ours and colours 0.005 - 0.5 % by weight of triclosan and 0.01 - 2.0 % by weight of amine fluoride .
screening and use of agents which inhibit or activate splicing of intein , using natural or homologous ex@@ t
an absorbent article having a front region ( 22 ) , a rear region ( 24 ) and a crotch portion ( 26 ) extending between the front region ( 22 ) and the rear region ( 24 ) , a body facing liner ( 30 ) , which is disposed on the outer cover ( 32 ) ; and c ) an absorbent composite core ( 34 ) according to any one of claims 1 to 15 disposed between the outer cover ( 32 ) and the bodyside liner .
k@@ 103@@ n substitution alone did not result in reduced susceptibility to rilpivirine , but the combination of k@@ 103@@ n and l@@ 100@@ i resulted in a 7-@@ fold reduced susceptibility to rilpivirine .
plant system for comprehensive gene functional analysis using full-length cdna
the particles of the enzyme granules have a water content of less than 15 % by weight , especially in the range of 1 to 12 % by weight , particularly in the range of 1 to 12 % by weight , in particular in the range of 1 to 12 % by weight , and in particular from 3 to 10 % by weight , and in particular at least 70 % by weight , preferably at least 90 % by weight , and preferably at least 90 % by weight , and especially at least 90 % by
formulations according to claim 3 , characterized in that detergents and additives are tris-@@ hcl , edta , polyvinyl@@ pyrrolidones , ta@@ b , tri@@ ton@@ x-@@ 100 , n-@@ laur@@ yl-@@ sarcosine , sodium citrate , dt@@ t , sds and / or tween .
the dna molecule of any one of claims 1-10 , wherein the radiation responsive promoter enhancer comprises 1@@ 205 nucleotides or less .
use of an effective amount of the recombinant vector of claim 4 for the preparation of a composition for modulating the cellular effects of vegf in a mammal .
the patients are distributed to two groups .
propa@@ fen@@ one and f@@ lec@@ ain@@ ide ) and metoprolol .
there may be an increase in thyroid tissue or metastases following treatment with thyrogen .
the full epar for mixtard can be found on the agency ’ s website : ema.europa.eu / find medicine / human medicines / european public assessment reports .
electro@@ therapy device according to claim 1 , characterized in that the evaluation unit is designed to form the reference signal path by averaging the reference signal path from several impedance or conductivity signals .
method for determining the rate of deple@@ ting of viruses and / or pathogenic material in organic preparations , characterized in that a sample of the material with viruses of the group le@@ vi@@ iri@@ dae is introduced as test virus , and the sample determines the number of viruses provided and the number of viruses is determined and the number of viruses is determined and the decrease in the virus level is determined therefrom .
if the level of methotrexate is &gt; 0.5 µmol / l , the dose of calcium fol@@ inate should be adjusted according to the following table :
there is no evidence that there is an interaction between ketoconazole h@@ ra and other steroid inhibitors ( i.e. , met@@ py@@ py@@ p@@ one ) .
the dispersion of stabilized collagen fibers of claim 2 , wherein the water soluble or water miscible polymeric material is selected from the group of : polyvinyl alcohol , polyethylene oxide , polyvinyl pyrrolidone , polyacrylamide , polyethylene glycol , polypropylene glycol , polyvinyl methyl ether , maleic anhydride copolymers , hydroxyethyl starches , methylcellulose , hydroxymethyl cellulose , hydroxyethyl cellulose , hydroxypropyl cellulose , agarose , dextrins , dextrans , pectins and alginates .
cephalosporin compound , process for its preparation and preparation for the prevention and treatment of bacterial infectious diseases .
a method according to any one of claims 13 to 24 , wherein the beginning and end of the compression event is obtained either by locating samples minimum amplitude , or by using a separate signal which is derived from a transducer responsive to an angular position of a rotary re@@ vola@@ sal head .
1 . a guide catheter ( 10 ) for penetrating a coiled non-linear channel , wherein the catheter has a longitudinal axis , a proximal end ( 10b ) and a distal end ( 10a ) , the catheter having a longitudinal axis ( 18 ) , a proximal end ( 10b ) and a distal end ( 10a ) , and wherein the catheter has a distal end ( 18 ) with a distal portion ( 18 ) and a distal end ( 10a ) having a distal portion ( 18 ) with a distal portion ( 18 )
use of the composition of claim 1 for the manufacture of a medicament for inducing the formation or maintenance of cartilage tissue in a patient .
patients who completed 14@@ 4-week treatment in one of the treatment arms gs-@@ 01-@@ 9@@ 34 could be switched to a non-@@ blinded extension phase of the study with atripla , on an empty stomach .
the immunogenic composition of any one of claims 6 to 11 , wherein the lymphocytes comprise a cell genetically engineered to express a cytokine at an elevated concentration .
a purified protein according to claim 2 or 3 or purified protein fragment according to claim 4 , wherein the fragment is capable of being bound by an antibody specific for human notch .
1 sterile polypropylene bag in a foil package containing in a compartment ( 50 ml ) vfend solvent for solution for infusion
the aqueous suspension of claim 1 , wherein the high molecular weight surfactant component has an average molecular weight of 1800 to 1,000,000 and the low molecular weight surfactant component has an average molecular weight of 100 to 1100 .
a vul@@ cani@@ zable polysiloxane composition according to claim 1 or 2 , wherein the condensation catalyst amount is in the range of 0.25 to 2.5 , preferably 0.25 to 1.25 , more preferably 0.50 to 1.0 parts by weight catalyst per 100 parts by weight of the vul@@ cani@@ zable polysiloxane or of the mixture thereof .
however , chemical and physical in-use stability of the reconstituted solution has been demonstrated for 48 hours at a temperature of 30 ° c.
use according to claim 8 for the preparation of a pharmaceutical composition for the treatment of tumours , especially for the treatment of liver , lung and colon tumors .
method for treating men with testosterone supplement and alpha-@@ reductase inhibitors
an apparatus according to claim 18 , characterized in that it comprises a carrier delivery device ( 32 , 103 , 334 ) for supplying a layered carrier to the former , and wherein the shaping device , in operation , forms a plurality of discrete w@@ ats on the support ; wherein the stabilizing and connecting means are formed on the support , and the support and connecting device are formed by the carrier , and the sub@@ dividing device divides the carrier to separate each wa@@ d and its associated portion of the carrier from the other .
6,11-dihydro@@ -11-@@ oxo-@@ dibenz ( b , e ) oxep@@ ines , process for their preparation , pharmaceutical composition containing them and their use as medicines .
atherectomy or thro@@ mbe@@ ctomy device according to claim 1 , characterized in that it comprises a rigid guide wire ( 12 ) which can be placed into the tube ( 2 ) .
a conjugate according to claim 1 of the formula transdermal pharmaceutical composition useful for treating impotence in men comprising a physiologically effective amount of a conjugate according to any one of claims 1 to 7 combined with a pharmaceutically acceptable carrier .
a recombinant bacterial cell containing a plasmid according to any one of claims 6 to 13 .
the use of claim 38 , wherein the second compound is an hmg-coa reductase inhibitor or a mt@@ p / apo b secretion inhibitor .
the dosage form of claim 1 , wherein said second semi-solid has a viscosity of 900 to 1,000 k@@ gm -1 s -1 ( 9@@ 0.000 to 1,000,000 centipoise ) at 25 ° c , a defoaming time of less than 8 seconds , and an injection capacity of less than 0.5 grams .
a compound according to claim 6 , wherein the compound is thre@@ o-@@ 3-hydroxy@@ -5-@@ guanidino-@@ 2- ( 2-oxo-@@ azetidin-1-yl ) -@@ pentanoic acid .
effects of lansoprazole on other active substances
use of a composition as defined in any one of claims 1 to 47 for the preparation of a product for cosmetic treatment of the skin , lips and hair , in particular for protecting and / or caring for the skin , lips and / or hair and / or as make-up product for the skin and / or lips .
we conclude that , after optimi@@ sation of the suspension technique , the osse@@ al screw fixation can provide a val@@ ali@@ de option for anchorage .
hycamtin was as effective as an infusion in the same way as hycamtin .
this indication was approved for both tablets and the intravenous formulation except one in all member states .
cuff , for example for generating and maintaining fluid and gas zones in certain areas of the body .
use according to claim 1 , characterized in that the cellulose ether is an alkyl hydroxyalkyl@@ cellulose .
a method for identifying the effect of an agent which is mutagenic , toxic or promo@@ tive for the metabolism of cells of the alimentary tract , comprising act in vitro ( 1 ) to a culture , which is expected to act with such a culture or to contact the metabolism of cells of the alimentary tract , or to contact with such a culture , and ( 2 ) the effects of said agent on said cell line .
an agent for prophylactic and / or therapeutic treatment of a complication of diabetes which comprises the condensed purine derivative or a pharmacologically acceptable salt thereof according to any one of claims 1 to 9 as an active ingredient .
stick preparations according to claim 1 , characterized in that the core phase is 15 - 40 % by weight and the shell phase contains less than 18 % by weight of an antiperspirant , a@@ stringent salt , the concentration in the core phase being at least 30 % higher relative to the concentration in the shell phase .
enzymes bound to a solid support .
dna construct according to one of claims 1 or 2 , characterized in that it comprises a second promoter which can be regulated in a different manner than the first promoter .
use of a pharmaceutical composition according to any one of claims 1 to 22 and 28 for the manufacture of a medicament for the treatment of cancer in a mammal , including a human , either as a single agent or in combination with other therapies .
tubular ureter splint from an elastic material , in particular plastic , which is located in its use with one of its two ends ( 2 , 3 ) in the kidney and with its other end ( 3 ) located in the bladder , and with its other end ( 3 ) in the bladder , a tube ( 6 ) which is arranged in the bladder and with its other end ( 3 ) in the bladder , a tube ( 6 ) which is arranged in the bladder and at least in its cross-section , a tube
use of 1,4-@@ benzothiazepine derivatives as medicaments for over@@ coming tolerance to carcino@@ st@@ tics
studies in pregnant rats and rabbits have shown no teratogenic potential for rivastigmine .
the assembly of claim 5 , wherein the second layer is deposited by radio frequency discharge , directional beam deposition , double ion deposition , hat@@ ching , plasma-@@ enhanced chemical vapor deposition or magnetically enhanced plasma systems .
the feed additive according to any one of the preceding claims , wherein the acidic salt of the basic amino acid is a salt of at least one basic amino acid selected from the group consisting of lysine , arginine , histidine , hydrox@@ ylysine and ornithine , with at least one acid selected from the group consisting of hydrochloric acid , phosphoric acid , nitric acid and acetic acid .
an apparatus according to claim 1 , further comprising sound control means ( 140 ) for positioning the plunger support member ( 101 , 102 ) at the advancing position before the end of the needle is reje@@ cted .
system for detecting leak sites and occlu@@ sions in a cryo@@ ablation catheter
the method of claim 16 , further comprising hydrolyzing or carboxy@@ lating poly ( lactic acid ) to obtain the derivative of poly ( lactic acid ) .
use of aryl oxi@@ mes for the prophylaxis and / or treatment of erythema and / or inflammatory reactions of the skin
follow carefully the instructions carefully to reach the full benefit of ali@@ sa@@ de .
powder for concentrate for solution for infusion .
a : as responders in patients with undetectable hcv-rna with undetectable hcv rna 24 weeks after treatment end .
an endodontic device according to claim 1 , wherein : the excitation light ( 44 ) generated by the light source ( 42 ) is a light having a narrow bandwidth having a wavelength of between 250 and 450 nanometers ; and the predetermined wavelength bands associated with the plurality of electrical signals are within a wavelength range which is between 50 and 250 nanometers longer than the wavelength of the excitation light with close bandwidth .
a method for producing a disc prosthesis which has in vivo an outer surface contour which is substantially the same as that of a natural intervertebral disc , comprising : ( a ) a plurality of biologically compatible and bioabsorbable fibers having the steps of : ( a ) the steps of : ( a ) applying a plurality of biologically compatible and bioabsorbable fibers into a mold , said mold comprising the step of : ( a ) applying a plurality of biologically compatible and bioabsorbable fibers into a mold , said mold comprising the step of : (
nitrogen donors for the treatment of disease and injury
composition according to any one of the preceding claims , characterized in that it comprises crosslinked polyvinylpyrrolidone as disintegrant .
a compound according to claim 18 , wherein r 5 is hydrogen and r 6 is c 1 -c 6 alkyl or c 1 -c 6 alkyl group 5 r 6 .
the method of claim 21 , and wherein the step of providing the hair separation means ( 22 ; 138 ; 214 , 218 ; 238 , 244 ) comprises the step of providing a hair separator ( 22 ; 138 ; 214 , 218 ; 238 , 244 ) which comprises a generally elongate base ( 20 ; 138 ; 238 ) , which comprises a generally elongate base ( 20 ; 138 ; 238 ) , which comprises a generally elongate base ( 20 ; 138 ; 238 ) having a generally elongate base ( 20 ; 144
a drug delivery system according to one or more of the preceding claims , wherein the active ingredient is a hormone , a growth factor , an enzyme , an antibiotic , or a combination of two or more of these substances .
it is used in children with a very rare form of epilepsy , called “ severe myoclon@@ ic epilepsy in childhood ” ( sme@@ i ) , also called dra@@ vet ’ s syndrome .
a composition according to any one of claims 1 to 9 , wherein the phospholipid is partially or completely hydrogenated .
no dose adjustment is necessary for antiepileptic medicinal products , including cyp3a4 inducers .
what benefit has by@@ du@@ re@@ on shown during the studies ?
an integrated structure ( 1 ) for detecting physiological signals comprising a tissue ( 2 ) consisting of conductive fibers and non@@ conductive fibers , a plurality of electrodes ( 5 ) having a plurality of electrodes ( 5 ) provided with the conductive fibers ; a plurality of electrodes ( 5 ) which are provided with a plurality of conductive fibers ( 5 ) , which are provided with a plurality of conductive fibers ( 5 ) , which are provided with a plurality of conductive fibers ( 5 ) , which are provided with a plurality of conductive
composition according to any one of claims 5 to 13 , characterized in that the polymer with a non-silicone organic backbone grafted with poly@@ siloxane@@ -containing monomers has a number average molecular weight of 10,000 to 2,000 000 and a glass transition temperature t m or a crystalline melting temperature t m or a crystalline melting temperature t m of at least -20 ° c. the composition of any one of claims 1 to 4 having the groups which can react with the reactive end group of the polysiloxane macromer to form a covalent bond which can react with the
at the time of the eu ra@@ r ( 2010 ) to zinc , there was too few effect or exposure data to account for the effects of these two parameters ( av@@ s / medium ) on the bioavailability of zinc .
a device according to claim 1 , characterised in that the cylindrical container ( 1 ) closed with the seal ( 87 ) is connected to a cylindrical container ( 1 ) formed from a u-shaped housing ( 67 ) , an axial contact contact ( 68 ) , a radial contact ( 88 ) between the gas developing cell ( 8 ) and the stopper ( 68 ; 88 ) and that the piston ( 6 ) is further electrically connected to a permanent magnet ( 73 ) acting on the coil ( 70 ) .
human voltage-@@ gated calcium channel splice variants with alpha@@ 2@@ delta@@ 2-@@ a or alpha@@ 2@@ delta@@ 2-@@ b
a method of amplifying a nucleic acid having a target sequence comprising the steps of : ( a ) generating a single-stranded template with the target sequence , ( b ) hybridization of an oligonucleotide pair to adjacent sequences of the template , said contiguous sequences comprising the target sequence , ( c ) to produce an original template and an oligonucleotide ligation product , and ( e ) repeating steps ( b ) to ( d ) so that both of said original template strand and said oligonucleotide ligation strand act as a template for a further ligation reaction
a pharmaceutical formulation comprising as an active ingredient a compound of formula i , or a pharmaceutically acceptable salt thereof , as claimed in any one of claims 1 to 4 together with one or more pharmaceutically acceptable carriers therefor .
use of a pharmaceutical composition according to claim 6 for the treatment and / or prophylaxis of impair@@ ments of perception , concentration , learning and / or memory .
an apparatus according to any of claims 1-15 , characterized in that a synchroni@@ sation unit ( 38 ) is arranged for synchroni@@ sation of the analysis unit ( 32 ) so as to always determine the catheter positions in the same phase of the cardiac cycle .
use of a compound according to any one of claims 1 to 10 , or a tautomer , ester , amide , solvate or salt thereof for the preparation of a pharmaceutical composition to treat a disease characterised by inflammatory , allergic or proliferative processes .
a process according to any one of claims 12 to 15 wherein the amount of alkanol , water and oil phase is from 83 to 96 % by weight of the composition .
a dic@@ t@@ yo@@ st@@ ide strain according to claim 16 comprising a recombinant dna molecule according to claim 13 and an enzymatically active protein expresses an enzymatically active protein .
the use according to claim 1 or 2 , wherein the medicament is to be administered to directly contact the surface of a tumor cell .
use according to claim 1 , wherein the cyclic hi@@ hi@@ per is obtained from a soybean protein hydrolysate which is for cyclic hi@@ hi@@ pro enriched .
the apparatus of claim 11 further comprising : a fourth bypass valve ( 62 ) adjacent the post treatment section ( 18 ) effective in disinfecting mode to return output fluid or output fluid flowing through the output short disruption ( 54 ) to the post treatment section ( 18 ) .
a compound according to claim 1 which is characterized by the following formula : wherein r 2 is h or br ; s is 1 or 2 ; r 3 is h or ch 3 and r 8 is h or lower alkyl of 1 to 6 carbons , or a pharmaceutically acceptable salt of the compound .
stent and method for making a stent
take special care with cialis
a risk to the breast-@@ fed newborns cannot be excluded .
a blood sampling device according to one of claims 1 to 5 , characterised in that a centrifuge insert ( 58 ) is provided which has a receptacle for the cannula lug ( 17 ) containing a pierceable membrane ( 18 ) , in which a pin ( 64 ) for supporting the membrane ( 18 ) is arranged in the receptacle .
pre@@ cancerous lesions ( grow@@ ths ) and cervix , vul@@ var , vaginal and anal carcinomas ;
opaque white hdpe bottles containing 14 , 30 , 60 and 90 hard capsules .
a method according to any one of claims 6 to 12 , wherein step ( b ) is repeated once prior to parturition .
a compound of the formula wherein : r ₁ is hydrogen , optionally substituted by hydroxy or branched alkyl having from 1 to 4 carbon atoms ; optionally substituted by hydroxy or branched alkyl having 1 to 4 carbon atoms ; optionally substituted by hydroxy or branched alkyl having 1 to 4 carbon atoms ; optionally substituted by hydroxy or branched alkyl having 1 to 4 carbon atoms ; or alkenyl having 1 to 4 carbon atoms ; or alkenyl having 1 to 4 carbon atoms ; or wherein r is substituted by hydroxy or branched having 1 to 4
the process of claim 9 wherein : ( a ) the reaction with the acylating agent is carried out at about 0 to 45 ° c and a weight ratio of acylating agent to wet tissue of from about 0.005 to 0.5 : 1 , wherein the ph of the aqueous medium is carried out at about 7 to 11 and ( b ) the reaction with the esterifying agent is carried out at about 0 to 45 ° c and a weight ratio of esterifying agent to dry tissue of from about 1 to 30 : 1 in a
an oil / fat composition according to any one of claims 1 to 3 having a po@@ v of 1 or less , having a colour ( 10@@ r + y ) of 20 or less and 53 to 8@@ 4.9 % by weight of the triglyceride , from 0.1 to 1.5 % by weight of the triglyceride , from 0.1 to 1.5 % by weight of the triglyceride , from 15 to 1.5 % by weight of the triglyceride , from 15 to 10 % by weight of an unsaturated fatty acid ; and from 70 to 100 weight
in a clinical trial of multiple doses in which desloratadine was administered at a dose up to 20 mg daily for 14 days , no statistically significant or clinically relevant cardiovascular effect was reported .
identification of a suppressor of an athero@@ genic apolipoprotein .
use of a g@@ se according to claim 1 to impart etoposide resistance to a eukaryotic cell in vitro .
two weeks after treatment end , leuko@@ cytosis and moderate bleeding were observed at the injection and infusion sites considered possibly related to peg@@ vi@@ som@@ ant .
( 1 h ) , days 28-@@ 31 , 35-@@ 38 , 42-@@ 45 ; 6-@@ mp 60 mg / m2 oral , days 26-@@ 46 dex 10 mg / m2 oral , days 1-5 ; vin@@ des@@ in 3 mg / m2 i.v. , day 1 ; mtx 1.5 g / m2 i.v.
use according to any one of the preceding claims , wherein each number of dosage units consists of 3 dosage units .
a compound according to claim 6 or claim 8 wherein both r 4 and r 5 are bromine .
a molded cover member according to any one of claims 11 to 13 , wherein the cover member is vacuum shaped .
a method according to claim 4 comprising determining the level of expression of the reporter gene in the presence of the test compound or absence of said compound , wherein an increase or decrease of the expression level of the reporter gene indicates the likelihood of the test compound to modulate reverse cholesterol transport .
polypeptide and process for the preparation of hiv active substances which are effective against hiv . the polypeptide according to any one of claims 1 to 3 , characterized in that the polypeptide is used in the form of a polypeptide which is active against hiv and active substances which are effective against hiv , and active substances which are effective against hiv , and which are produced against hiv . the polypeptide of claim 2 , wherein the polypeptide is effective in the form of a polypeptide which is effective against hiv and is active against hiv .
treatment of unstable angina pectoris and non-@@ st segment myocardial infarction ( n@@ ste@@ mi ) in combination with acetylsalicylic acid ( asa ) .
≥ 12 to &lt; 18 years , n ( % ) ≥ 18 years , n ( % ) mean change from baseline at baseline ( sd ) mean change from day 28 to baseline , mean change from baseline in day 28 ; itt = in@@ tent to tre@@ at ( all randomised patients ) ; p = p-value ; sd = standard de@@ vit@@ ation ( standard deviation ) ; p = p-value ; sd = standard de@@ vi@@ ation ( sd ) ; p = p-value ; sd = standard de@@ vit@@ ation ( sd ) ;
the process of claim 68 , wherein the compound of formula ( i ) is butyl-@@ meta-@@ cyclohep@@ ty@@ di@@ formate or a pharmaceutically acceptable salt thereof .
a support device according to claim 6 or claim 7 , further comprising : means ( 204 ) for detecting venting from predetermined bags of said plurality of said sacks ( 70 ) .
pvc / aluminium blisters in packs of 2 , 10 , 14 , 20 , 28 , 30 , 50 , 56 and 100 film-coated tablets or pvc / aluminium blisters in packs of 10@@ x1 , 14@@ x1 , 28@@ x1 , 30@@ x1 , 56@@ x1 and 100@@ x1 film-coated tablets as single dose .
a device for calculating coordinate data of a desired point in an object ( 40a ) to be examined using a frame ( 20 &apos; ) , which has a form ( 20 &apos; ) , which is in the form of a frame ( 20 &apos; ) , which is in the form of a frame ( 20 &apos; ) which makes it possible to hold the object ( 40a ) in the interior and which is in a photo@@ graphical region in a frame of a computer tomograph , and a coordinate system ( 20 ) which is
the metabolism of rasagiline is two major pathways :
a pharmaceutical composition comprising a ) a pharmaceutically acceptable carrier or diluent and b ) a conjugate compound according to claim 1 . use of a conjugate compound according to claim 1 for the manufacture of a medicament for treating an individual with diagnosis or suspected for a metastatic colorectal carcinoma .
an apparatus according to claim 8 , wherein at least one inner surface of the first or second strip comprises adhesive means , and the inner surfaces are fixedly bonded to each other at intervals between the barrel cylinder portions ( 24 ) , or the first and second films are heated together to remain firmly in relation to the syringe barrel portions ( 24 ) in such a way that the syringes ( 22 ) are held at the relative orientation ; or the first and second stripes are transparent .
use of the dental compositions according to one of claims 1 to 15 as dental impression materials .
lipid nanoparticles according to claim 3 , characterized in that the cosurfactant is selected from the group consisting of butanol , butyric acid , hexanoic acid , sodium cholate , sodium tauro@@ cholate or sodium glyco@@ cholate .
the oligonucleotide of formula i as claimed in claim 1 , wherein x is 15 to 45 .
method for producing a gra@@ ded coating of calcium phosphate phases and metal oxide phases on metallic implants
10 . the bone cement of claim 7 , wherein the emulsifier is sodium di@@ hexyl@@ sulfosuccinate .
a combinatorial library comprising chemical compounds or compositions according to any one of claims 1 to 25 .
appropriate procedures for handling and disposal of antineoplastic medicinal products should be used .
the use of a peptide compound having 5 to 15 amino acids , which comprises an amino acid sequence selected from the group consisting of d@@ kel@@ ri , d@@ well y@@ tu@@ ri y@@ ae@@ fr@@ g , e@@ ae@@ fr@@ g , dy@@ e@@ fr@@ g , dr@@ ri@@ ri , gre@@ fr@@ n , eye@@ fr@@ g , dr@@ ri@@ ri , gre@@ fr@@ n , eye@@ fr@@ g , d@@ we@@ fr@@ i , s@@ we@@ fr@@ n , eye e@@ ke@@ fr@@ g , d@@ we@@ fr@@ i , s@@ we@@ fr@@ n , and
what is in this leaflet 1 .
an article according to claim 5 , characterized in that the lubricating layer ( 9 ) contains from 0 % to 30 % by weight polyurethane , from 1 % to 40 % by weight polyacrylate , from 1 % to 20 % by weight of polysiloxane , from 0 % to 40 % by weight of fillers .
dye composition intended to be used for dyeing keratin fibres and in particular human keratin fibres , characterized in that it comprises , in a medium suitable for dyeing , at least one indoline represented by the following formula : in which , in a medium suitable for dyeing , at least one indoline of the following formula : in which : the radicals r and r are at least one indoline , c denotes an oxygen atom or a sulfur atom , in which the indoline is present in the composition in proportions of 0.01 to 8 % by
the process of claim 7 , wherein the organic solvent is a hydrocarbon .
the first vaccination will be carried out at an elec@@ ted date , both of which are given 1 and 1 , respectively .
a process for producing fragment c of tetanus toxin which comprises culturing a transformed yeast organism according to any one of claims 8 to 10 and recovering the fragment c expressed in this manner .
a dispenser according to any one of claims 1 to 5 , wherein the reservoir housing is connected to the tubing for a dental stone removal device .
the method of claim 27 , wherein the amino acid is selected from the group consisting of arginine , lysine , histidine , and aspartic acid .
compound of formula ( i ) according to any one of claims 1 to 13 , 16 , 17 , 20 or 24 which is 4- &#91; 3- ( hexahydro@@ cyclopenta &#91; c &#93; pyrrol-3-yl 2 ( 1h ) -yl ) propoxy &#93; -n , n-dimethyl-@@ benzamide , its enantiomers , diastereoisomers , and addition salts thereof with a pharmaceutically acceptable acid .
aranesp 150 micrograms solution for injection in a pre-filled pen .
computer tomographic apparatus and method for reconstructing an object cross-sectional image .
do not open , crush or chew the capsules .
insuman comb 30 must not be administered intravenously and must not be used in infusion pumps or external or implanted insulin pumps .
absorbent article according to claim 1 , wherein said adhesive members ( 5 ) run in continuous lines or non-@@ continuous lines with arcuate portions and / or cal@@ ds .
the duration of treatment depends on the patient ’ s response to treatment .
always take this medicine exactly as your doctor has told you .
if bleeding does not arrest , treatment should be considered in the clinic .
the method according to any one of claims 8 to 10 , characterized in that the base ( 31 ) is a wire of superelastic alloy .
antibodies directed against pro@@ calcitonin , their preparation and use
within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
the assembly of claim 13 , wherein the tensioning member ( 56 ) in the spring housing ( 44 ) and / or the stop member ( 40 ) is compressed in a first length of the spring housing ( 44 ) and the stop member ( 40 ) and in a second length larger than the first length is substantially not compressed .
a vaccine for immunizing a mammal against infection with s . pyogenes , comprising an amount of purified s. pyogenes dnase b enzyme sufficient to stimulate antibodies for s. pyogenes dnase b , wherein the purified s . pyogenes dnase b enzyme is encoded by the dna sequence of claim 1 .
gas filling / gas discharge system and closure system with compression closing mechanism for guidewire assembly with closing element
danmark am@@ gen fili@@ al af ab , sverige tlf : + 45 39@@ 6@@ 17@@ 500
use of oxiran@@ e-@@ carboxylic acids of the formula i according to claim 1 , in which r1 is meta or para@@ dentate and r1 denotes a hydrogen atom , a chlorine atom or a trifluoromethyl group , r2 denotes a hydrogen atom , r3 denotes a hydrogen atom , and n denotes an integer of 4 to 6 and n denotes an integer of 4 to 6 and the pharmaceutically acceptable salts of the carboxylic acids .
implant according to claim 5 , characterized in that the pharmacological agent is a growth factor .
active agent stabilized with protein , process for producing the same and method of using the same
aza-@@ bridged bicyclic amino acid derivatives for use as antagonists of alpha@@ 4-@@ integrin
the vaccine of claim 35 , wherein the tk ⁺ host cells are r@@ ab@@ 9 .
the compound of claim 22 wherein r 29 and r 46 are groups independently selected from the group consisting of alkyl substituted with a polycyclic aryl group .
lev@@ vi@@ ax 400 mg film-coated tablets telithromycin
scientific conclusions and grounds for amendment of the summaries of product characteristics
zonegran orodispersible tablet should be placed into the mouth on the tongue where it rapidly disintegra@@ tes in saliva .
nonwoven absorbent article and process for its manufacture .
denatured recombinant fusion proteins are used in the presence of a heat shock protein , which acts after the functional principle of the bacterial gro@@ el or the equivalent porphy@@ chondro@@ idal component hsp@@ 60 , and of atp is folded correctly .
method for producing active bone ce@@ ments containing active substances
the electrochemical cell according to any one of claims 1 to 3 , wherein the phosphate additive is di@@ benzyl@@ phosphate present in the electrolyte at a concentration of up to about 0.20 m .
you must not breast-feed the treatment with xeloda .
a transformant wherein a host cell selected from the group consisting of escherichia coli , cultured insect cells and cultured animal cells is transformed with a recombinant vector according to claim 10 .
a single chain avidin according to claim 16 , characterized in that the linker is a 12 amino acid residue g@@ gs@@ g@@ sg@@ gs .
a controlled release oxycodone formulation as claimed in claim 1 or 2 comprising from 10 mg to 40 mg of oxycodone salt , wherein said formulation provides a mean maximum plasma concentration of oxycodone from 6 to 60 ng / ml for 2 to 4.5 hours after administration , and a mean minimum plasma concentration of 3 to 30 ng / ml provides 10 to 14 hours after administration .
rna interference mediated inhibition of the gene for the insulin-like growth factor type 1 receptor ( igf-@@ r ) receptor using short interfering nucleic acid ( sin@@ a )
the connector of claim 2 , wherein each of the gripping members ( 60a , 60@@ b ) has a grip edge ( 6@@ 4a , 6@@ 4b ) at one end and a handle ( 62a , 6@@ 2b ) at the other end .
powder for solution for infusion
betaine acts as a methyl group donor in the re@@ methylation of homocysteine to methionine in patients with homo@@ cyste@@ in@@ uria as a methyl group donor .
do not freeze store in the original package in order to protect from light .
the use of claim 14 , wherein the cells are implanted at the site with the allograft or implant .
the vehicle of claim 1 , 2 , 3 or 4 , wherein the polysaccharide is selected from the group consisting of methyl cellulose , ethyl cellulose , ethyl hydroxyethyl cellulose , hydroxypropyl cellulose , sodium carboxymethyl cellulose , hydroxypropylmethyl cellulose , ethyl methylcellulose , guar gum derivatives , xanthan gum , psyllium gum , alginate , locust bean gum , and mixtures thereof .
dispose of the syringe , needles and any unused solvent .
the use of claim 10 , wherein the poly@@ specific antibody comprises a plurality of determinants which specifically bind to the same or different epitopes of a tumor cells produced by the tumor cells or which bind to different antigens or antigens associated with the tumor cells .
the dna construct according to claim 1 , wherein the nucleotide composition of the dna spacer sequence is 5 &apos; -a@@ a@@ a@@ aat@@ gg@@ ca@@ ac@@ g-3 &apos; .
therapeutic composition comprising poli@@ hex@@ ide for the treatment of ophthalmic , dermatological and irritable herpes zoster .
a method according to claim 17 , 18 or 19 , wherein the aqueous solution , aqueous suspension or aqueous isotonic solution further comprises zinc ions and / or a buffer such as acetate or citrate and / or a preservative such as m-cresol , methyl paraben or phenol .
a device for post-@@ stationary monitoring of a patient for detecting pneumonia , a postoperative haemorrhage , a wound healing disorder , a lung complication , a urinary tract , or a patient &apos;s thrombosis , a patient ( 1 ) , which comprises : - a database ( 13 ) for post-@@ stationary monitoring of the patient ( 1 ) , - for the evaluation of the relevant data and an alarm means associated with the database ( 13 ) for evaluating the relevant data and an alarm means for generating an alarm signal when the evaluated relevant data
a vial containing medication , for use as a syringe accessory , comprising : a tubular syringe barrel ( 1 ) , an end wall ( 3 ) that forms a permanently closed end of the drum ( 1 ) , the other end of the drum ( 1 ) , the other end of the drum defining a permanently closed end ( 2 ) , the other end of the drum ( 1 ) , the other end of the drum being a permanently closed end ( 2 ) , the other end of the drum ( 1 )
serum cholesterol and blood glucose were minimal to slightly increased in rats but not in mice or dogs .
kineret should not be used in patients with severe kidney problems .
methods and compositions relating to polypeptides having rna@@ se-@@ iii domains which mediate rna interference
joint endoprosthesis according to claim 2 , characterised in that the inorganic composite component contains secondary phases in an amount of 5 - 20 ; preferably 8 to 15 % .
active substance : inactivated blue@@ tongue disease of serotype 1 ................................@@ ............@@ .. ≥ 1.9 log 10 pixels * ( * ) antigen content ( vp2 protein ) in immunoassay
the endoscopy illumination system according to claim 1 , wherein a ccd or c@@ mo@@ s camera mounted at the tip is detachably attached to the elongate member .
always make sure you always have a sufficient supply of norvir .
the connector of claim 1 , wherein the second internal volume is substantially equal to the first internal volume .
a medicament delivery device ( 10@@ 1,@@ 90@@ 1,@@ 100@@ 1,@@ 110@@ 1,@@ 120@@ 1,@@ 1@@ 301 ) according to claim 12 , wherein the piercing member ( 5@@ 53 ) is configured to engage the surface of the first membrane ( 552 ) facing the reservoir ( 166 ) on the first membrane ( 552 ) .
side effects may occur if you start to start treatment or if you have increased the dose .
a method according to any one of claims 1 to 6 , wherein the biomolecule is an antimicrobial agent , an antimicrobial agent , an anticoagulant , an anti-@@ thrombotic agent , a platelet agent , an anti-inflammatory agent , an enzyme , a catalyst , a hormone , a dna segment , a nucleic acid , a dye , a dna segment , a rna segment , a protein , a dna segment , a rna segment , a protein or a peptide .
an apparatus for detecting the reje@@ cting reactions following a heart transplantation , comprising sensing electrodes ( 1 ) , which are applied either at an endocardial or epicar@@ dial site of the heart , and a reference unit for comparison with a waveform or epicar@@ dial point of the heart , and a reference unit for comparison with a waveform or epicar@@ dial point of the heart , and a reference unit for comparison with a waveform or epicar@@ dial point of the heart , and a reference unit for comparison with a waveform or epicar@@ dial site ,
an injection device comprising a plurality of operating elements ( 8 , 3 , 5 , 4 ) for adjusting and injecting set medicament doses , signalling generators ( 11 , 12 , 13 , 14 ) , and an electronic circuit , which is connected to at least two of the operable elements ( 8 , 3 , 5 , 4 ) , and an electronic circuit which is connected to at least two of the operable elements ( 8 , 3 , 5 , 4 ) , and an electronic circuit which is connected to at least two
a nail enamel according to claim 11 , wherein the plasticizer component comprises neopentyl benzoate .
the stent delivery system of claim 1 or 2 , wherein the retraction means comprises a pull wire ( 41 ) attached to the retractable distal sheath ( 14 , 16 ) , the retraction wire ( 41 ) being longitudinally movable , and wherein the inner core comprises a spring winding .
the method of claim 12 , wherein the concentrate is acidified to a ph in the range of 6.0 to 7.0 .
the sole of claim 14 , wherein the layers ( 40@@ 1-4@@ 410 ) include layers of different fiber directions .
6.4 special precautions for storage
process according to any one of the preceding claims , characterized in that the sugar is present at the beginning of the fermentation in the fermentation broth in an amount between 20 % and 45 % .
infections and infestations laryngeal vascular disorders
the method of claim 7 , wherein s1 and s2 are linked via a nucleotide linking group and s3 and s4 via a nucleotide linking group .
use of one or more compounds according to claim 1 or 2 as active ingredients for the preparation of pharmaceutical compositions for the treatment of disorders associated with a role of endothelin , especially circulatory disorders such as hypertension , ischaemia , vasospasm and angina pectoris , and proliferative disorders such as cancers .
in accordance with the risk management systems for medicinal products for human use , the updated rmp should be submitted at the same time as the next periodic safety update report ( psur ) .
the method of claim 8 , wherein the polyester plastic is selected from polyethylene terephthalate and the polymeric material is selected from the group consisting of polyethylene , urethane and amorphous polyethylene terephthalate .
a package assembly intended for the spontaneous preparation of suspensions or solutions of an active solid product in a liquid product , wherein each of said products is contained separately in a sealed vial , and wherein each of said products is contained separately in a hermetically sealed vial , and said two vial is contained separately in a hermetically sealed vial , and said two vials are contained in a sealed vial , and said two vial is contained separately in a sealed vial , and said two vial is contained separately in a sealed vial , and said
a process for preparing a compound of formula iii &quot; wherein r &apos; 23 , r &apos; 25 and r 10 are as defined in claim 3 , wherein r &apos; 23 is halo , for example br , with the corresponding r &apos; 23 ketone or the activated r &apos; 23 precursor , and subsequently , if desired , conversion of the compound of formula iii &quot; into another compound of formula iii &quot; , or a pharmaceutically acceptable and cleavable ester thereof , or an acid addition salt thereof .
vedo@@ lizumab is used to treat moderate to severe acute disease where conventional therapy or medication with tnf alpha antagonists have been shown to be effective or not tolerated by the patient .
a composition according to claim 7 , which uses an mmp inhibitor selected from 4- ( 4 &apos; -chloro@@ biphenyl-4-yl ) -4-hydroxy@@ imino@@ butyric acid or 2- ( 4 &apos; -bromo@@ -biphenyl-4-@@ sulfonylamino ) -3-methyl@@ butyric acid .
the preparation form according to claim 2 , wherein the reducing agent is cys , n-acetyl-@@ cys , thio@@ glycerol , sodium sulfide or glutathione or mixtures thereof , optionally in the presence of a complexing agent .
ambulatory blood pressure measurements indicated that the combined use of 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily resulted in consistent reductions in blood pressure over 24 hours with mean reductions in systolic / diastolic blood pressure by 15.@@ 8 / 10.0 mmhg for 24 hours after the placebo effect .
the surgical instrument of claim 3 , wherein the bias of the spring during movement of the connecting member assembly through the first and second stages allows movement of the connecting member assembly from the second stage to the third stage and thereby release the surgical fasteners .
careful monitoring of the therapeutic effects and adverse reactions of tricyclic antidepressants ( for example desipramine and nor@@ tryp@@ ti@@ line ) is recommended when agenerase is co-administered ( see section 4.4 ) .
nitro@@ loxy@@ ethyl apo@@ vinc@@ amine and pharmaceutically acceptable salts thereof .
a process according to claim 1 , characterized in that the hair dye component additionally contains a primary intermediate of a hair dye , a hair dye coupler or a mixture thereof .
now , each day is a gi@@ ft .
the catheter system of claim 5 , wherein the magnetically responsive element is a permanent magnet ( 50 ) having a long elongated cylindrical shape and planar pole surfaces ( 50a , 50b ) at its pole ends .
no dosage adjustment is necessary in patients with hepatic impairment and in patients with mild to moderate renal impairment .
a pharmaceutical composition comprising as an active ingredient a pe@@ f-@@ derived bioactive product according to any one of claims 1 to 3 , 8 and 9 and a pharmaceutically acceptable carrier material , preferably in a weight ratio of between about 1 : 5 and 1 : 25 and most preferably between 1 : 9 and 1 : 19 , and the most preferably from 1 : 9 to 1 : 19 and 9 in an amount of 0.0@@ 1-10 % by weight , preferably 0.0@@ 5-@@ 1 % by weight , more preferably 0.05-@@ 0.1 % by weight
infections and infestations not known :
viruses for the treatment of cellular proliferative diseases
hair treatment composition according to claims 1 to 4 , characterized in that it contains 0.2 - 5 % by weight of d-@@ panthenol 0.5 - 5 % by weight of glucose 0.5 - 3 % by weight of polyvinylpyrrolidone .
a stereotactic frame as claimed in claim 1 , characterised in that the adjustable fastening means and the means for locking the first disc ( 40 ) comprises a snap-@@ like retractable retraction arm which extends from the stationary mount member ( 32 ) .
substituted piperazine derivatives and their use as inhibitors of the micro@@ somal triglyceride transfer protein ( mt@@ p )
a device according to claim 1 , characterised in that for deriving the synchronization signal from the electrocardiographic signals without time delay a non-@@ recur@@ sive predic@@ tor ( 5 ) for noise signals of the network frequency and their surface oscillations is used , the said signals being used by means of a non-@@ recur@@ sive predic@@ tor ( 5 ) for noise signals of the network frequency and their surface vibrations , said signals being used by determining the temporal location of the qrs ( chamber ) complex in the electrocardiographic signals , which are based on the
method and apparatus for needleless subcutaneous injections .
use according to claim 5 , in which the α-@@ hydroxycarboxylic acid is selected from glycolic , tartaric , lactic and mandelic acids .
the aortic graft of claim 9 , wherein each of the graft members ( 80a , 80@@ b ; 16@@ 0a , 16@@ 0b ) further comprises an expandable or expandable stent ( 82 ; 162 ) attached to the distal end ( 17@@ 2a , 17@@ 2b ) of the graft member to secure the graft ( 80 ; 150 ) within a body of a patient .
• 3@@ 1.@@ 1.@@ 2002 • 3@@ 6.@@ 1.@@ 2002 • 54 days
the apparatus of claim 1 , wherein the shaft further comprises a distal tip , the distal tip having a proximal end having an outer diameter that is not less than an outer diameter of the sheath .
                                                                                   
the apparatus of any one of claims 11 to 14 , wherein the gas delivery means comprises a gas manifold ( 26 ) formed with at least two gas channels ( 68 , 70 ) , each communicating with a corresponding end of each diaphragm ( 32 ) and communicating with a gas inlet port ( 28 ) or gas outlet port ( 30 ) .
a method according to claim 5 , wherein the carrier is used with immobilized nucleic acid for analyzing the nucleic acid by hybridization .
the method of claim 16 , further comprising oxidizing the product of claim 16 .
a surface-@@ treated optical plastic article according to any of claims 13 to 17 , wherein the carboxyl functional polymer is a polymer selected from poly ( meth ) acrylic acid , poly@@ itaconic acid and a copolymer of ( meth ) acrylic acid , maleic acid , itaconic acid or maleic anhydride with a reactive vinyl monomer or mixtures thereof .
a cloned tyrosine phen@@ ol-@@ lyase gene , a recombinant plasmid containing said plasmid and e. coli transformed with said plasmid .
a method of calibration of a sensor ( 1 ) for measuring the concentration ( pg ) of a gas ( g ) dissolved in a liquid ( b , c , c &apos; ) , and in that the gas ( 16 ) dissolved in said predetermined calibration liquid ( c ) is fed to the predetermined other concentration ( pg ( c &apos; ) of the gas ( g ) to the predetermined other concentration ( pg ( c &apos; ) to the predetermined other concentration ( pg ( c &apos; ) of the gas ( g )
process according to any one of claims 1 to 7 , characterized in that the quinone derivative in the composition ( b ) is present in concentrations ranging from 0.005 to 1 mol / l .
the use of claim 1 , wherein the disease is cancer / neoplasms wherein enhanced t cell proliferation responses , increased lymphokine secretion and elevated nk cell activity would lead to destruction of cancerous tumor and remission of the disease .
the method of claim 30 or claim 31 , wherein the host cell is an e. coli cell .
all patients received adequate quantities of vitamin d and calcium in the postmenopausal osteoporosis study , in the study to avoid clinical fractures after hip fracture and in the mor@@ bus pa@@ ge@@ t studies ( see section 4.2 ) .
felodipine , nifedipine , nicardipine , diltiazem , ni@@ modi@@ pine , verapamil , amlodipine , n@@ iso@@ l@@ dipine , iso@@ chro@@ pine ( saquinavir / ritonavir )
preparation according to one of claims 1 to 3 , characterized in that it comprises 0 to 90 % other components , preferably vegetable concentrates , foodstuffs and / or auxiliary components , and preferably 20-@@ 70 % of micro@@ nutrients and 20-@@ 70 % of micro@@ nutrients .
a method according to any one of the preceding claims , wherein the echin@@ acea plant press juice is cooled to -8 ° c for two to three days , then filtered and is adjusted to a ph of 4.9 by addition of 0.1 % citric acid .
a process for the preparation of a composition based on hydrated lipidic lamellar phases or liposomes , preferably for the preparation of cosmetic or pharmaceutical compositions , characterized by incorporating a composition according to any one of claims 1 to 4 .
iclu@@ sig film-coated tablets are white , round and convex on the upper and lower sides .
in most patients with severe hypercalcaemia ( albumin@@ -@@ corrected serum calcium * ≥ 3 mmol / l or ≥ 12 mg / dl ) a single dose of 4 mg is sufficient .
the extent of lamivudine and zidovudine absorption ( auc ∞ ) and estimated half-lives after lamivudine / zidovudine administration were similar to that observed in fasted subjects , although absorption rates ( cmax , tmax ) were delayed .
a process for producing a treated granular pigment product in a fluidized bed using a binder as a granulating agent , wherein the binder comprises at least one water-dispersible , sulfon@@ ate-containing polyester .
the catheter device of any one of claims 10 to 12 , including a tubular liner ( 61 ) in the tubular housing ( 60 ) for the tissue penetrating element .
a method of producing an intraocular lens according to claim 1 , wherein one of said opposite forming surfaces of said press pair of said press pair corresponds to said contour of a surface of said lens of said intraocular lens and said contour corresponding to a surface of the lens of said lens and said contour of said one surface of said lens of said lens and said other of said opposing forming surfaces and said one surface of said one surface of said lens is equal to a surface of said lens and said one surface of said
sulphur@@ -containing para-phenylenediamines according to claim 16 , characterized in that they are chosen from : 2-@@ acetyl@@ ylamino@@ thio-@@ para-phenylenediamine , 2,6-dimethyl@@ thio-@@ para-phenylenediamine , 2-@@ β-hydroxy@@ thio-@@ para-phenylenediamine , 2-ethyl@@ thio-@@ 1-@@ n- ( β-hydroxyethyl ) -p-phenylenediamine , 3-@@ ethyl@@ thio-@@ 1-@@ n- ( β-hydroxyethyl ) -p-phenylenediamine , and the addition salts thereof with an acid .
the compound of claim 23 , wherein q is q 5 and the solubilizing group is selected from the group consisting of residues of formulae a 1 to a 10 of claim 9 .
the apparatus of claim 3 , further comprising air inflow means ( 29 ) for supplying air into the first conduit ( 24 ) when the connected valve means ( 26 ) is closed .
device according to claim 13 , characterized in that the working fluid is formed by a working liquid ( 22 ) , preferably water , and in that the conveyor arrangement ( 20 ) comprises a liquid pump ( 62 ) , preferably a rotary wheel pump for conveying the working liquid ( 22 ) .
cannula for dispensing liquid products for vaginal and anal applications
device for administering a closure device
apatite glass ceramic with at least one glass phase and at least one apatite phase , characterized in that at least one of the apatite phases is a phosphate and fluoro@@ free silicate phase of the formula me &#91; i &#93; x me &#91; ii &#93; y me &#91; i &#93; x &#91; ii &#93; y me &#91; i &#93; x &#91; ii &#93; y me &#91; i &#93; x ( sio 4 ) 6 o 2 , the percentages relating to the total weight of the glass ceramic related : apatite glass ceramic of claim 1 , wherein all
a compound of formula ( i ) , or a pharmaceutically acceptable salt thereof : wherein z is a heterocycle or a c 1 , a 2 and a 3 membered aromatic group , or a group consisting of a 1 , a 2 and a 5 membered aromatic ring , or a group comprising a 1 , a 2 and a 5 membered aromatic ring , or a 3 membered a 5-membered aromatic ring , or a group comprising a 1 , a 2 and a 5 membered aromatic ring , or a 3 membered aromatic ring , or
an ocular implant according to any one of claims 1-4 , wherein the thickness of the flat member is between 1 and 250 microns .
a delivery device according to claim 15 , wherein the medicaments are selected from the group consisting of beclomethasone dipropionate , fluticasone , budesonide and flun@@ iso@@ lide .
use according to claim 1 , in which the stabilizing agent in the emulsion is present in an amount ranging from 0.1 to 50 % by weight and preferably from 0.5 to 20 % by weight .
the adhesive of claim 1 or 2 , wherein the addition weight of the polyethylene oxide is from 2 % to 8 % of the weight of the perforated plastic film as the wound covering .
use according to any one of the preceding claims , characterized in that the oleo@@ ates of plant oils are chosen from the group formed from the oleo@@ deca@@ tes of avocado oil , soybean oil , lu@@ pin oil , sunflower oil and the mixtures of these latter .
a process for the production of epa , characterized in that it comprises : ( a ) cultivating colorless silica algae in a fermenter containing a nutrient solution containing at least available nitrogen ; ( b ) maintaining a dissolved oxygen content of 10 % to 70 % of the air saturation in the nutrient solution ; ( d ) maintaining the ph of the nutrient solution to from 7.0 to 8.5 ° c ; ( f ) maintaining the ph of the nutrient solution to from 7.0 to 8.5 ; ( f ) maintaining the ph of the nutrient
abdominal pain , constipation , dyspepsia , vomiting
a compound according to claim 17 which is 1- ( 4-amino-@@ 5-chloro@@ -2-methoxyphenyl ) -3 { 1- &#91; 3- ( 3,4-dimethoxyphenyl ) prop-1-yl &#93; piperidin-4-yl } propane@@ -1-@@ one hydrochloride .
in order to control the actual pressure in a face mask ( 5 ) on a therapy pressure , the pressure drop produced by an air flow in a breathing tube ( 4 ) calculates , and a desired pressure for a pressure sensor ( 3 ) which is supported in the housing of the cpap device .
the dental kit of claim 1 , wherein the liquid composition comprises a acid ester of the following general formula : wherein r 1 is a hydrogen , lower alkyl of from 1 to 5 carbon atoms , halo or c@@ n-@@ radical ; n and m are independent integers of 1 or greater , z is an aliphatic , cycloaliphatic or aryl radical comprising a carbon chain comprising at least 2 carbon atoms and 0 or more oxygen or sulfur atoms , and has a valence or valence of m + n .
container according to one of claims 5 and 6 , characterized in that the shaft ( 29 ) has a substantially cylindrical shape and is provided with a longitudinal mixing channel for the product and has perforations ( 42 ) in the remaining at the opposite end .
process according to any one of the preceding claims , characterized in that the composition is in the form of an oil-in-water emulsion .
hip nail and method of use .
liposomal formulations according to claim 1 , characterized in that the polymers are carbo@@ pol , cellulose or acrylic acid derivatives , alginates , collagen or hyaluronic acid and derivatives thereof .
pharmacotherapeutic group : other nervous system agents ; agents for the treatment of addic@@ tive disorders ; drugs for the treatment of opiate dependence atc code : n@@ 0@@ 7@@ bc@@ 51 .
the method or device of any preceding claim , wherein the second population of cells is substantially a uro@@ thelial cell population .
composition according to any one of claims 1 to 3 , characterized in that the alkoxylated radical substituted in α , ω@@ -@@ positions corresponds to the following general formula ( i ) : r = - ( ch ) -o- ( c h o ) ( c h o ) ( c h o ) ( c h o ) ( c h o ) and ( c h o ) units randomly or in the form of blocks which are r c alkyl or phenyl , 5 ≤ m ≤ 300 .
a method according to claim 9 , wherein said ingredients are combined in a form suitable for oral administration .
caution should be exercised when sorafenib is administered concomitantly with medicinal products predominantly via ugt@@ 1a1 ( e.g.
for storage conditions of the reconstituted medicinal product , see section 6.3 .
compounds according to claim 15 , wherein r 5 is hydrogen .
a chair according to claim 3 , wherein each releasable rear wheel is attached to a frame member which is telescopically movable with respect to a main frame portion .
a sealed sachet according to claim 3 or any claim dependent thereon , characterised in that the two or more layers comprise three layers .
adults with newly diagnosed phi@@ la@@ del@@ ph@@ ia chromosome positive acute lymphoblastic leukaemia ( ph + all ) in combination with chemotherapy .
transdermal therapeutic system according to one or more of the preceding claims , characterized in that one or more matrix layers or in the presence of an adhesive layer comprises said one or more substances selected from the group of the ta@@ vic@@ tim , skin permeation enhancing additives , fillers , solubility enhancers or in water swellable additives .
these are based on spontaneous reports , therefore the frequencies are not known .
process according to one or more of the preceding claims , characterized by compressing water from the wetted structure before drying the structure .
the conservative treatment is indicated in the initial spontaneous fracture of small cysts .
the committee therefore decided that ke@@ tek should be restricted to the treatment of commun@@ ity-@@ acquired pneumonia , to the treatment of bronchitis and sinusitis when they are caused by bacteria resistant to bet@@ al@@ lactam or macrolide antibiotics , and to the treatment of ton@@ sil@@ litis / pharyngitis when these antibiotics are not indicated .
every 3-4 weeks to maintain the igg plasma levels at least 4-6 g / l
use of sigma receptor antagonists to enhance the effect of antipsychotic drugs .
cellular reproduction device for cellular propagation
an mri device comprising : means for externally displaying an rf pulse ; a means for applying a magnetic gradient field ; an nmr signal receiving means ; and a method for performing the steps of evaluating a phase storage circuit having the steps of evaluating the steps of evaluating the steps of evaluation of a phase storage circuit ; using a method for performing the steps of evaluating the steps of evaluating a phase storage circuit ; using a method for performing the steps of evaluating the steps of evaluation of a phase storage circuit ; use of a
a method according to claim 9 , wherein the composition is useful for the regulation of immune responses .
method and route ( s ) of administration
use according to claim 1 or claim 2 , wherein the topical pharmaceutical formulation contains 0.25 % to 75 % by weight of active agent .
the maximal blood pressure lowering effect should be reached 4 to 6 weeks after initiation of therapy .
the assembly ( 10 ; 200 ) of claim 7 , 8 or 9 , wherein the respective band ( 84 , 86 , 88 , 98 ; 262 , 264 , 266 , 272 , 27@@ 4,@@ 276 ) only is part of the distance about the assembly ( 10 ; 200 ) , preferably less than half of the distance about the assembly ( 10 ; 200 ) .
intervertebral implant ( 15 ) according to one of claims 1 to 8 , characterised in that the anchoring members ( 1 ) have fixed fastening means ( 9 ) fixed to the end plate ( 13 ; 14 ) with respect to rotation about the central axis ( 6 ) .
you may first be given other medicines .
in addition , effective surgical ap@@ op@@ lexy is considered to be a low perioperative apop@@ lexy rate .
adeno-associated virus vectors with intra@@ vector heterologous terminal pal@@ ind@@ ro@@ mic sequences
a process for producing a live vaccine comprising formulating a pharmaceutical composition according to any one of claims 1 to 6 in a pharmaceutically effective amount with pharmaceutically acceptable diluents , carriers and / or excipients .
process according to any one of claims 1 to 15 , characterized in that the composition is in the form of a mascara for the eyelashes or mascara .
continuous sterilization and filling device .
polynucleotide sequence suspected for a cell adhesion molecule
process according to claim 7 , characterized in that the insulin derivatives of formula iii and / or their physiologically tolerable salts are used in dissolved , amorphous and / or crystalline - preference in amorphous and / or crystalline form .
the mechanism of action of lenalidomide involves anti-neoplastic , anti-angiogenic , erythropoie@@ sis-@@ stimulating and immunomodulatory properties .
compounds according to claim 5 , wherein r 2 represents a hydrogen atom , -or 8 or a lower alkyl ( which is optionally substituted with one or more of the radicals -or 8 and -nr 8 r 9 ) .
use of a compound according to claim 1 for the manufacture of a medicament for treating an allergic or inflammatory condition .
a kit according to claim 1 , wherein the oxidizing agent is hydrogen peroxide .
a cell comprising the nucleic acid of claim 13 . a cell comprising the nucleic acid of claim 15 . a method of producing a peptide , said method comprising culturing the cell of claim 19 under conditions permitting expression of said polypeptide from said nucleic acid .
bolt element according to claim 1 or 2 , characterised in that the wire bow ( 31 ; 41 ; 47 ) is itself resilient and its two ends are anchored on the removable part of the dental prosthesis part .
a plunger needle according to claim 1 or 2 , characterised in that the plunger tip ( 4 ) has a generators with substantially circular , flattened or elliptical basic shape .
medical container with improved detachable sealing member
the method of any one of claims 1 to 14 , wherein the subject is a non-human animal .
a polynucleotide according to claim 19 , wherein the poly@@ protein has at least 70 % homology to the total poly@@ protein selected from ( i ) the polyprotein shown in figure 17 or ( ii ) the polyprotein of a viral isolate of the genome from which the cd@@ nas deposited in a lambda g@@ t-@@ 11 cdna library with the american type culture collection ( atcc ) has been produced with the accession number 40@@ 394 .
process according to one of claims 1 to 3 , characterized in that the cells are dissolved by sonication .
a method according to any one of the preceding claims , further comprising the steps of : purifying the vein segment ( 12 , 112 ) ; and dividing the segment into individual pieces containing a single flap ( 14 , 118 , 142 ) .
the results in patients with or without previous systemic treatments for their psoriasis were similar .
a replicable nucleic acid molecule according to claim 21 , which is free from its complementary strand in a predomin@@ ately single-stranded form .
the hepatitis b surface antigen is produced in recombinant yeast cells ( saccharomyces cerevisiae ) .
however , if ari@@ mi@@ dex asthenia and somnolence have been reported , caution should be exercised when driving or operating machines , as long as these symptoms persist .
a crosslinking agent as claimed in claim 1 of the formula ( ii ) ( wherein q may be a leaving group l or a group of formula -x@@ .@@ y. ( z ) n , y , z , m , x , y , z , m and n are as defined in claim 1 ; r . r , z and n are as defined in claim 1 , which may be the same or different , in association with the groups r , r ⁹ , b , x , y , z , m and
use of an agent which modulates tyrosine phosphorylation to modulate the permeability of a physiological barrier
therefore , the chmp considered a different proposal with appropriate evidence .
a compound according to claim 1 , which is 1 ( s ) , 3 ( r ) -dihydroxy-@@ 20 ( r ) - ( 5-ethyl-@@ 5-@@ hydroxy-@@ spiro 1 ( e ) -3-@@ en-3-one ) -@@ pregna@@ pregna@@ -5-@@ ( z ) , 7 ( e ) , 10 ( 19 ) -tri@@ ene .
in order to induce ovulation induction , a lower median total dose and a shorter median duration of treatment was required than with urinary fsh .
injection site reactions ( 1 ) individual a@@ es have not been considered unless they were considered medically relevant .
a complete remission ( cr ) was achieved in 33 % ( 34 out of 102 patients in the itt group ) .
the catheter with an expandable body according to claim 1 or 2 , wherein the expandable body ( 3 ) is provided in the condition that it is folded around the distal end portion of the shaft prior to stretching .
10 , and the pupi@@ ls are the same and react .
the composition of claim 5 , wherein the concentrate further comprises one or more flavouring agents and one or more pharmaceutically acceptable preservatives .
use of a compound according to claim 1 for the manufacture of a medicament for the treatment of hypertension , heart failure , glaucoma , renal diseases , hyper@@ aldosteronism or acute or chronic pain .
the mah proposed to accept some details from these studies in the harmonised spc .
the effects of treatment for os were affected for the majority of the determined criteria ( including gender , k@@ ps , geo@@ graphic region , primary pancreatic cancer , stage of diagnosis , presence of liver metastases , presence of a peritoneal cancer , previous wh@@ ip@@ ple surgery , presence of a biliary stent at baseline , presence of lung metastases and number of metastasis sites ) in favour of the abraxane / gemcitabine arm .
a method according to claim 1 , wherein the protein is selected from lectins and lipo@@ oxid@@ ases .
transgenic mammals and cell lines for the identification of glutamate transporter modulators
the substrate of claim 6 , wherein the donor substrate comprises a fabric softener compound .
an apparatus according to claim 63 or 64 , wherein the switch ( 52 ) comprises an electric switch and the energy of the second form comprises electric energy .
it encodes a new lytic enzyme .
an arrangement according to claim 2 , characterized in that a terminal of the capacitor is connected in each of the magneto@@ gen@@ generating circuits to the return terminal of a direct current source ( dc ) , and in that a terminal of the main current path of the first thy@@ ri@@ st@@ is is connected to the output terminal of a direct current path , and in that a terminal of the main current path of the first thy@@ ri@@ st@@ is is connected to the output terminal of the first thy@@ ri@@ st in one of the
the most common ( ≥ 10 % ) non-@@ haematological adverse reactions were rash , pruritus , headache , nausea , fatigue , alopecia , myalgia and upper abdominal pain .
the process according to claim 4 , wherein the pharmaceutically acceptable salts are formed together with a multivalent anionic substance .
stereo@@ microscopy arrangement according to one of claims 1 to 8 , wherein the beam depletion and image reversal system ( 89 ) can be pivoted or insertable into the beam path .
apparatus for separating cells and separation procedures .
dermal or transdermal therapeutic system according to at least one of the preceding claims , characterized in that the or@@ mo@@ ler layer is applied to the support layer in such a way that it is adjacent to the active substance-containing layer .
quick coupling according to claim 1 , 2 or 3 , characterised in that the locking nose ( 8 ) is provided on a resilient clip ( 5 ) .
benefix vials are to be used with insulin syringes with a corresponding unit gradu@@ ation and in conjunction with an insulin pump system .
the invention preferably relates to an open packaging package for adhesive dressings comprising a bandage dressing or bandage pad ( g ) secured to a strip of adhesive ( a ) and with two protective layers ( g ) , which is secured to a strip of adhesive support ( a ) , and with two protective material sheets ( g ) , which are secured to a strip of adhesive support ( a ) , and with two protective material sheets ( g ) , which are secured to a strip of adhesive support ( a ) , and
zyprexa is usually taken orally ( by mouth ) .
operating table according to claim 3 , characterized in that the mechanical coupling means comprise at least one pair of projections ( 29 , 30 ) associated with the head ( 11 ) and each complementary shaped seats ( 33 , 34 ) associated with the plate element in operation .
the use of side panels and the front of fron@@ t-@@ air@@ spots could provide an additional protection , if not in the case of a recovery and additional loads .
the invention relates to a coupling for sealing two prostheses of medical instruments ( 10 , 90 ) along the shaft axis ( 53 , 97 ) thereof , in particular for connecting an arthro@@ scope with an optic .
there have been reports of nephro@@ genic systemic fibrosis ( n@@ sf ) associated with the use of optimark and some gadol@@ ini@@ um-containing contrast agents in patients with acute or chronic , severe renal impairment ( gfr &lt; 30 ml / min / 1.73 m2 ) and / or acute renal impairment .
it may not cure hiv infection or aids , but the damage to the immune system stops and prevent infections and diseases associated with aids .
a process for the preparation of hydrogel-forming polymers as claimed in any of claims 1 to 12 , wherein a base polymer is a polymer having a ph of less than or equal to 5.7 surface .
a compound according to claim 9 wherein the 1-@@ indolyl group is unsubstituted or substituted with halogen .
lymphadenopathy localized in the region of the injection site .
composition according to any one of claims 12 to 14 , comprising a complex of dendritic polymer with genetic material in solution either with dea@@ e-@@ dextran or with glycerol .
 we@@ d@@ ne@@ s@@ day , 21 march and thur@@ s@@ day , 22 march
abilify 7.5 mg / ml solution for injection aripiprazole
the apparatus of claim 1 , further comprising means for providing an intermittent ciliary calendar period while the target region is located , and means for directing the radiation treatment beam to the target region during intermittent target treatment periods , each of the intermittent treatment periods being followed immediately at least one of the ciliary caloric periods .
benzimidazole derivatives for ige modulation and cell proliferation inhibition
a method of converting a ligno@@ cellulosic feedstock into glucose consisting essentially of the following steps : a . selection of an feedstock consisting of a hemicellu@@ lose and cellulose , which comprises the ratio of an arabin@@ an-@@ plus cellulose to the entire non-@@ starch polysaccharides ( ax / n@@ sp ) to the entire non-@@ starch polysaccharides ( ax / n@@ sp ) in a treatment with cellulase enzymes ; and c hydrolysing at least 40 % of the cellulose in the feedstock obtained in step b. by cellulase enzymes .
the use of proto@@ porphyrin i@@ i@@ zn ( ii ) for the manufacture of a medicament for the treatment of hepato@@ pathy by oral administration .
1 . use of perfluoro@@ -1@@ 5-@@ cro@@ wn-@@ 5 ethers for the preparation of a preparation for use in a method of obtaining fluoro@@ magnetic resonance images or spectra of body organs or tissues .
a method of purifying hepatitis c virus ( hcv ) -@@ asi@@ alo@@ glycoprotein , expressed from an asi@@ alo@@ glycoprotein from the e1 region of hcv , an asi@@ alo@@ glycoprotein expressed from the e2 region of hcv , and aggregates thereof , said method comprising contacting a composition suspected to bind to said manno@@ se-@@ binding protein with less than about 10 % of the total n-linked carbohydrate of asi@@ alo@@ glycoprotein sialic acid .
the method of claim 9 , wherein the gene product is mrna .
a process according to claim 1 wherein is used : as styrene-@@ vinyl copolymer am@@ ber@@ lit@@ e x@@ ad-@@ 11@@ 80 ; as a strong cation exchanger s-@@ sepharose ; as an alkane -@@ 4b matrix based on polysaccharide octyl-@@ sepharose , cl 4b ; and as a weak anion exchanger dea@@ e-@@ sepharose .
the system of claim 2 , wherein : the system further includes a medical device ( 12 ) positioned in the region of interest ; the location system ( 100 ) is further provided for determining the relative three-dimensional position of the medical device ( 12 ) when positioned in the region of interest in the living body ; and the display for graphic representation of the medical device ( 12 ) is disposed on the model ( 12@@ 4a ) in the determined three-dimensional position .
method for producing a dental element
the device of any one of claims 16 to 20 , wherein the means for detecting the fluorescent characteristic comprises an optical fiber .
method for random synthesis and amplification of complementary dna
composition according to any one of the preceding claims , characterized in that it is in the form of an emulsion and in that it also contains at least one dispersant chosen from emulsifiers , vesicles and particles .
the pharmacokinetic properties of simeprevir have been studied in healthy adult subjects and in adult hcv-@@ infected patients .
an anaesthetic evaporator bath having a evaporator chamber ( 21 ) for liquid anaesthetic means , and a heating device ( 27 ) disposed in the evaporation chamber ( 21 ) , wherein a partition in the form of a plate ( 31 ) extends transversely through the evaporation chamber ( 21 ) , in which a partition is in the form of a plate ( 31 ) in a position above the maximum liquid level in the space formed by the partition and the inner wall of the evaporation chamber ( 21 ) through which steam can pass through
use of anti-@@ helmin@@ th vaccines to control parasitic diseases associated with a loss of natural immunity
a method of amplifying a target nucleic acid whose nucleotide sequence is complementary to the capture probe , said method comprising the steps of : a ) providing a nucleic acid containing sample , b ) the method comprising the steps of : a ) providing a nucleic acid containing sample , b ) the method of treating said sample with a lysis buffer , said method comprising the step of expanding said nucleic acids with a lysis buffer , said method comprising the step of subjecting said nucleic acids to said captured nucleic acid , said step of amplifying
maintenance therapy may be continued as long as the patient continues to benefit from a therapeutic benefit .
the use of erythropoietin in the first three months after the start of peritoneal dialysis is not necessary because haemoglobin is often increased during this period .
pharmaceutical compositions comprising insulin and insulin hexa@@ mer ligands
in the second study , 39 ( 28 % ) of 141 adults receiving zenapa@@ x in combination with ciclosporin , prednisone and azathioprine developed kidney rejection , compared with 63 ( 47 % ) of 134 adult patients adding placebo .
the medicine can only be obtained with a prescription .
process for the cleavage of beta-lactam esters .
the media system of claim 39 , wherein the microorganisms are selected from the group consisting of streptococcus , pseudomonas , yeast , mould , bacillus and mixtures thereof .
studies with abacavir show that the ratio of cerebrospinal fluid to plasma auc is between 30 and 44 % .
a method for producing the stable bioadhesive nanoparticulate active agent composition of claim 2 comprising contacting an active agent particle with at least one cationic primary surface stabilizer for a time and under conditions sufficient that the cationic primary surface stabilizer is adsorbed to the surface of the particle to provide a stable , nanoparticulate active agent composition to the surface of the particle to form a stable nanoparticulate active agent composition , wherein : ( a ) the surface of the particle is adsorbed to the surface of the particle to form a stable nanoparticulate active agent composition ,
common ear and labyrinth disorders
the synthetic plant promoter dna sequence of claim 3 , wherein the upstream activation region comprises an upstream activation region from cam@@ v 35s .
amphoteric sterols and their use for producing ph@@ - sensitive lipo@@ se
the apparatus of claim 25 , wherein the fibers comprise at least one bioresorbable fiber ( 10@@ 3b ) and a non-@@ resorbable fiber ( 10@@ 3a ) .
a blood circulation and filtration system ( 34 , 35 ) for selectively removing certain plasma components from blood , which comprises : ( a ) a closed plasma chamber ( 31 ) , which is filled with an electrolytic plasma chamber solution , a &quot; u &quot; shaped hollow chamber membrane ( 30 ) , which is filled with an electrolytic plasma chamber solution , a &quot; u &quot; shaped hollow fiber membrane filter , a &quot; u &quot; shaped hollow fiber membrane filter ( 30 ) , wherein a &quot; u &quot; shaped hollow fiber membrane filter (
compounds of formula ( i ) according to claim 1 which is 3-methoxy@@ methyl-@@ 7- ( 4,@@ 4,@@ 4-trifluoro@@ -3-hydroxy@@ butoxy ) -3,@@ 3a , 4,5-@@ tetrahydro-@@ 1 h oxazolo &#91; 3,4- a &#93; quinolin@@ -1-one , its enantiomers and its diastereoisomers in pure form or in the form of mixtures .
use according to claim 20 or 21 , wherein the medicament acts as an agonist in human s@@ 1@@ p1 and s@@ 1@@ p2 receptors but is substantially inactive at s@@ 1@@ p3 receptors .
use of thiazolidin@@ edi@@ ones for the treatment of atherosclerosis and eating disorders
in this study , levetiracetam dose was 3,000 mg / day given in 2 divided doses .
the steady state volume of distribution is 0.1 l / kg .
the undergarment protective garment of claim 9 , wherein the material having a weak tightening force is a woven tissue that is stretchable in all directions .
the method of claim 1 , wherein the third differential image is displayed with respect to the anatomy of the organ .
this may result in an effect on efficacy .
3 . a composition according to claim 1 , characterised in that the buffer contains acetate ions and the ph is from 5.0 to 5.5 .
the polypeptide of claim 3 , wherein the additional polypeptide is a polypeptide rich in histidine residues .
process according to one of claims 13-@@ 35 , characterized in that the 2-@@ aryl@@ propionic acid derivative is used as a mixture of s- and r enantiomers .
≥ 0.5 x 109 / l and &lt; 0.75 x 109 / l ≥ 25 x 109 / l and
antibodies for specific binding to compounds .
a medical device according to any preceding claim , wherein the inflec@@ tion point ( 21a ) is substantially centrally located between a tip and a valley .
anti-@@ egfr and anti-@@ egfr antibodies
compositions for efficient drug release
use of od@@ c inhibitors , dac@@ arb@@ azine and interferon in the treatment of malignant melanoma .
control pulse for an intravascular imaging device
what avandamet is and what it is used for 2 .
compounds according to claim 1 , characterized in that r is a methyl group ( -ch 3 ) .
an amide derivative of formula i according to claim 1 , wherein r is hydroxyl , c alkoxy , carboxyl , c -alkoxycarbonyl , nitro , c , c , c is 0-3 , c is 0-3 , m is 0-3 , m is 0-3 , m is 0-3 , m is 0-3 , m is 0-3 , m is 0-3 , and , where m is 2 or 3 , the r groups are equal or different ; p is 0-3 ; and the r groups are equal or different ; p is 0-3 ; and the pharmaceutically acceptable
a method for producing a human anti-@@ p. aeruginosa monoclonal antibody according to claim 1 , wherein ( i ) cultured a hybridoma or a cell line according to claim 1 or ( ii ) a hybridoma by a process according to claim 2 which is cloned and cultured .
the method of claim 13 , wherein both of said one or more site-specific sensed measured quantities and said one or more site-specific sensed measured quantities of measured values have measured values that have been captured from different bends .
the dose of increlex should not be doub@@ led in any doub@@ t to get one or more doses . • within 2 - 3 hours after the dose of increlex , patients should not have a high break@@ point activities ( e.g.
according to the invention , compounds of formula i , in which a ₁ and a ₂ are hydrogen , optionally substituted lower alkyl , lower alkyl or lower alkynyl ; heterocyclylalkyl lower alkylene , acyl , lower alkyl or arylsulfonyl ; or a lower alkylene substituted with the r , ar ₁ and ar ₂ aryl , heteroaryl , and nitrogen atom which is bonded to the r bearing nitrogen in formula i , wherein r has the meaning of meaning not having the meaning except acyl , salts thereof and tautomers thereof .
water , gas , flow and heating .
the dna molecule according to claim 1 , wherein the ε-@@ rhodo@@ myc@@ inone conversion protein has the sequence of seq id no : 2 .
the method of any one of claims 1-9 , wherein the amino@@ alkyl-@@ functionalized polynucleotide has a reactive amine at its 3 &apos; or 5 &apos; end .
the method of claim 12 , wherein the subject is a human fetus in u@@ tero .
circuit arrangement according to claim 1 , in which the drive motor ( 1 ) is connected in a semiconductor full bridge circuit ( 2 to 5 ) whose switching elements generate the motor clamps preferably within 1 µ@@ s and thereby generate a counter@@ em@@ mer .
in 10 patients ( 48 % ) , 11 ( 52 % ) had a negative vascular function ( 52 % ) treated with ischemia , 11 ( 52 % ) patients treated with ischemia in up to 3 different vessels .
the stent of any one of claims 1 to 9 , wherein the stent is a self-expanding stent .
the use of a contrast agent as claimed in any one of claims 1 to 3 , wherein said contrast agent includes one or two chelate complex units of bi- or trivalent paramagnetic metal ions in its structure , or a salt thereof with a physiologically acceptable organic base selected from primary , secondary , tertiary amines or basic amino acid , or an inorganic base whose cations are selected from sodium , potassium , magnesium , calcium or mixtures thereof .
vascular prosthesis according to one or more of claims 14 to 16 , characterized in that a second end of the tubular body ( 40 ) is provided with connecting means ( 70 ) which can be fluid-tight with a free end of another vessel prosthesis ( 80 ) .
the use of an oligonucleotide probe or oligonucleotide primer which specifically hybridizes to dna encoding a polypeptide having endo@@ glyco@@ cera@@ mid@@ ase activity comprising a dna sequence selected from the group consisting of : ( a ) dna sequences selected from the group consisting of : ( a ) dna sequences comprising a dna sequence selected from the group consisting of : ( a ) dna sequences comprising a dna sequence selected from the group consisting of : ( a ) dna sequences comprising a dna sequence selected from the group consisting of : ( a ) dna sequences
jo@@ e , you need to stop these pants .
increased aldosterone levels ( water and salt retention in the body are associated with an imbalance of different mineral substances in the blood ) .
protect your solostar from dust and di@@ rt .
ce@@ ren@@ ia can be used to prevent and treat vomiting either in tablet form or as a solution for injection once a day .
ren@@ ve@@ la should be used in patients with secondary hyperparathyroidism in a multiple therapy , which could contain calcium supplements , 1,@@ 25-di@@ hydroxy vitamin d3 or an analogue thereof for the reduction of intact parathyroid hormone ( ip@@ th@@ - ) levels .
zoledronic acid teva generics is also used to treat paget ’ s disease of the bone in adults .
a blood compatible material according to claim 10 , which has a platelet density of 100 or less with the platelet pressure test .
compound according to claim 4 , characterized in that the condensing aid is carbonyldiimidazole or dicyclohexyl@@ carbodiimide .
not all pack sizes may be marketed .
positioning system according to claims 11 and 20 , characterized in that the ball holder ( 8 ) is slit in such a way that it resiliently encloses the ball ball ( 9 ) and the ball seat is compressible by tightening a clamping screw ( 31 ) forming the adjusting element against the ball ball .
the method of claim 1 , wherein , after attaching the absorbent layer , the outer portion of the wafer to be totally removed or partially removes a further region of the adhesi@@ ve-@@ coated film to be applied to which one or more protective films are applied to prevent contamination of the absorbent layer prior to use .
al@@ am@@ da fer@@ ã@@ o lo@@ es , 12-@@ 8.@@ º a p-@@ 14@@ 95 - 190 alg@@ é@@ s tel : + 351 / 214 72 63 00
tell your doctor immediately if you experience numbness or weakness in the legs or problems with your digestive or bladder emptying , as appropriate treatment should be necessary .
the use of claim 3 , wherein the gene is a member selected from the group consisting of genes encoding suicide enzymes , toxins , and ribozymes .
a composition according to any preceding claim , wherein the level of protease inhibition in a 1 % washing solution in water is less than 10 % .
method according to one of claims 19 to 25 , characterized in that the test kit comprises at least one affinity marking and / or a separating assisting instrument provided with a counterpart of the affinity marking .
use of a selenium compound according to claims 12 , 14 or 15 , wherein x denotes nh or o , preferably nh .
you may need to read it again .
that &apos;s nothing , why are you gonna have to emb@@ urt .
two generation methods of generation and ce@@ ce@@ less hip endo@@ prostheses seem to be better results to provide better results than early used prosthesis models or ce@@ menting techniques .
a771726 displaced ibuprofen , diclofenac and tol@@ buta@@ mide , but the unbound fraction of these drugs increased only by 10 to 50 % .
a compound according to claim 3 wherein r 1 is c 3 -c 6 alkyl and r 2 is c 2 -c 3 alkyl .
each pack of ad@@ ce@@ tris contains one vial .
a compound according to claim 1 , wherein r 13 is independently selected from aryl , substituted aryl , optionally substituted heteroaryl , halogen , -cf 3 , -cn , -or 15 or -co 2 r 15 , wherein r 15 is hydrogen , lower alkyl or optionally substituted aryl .
other information about versican plus pi / l@@ 4r
acid-@@ stable alpha-amylase composition , preparation and use thereof
device according to claim 27 , characterized in that it comprises measuring sensors capable of measuring the duration of the penetration of ultrasonic waves in blood vessels or chambers of the heart .
pharmacodynamic effects natural killer ( nk ) and t cell count it is known that nk cells are highly expressing cd@@ 38 and susceptible to cell lysis mediated by dar@@ at@@ umumab .
an apparatus according to claim 14 , wherein the level indicator ( 30 ) comprises a medium that triggers a detectable change in fluid when contacted with liquid .
a method of producing a non-reducing oligosaccharide according to claim 1 , comprising the steps of : ( a ) reacting an aqueous solution containing neo@@ trehalose and α-@@ glucosyl saccharide either with a saccharide-@@ transfer enzyme or with a saccharide-@@ transfer enzyme together with a hydrolase to thereby form said non-reducing oligosaccharide , and ( b ) collecting said non-reducing oligosaccharide .
thin hygienic paper for home use
a bi@@ sulfate salt of the formula pharmaceutical dosage form comprising the bi@@ sulfate salt of claim 1 and a pharmaceutically acceptable carrier .
substituted bicyclo &#91; 3.3.1 &#93; nonan@@ -2,4,@@ 9-@@ tri@@ ones as pharmaceutical active ingredients
ca@@ b@@ 414 : antigen that is overexpressed in multiple tumours
in phase iii placebo-controlled studies , strontium ran@@ ela@@ te treatment was associated with an increase in the annual incidence of venous thromboembolism ( vte ) , including pulmonary embolism ( see section 4.8 ) .
use according to any one of the preceding claims , wherein the nutritional composition is in the form of a dietary supplement .
laboratory and dialysis at the week of the week . • if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse if you are taking or have recently taken any other medicines , including medicines obtained without a prescription , ask your doctor or pharmacist for advice before taking this medicine . • if you have any further questions on the use of this medicine , ask your doctor , pharmacist or nurse .
the method of claim 35 , wherein the multivalent antibody or multivalent , multi@@ specific antibody is associated with alzheimer &apos;s disease .
the apparatus of claim 2 or 3 , wherein the detection means comprises a pressure sensor ( 83 ) for providing information about the pressure of the collection fluid .
a method according to any one of the preceding claims , wherein the anti@@ static material is an alcohol phosphate salt .
special embo@@ di@@ ments are characterized by a-@@ amylase variants , having the following amino acid residues : 9@@ l , 14@@ 9a , 18@@ 2@@ t , 18@@ 6a , 20@@ 2@@ l or 20@@ 2@@ i , 25@@ 7@@ t , 33@@ 5@@ f , 29@@ 9@@ y , 3@@ 23@@ t , 33@@ 20@@ s and 34@@ 5r , and optionally additionally 118@@ k , 18c , 3@@ 20@@ k and 45@@ 8@@ k ( each in the counting according to a-@@ amylase aa@@ 560 ) .
medical instrum@@ ent@@ arium for providing an operative working space in jaw operations
an ultrasonic diagnostic apparatus comprising : an ultrasonic emitting / reception device ( 2 ) for sending ultrasonic pulses in a living body and for receiving reflected ultrasonic waves that are reflected by the living body , by an ultrasonic probe ( 1 ) , which is reflected by an ultrasonic probe ( 1 ) , which is reflected by an ultrasonic probe ( 1 ) , by an ultrasonic probe ( 1 ) which is reflected by an ultrasonic probe ( 1 ) , by an ultrasonic probe ( 1 ) which is reflected by an ultrasonic probe (
however , the dose may vary from one another and your doctor may adjust the dose according to your needs : • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
compositions and methods for preventing microbial contamination from plant tissue culture media
the use of claim 1 , wherein the ig@@ y is formulated as a freeze dried or lyophilized powder , solution , emulsion , lozenge , tablet or capsule together with any other pharmaceutically acceptable carrier or diluent .
an orally administered preparation with a controlled release of an opioid analgesic in the form of crystals having a particle size of 10 µm to 3 mm , having at least one retarding coating on the basis of polymers , wherein the polymers are acrylic resins and / or ce@@ lio@@ se derivatives and / or waxes .
a system according to any one of the preceding claims , characterized in that means are provided for controlling the function of the artificial body member proportional to the mean absolute value or the mean absolute sum of the myo@@ electric signal calculated over a predetermined average window or a predetermined number of samples .
the method of claim 11 , further comprising the step of isolating the polypeptide product of expression of the polynucleotide sequence in the host cell .
eu / 2 / 06 / 0@@ 65 / 009 – 1 blister card of 3 pipettes of 6.@@ 66 ml eu / 2 / 06 / 0@@ 65 / 010 – 2 blister cards of 3 pipettes of 6.@@ 66 ml
exchange accessory for use with a mono@@ rail catheter
only use syringes made of polyethylene , polypropylene or glass .
due to an acute disease ( such as a gastrointestinal disorder ) .
a tracheostomy cannula assembly according to claim 1 or 2 , characterised in that the obturator ( 2 ) has a strap ( 20 ) of rectangular cross-section extending between its appliance end and the patient end thereof .
interaction with other medicinal products and other forms of interaction
a surgical device as claimed in any one of claims 1 to 18 , wherein the drive means ( 80 ) is operably connected to the cutting head assembly ( 50 ) by its upper surface such that the drive means is disposed in a generally vertical orientation .
gardasil 9 is given according to official recommendations .
combination of a dental handpiece with a valve according to one of claims 1 to 7 , characterised in that it is disposed near the exit point of the fluid in an axi@@ al-@@ parallel line ( 8 , 12 ) of the head part ( 3 ) of the dental handpiece , the conduit channel being connected to a branch channel ( 16 ) leading to the outlet opening ( 10 ) , and the conduit channel ( 12 ) is closed in the axial direction seen in the axial direction after the branch direction .
the manufacturing method according to claim 5 , wherein the needles ( 6 ) are arranged on a mounting ( 3 ) and the needle hub lie substantially on a circular line located above the contact portion of the plug ( 8 ) .
device according to one of claims 8 to 12 , in combination with a chair ( 20 ) , characterised in that the horizontal legs ( 15 ) of the angle frame ( 2 &apos; ) are integrated into the side parts of the arm legs ( 24 ) of the chair ( 20 ) in the side of the arm legs ( 24 ) of the chair ( 20 ) , each of the parts of the angle frame ( 2 &apos; ) being pivotable and , in each case , the angular frame ( 2 &apos; ) being
the apparatus of claim 1 , further comprising a reflector disposed near the flash light to reflect the pulses in the direction of the target object .
a compound corresponding to general formula ( i ) : wherein r 2 is a chlorine atom , a methyl group or a 3-@@ thienyl group , as a base or as an acid addition salt .
splint according to one of the preceding claims , characterized in that the one or more flexible zones ( 7,8 , 10,12 , 13,@@ 15 ) consist of a zone of soft material mixed with rigid plastics material from which the rigid part ( 9 , 14 ) of each shell ( 1 , 2 ) is realised .
a process for producing an encapsulated microparticle to form microcapsules , wherein a bound microparticle is encapsulated in copolymers of any one of claims 1 to 26 with an absorbable polymer selected from crystalline or non-@@ crystalline lactide / glycolide copolymer , amorphous l-lactide / d , l-@@ lactide copolymer , caprolactone / glycolide copolymer or trimethylene carbonate / glycolide copolymer which is soluble in chloroform , methylene chloride , acetone , acetonitrile , ethyl acetate or ethyl formate .
absorbent structure ( 14 , 15 , 16 , 21 , 38 , 41 , 51 ) according to any one of claims 4-8 , characterized in that the cellulose fibres consist mainly of fibres of a chemi@@ -@@ thermo@@ mechanically produced pulp .
process according to claim 9 or 10 , characterized in that the average molecular weight of the copolymer used is about 150 &apos; 000 .
these fertility studies did not indicate direct or indirect harmful effects with respect to mating , fertility , embryonal / foetal development , or on sperm count and motility ( see section 5.3 ) .
dye composition for individually coloring prosthetic plastics
the method of claim 1 , wherein the bacteria comprise a method according to claim 1 , wherein the bacteria comprise .
if you use more pic@@ ato than you should contact your doctor or pharmacist if you are using more pic@@ ato than you should .
a catheter shaft according to any preceding claim , wherein the shaft has a diameter of not more than 3.@@ 05 mm ( 0.@@ 120 inches ) .
agent according to claim 27 , characterized in that the composition ( a ) contains the 5,6-dihydroxy@@ indoline of formula ( i &apos; ) and the composition ( b ) is aqueous acidic , the composition ( a ) or composition ( b ) comprising at least one nitrite chosen from alkali metal , alkaline earth metal or ammonium nitri@@ tes or any other nitrite of a cosmetically acceptable cation , from an organic derivative of nitrite and from nitrite , which produces a nitrite of the above type .
a method for producing a device comprising the steps of : ( a ) providing a solution comprising dissolved osteoinductive protein ; ( b ) contacting the solution according to step ( a ) with a carrier comprising a surface of metal or metal alloy ; ( c ) coating the coated carrier obtained in step ( c ) , the steps ( b ) to ( d ) being carried out at a reduced level of oxygen .
the method of claim 11 , wherein the removing excess coating comprises drying the medical device at room temperature .
a nasal vaccine preparation according to any one of claims 1 to 3 , wherein the particulate antigen is hbsag ( hepatitis b surface antigen ) in soluble state .
use of poly@@ acids with close molar mass distribution
the method of claim 1 , wherein extracting the lung and arterial component p 2 ( t ) and a 2 ( t ) from s 2 ( t ) comprises the steps of : ( ( i ) determining a fi@@ gn@@ er-@@ vi@@ le distribution w ( t ) with the following function : ( t ) : obtaining a shift signal ( t ) of the aortic component ( t ) obtained by the following function : ( ( f ) : ( ( ( f ) : ( ( ( f ) : ( f )
always take thelin exactly as your doctor has told you .
allergic reactions , skin reactions or anaphylactic reactions are possible .
process for the production of amino acids using whole cell catalysts according to claim 21 . process according to claim 26 , characterised in that methionine , valine , threonine , lysine or tert.@@ leucine is produced .
polska e@@ wo@@ pharma ag sp. z o. o. o . ś@@ wi@@ ę@@ to@@ kr@@ z@@ ska 36 / 16 pl@@ -@@ 00 116 war@@ s@@ za@@ wa tel . : + 48 22 620 11 71 e-mail : uk _ me@@ din@@ fo @ aller@@ gan@@ . com
an apparatus according to any preceding claim , comprising : a mechanism comprising the portion of the skin of a patient at least above said selected surface coordinate ; and operating elements for selectively operating the mechanism to bias at least said portion of the skin of the patient for a selected duration before and during radiation .
multi-compartment dyeing device or &quot; kit &quot; , wherein a first compartment contains the dyeing composition according to any one of claims 1 to 11 and a second compartment contains an oxidizing composition with the oxidizing agent .
process according to claim 2 , characterized in that a preparation of wholly or partially purified lectins is used .
if the combination is used , patients should be observed for signs and symptoms of heart failure , weight gain and oedema .
tumors directed by metallo@@ -@@ matrix proteinases activated prodrugs
an air@@ cra@@ ft medical unit as claimed in claim 1 , wherein the access opening is open with do@@ ors ( 36 , 38 ) and closes .
a method for producing an iron-@@ dextran composition for the treatment of iron deficiency , comprising the steps of : producing an iron dextran suspension , wherein the suspension comprises iron dextran particles with a beta-@@ fe@@ o ( oh ) core ; purifying the composition by removal of contaminated and by-@@ products , which comprises the step of : reacting the composition by removal of contaminated and by-@@ products , and purifying the iron / dextran composition in the form of iron-@@ dextran complexes in the form of a medicament for reducing anaemia in a human subject or animal
method according to one of claims 1 to 7 , characterized in that the core component is metered by means of a metering piston pump .
a prodrug composition according to any one of the preceding claims , wherein the fatty acid group has 22 carbon atoms and 6 double bonds .
1 . sialic acid conjugated protein derived from cow &apos;s milk , or sialic acid conjugated peptide obtained by treating the sialic acid conjugated protein with a protease , for use as a medicament or a prophylactic against infections .
a composition comprising : ( a ) at least one lipophilic compound ; and ( b ) a textured glyceride component , containing any triglyceride species , and that at least 40 % of the triglyceride species comprises : the composition of claim 1 wherein the structured glyceride component comprises predominantly triglycerides .
an immunological composition comprising an isolated , purified ospa antigen from borrelia burgdorferi or a vector expressing the antigen and at least one additional antigen of a mammalian pathogen that is not borrelia burgdorferi , or a vector expressing the antigen , and which is not borrelia burgdorferi , or a vector expressing the antigen , and optionally a pharmaceutically or veterinarily acceptable vector , or wherein the at least one additional antigen is an adenovirus antigen , an adenovirus antigen , a coronavirus antigen , a parainfluenza antigen , an adenovirus antigen , and a parvovirus antigen .
an isolated dna encoding the kappa a-chain gene or the gamma chain of the monoclonal t@@ 8@@ 4.@@ 6@@ 6 antibody ( atcc accession no bh 87@@ 47 ) against carcino@@ embryonic antigen or a biologically active fragment thereof .
no@@ day and din@@ ner ... it &apos;s gonna be serious .
compound or composition according to any one of claims 1 to 4 , characterized in that the compound or the compound of the composition is associated with a physiologically acceptable polymer .
the apparatus of claim 5 , further comprising means carried by said arms for applying heat to each of said arms .
the method of claim 12 , further comprising removing the solvent from the pha filtrate to obtain the pha .
claims for the following contracting state : es a process for preparing a pharmaceutical composition wherein a modified glycoprotein hormone antagonist maintains the hormone in unmodified form , the hormone being modified in such a way that at least one n-linked oligosaccharide chain is absent or deleted by mixing the hormone antagonist with a plasma half-life which is approximately equal to that of the natural ( unmodified ) hormone , with a pharmaceutically acceptable carrier .
a proteinaceous blood product obtainable according to any of claims 1 to 5 , selected from blood plasma , serum , cryo@@ precipitate and cryo@@ depleted plasma , wherein the blood product is infected with virus and has been treated so that the level of inactivation of the virus is greater than 6 logarithmic units of at least 45 % and does not have more than physiologically acceptable values for lipid-@@ soluble process chemical .
box 552 2003 rn ha@@ ar@@ le@@ m , the netherlands
in type 1 patients , the small differences between the treatment groups ( 0.0@@ 10 l in favour of the comparator group ) returned to return after 12 weeks of exubera therapy for 12 weeks .
the method of claim 17 , wherein the output diameter is 10 to 300 % greater than the oriented diameter .
use according to any one of claims 1 to 4 , wherein the medicament or composition is for improving cognitive function in an animal patient suffering from age-related cognitive dysfunction .
the apparatus of claim 7 , wherein the tubular tip ( 25 ) is made of plastic material .
the article of claim 5 , wherein the article is a single filament dental floss having a polytetrafluoroethylene surface and the drug is selected from the group consisting of anti@@ calci@@ lemic agents , fluo@@ rides , coagul@@ ants , antibiotics , and mixtures thereof .
a shut-off device for an air trap according to claim 1 or 2 , characterised in that two concentric pressure springs ( 9a , 9b ) are arranged on the planar head ( 6 ) .
the use of l-carnitine or alkano@@ yl-l-@@ l-carnitine , wherein the alkanoyl radical is linear or branched , 2 to 8 , preferably 2 to 6 carbon atoms , or the pharmacologically acceptable salts thereof and a tri@@ hydroxy or tetrahydroxy@@ stilbene for the preparation of a pharmaceutical composition for the prophylaxis and treatment of cardiovascular disorders , peripheral vascular disorders and peripheral diabetes neuropathy .
method and apparatus for analyzing ocular motion .
catheter with improved connection between balloon and catheter
the method of claim 17 , further comprising a step of applying heat during compression of the intestinal submucosa .
you should check with your doctor or pharmacist if you are not sure .
a pharmaceutical composition according to claim 5 for the treatment of pain , stroke , brain trauma , parkinson &apos;s disease , alzheimer &apos;s disease , depression , anxiety or migraine .
soni@@ de@@ gi@@ b was shown to be foe@@ to@@ toxic in rabbits , looking at mis@@ carriage and / or complete absorption of foe@@ tuses , and as teratogenic , as it has already been shown to cause severe malformations in very low exposure .
a method according to claim 1 , wherein the compression according to step ii ) is carried out using a roller compaction technique or a impact technique .
treatment of hyper@@ andro@@ genicity of the skin using pregn@@ en@@ olone compositions .
a pancreatic controller according to claim 24 , wherein the pharmaceutical treatment comprises a pancreatic treatment .
wheelchair according to one of claims 13 to 25 , characterized in that the drive means consists of a toothed rod connected to the driver ( a3 ) and connected to a drive wheel , which is fixedly connected to the driven axis .
i mean , i &apos;ve been so good ho@@ b@@ bi@@ es , such as ho@@ gh@@ i or , um , the collection of this small ceramic pu@@ ke , you know ?
the infusion will last about 10 minutes .
method for transferring the ability of natural substances to be synthesized in suitable host organisms
a compound as claimed in claim 1 wherein r 7 is methoxy .
the catheter of claim 1 , wherein an area is treated to inhibit association of materials with the lead tube , and optionally the surface being treated with heparin .
a method according to any one of the preceding claims , wherein the insect repe@@ llant , insecticides , antimicrobial or antiallergic composition is distributed from a slow release formulation .
method for non-invasive examination of bone
the use of compounds of the formula i as claimed in one or more of claims 1 , 3 , 4 and 5 in all its stereoisomeric forms and mixtures thereof in all ratios , and of its physiologically tolerable salts , wherein in the formula i is simultaneous , w is an unsubstituted or substituted methylene radical , wherein in the formula i is simultaneous or substituted ( c -c ) alkyl , c is an unsubstituted or substituted methylene radical , where in the formula i is concomitant ( c -c ) alkyl , ( c -c )
use according to claim 1 or 2 , wherein a fraction of the pollen extract which is enriched in amino acids and / or peptides and / or proteinaceous substances is used for the preparation of the pharmaceutical preparation .
barium selen@@ ate is used in injectable depot formulations of veterinary medicines for the therapeutic and prophylactic treatment of selenium deficiency in cattle and sheep .
a process according to claim 1 , wherein a compound of formula ( 13a ) or ( 13b ) wherein r &apos; &apos; 3 is -cf 2 -ch = ch-ch 2 , -cf 2 ( ch 2 ) 2 co 2 et , -cf 2 ( ch 2 ) 2 conhch 3 or -cf 2 ( ch 2 ) 4 conhch 3 , -cf 2 ( ch 2 ) 2 conhch 3 or -cf 2 ( ch 2 ) 4 conhch 3 .
the implantable medical device of claim 16 , wherein the isocyanate-@@ blocked poly ( ethylene oxide ) has a molecular weight of from 100 daltons to 200,000 daltons .
screening assay for antibacterial compounds
a pharmaceutical formulation comprising an effective amount of the hepar@@ anase formulation of any one of claims 1 to 3 in combination with a pharmaceutically acceptable carrier .
new use of local anaesthetics for the treatment of vascular headache
dr. grey is gonna connect the iliac vein with the p@@ ind@@ ta@@ ther , but the man has a marked deep thrombosis in his upper limbs and the iliac vein .
a method according to any one of claims 1 to 6 , wherein the chemically treated cells are present in a histological chemical section or a cyto@@ chemical sme@@ ar .
the method of claim 23 , wherein separating includes precipitating rna and collecting the precipitate .
use of the combination according to any one of claims 1-3 for the manufacture of a medicament for the prophylactic or therapeutic treatment of fungal infections .
the method of claim 1 , comprising the step of adding the binding solvent to the slurry of the cellulosic fiber material .
the thigh and abdomen are well suited for subcutaneous injection .
the effects of di@@ rac@@ tin were first tested in experimental models before being studied in humans .
labora@@ toires take@@ da sa 15 , qua@@ ai de dione bo@@ u@@ ton 9@@ 28@@ 16 pu@@ te@@ au@@ x cedex , france
a device as claimed in any one of claims 1 to 18 , characterised in that it consists of : a plurality of individual trays ( 1 ) having a first region ( 3 ) adapted for supporting a portion of food adapted for wearing a portion of food adapted for warm eating , and a second portion ( 130 ) which is adapted for use in the first region ( 3 ) of the tray , and a second portion ( 130 ) which is adapted to receive a suitable number of individual trays ( 1 ) which is
a filter for serial rotational tomography as claimed in claim 1 or 2 , wherein the radiopaque fluid substance is filled into the container to an extent of 10 % to 50 % of the capacity of the container .
a kit according to claim 5 , wherein the tag sequences are random sequences produced in a dna synthesi@@ zer which have been delivered at least two nucleotides at each additional step .
if a haemophilia a patient is injected factor viii , it attaches to the von willebrand factor ( vwf ) in the blood circulation .
a process according to any one of claims 1 to 8 , characterized in that it comprises at least one active substance selected from the group consisting of heparin or heparan sulfate , and the amount of heparin or heparan sulfate is preferably between 1 and 5 % by weight of the final base composition .
50 ml of an acetate buffer ( 0.5 m , ph of about 4.6 ) is added to all four viscosity glasses with vigorous magnetic agitation , with the ph of the pectin solution to be above ph 4.0 .
a stable host cell line according to claim 7 , wherein the foreign gene encodes the entire amino acid sequence represented in figure 13 of the accompanying drawings .
if such inhibitors occur , it may be a sign that the amount of refacto af that you need typically to treat bleeding , increases and / or stop bleeding after treatment .
retractor according to claim 3 , characterized in that the middle val@@ ven@@ y-@@ holding rail ( 16 ) is provided with an actuating coupling ( 19 ) for connection to a member ( 3 ) of the operating instrument ( 25 ) and this is provided on the other member ( 3 ) a val@@ ve ( 17 ) or a val@@ val coupling ( 10 ) .
claims for the following contracting states : es , gr a process for the preparation of a compound of the formula : , gr a process for the preparation of a compound of the formula : or a pharmaceutically acceptable acid addition salt thereof , wherein r ¹ is hydrogen , an alkyl of from 1 to 3 carbon atoms , cycloalkyl having from 3 to 5 carbon atoms , cycloalkyl having from 3 to 5 carbon atoms , cycloalkyl having from 3 to 12 carbon atoms , and r ⁵ and r ³ are taken together with a compound
esters of acidic polysaccharides according to claim 2 , wherein the alcohol is glycerol .
a eukaryotic helper cell for the helper virus-@@ free packaging of gene vector dna into the viral particles of a herpes helper virus , at least comprising : ( a ) a herpes helper virus vector dna , at least 100 kbp , on one or two molecules , with a mutation which comprises a gene vector dna having at least the eukaryotic helper cell of claim 14 , characterized in that the herpes helper virus vector dna contains ebv dna as helper virus dna .
pack according to claims 1 to 3 , in which ( 1 ) and ( 2 ) are mixed in a single dosage form .
a process according to claim 4 , wherein the mixture of acetone and water or the mixture of acetonitrile and water has a water content of from 40 to 50 % by weight .
a surgical fastener system for surgical fastener platelets comprising a plurality of surgical fasteners fixed to at least one further object , whereby the fixation plates are detachable by tearing from the other object .
hygiene products provided with absorbent agents which are formed from a substrate as claimed in any one of claims 1 to 16 , or consist of at least partially thereof .
mutagenesis assay using non-@@ human animal test sequences containing test dna sequences .
chemical and physical in-use stability has been demonstrated for 10 days at 2 ° c – 8 ° c or for 96 hours at or below 27 ° c.
an oligonucleotide of the formula v 5 &apos; -@@ u@@ - ( o-@@ y@@ -o-@@ v ) x o-@@ y@@ -o-@@ w@@ -3 &apos; or an analogue thereof ; and r 3 is a group of the formula ia , c 1 -c 21 or an analogue thereof ; and r 3 is a group of the formula ia , c 1 -c 21 or an analogue thereof ; and r 3 is a group of the formula ia , c 1 -c 21 or an analogue thereof ; and r 3 is a group of the formula ia ,
adults very rarely : the following side effects may affect less than 1 in 10,000 people ● severe allergic reactions ● palpitations or irregular heart beat ● feeling sick ( nausea ) ● diarrhoea ● insomnia ●
sulphur pentafluoro@@ phenyl@@ pyrazo@@ les for controlling ecto@@ parasites
an aqueous dispersion according to claim 18 , wherein the polyols are polyalkylene glycols , poly@@ alkylene@@ sugars and other carbohydrates and poly@@ alkylene@@ glycerol .
the jaw dental sha@@ de of claim 5 , wherein the means for selecting the percentage of cutting layer for covering a denture body includes a plurality of jaw tooth models ( 42 a - e ) which covers different percentages of cutting layer covering the dental prosthesis body .
use of ifn@@ γ according to claim 1 for the prevention and treatment of diseases caused by combined primary immune deficiencies ( sc@@ id ) .
a method for producing a polypeptide having degrading activity for the polysaccharide , or a polysaccharide having identical activity thereof , characterized in that the transformant according to claim 7 is incubated and a polypeptide having a degradation activity for the sulfated fucose or the polysaccharide which is functionally identical to that of the incubated product .
the method of claim 3 , wherein said somatotropin is administered during a first period for increasing fertility , said method further comprising administering somatotropin during a second period to increase the yield of fat corrected milk in cows .
a product as claimed in any one of claims 1 to 9 wherein the polymer composition comprises about 47 % stearyl methacrylate residues , about 47 % lauryl methacrylate residues and about 6 % acrylic acid residues .
let &apos;s get an appointment in the rat@@ house and this would be that .
an enzyme according to claim 1 or 2 which is stable to a temperature of about 85 ° c in incubation at a ph of 7.0 for 60 minutes the enzyme according to claim 1 , 2 or 3 , which is derived from a microorganism .
4.4 special warnings and precautions for use
granules according to claim 1 , characterized in that the neutral core consists of a substance selected from sugar , starch , mannitol , sorbitol , xylitol , cellulose , talc and mixtures thereof .
the feed or feed additive according to claim 1 , comprising all three of said crude drugs .
process for the preparation of hyaluronic acid .
self-expanding stent , catheter and method for treating blood vessel bifur@@ cations
treatment of heart failure with csf-1
use according to claim 25 , characterized in that the film thickness of the deposited polymer composition is from 0.01 to 25 µm .
( 1 h ) , days 28-@@ 31 , 35-@@ 38 , 42-@@ 45 ; 6-@@ mp 60 mg / m2 oral , days 26-@@ 46 consolidation treatment dex 10 mg / m2 oral , days 1-5 ; vin@@ des@@ sin 3 mg / m2 i.v. , day 1 ; mtx 1.5 g / m2 i.v.
use of a catechin compound for the manufacture of a medicament for reducing hair growth in mammals .
in case of concomitant use , the plasma levels of the immunosuppressive agent should be monitored .
if you have overweight , continue to take your low calorie diet as directed .
idelalisib should not be co-administered with lovastatin or simvastatin .
additional syringes are provided when more than one syringe is needed per day .
use according to claim 6 , wherein the treatment-@@ free period is longer than the first and second treatment periods .
a compound of the formula ( i ) , which is unsubstituted or substituted from one or two substituents selected from the group consisting of ( ch ) y , c , c , c , c is substituted or substituted from the substituent ( ( ch ) y , which is unsubstituted or substituted from a nitrogen , oxygen , and sulfur group , which is unsubstituted or substituted from a nitrogen , oxygen , and sulfur group , which is unsubstituted or substituted from a nitrogen , an oxygen and a sulfur atom , which is unsubstituted or
the powder is white to off-white .
the effects of fa@@ rest@@ on were first tested in experimental models before being studied in humans .
an acoustically operating medical treatment device , in which electroacoustic transducer elements for use are used , and said electroacoustic transducer elements are caused , and said electroacoustic transducer elements are caused , comprising a sound wave to a diseased portion in a living body , in order to deliver a sound wave to a diseased portion in a living body , in order to deliver a sound wave to a diseased portion in a living body , in order to produce a sound wave to a diseased portion in a living body , in order to obtain a medical
the process of claim 32 wherein in step ( c ) the emulsifier having an hlb of less than 5 is selected from the group consisting of sorbitan sesqui@@ oleate , sorbitan trioleate , sorbitan tri@@ stearate , poly@@ ethylene@@ sorbitan monostearate , cellulose lactate butyrate , and tetra@@ decanol .
take your bottle of vfend suspension .
device according to claim 2 , characterized in that the lever transmission comprises four levers ( 18 ; 19 ; 20 ; 21 ) , in which an upper lever ( 18 ) and a lower lever ( 21 ) are arranged in parallel , the upper lever ( 18 ) being connected to the respective clamping lever ( 8 ) and the connecting levers ( 19 ; 20 ) are connected to the base ( 2 ) , so that the upper lever ( 18 ) and the lower lever ( 21 ) are movable in parallel with or
a removable filter according to any one of the above claims , wherein the struts are comprised of a shape memory alloy with a transition temperature .
a blister pack assembly ( 3 ) comprising the blister pack unit ( 5 ) of claim 6 or 7 and a suction tube ( 7 ) , which is adapted for insertion into a respective of the blisters ( 21 , 22 ) , and an inhalation channel ( 71 ) by which powder is inhaled .
a ph-@@ sensitive microcapsule comprising a non-@@ water miscible active ingredient in a shell , wherein the shell is incorporated in the shell with a free carboxylic acid groups incorporated therein , the coating being formed with a carboxylic acid group incorporated therein , a polyester having a free carboxylic acid group incorporated therein , a polyester having a free carboxylic acid group incorporated therein , a polyester having incorporated therein the polyamide , polyester and polyamide / polyester coating materials from about 2 : 1 to 3 : 1 , and the ratio by weight of the amino acid
the device of claim 1 or claim 2 , further comprising an expansion means ( 20 ) selected from the group consisting of os@@ mium agents , osmo@@ polymers and mixtures thereof in the second housing .
we present the compliance between the technical parameters of different mr scans and the quality of the ce-@@ m@@ ra able to be able to be able to perform a number of different tasks and practical guidelines for contrast medium injection .
composition and method for permanent hair waving based on n-@@ branched-chain alkyl-substituted mercapto@@ aceta@@ mides
i &apos;m a surgeon who sa@@ ved his life today .
infusion suction ( i / s ) cassette according to claim 1 , characterized in that the valves ( 23 , 24 ) are compression valves or are designed as any other type adapted to interrupt the passage of sterile fluids .
piezo@@ ceramic shock-@@ wave source , in particular for lithotrip@@ sy , with a carrier ( t ) , a plurality of piezoelectric elements ( p ) , a plurality of pie@@ zo elements ( p ) , which are flat or in the form of a ball of the pie@@ zo elements ( p ) , the support ( t ) comprising the pie@@ zo elements ( p ) both laterally and on the back side , so that it comprises the pie@@ zo elements ( p ) both laterally and on the back side , so that it
the method of claim 14 or 15 , wherein the peptide sequence further comprises at least one terminal lys residue to anchor the sequence on the support .
5 . process according to any one of claims 1 to 4 , characterized in that the bio@@ conversion is carried out in a culture medium of the microorganism containing glyceryl trin@@ itrate .
in@@ ordered po@@ y@@ mer system for use with a medical device
composition according to any one of claims 29 to 33 , characterized in that the liquid fatty phase is present in an amount ranging from 2 % to 98 % by weight relative to the total weight of the composition , and preferably from 5 to 85 % by weight .
l keep the push-button fully depressed until the needle is drawn out of the skin .
this leaflet was last approved in { mm / yyyy } .
talk to your doctor if you do not feel better after two months .
catheter and method of using such catheters .
dispersion according to any one of the preceding claims , characterized in that the mean diameter of the colloids is between 4 and 20 nm .
methods , systems and software for identifying functional biomolecules
a pharmaceutical composition according to claim 1 or 2 which comprises a carrier which is unstable in the presence of water .
absorbent article having improved elastic design for improved appearance and improved containment
a method according to claim 1 or 2 , wherein the maturation phase is at least six months .
a compound according to claim 1 wherein x and y together represent - ch ( r g ) ch ( r g ) - , -ch ( r g ) ch ( r g ) ch ( r g ) - , -o-ch ( r g ) ch ( r g ) - ; each r g is ch ( r g ) - ; each r g is independently hydrogen , c 1-7 alkyl , aryl or ( aryl ) c 1-7 alkyl .
somavert powder for solution for injection peg@@ vi@@ som@@ ant subcutaneous use
the apparatus of claim 1 , wherein : a ) the sensors ( 20 ) include photo@@ diodes .
a block according to claim 1 or claim 2 , wherein the component of the halogenating agent comprises one or more chlorinated cyan@@ uric acid derivative chlor@@ rate-@@ releasing agents .
it contains the active substance filgrastim ( 30 and 48 million units ) .
a sphygmomanometer according to any one of claims 7 to 12 , characterised in that the ple@@ thysmo@@ graphic sensor ( 2 ) is a photoelectric reflex module ( 10 ) with a light source ( 10 ) and a photodetector ( 11 ) arranged in the inner sheet ( 9 ) of a pressure cuff or pad as a pressure device ( 1 ) or on an opposite solid support near the measured artery ( 12 ) .
bradycardia , atrioventricular block , atrial fibrillation and tachycardia ) sick sinus syndrome
the method of claim 1 , wherein the amount of dextran to be added is 0.2 to 5 parts by weight per part by weight of the platinum compound .
a pharmaceutical composition according to claim 1 wherein y is ch 2 .
use according to claim 2 , wherein the emulsifier as a main ingredient comprises the rice fermented rice fermented rice obtainable by fermenting rice with lactic acid bacteria substantially in the absence of sodium chloride .
recombinant antigen containing a heterologous antigen in its sequence as a vaccine .
oligonucleotides for the in vitro detection of hiv-@@ retrovirus infections and methods for the detection of hiv retroviruses .
a method according to any preceding claim , wherein the polyanionic polysaccharide is alginate .
• once the needle is completely inserted into the skin , let the skin fold again .
date of first authorisation : 28 / 03 / 2011 date of latest renewal : 14 january 2016
process according to claim 12 or 13 , characterized in that the amount of active ingredient according to one or more of the preceding claims 1 to 8 is between 0.1 and 2.5 mg / kg of body weight per day .
as essential cations , sodium ( 134 + / - 38 mmol / l ) and potassium ( 37 + / - 16 mmol / l ) were to be considered .
implant according to one of claims 1 to 11 , characterized in that at least one of the through-@@ holes ( 28 ) is designed as a self-@@ compressing hole .
microemulsion concentrates for oral administration of water insoluble drugs for col@@ ings and process for producing the same
5-chloro-3- ( 4-pent@@ methylphenyl ) -6-@@ methyl@@ 2,1-@@ 2,3- d bi@@ pyridinyl in pure crystalline form and methods of synthesis
a method according to claim 1 , characterized in that the ty@@ st@@ up@@ -specific antigen or the plurality of ty@@ st@@ up@@ specific antigens comprise an hsv gy@@ ko@@ protein b ( gb ) polypeptide .
the plate system of claim 1 , wherein the locking element comprises at least one of a screw ( 508 ) , a rivet ( 522 ) and a cap ( 506 ) .
a gel composition according to claim 1 , characterized in that the hydroxy fatty acid is 12-hydroxy@@ stearic acid .
50 micrograms fentanyl ( as citrate ) 100 micrograms fentanyl ( as citrate ) 200 micrograms fentanyl ( as citrate ) 300 micrograms fentanyl ( as citrate ) 400 micrograms fentanyl ( as citrate ) 600 micrograms fentanyl ( as citrate ) 800 micrograms fentanyl ( as citrate ) 800 micrograms fentanyl ( as citrate )
unit for the post-authorisation evaluation of medicines for human use
we describe an ortho@@ cardi@@ e that had received a hh@@ s in its operative case . ~ ~ ~ m@@ m-@@ h@@ mm . ~ ~ ~ m@@ m-@@ h@@ mm . ~ ~ ~ m@@ m-@@ h@@ mm . ~ ~ ~ m@@ m-@@ h@@ mm . ~ ~ ~ m@@ m-@@ h@@ mm . ~ ~ ~ m@@ m-@@ h@@ mm . ~ ~ ~ m@@ m-@@ h@@ mm . ~ ~ ~ m@@ m-@@ h@@ mm . ~ ~ ~ m@@ m-@@ h@@ mm . ~ ~ ~ m@@ m-@@ h@@ mm .
a device according to any one of the preceding claims , characterised in that the fatty acid ester is myristic acid isopropyl ester .
a process according to any one of the preceding claims , characterized in that the reducing agent is selected from n@@ ab@@ h 4 , k@@ bh 4 , bh 3 , nadph , nad@@ h , h 2 , 9-@@ bb@@ n ( 9-@@ born@@ abicyclo &#91; 3.3.1 &#93; nonane , li@@ al@@ h 4 , na@@ ala@@ t , n &apos; -bis ( mercapto@@ acetyl ) hydrazine ) , thi@@ ene ( mercapto@@ acetyl ) hydrazine ) , thi@@ ols , bi@@ lates , alkali metal mono@@ sulfates and alkali metal bi@@ sulfates , enzymes ( such as
preparation comprising tauro@@ lidine and / or ta@@ ur@@ ul@@ tam for the treatment of cancer
use of hydroxyapatite particles having an average size of 5 to 2000 µm as a β ₂ microglobulin adsorbent .
the effect of renal or hepatic impairment on the pharmacokinetics of effentora has not been studied .
a protein according to claim 2 having a molecular weight of 52 kd .
acid reg@@ ur@@ g@@ itation ; difficulty swallowing ; pain in swallowing ; ulcers in the gul@@ let , chest pain , heartburn or pain or discomfort when swallowing
immuno@@ histological investigations with actino@@ antibodies showed positive responses in both musc@@ le-@@ differentiated tissues of angio@@ myo@@ lipo@@ ma as well as smooth muscle prolifera@@ tions of the lung .
a pharmaceutical composition according to claim 1 , wherein the non-@@ se@@ dating antihistamine comprises a@@ h@@ -1@@ 11@@ 325 , astemizole , azela@@ stine , cetirizine , e@@ ba@@ u@@ stin , ke@@ o@@ fen , lo@@ aban , lo@@ rati@@ stin , z@@ oc@@ aba@@ stine , me@@ qu@@ azine , ox@@ ato@@ mide , se@@ ast@@ stine , tazobactam , glu@@ elastin , terfenadine , or a pharmaceutically acceptable salt thereof .
take special care with galvus :
the garment of claim 1 , wherein said side flaps ( 1a ) are provided with a pair of substantially liquid impermeable leakage cuffs ( 6 ) extending in the longitudinal direction of said garment ( 1a ) and adjacent side edge portions ( 6a ) extending in the longitudinal direction ( 21 ) along the side edges ( 21 ) along the side edges of said side flaps ( 1a ) , and wherein said side flaps ( 6c ) are connected to said side panels ( 1a ) and wherein said side flaps are connected to said side
the target organs relating to toxicity in cynomolgus monkeys were liver , kidneys , stomach , reproductive organs , thymus , spleen , and lymph nodes at more than 4@@ 50@@ times human exposure .
if an inherited predisposition is suspected , the woman should be referred to a specialist before you are able to respond to or against the use of a hormonal contraceptive – longer immobilisation to the legs or large trauma .
propagation material of a transgenic plant according to claim 7 . a composition comprising an antimicrobial protein according to claim 1 together with an agricultu@@ rally acceptable carrier or excipient .
in a first insertion position ( fig . 2 ) for a knee joint with intact cruci@@ bands , the guide tracks ( 13 , 33 ) and guide body ( 21 , 41 ) permit both translational and rotational movement of the bearing part ( 49 ) on the tibia plateau ( 11 ) , while in a second application position ( fig . 1 ) for a knee joint with functional cross-@@ bands , only rotation of the bearing part ( 49 ) is possible .
a therapeutic cream according to claim 2 , wherein the sucrose based ester is comprised of between 5 % and 15 % by weight of the cream as surfactant .
i don &apos;t tru@@ st him .
in this paper , the german version is provided with first data on the relief and validation of the german version .
an apparatus according to claim 10 , wherein the operation device is a pneumatic actuation device ( 96 ) .
a pharmaceutical composition according to claim 19 , wherein the steroid is an 4,@@ 15-@@ pregn@@ adi@@ ene or -@@ est@@ radi@@ ene .
the method of claim 1 , wherein the vector and the transposon carry different selectable markers .
an absorbent structure ( 20 ) according to claim 1 , wherein said topsheet ( 28 ) comprises a first fibrous assembly ( 52 ) and said first fibrous assembly ( 52 ) is provided with openings , said apertures ( 50 ) being provided with a density between about three openings / cm 2 ( 20 openings per square inch ) and about 17 openings / cm 2 ( 111 openings per square inch ) .
the pharmaceutical composition according to claim 17 , wherein the amount of the first compound is at 1-4 parts by weight and the amount of the second compound is at 1-4 parts by weight .
the recommended dose depends on the disease being treated and the patient ’ s response .
a washing device according to claim 2 , further comprising a control circuit and a switch means connected between the battery and the pump .
a method as claimed in any one of claims 2 to 7 for providing a sterile connection to urinary drainage , wherein a drainage tube connected to a catheter implanted in the urethra of a patient in the urethra of a patient is connected to a second drainage container , with a second drainage tube , which is connected to a second drainage vessel , having a second drainage container which is connected to a patient in the urethra of a patient , and having a second drainage vessel , which is provided with a second drainage container , and
the catheter of claim 6 , wherein said tip portion ( 22 ) is concentrically disposed over a distal portion ( 50 ) of said bridging portion ( 18 ) .
2-@@ carbamoyl-@@ 1,4,@@ 5,6-@@ tetrahydro@@ pyrazine of the general formula ( i ) , in which r , r and r are the same or different , and each for a straight or branched c1 to c3 alkyl group , a c@@ 5- to c6 cycloalkyl group , a c@@ 5- to c6 cycloalkyl group , and r has the same meaning or in which r and r have the same or different and have the same meaning or in which r and r have the same or different and have the same meaning , in the r and r
the method of claim 1 , wherein the beads have a mean diameter in the range of from 5 µm to 100 µm .
an idio@@ type antibody which can form a complex with the antibodies of claim 9 , as obtained by immunizing an animal with the antibodies of claim 9 .
an implantable device coated with a composition according to claim 33 .
use of mixtures of polyglycerol fatty acid esters according to claims 1 to 4 , wherein the degree of esterification of the polyglycerol mixtures is between 25 and 50 % .
solution according to either of claims 1 and 2 , characterized in that the solution comprises 0.001 to 0.02 parts ( w / v ) benzalkonium chloride .
the use of the composition of claim 7 wherein the steroid is estradiol .
container according to any one of the preceding claims , characterized in that it comprises a liquid ( 5 ) and a propellent gas ( 7 ) for the liquid .
a compound according to claim 14 , wherein pro@@ 55@@ 9-@@ gly@@ 560 of wild-type plasminogen are replaced by val-@@ glu-@@ leu-@@ gln-@@ gly-@@ leu-@@ arg-@@ pro .
the immunoassay according to claim 1 , wherein the immunoassay is used to test the quality of milk .
system according to claim 22 , characterized in that the easily folded regions ( 20 &apos; ) are formed with a folding of the balloon portions ( 20 ) at the half of the half and the two folded portions ( 20 &quot; ) are formed with folding of the simply folded areas approximately in half .
a process for preparing a solution , characterized in that : a ) a composition in the form of an aqueous solution containing 0.1 to 20 % by weight of peracetic acid and 2 to 45 % by weight of acetic acid and from 2 to 45 % by weight of acetic acid and b ) from 0.005 to 2 % by weight of acetic acid and b ) from 0.005 to 2 % by weight of acetic acid and ( b ) from 0.005 to 2 % by weight of acetic acid and from 0.005 to 2 % by
and then a post@@ t ... put me on the bin@@ o@@ tic with mar@@ on .
the intraoperative ultrasonic probe of any one of claims 6 to 8 , wherein said angled member ( 30 , 32 , 34 ) comprises a circuit board ( 30 ) having said plurality of conductor tracks ( 36 ) thereon .
polska msd polska sp. z o. o .
- first general report of the european agency for the european agency
tell your doctor if there is someone who falls in this group and may come into contact with the vaccinated person .
the host cell of claim 7 , wherein the host cell is an animal cell .
in addition , the area will contribute to the ongoing monitoring and management of the agency ’ s website .
medical or dental-@@ medical treatment element according to claims 3 and 6 or 7 , characterized in that , in the case of the pressure regulator ( 7@@ 1a ) and the control device ( 72 ) , it is pre@@ located .
the zinc oxide powder according to claim 3 , characterized in that it comprises a silicone oil as the hydrophobicity agent .
busilvex is supplied in a pack containing 8 vials .
the advantages of the invention are in a reliable protection of the implant ( 1 ) against fracture or shearing .
a hand-held mixing apparatus according to any one of the preceding claims , wherein the mixing stirring arm ( 7 ) comprises a shaft ( 8 ) and at least one wing ( 9 ) extending outwardly from the shaft , said wing ( 9 ) extending toward the edge of the chamber and adapted to the inner shape of the chamber .
the mechanism is not known .
the use of claim 12 or claim 13 , wherein the nucleic acid is complexed with a conjugate , the conjugate consisting of an endo@@ so@@ mo@@ lytic agent and a dna binding agent .
constipation cholestagel may induce or exacerb@@ ate existing constipation .
the use according to claim 9 , wherein r 4 and r 5 are independently hydrogen or cooc 3 h 2 groups .
a laser irradiation apparatus according to claim 5 , wherein said body has a guide groove parallel to an axial direction of said body to guide movement of said arm .
the invention relates to a method for the selective purification of bacterial cells and / or cell constituents , wherein the purification is carried out by means of a solid support .
a medical catheter for use in re@@ viewing a medical device ( 58 ) within a body cavity ( 54 ) having : a distal tip member ( 10 ) having an inner surface ( 36 ) having an inner surface ( 36 ) having an inner surface ( 36 ) having an inner surface ( 36 ) having an inner surface ( 36 ) having an inner surface ( 36 ) and an outer surface ( 38 ) , wherein said wall ( 34 ) has a distal end ( 24 ) with an inner surface ( 36 )
medicinal product subject to medical prescription .
a method according to claim 1 , characterized in that probes s1 and s3 are labelled with a fluorescent reporter dye , preferably a fluorescein derivative selected from 6-@@ carboxy-@@ fluorescein , tetrachloro@@ -6-@@ carboxy-@@ fluorescein , and , preferably , with a quencher , preferably a rhodamine derivative , preferably with 6-@@ carboxy@@ tetramethyl@@ rhodamine ( tam@@ ra ) .
the apparatus of claim 10 , further comprising a third valve ( 46 ) connected to the chamber outlet ( 38 ) , the third valve controlling the gas passage from the chamber ( 36 ) to a gas device .
therapy includes hemodynamic stabilization , blood pressure lowering and reduction of pulsed aortic flow ( wall tension ) .
enzymatic detergent additive , cleaning agent and washing process .
the use of claim 1 , wherein the compound is present in an amount for providing a dose of 10 to 200 µg / day .
a process according to claim 1 , wherein the oxidizing agent is excess benzo@@ quinone starting reagent of formula ii .
patients should be monitored closely to ensure that epoetin alfa is administered at the lowest approved dose required for the control of symptoms of anaemia .
there are insufficient data on the treatment of hbv infected patients with antiviral therapy and concomitant therapy with tnf-@@ antagonists .
i mean , uh , i could do a debri@@ de@@ ment or , uh ... ~ ~ ~ uh ...
response to response was defined by virological suppression of hbv ( hbv dna &lt; 0.7 meq / ml with b@@ dna ) and loss of hbeag ( in hbeag positive patients ) or alt &lt; 1.@@ 25@@ fold uln ( in hbeag negative patients ) .
the method of claim 3 , wherein the cell line is selected from human cell lines .
dental floss according to claim 7 , characterized in that the first component is incorporated in the binder .
head@@ bar side tendon for beds or the like
composition according to any one of the preceding claims , characterized in that the dyestuff is present in proportions ranging from 0.01 % to 40 % of the total weight of the composition and preferably from 5 % to 25 % .
a pharmaceutical composition comprising the liposome composition of any one of claims 1 to 32 and a pharmaceutically acceptable carrier or diluent .
the method of claim 4 , wherein the target material is applied using an electro@@ plating .
if you weigh more than 100 kg , the dose may be increased to 100 mg ( the content of 1 pre-filled syringe ) once a month and should be given every month on the same day .
at the same time , it is possible to prevent an infection spread with this device .
a pharmaceutical composition according to claim 1 , an acryloyl dist@@ amycin derivative comprising , optionally in the form of a pharmaceutically acceptable salt selected from the group consisting of : 1 . n- ( 5- { &#91; ( 2- { &#91; ( amine ( imino ) methyl &#93; amino } ethyl ) amino &#93; carbonyl } -1-methyl-1h-@@ pyrrol-3-yl ) amino &#93; carbonyl } -1-methyl-1h-@@ pyrrol-3-yl ) amino &#93; carbonyl } -1-methyl-1h-@@ pyrrol-3-yl ) amino &#93; carbonyl } -1-methyl-1h-@@ pyrrol-3-yl ) amino &#93; carbonyl } -1-methyl-1h-@@ pyrrol-3-yl ) -4- &#91; ( 2-@@ chromo@@ acryloyl ) -3- &#91; ( 2-@@ chromo@@
4.5 interaction with other medicinal products and other forms of interaction
the method of claim 10 , wherein the protein or polypeptide comprises an amino acid sequence selected from seq id nos : 137 and 138 .
a method for improving the skin , mucosa and tissue tolerance of anionic surfactants , characterized in that the surface-active or surfactant solutions are added with ethoxylated alcohols which follow the formula ( iii ) , r 3 o- ( eo ) x -z ( iii ) wherein r 3 is an alkyl group having 6 to 22 c atoms , x represents an integer of 2 to 10 carbon atoms , and z represents a hydroxycarboxylic acid residue .
device according to claim 6 , characterized in that the superstructure unit ( 12 ) is designed as a ser@@ ft configuration .
this was an increase in the previous year that corresponds to the schedule .
the composition of claim 2 , wherein the plasticizer is a solvent for the n-vinyl lactam monomer and the multiple-@@ ethylenically unsaturated compound .
synergistic combination of a ginkgo biloba extract and β-@@ glucan or one of its derivatives .
data from both paediatric age groups were supplemented with data from the use of levetiracetam since marketing .
use according to claim 4 , characterized in that substrates are used as the effectors .
device for treating , in particular rinsing of bones , of wounds , the abdominal cavity or the like .
tap the syringe gently to make any air bubbles rise to the top of the syringe ( close to the needle ) ( see diagram 3 ) .
the system of claim 2 , wherein the connector housing ( 6@@ 21a ) has at least one auxiliary channel which is in fluid communication with at least one auxiliary lumen defined in the outer tube and is separate from the apparatus lumen , wherein the main channel and the auxiliary channel diver@@ ge from the outer tube so that it does not intersect in the connector housing .
he stops the osteocla@@ sts , the cells in the body that breaks down the bone substance .
the application was carried out in accordance with article 12 ( 3 ) of directive 2001 / 82 / ec as an autologous application .
a flowable composition comprising a chemically solidifying gelling agent , wherein at least a portion of the gelling agent has been rendered chemically for solidification , and wherein the chemically solidified gelling agent is predominantly in the form of micro@@ gels having an average equivalent diameter of less than 100 microns , and wherein the chemically solidified gelling agent is predominantly a gelling agent selected from the group consisting of pectin , io@@ ta-@@ carrageenan , kappa carrageenan , fur@@ cel@@ ar@@ ane , and mixtures thereof , and / or ( b ) the micro@@ gels are un@@ regularly
a formulation according to claim 1 , characterized in that the lecithin is selected from the group consisting of saturated phosphatidylcholine , unsaturated phosphatidylcholine , phosphatidylserine , sphingo@@ myelin , phosphatidylethanolamine , cephal@@ ine and lyso@@ lecithin .
bactericidal serum test for n. meningitidis specific antisera
the use of a compound according to any one of claims 1 to 7 in the manufacture of a medicament for the prevention of amyloidosis or a disease occurring in amyloid storage in a subject , wherein said compound is selected from the group consisting of propane@@ -1,3-di@@ sulfonic acid and pharmaceutically acceptable salts thereof .
information in bra@@ ille axura 10 mg tablets 46 particulars to appear on the outer packaging carton for 42 , 50 and 98 tablets as intermediate pack / part of a multipack ( without blue box ) 1 .
split influenza virus , inactivated , containing antigen * equivalent to :
a dressing according to any one of the preceding claims , characterised in that it contains a vaso@@ dilating agent such as nitroglycerin .
opioids ) as maintenance therapy .
similar findings are available with the approved dose of darunavir / ritonavir .
the invention relates to a method for producing an enzyme granulate from an aqueous , purified enzyme solution , characterized by steps ( a ) ion exchange chromatography , while the enzyme of interest remains in solution , ( b ) adjustment of an appropriate concentration and ( c ) granulation .
a sof@@ t@@ gel fill formulation according to any one of the preceding claims , wherein the surfactant is selected from the group consisting of esters of d-@@ alpha-@@ tocopheryl , polyoxyethylene castor oil derivatives and polyglyco@@ ly@@ zed glycerides .
bicyclic carbamoyl@@ pyridone derivative having hiv integrase inhibitory activity
a method as claimed in any one of the preceding claims , wherein the isolated vessel is : ( c ) a vein , which is just subjected to an arterial venous anastomo@@ tic surgery , or ( d ) a vessel suitable for use in a bypass procedure .
a pharmaceutical composition according to claim 1 , wherein the fviii is derived from a natural source .
the apparatus of any one of claims 1 to 6 , further comprising a spring ( 412 ) for retracting the distal segment of the inner cannula toward the proximal segment of the inner cannula at the return movement of the distal segment of the inner cannula .
particulate vector according to any one of claims 1 to 4 , characterized in that it contains a diameter of between 20 and 200 nm , of particulate vector according to one of claims 1 to 5 , active agent , anti@@ malarial , anti-@@ asthmatic agents , anti-@@ tumoral agents , anti@@ malarial agents , anti-@@ asthmatic agents , compounds which exert an effect on the skin , constituents of the milk fatty globules .
oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use oral use
an absorbent article ( 20 ) according to any preceding claim , characterized in that said absorbent article ( 20 ) is elastic in response to laterally directed compressive compressive forces .
the highest serum concentrations of the glucuronide are 2 to 3 hours after defe@@ ri@@ prone administration .
a method for the production of monoclonal antibodies according to claim 20 , wherein the non-@@ biological substrate is selected from nitrocellulose , nylon and polytetrafluoroethylene membrane .
the apparatus of claim 4 , wherein an arcuate flange ( 262 ; 362 ) extends from the rim ( 252 ; 352 ) and defining a stress receiving portion ( 254 ; 354 ) between the flange ( 262 ; 362 ) and the rim ( 252 ; 352 ) .
potentially dangerous reduction of your blood pressure may result in an increase in your blood pressure . • if you have any further questions on the use of this medicine , ask your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription , ask your doctor or pharmacist if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
0.1 0.0 0.0 0.1 0.0 0.0 0.2
use of a compound or combination according to any one of claims 1 to 13 for the preparation of a pharmaceutical composition for treating or preventing a disease in humans and / or other mammal characterized by abnormal angiogenesis or hyper@@ permeability processes .
the drainage chamber ( 12 ) of claim 1 wherein the pore size of the porous material ( 48 ) is from 0.45 µm to 5.0 µm .
the cyclic octa@@ peptide of claim 22 , wherein a 6 is a d-@@ or l-@@ isomer of an amino acid selected from the group consisting of leu , ile , nle , trp , val and abu .
introna 10 million iu / ml solution for injection or infusion
use according to any one of the preceding claims , characterized in that the concentration of the compounds of formula ( i ) in the preparation is between 0.01 % and 10 % by weight relative to the total weight of the composition .
use according to any one of claims 6 to 10 wherein the angiotensin converting enzyme inhibitor is enala@@ prilat .
device for the disintegration of concre@@ tions in a medium or animal .
a process for preparing a nhr 1 r 2 r 3 + salt of omeprazole and esomeprazole according to any one of claims 1 to 10 , wherein : a ) dissolving omeprazole or esomeprazole in an organic solvent ; b ) is added to a nr 1 r 2 r 3 compound and the desired salt ; c ) the obtained salt of omeprazole or esomeprazole is isolated and dried .
patients who need more than 8 inha@@ lations daily should speak to their doctor as their asthma therapy may need to be re@@ considered .
2 micrograms 2 micrograms 2 micrograms 2 micrograms 2 micrograms 2 micrograms 2 micrograms
5 years after dilution : 24 hours .
process for obtaining stable factor viii / vw@@ f-@@ complex , characterized in that factor viii / vw@@ f-@@ complex is bound from a protein solution to a heparin affinity carrier , and factor viii / vwf complex is obtained at a salt concentration between ≥ 200 and ≤ 300 mm .
nederland fort do@@ dge animal health bene@@ lu@@ x b. v.
the use of claim 12 , wherein the medicament is suitable for topical administration .
host / plasmid system according to claim 33 , characterized in that the host consists of the escherichia coli strain a@@ 4@@ 200 ( atcc deposit no. 5@@ 32@@ 18 with ph@@ g@@ 44 and the f &apos; -@@ gal plasmid and designation a 43@@ 46 ) .
surgical equipment for dental implant , dental implant , drilling instrument and components
8-azabicyclo ¬ 3.2.1 oct@@ ene derivatives in labelled form and use of 8-azabicyclo ¬ 3.2.1 oct@@ 2-@@ ene derivatives in labelled and un@@ labelled form
use according to claim 39 , wherein the biologically active material is insulin and the disease is diabetes .
the surgical instrument of claim 3 , wherein the external restriction means comprises different diameters on the hollow vibrating needle ( 16 ) so that a distal portion of the hollow vibrating needle ( 16 ) is a first inner diameter ( i@@ 1-@@ i@@ 1 ) and a first outer diameter ( o@@ 1 o@@ 1 ) having greater than the inner sleeve diameter of the hollow rigid sleeve ( 18 ) and a proximal portion of the hollow , stretchable needle ( 16 ) has smaller inner and outer diameters than the distal section .
a method of producing a tapered tip wire member having the steps : rotatable attaching a plurality of wire-@@ type ( 31 ) to a support means ( 21 ) , wherein the support means ( 21 ) is coupled to a support means ( 21 ) , the support means ( 21 ) having a succession of processing means ( 31 ) , the support means ( 21 ) having a succession of processing means ( 31 ) , the support means ( 21 ) being moved to a train of the beam ( 31 ) with each blank
porphyrin complex compounds consisting of a meso@@ -tetra@@ phenyl porphyrin ligand , optionally at least one ion of an element of the atomic plants 13 , 21 , 32 , 50 , or 5@@ 7-@@ 83 , and optionally cations of inorganic and / or organic bases , amino acids or amino acid amides are valuable diagnostics and therapeutics .
this means that pramipexole teva is similar to a ‘ reference medicine ’ already authorised in the european union ( eu ) called sifrol .
solid emulsion according to one of the preceding claims , characterized in that it comprises 5 to 60 % by weight of water , preferably from 10 to 50 % , relative to the total weight of the solid emulsion .
marketing authorisation holder roche registration limited 6 f@@ alcon way shire park wel@@ w@@ yn gar@@ den city al@@ 7 1@@ tw united kingdom
position paper to seek advice on the cvmp and adopted by the cvmp : • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
&quot; heterocyclyl &quot; refers to a stable 5 membered monocyclic or 8-@@ 11-@@ membered bicyclic heterocycle residue , which is either saturated or unsaturated , and wherein each heterocycle is selected from carbon atoms and 1 to 4 heteroatoms selected from nitrogen , oxygen and sulfur ; and the pharmaceutically acceptable derivatives thereof .
the apparatus of claim 9 , wherein the sensing elements ( 15 , 72 ) are adapted and attached to the band means ( 12 ) such that at each time less than all of the sensing elements are ten@@ led under tension .
con@@ glutinin fragments , their preparation and use .
3 administration with atorvastatin increased auc and cmax of tekturna at steady state by 50 % .
use according to any one of the preceding claims , characterized in that the concentration of the second compound is 5 to 20 % by weight , based on the concentration of oligosaccharides .
therefore , patients treated with ciprofloxacin should be advised to avoid exposure to sunlight or exposure to uv light during treatment ( see section 4.8 ) .
the invention relates to peptides which are suitable for inhibiting hbv cor@@ e proteins , dnas coding for the same and the use of both , in particular for inhibiting hbv replication .
device for the three-dimensional measurement of objects ( 1.1 ) with at least one electronic image transducer ( 3.5 ) , at least one optical image ( 3.4 ) for the image of the object on the image transducer ( 3.5 ) and at least one beam source ( 2.7 ) for the image of the object , characterized in that the means ( 2.1 to 2.7 ) for the pixel of the pattern are spatially connectable to the means ( 3.1 to 3.5 ) for the image acquisition of the image of the image .
use of a polypeptide according to claim 9 , wherein the immune syste@@ m-@@ related cell damage is caused by an autoimmune disease , a graft versus host response or a host vs. graft reaction .
low to moderate ( 8 to 20 % ) resistance rates to ciprofloxacin have been observed with indicator isolates of e. coli for the different target species in different european countries .
the liposome of claim 12 , wherein the additional lipid is a phosphatidylethanolamine .
the disposable balloon subassembly according to any one of claims 23 to 25 , wherein the expandable balloon ( 22 ) is within the rigid sleeve ( 26 ) whereby the expandable balloon ( 22 ) is protected prior to damage prior to a damage .
in a tolerance study of je@@ se@@ se@@ y cows , the safety margin of this medicinal product was 1.5 times the highest recommended dose ( an overdose of 60 μg / kg administered to three doses ) .
products according to claim 13 , wherein the sn-@@ 38 prodrug is cam@@ pto@@ s@@ ar .
and then in the ber@@ ner office of the inst@@ itor , he started from 19@@ 72 to 19@@ 76 .
expression of retroviral gag proteins in eukaryotic cells .
the indication for both forms of immunotherapy should be strictly placed .
if you are allergic to memantine hydrochloride or any of the other ingredients of this medicine ( listed in section 6 ) .
claims for the following contracting states : at , be , ch , de , dk , fr , gb , gr , ie , it , li , lu , mc , nl , pt , se 3- ( cis@@ -3-@@ hex@@ en@@ yloxy ) -@@ propane@@ -n@@ itrile .
- sudden numbness or weakness in the face , arm or leg , especially on a
granulate according to claim 1 or 2 , characterized in that the pores in the granules each represent from 10 % to 60 % by volume relative to the volume of the granule .
the use of at least one derivative of the following formula ( i ) in a cosmetic composition comprising a cosmetically acceptable medium and is intended for topical application to the skin and / or skin appen@@ dages , for bleaching human skin , body hair or hair , for bleaching the skin , body hair or hair , for bleaching the skin , body hair or hair , for bleaching the human skin , body hair or hair , for bleaching the human skin , body hair or hair , for bleaching the skin , body hair or hair
prion free collagen and collagen derived products and implants for various biomedical applications and methods for their preparation .
method for detecting cathepsin , asparag@@ in@@ yl@@ endopeptidase and iso@@ zymes thereof , and leuko@@ cy@@ tin
right , but not any brain tumor .
a pharmaceutical composition comprising a compound according to any one of claims 1 to 5 in admixture with one or more pharmaceutically acceptable excipients .
antisense oligonucleotides inhibiting the delivery level of hi@@ f-1
use of a fatty acyl derivative according to any one of claims 1 to 6 in the manufacture of a medicament for use in the treatment of a viral infection .
a device according to any one of claims 1-8 , wherein the transverse scanning means ( 86 , 100 , 110 , 95 ) includes means for performing a two-dimensional transverse scan , the depth in the longitudinal direction in the sample is determined by the depth change means in the longitudinal direction ( 46 ) .
29 internal and external setting procedures were performed .
severe birth defects have been observed in unborn animals and in babies born to women treated with efavirenz or a combination drug with efavirenz , emtricitabine and tenofovir .
133 erythropoietin is a growth factor that primarily stimulates red blood cell production .
make sure that the tablet does not dissolve in the mouth .
1@@ è@@ re avenue 20@@ 65 m – l. i. d f-@@ 0@@ 65@@ 16 car@@ ro@@ s tel :
composition according to claim 3 , characterized in that the non-@@ film-forming polymer is chosen from polyesters , poly@@ ester@@ amides , alkyl@@ resins , polyacrylic compounds , polyvinyl compounds , polyurethanes , poly@@ styrene@@ s , natural or modified hydrocarbons and their derivatives and natural or modified natural globular proteins , such as natural or modified natural globular proteins , which are used alone or in the mixture .
process according to claim 2 , characterized in that the water-miscible organic solvent is methyl acetate .
a re@@ p polypeptide that allows in di@@ cyto@@ ste@@ ium spp the extrac@@ h@@ romo@@ somal replication of a recombinant plasmid contains one of plasmids dd@@ p2 or pd@@ 1 derived from plasmids dd@@ p2 or pd@@ 1 , the plasmid but lacks functional genes which are lacking for extrac@@ h@@ romo@@ somal replication in wild-type dic@@ yo@@ ste@@ lium spp , and further wherein the amino acid sequence of the re@@ p polypeptide is substantially the same as shown in figure 2 .
device according to any one of the preceding claims , characterized in that the composite structure comprises an impermeable or partially impermeable layer ( 115 ) .
a polymeric composition produced by the co-@@ polymerization of one or more macro@@ monomers as defined in claim 1 with one or more hydrophilic monomers on non-@@ aroma@@ tic-@@ base .
the plant of claim 10 , wherein the construct further comprises a sequence encoding a chloroplast transit peptide .
3- &#91; 2- ( 3-@@ azoc@@ ylamino-@@ 2-oxo-@@ 2h-@@ pyridin-1-yl ) acetylamino &#93; -4-@@ oxopent@@ anoic acid derivatives and their use as cas@@ pase inhibitors
a method of manufacturing a disposable pull-@@ on diaper ( 10 ) according to claim 12 , characterized in that said steps further comprise : elastic@@ ating the lateral zone of the cover sheet ( 24 ) to form elastic panels ( 30 ) with a lateral edge ( 25 ) , along a boundary line between the base structure ( 20 ) and each elastic panel ( 30 ) ; folding the elastic panel ( 30 ) along a boundary line between the base structure ( 20 ) and each elastic panel ( 30 ) , along the boundary
since 19@@ 50@@ s , as tablets and capsules with immediate release , which contains methylphenidate immediate release , and as modified-release tablets , which release a part of the active substance or the entire active substance is available more slowly over a period of more than several hours .
process according to claim 1 , characterised in that the plasma treatment is split into a plurality of roun@@ ds .
the cutting system according to any one of claims 13 to 17 , further comprising a position detecting device ( 80 ) for determining a position of the elongate object relative to the at least one round saw blade such that the vertically movable member and the horizontally movable element can be positioned correctly for the execution of an incision .
use of a plant cell as claimed in claim 21 to 29 for its regeneration from a sugar beet plant resistant to b@@ ny@@ vv .
a wri@@ st-@@ worn device according to claim 1 , wherein the rotation stop extends at an angle within a range of about 105 ° to about 125 ° to the bottom member of the main housing .
antisense oligonucleotides for inhibiting vegf expression
an aqueous solution having the ability to form a foam which comprises a greater proportion of water in which 1 to 20 % by weight of a fro@@ fiable agent and 10 to 1500 mg / l chlorine dioxide are dissolved , the chlorine dioxide being produced outside the solution and then dissolved therein .
immobilized nucleic acid libraries , process for their preparation and their use in sequencing and screening methods
the method of claim 9 , wherein the baculovirus expression vector is the baculovirus expression vector of any one of claims 1 to 6 .
process according to one of claims 13 to 15 , characterized in that the sintered shaped body is treated with a liquid and / or vapour alkali metal or alkaline earth metal .
device according to claim 1 or 2 , in which the washer ( 20 ) rests on the base ( 1 &apos; ) via a lubricant ( 9 &apos; ) .
biotransformation the metabolic pathways following buccal administration of effentora have not been established in clinical trials .
in post-marketing experience , angioedema or angio@@ ede@@ m-@@ like reactions have been reported when aliskiren was co-administered with ace@@ s and / or ar@@ bs ( see section 4.8 ) .
use according to claim 94 , wherein the disorder is diarrhoea .
102 particulars to appear on the outer packaging and the immediate packaging
the method of claim 40 , wherein the selective release of mass intensity occurs upon hybridization of the probe to the amplified target molecule and the nuclease digestion of the complex probe : amplified target nucleic acid molecule .
an apparatus according to any preceding claim , wherein the extra@@ systole counter comprises at least one counting threshold , further comprising means for suppressing and inducing specific functions of the active implantable medical device when one of the determined pig of the extra@@ systole counter is performed .
the method of claim 1 , wherein the primer is oligo-@@ dt .
a process for preparing a compound according to claim 1 , comprising : ( a ) reacting a compound of formula ( ii ) : wherein : there are : to obtain a compound of formula ( i ) : wherein : r , r , r , y , a and w are as defined above and x is a compound of formula ( i ) , in which x , r and r have the meanings defined above , with a compound of formula ( iii ) in order to obtain a compound of formula ( i )
cholesterol glycerol tri@@ folate co@@ oleate ( dop@@ c ) 1- ( 1,2-di@@ palmitoyl-@@ 3-@@ sn-@@ phosphatid@@ yl ) glycerol ( dpp@@ g ) sodium chloride water for injections .
the method of claim 13 , wherein the finger of said person is transmitted to said light .
method and device for treatment of treatment with iono@@ phore@@ sis or gal@@ va@@ ano@@ therapy .
a process according to claim 1 for the preparation of compounds of formula i wherein r is either c ₂ -c ₇ alkyl , c ₂ -c ₇ alkenyl , c ₂ -c ₇ alkynyl or c ₁ -c ₄ -alkoxy-c ₁ -c ₄ alkyl and r ¹ , r ² and r ³ are hydrogen , and salts thereof .
administration of fosamprenavir in the tablet formulation after a standardi@@ sed high-@@ fat meal ( 9@@ 67 k@@ cal , 67 g of fat , 33 g protein , 58 g carbohydrate ) was associated with no change in the pharmacokinetics ( cmax , tmax or auc ) of amprenavir compared to the administration of this formulation in the fasted state .
a biopsy forceps according to claim 4 , wherein the medical instrument comprises at least one guidewire ( 712 ) .
method and apparatus for monitoring the circulatory control system by spectral analysis of heart rate .
an antioxidant extract comprising 2 &apos; -o-@@ glucosyl@@ iso@@ vi@@ tex@@ in obtainable by a process comprising : ( a ) a first green juice produced from the green leaves of a plant of the gra@@ mine@@ e family or a dry powder thereof ; or ( b ) a second green juice , or a dry powder thereof ; or a dry powder thereof ; or a dry powder thereof ; or a dry powder thereof ; or a dry powder thereof ; with a water content of up to 80 percent by volume , and optionally in the
a method of increasing the production of 4-@@ hb@@ -containing polymers in a host microorganism , said method comprising stably incorporating a gene encoding a heterologous enzyme selected from the group consisting of a polyhydroxyalkanoate synthase and a 4-@@ hb@@ -coa transferase , into the genome of the host microorganism .
double side arm training and method of using the same
an electrosurgical handpiece ( 10 ) for use in minimally inverting surgery according to claim 4 , wherein said prongs comprise a first prong and a second prong , said second prong being further extending away from said tubular housing than said first prong .
derivatives of n- ( 3-aminopropyl ) -3h-@@ 5,6,7,8-tetrahydro@@ naphthalene@@ naphthalene@@ -2-ol with neuroprotective and anti@@ aesthe@@ tic properties , their preparation and their therapeutical use .
rare ( may affect up to 1 in 1,000 people ) : -
param@@ un@@ ity inducers according to claim 2 or 3 , characterized in that the pox@@ viruses are inactivated .
production of protein microparticles by precipitate an anti-solvent .
use according to claim 1 , wherein 11- ( 3-dimethylamino@@ propy@@ lidene ) -6,@@ 11-dihydro@@ dibenz &#91; b , e &#93; oxep@@ in-2-@@ acetic acid ( e ) -1@@ 1- ( 3-dimethylamino@@ propy@@ lidene ) -6,@@ 11-dihydro@@ dibenz &#91; b , e &#93; oxep@@ in-2-@@ acetic acid is substantially free of ( z ) -1@@ 1- ( 3-dimethylamino@@ propy@@ lidene ) 6,@@ 11-dihydro@@ dibenz &#91; b , e &#93; oxep@@ in-2-@@ acetic acid .
the method of claim 4 , wherein the plurality of unit specific markers are two units , a first unit at a first end of the polymer and a second unit at an opposite second end of the polymer .
a compound according to claim 11 in the form of a salt with hydrochloric , hydrobromic or io@@ io@@ dic acid .
latvija glenmark pharmaceuticals europe limited tél / tel : + 44 ( 0 ) 800 45@@ 80 3@@ 83
claims for the following contracting states : be , ch , de , fr , gb , it , li , lu , nl , se the imidazo 4,5-b &#93; pyridine compound of the general formula characterized in that r ¹ can be a straight-chain or branched alkoxy group having from 1 to 8 carbon atoms , r ² is a hydrogen atom , a methyl group or a methoxy group and r ³ and r ⁴ are each a hydrogen atom or a methyl group which may be the same or different .
compounds according to claim 20 , wherein x represents a group of general formula x2 wherein n is 4 or 5 ; r2 , r3 , r4 , r5 , r6 and r7 are residues as described in claim 1 .
a compound according to claim 1 wherein : a = -ch - or -ch ch - , r = hydrogen , r = hydrogen , r = -c ≡ c-ch , r = hydrogen , r = hydrogen or methyl , r = hydrogen , and r = hydrogen .
furthermore , the age and sex distribution of the k@@ hd events , which account for age and sex , are also considered to be the number of patients with the age and the number of be@@ ff@@ rs .
medical articles of polymer blends containing deep-@@ melt liquid crystal polymers
the tissue of claim 2 , wherein said medical component comprises material selected from vir@@ cides , germicidal agents and analgesics .
novel heterocyclic compound and anti-inflammatory agent
a catheter according to any one of claims 1 to 5 , characterised in that the wires ( 2,3 ) are longitudinally displaceable relative to the catheter and are displaceably connected to the catheter at their distal arch ends .
an injection device as claimed in claim 8 , characterised in that the perforator ( 16 ) further comprises support and retaining means ( 18 , 24 , 26 , 28 ) for the bottle stopper ( 12 ) allowing the bottle ( 12 ) to allow the insertion means ( 12 ) and the pumping means ( 72 ) and the pumping means ( 72 ) are connected together with the attachment means , simultaneously the attachment and the production of the circulation of the liquid .
absorption ra@@ vic@@ ti is a prodrug of p@@ ba .
2@@ g-@@ 8-@@ 5-@@ 1a ( nr@@ ll-@@ b-1@@ 8@@ 33 ) , p. pu@@ tida 5@@ b-@@ m@@ gn@@ -2@@ p ( nr@@ -1@@ 8@@ 6@@ 68 ) , p. au@@ ro@@ faciens mo@@ b c2 ( nr@@ ll b-1@@ 8@@ 34 ) , p. pu@@ tida 2@@ d-@@ 11-@@ 5@@ 1b , nr@@ r@@ l-@@ b-1@@ 8@@ 20 , or a mutant or variant thereof , which is capable of converting a racemic nitrile stereo@@ specific to the corresponding enantiomeric or s-@@ amide .
system according to one of the preceding claims , characterized in that it also comprises means for controlling adjustment mechanisms of the working device ( the working equipment ) .
a compound according to claim 9 which is selected from the group consisting of p-@@ methyl-@@ benzyl-@@ ala ester , p-nitro@@ benzyl-@@ ala-@@ ester , p- ( trifluoromethyl ) benzyl ala ester , p-@@ fluoro@@ benzyl ala-@@ ester , 4-chloro@@ benzyl-@@ ala-@@ ester , 3-methyl@@ benzyl-@@ ala ester , and 2-methyl@@ benzyl-@@ ala-@@ ester .
the method of claim 1 comprising the step of providing a plurality of particles ( 42 ) on a plurality of discrete discrete locations on the substrate ( 32 ) , each site forming a dosage .
a respiration device according to claim 1 or 2 , characterised in that the identification means ( 14 , 15 ) is arranged to identify the bellows unit ( 2 ) which is being used on the basis of a marking ( 16 , 17 ) on the bellows unit ( 2 ) .
a process for preparing a pharmaceutical composition which comprises mixing an effective amount of mature human n@@ t-@@ 4 of figure 1 or a neurotrophic protein according to any one of claims 16 to 21 with a pharmaceutically acceptable carrier .
the method of claim 1 , wherein the labeled oligonucleotide is labeled with a fluorescent label .
do not use in pregnant or lactating animals .
medical treatment device according to one of claims 12 to 15 and claim 8 or 9 , characterised in that the plurality of switches ( 68 ) are arranged in the longitudinal direction of the leaf spring ( 67 ) and thus are varied differently depending on the deflection of the second end of the leaf spring ( 67 ) .
apparatus according to claim 1 , characterized in that the roller is cylindrical .
the method of claim 15 , wherein said enzyme is derived from fusarium sp . , preferably f. an@@ gu@@ i@@ la@@ ce@@ um , f. a. gi@@ gi@@ i@@ la@@ ce@@ um , f. di@@ ace@@ ace@@ um , f. operon , f. sol@@ ani or f. sulf@@ ure@@ um . the method of claim 12 , wherein said enzyme is nitrilase , preferably from rhodococcus sp . ( preferably erythro@@ mon@@ ol@@ i ) , pseudomonas sp. or brevibacterium sp .
fused triazoles , their preparation and their use as medicaments .
this leaflet was last revised in month yyyy .
a process according to claim 12 , wherein the cyclisation base is an alkoxide .
surface treatment for pas@@ si@@ sing surfaces of organic polymer material with polysaccharides as pas@@ si@@ zer , wherein the pas@@ si@@ sing agent contains at least one primary functional group which is substituted by a reagent such as benzophenone 4 isothiocyanate or by di@@ azo@@ o-@@ aryl isothiocyanate , and said reagent is converted to a reactive species , whereby said reactive species reaches a covalent bond of the passive agent to said surfaces of organic polymer material .
a pharmaceutical composition comprising : ( a ) a compound having activity as an anxiolytic agent or an antidepressant selected from fluoxetine , fluvoxamine , paroxetine and sertraline or a pharmaceutically acceptable salt thereof ; ( b ) a central nervous system which is selected from fluoxetine , fluvoxamine , paroxetine , and sertraline , or a pharmaceutically acceptable salt thereof ; ( b ) a 3- ( 5-@@ tert-butyl-@@ 2-methoxyphenyl ) methyl-@@ &#93; -@@ octane@@ -3-amine &#91; 2.2.2 &#93; -@@ octane@@ -3-@@ amine ; or a pharmaceutically acceptable salt thereof ; and ( c ) a pharmaceutically acceptable carrier
in most patients , the most frequent patients and the maximum internal rotation of the leg in the prosthesis implantation could be pre@@ disposing . &quot; posterior access &quot; can be pre@@ disposed .
danmark sanofi-aventis denmark a / s tlf : + 45 45 16 70 00
a process for producing the linear high molecular weight polyethylene according to claim 25 , substantially consisting of the following steps : ( a ) forming said article from a linear ultrahigh molecular weight polyethylene having a molecular weight of from 400@@ ,000 to 10,000 ° ( b ) allowing the temperature of at least about 0.5 ° c to 10 ° c to said article ; ( d ) at a temperature of between 320 ° c and 300 ° c to said article ; ( d ) maintaining temperature gradients in the shaped article , and ( f
method and apparatus for automatic handling of medical devices during manufacture
a process for the preparation of composite materials according to claim 8 by precipitation from an acidic solution of a water-soluble calcium salt and a stoichiometric amount of a water-soluble phosphate and / or fluoride salt having a ph below 3 by raising the ph with aqueous alkal@@ alia or ammonia in the presence of protein components .
in order to eliminate this effect , either the focal spot ( ll ) or the radiation receiver ( 3 ) is laterally displaced relative to the ide@@ alized tomographic plane ( l3 ) , so that the plane caused by the focal spot ( ll ) and the radiation receiver ( 3 ) during scanning of the receiving object carries out movement movement .
therefore , the safety margin for potential ip receptor-@@ mediated effects on reproduction is lower than non-@@ i@@ p-@@ associated effects ( see section 5.3 ) .
ven@@ o-@@ occlusive disease is a major complication that may occur during busulfan treatment .
pharmaceutical composition according to any one of the preceding claims in the form of an injection concentrate for parenteral use with customary physiologically tolerated excipients .
the method of claim 3 , wherein step ( i ) of selectively providing further comprises the step of adjusting the reference marker information to a separation information for generating at least one phase relationship recording information which is compared to the fixed reference to determine a phase-@@ relationship error information to determine a phase relationship error information to determine an amount of incremental movement of the web material .
concentrations of these immunosuppressants may be increased when co-administered with evo@@ ta@@ z .
carcino@@ genesis , mutagenesis , impairment of fertility in male rats , a statistically significant increase in urinary bladder tumours ( transient cell papilloma and carcinomas ) was found in association with xanthine stones in the high dose treated group at approximately 11-@@ fold of human exposure .
claims for the following contracting state : es a process for the preparation of the products of the general formula ( i ) : es a process for the preparation of the products of the general formula ( i ) wherein r ₁ is an aliphatic hydrocarbon radical having 1 to 8 carbon atoms , r and r which are identical or different , represent a hydrogen atom or an alkyl radical having from 1 to 12 carbon atoms , in which r ₁ is a hydrogen atom or an alkyl radical , which is the same or different ,
process for the treatment of human keratinous fibres , in particular the hair , for non-@@ permanent deformation , characterized in that it consists in contacting ( i ) a gas containing water vapour and whose temperature is at least 75 ° c , for a period of time containing at least one oil , with the exception of ( ii ) to cooling the fibres so treated and finally ( iii ) the fibres applied to the fibres , and finally ( iii ) the fibres applied to the fibres are subjected to mechanical stress .
the pharmacokinetics of aliskiren and hydrochlorothiazide were not significantly affected in patients with mild to moderate hepatic impairment .
a process according to claim 2 wherein the detergent is polysorbate 80 .
bone screw according to one of claims 1 to 6 , characterized in that the transition section ( 4 ) is provided with a light thread ( 7 ) .
your body ’ s response to pran@@ din may change if you are taking other medicines , specifically these : • monoamine oxidase inhibitors ( used to treat depression ) • beta-blockers ( used to treat high blood pressure or certain heart conditions ) • ace inhibitors ( used to treat certain heart conditions ) • salicylates ( e.g.
composition according to any one of the preceding claims , characterized in that it comprises an active principle chosen from the group consisting of active substances acting on the micro@@ circulation and / or active agents and / or anti-@@ gly@@ cation agents and mixtures thereof .
127 minimum particulars to appear on blisters or strips
the device of claim 5 , wherein the ceramic electrode is biocompatible and hermetically sealed .
use of a glucoamylase variant according to any one of claims 1-3 in a continuous starch conversion process .
the detergent composition of claim 13 or claim 14 , further comprising at least one conditioner selected from : 1. a cationic cellulose derivative ; and 3 . a cationic guar derivative ; and a homopolymer or co-@@ polymer of a cationic guar derivative ; and a homopolymer or co-@@ polymer of a cationic derivative ; and a homopolymer or co-@@ polymer of a cationic monomer ; and a homopolymer or co-@@ polymer of a cationic monomer ; and a homopolymer or co-@@ polymer of a cationic monomer ; and a homopolymer or co-@@ polymer of a cationic monomer selected
a method of removing human factor xii and factor x@@ ii fragments which are capable of activating factor xi or pre@@ kallikrein , from a liquid with an immobilized monoclonal antibody which binds to an antigenic determinant in the region of human factor xii , wherein the determinant is obtained and absorbing factor xii and factor x@@ ii fragments , which are capable of activating factor xi or pre@@ kallikrein from the liquid .
the aim of the invention is to provide hair treatment products with at least one conditioner in cosmetics with at least one conditioner which makes it possible to improve the state of the hair during treatment .
a compound selected from the group consisting of 3- ( 2-bromo@@ -5-@@ methoxy-@@ phenyl-@@ 1-phenyl-@@ -@@ propan-1-one ; 2- &#91; 2- ( 2-bromo@@ -5-methoxy@@ phenyl ) ethyl &#93; -2-@@ phenyl- &#91; 1,3 &#93; diox@@ ane ; 3- &#91; 2- ( 4-benzyloxy@@ benzoyl ) -5-methoxy@@ phenyl &#93; -1-phenyl-@@ -@@ propan-1-one ; 4- ( 4-benzyloxy@@ phenyl ) -7-methoxy@@ -3-@@ 1,2-di@@ hydro@@ naphthalene ; and ( 4-benzyloxy@@ -phenyl ) - { 4-methoxy@@ -2- &#91; 2- ( 2-@@ phenyl- &#91; 1,3 &#93; diox@@ olan@@ -2-yl ) -ethyl &#93; -phenyl } -methanone .
the vaccine should not be given to the vaccine .
it is not known whether the use of interleukin-1 ( il-1 ) inhibitors , such as il@@ aris , increases the risk of reactivation of tuberculosis .
an automatic weight balancing apparatus for a stand with weight compensation with : a vertical arm ( 1 ; 25b ) and a horizontal arm ( 3 ; 26b ) , and a horizontal arm ( 3 ; 26b ) , and a horizontal arm ( 3 ; 26b ) , and a horizontal arm ( 3 ; 26b ) which is secured to the central portion ( 15 ) at the vertical arm ( 1 ; 25b ) or horizontal arm ( 3 ; 26b ) , and a pair of switches ( 20a , 20b ) which are
mixing capsule according to one of the preceding claims , characterized in that a plunger rod ( 44 ) of the plunger ( 14 ) , in particular in a signal colour , is externally smooth and thin and free from a handle handle , so that it cannot be pulled out from the piston ( 14 ) without a tool .
live infected birds can remain support , and although antibiotics can be involved in clinical signs and lesions , do not remove the infection in any of the following situations : • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
a method according to any one of the preceding claims , wherein the human tissue plasminogen activator has a concentration of at least 0.1 mg / ml and the argin@@ inium ion has a concentration of 0.05 to 1.0 m .
the device of claim 21 , wherein the liquid suppli@@ er ( 5 ) is releasably attached to the vibration member housing ( 4 ) by a snap engagement .
the use according to claim 5 , wherein the medicament is administrable by intravenous injection .
the method of claim 12 , wherein the inhibitor is selected from ( &#91; l@@ -2-amino@@ 3- ( n-@@ hydroxy , n@@ -nitro@@ samin@@ o ) propanoic acid &#93; ) , 6-mercaptopurine ribo@@ side@@ -5 &apos; -phosphate , 8-@@ aza-@@ guanosine monophosphate , 7-@@ de@@ aza-@@ 8-@@ az@@ agal@@ sine monophosphate and β-d-@@ arabino@@ syl@@ guanosine monophosphate .
dna encoding gluta@@ ma@@ te-@@ gated chloride channels
the absorbent article ( 20 ) of claim 6 further characterized in that said absorbent core ( 22 ; 28 ) has an ultimate storage capacity of at least 90 ml .
6.6 special precautions for the disposal of unused veterinary medicinal product or waste
cosmetic or pharmaceutical preparations containing extracts of the plant ar@@ gan@@ ia sp@@ inosa
a pharmaceutical composition comprising a compound of formula i as defined in claim 1 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier .
the method of claim 7 , ( i ) , the method comprising determining whether the compound inhibits transcription , the inhibition of transcription indicates that the inhibition of the transcription is a potential autoimmune disease therapeutic agent , and the inhibition is a potential autoimmune disease therapeutic agent , and the inhibition is for example , by ( ii ) measuring the ability of the compound to inhibit the ability of the compound to inhibit its target protein , the second polypeptide comprising an iso@@ type-specific ci@@ it@@ a interaction domain , the second polypeptide comprising an iso@@ type-specific
a process for producing the protein encoded by the dna coding region 89@@ 9-@@ 32@@ 53 of fig . 1 in at least partially purified form , by natural pure imaging , by recombinant dna technology and / or by chemical synthesis .
the crystal modification is differenti@@ able from other crystal modifications of 8-@@ cyano-@@ -1- cyclopropyl -7- ( 1s , 6@@ s-@@ 2,@@ 8- di@@ azabicyclo &#91; 4.3.0 &#93; non@@ an -8-yl ) -6-@@ fluoro -1,@@ 4- -di@@ oxo-@@ 3-@@ quinoline carboxylic acid of the formula ( i ) by its characteristic x-ray powder diffraction gram and its differential thermo@@ graph .
pregabalin accord 25 / 50 / 75 / 100 / 150 / 200 / 225 / 300 mg hard capsules are supplied in pvc / aluminium blisters in pack sizes of 14 , 21 , 56 , 60 , 84 , 90 , 100 or 112 capsules .
the composition of claim 24 , wherein said isotonic agent is a polyol selected from mannitol or sorbitol .
use of a therapeutic composition according to any one of claims 1 to 18 for the preparation of a medicament for the treatment of a wound .
appropriate monitoring is a standardi@@ sed measurement of bladder pressure .
the self-adhesive laminate according to claim 9 , characterized in that the adhesive and / or the polymer layer contains clotrimazole , miconazole , ketoconazole , e@@ conazole , naf@@ ti@@ f@@ in , ciclo@@ pi@@ lo@@ lamine , f@@ enti@@ or , sul@@ ben@@ tin , tol@@ naf@@ tate and / or halo@@ pro@@ h@@ ine as antimycotic agents .
cysteine protease inhibitors containing heterocyclic leaving groups
the method of claim 1 , wherein the hydrogen gas partial pressure is not less than 0.5 atmo@@ spheres ( absolute pressure ) .
cement according to one of claims 1 to 13 , characterized in that the de@@ binder is a setting retar@@ er .
the method of claim 11 , wherein the desired exogenous gene is expressible to a polypeptide .
the method of claim 11 , wherein the verapamil is dry granulated prior to tabletting with the modified release binding agent .
the stem of claim 1 , wherein the cross-section further comprises a substantially curved posterior / lateral corner ( 27 ) having a radius of curvature ( r1 ) greater than the radius of curvature ( r2 ) of the central side ( m1 ) .
arrangement for determining the position of a medical instrument ( 3 ) which is introduced into the body of a patient ( 2 ) , in relation to a periodically moving body member ( 3 ) , in relation to a periodically moving body member ( 3 ) , in relation to a periodically moving body organ ( 3 ) , in relation to a periodically moving body organ ( 3 ) , and the reference probe ( 6 ) for determining the spatial position ( c , r ) of the medical instrument ( 4 ) and the reference
the patient ’ s response to treatment should be monitored clinically and by pulmonary function tests .
a probe according to claim 11 , wherein at least one of the plates ( 48 ) includes a marker ( 50 ) for aligning on a respective mark ( 49 ) on the head ( 45 ) to indicate when a selected force is exerted on the needle member .
patients who experience these symptoms should not take the medicine and should seek immediate medical attention .
special populations the analysis of the population pharmacokinetics of tmz indicated that plasma clearance of tmz is independent of age , renal function or smoking status .
process according to claim 28 , characterized in that the solution used for de@@ sulfu@@ rization of the fibre contains approximately 3 g / l of sodium sulphate .
antibody persistence after vaccination with gardasil
mer is that with the problems .
in the method according to the invention , a release layer consisting of two or three metal layers is generated between the implant structures and the substrate , which serve to release the finished processed multi@@ layers by a sub@@ etching process by a sub@@ etching process .
trocar unit according to claim 1 , characterized in that it comprises means for securing the obturator ( 6 ) to the handle part ( 4 ) in order to thereby provide for said free rotation .
this includes the treatment of both sides of the spine from the spine to mild , including shoulders and hi@@ ps .
patients should be advised that they need to have fever , headache , with fever and / or neck stiffness or photosensitivity to a physician , as this may be signs of meningococcal infection .
an apparatus according to claim 1 , characterized in that a test head ( 34 ) is provided , which ( i ) has a sound cavity ( 23 ) and ( ii ) a hollow probe ( 25 ) , which has a large end ( 251 ) in communication with the sound cavity ( 23 ) and a small end ( 252 ; 422 ) for the arrangement at the inlet of the ear to be tested , the small end having a diameter approximately equal to the diameter of the ear channel of the ear to be
antibody formation did not result in clinically relevant effects on safety , reduced efficacy or altered pharmacokinetics of reve@@ stive .
the nucleic acid of claim 1 , wherein the nucleic acid is cdna .
a method according to claim 1 or 2 , wherein the gp@@ vi alle@@ lo@@ type is determined with restriction enzyme cytotoxicity .
a nebuliser device for the nebuli@@ sation of aqueous or oily medicaments for inhalation therapy with a spray nozzle for the exit of compressed air , said nebuliser device being adapted for insertion into a two-@@ piece nebuliser device , whose lower part is adapted for insertion into a two-@@ piece nebuliser device , the lower part of which is adapted to be inserted into a two-@@ piece nebuliser device , the lower part of which is adapted to be inserted into a two-part nebuliser device , the lower part of which is adapted to be inserted into a two-part
an assembly as claimed in any one of claims 1 to 3 , further characterised in that ( a ) the film is in the vicinity of the interface between the stopper ( 28 ) and the container ( 20 ) mating manipulation indicators .
pharmaceutical composition according to claim 1 , characterized in that r 1 and r 2 together with the nitrogen atom connecting them , as ring member , forms a saturated or unsaturated , optionally substituted five- or six-membered cycloaliphatic radical , optionally preferably together with at least one other heteroatom , in particular for a ( ch 2 ) 4 - , ( ch 2 ) 5 or ( ch 2 ) 2 -o- group , characterized in that r 3 represents an unsubstituted or at least mono-@@ substituted five- or six-membered aryl or heteroaryl group or an alkyl ester
use of the myo@@ tilin protein or a fragment thereof according to claim 1 for the preparation of an antimicrobial medicament .
a compound according to claim 2 , wherein v is selected from the group consisting of o and c ( r 2 ) ( r 3 ) ; r 2 and r 3 are independently selected from the group consisting of hydrogen and alkyl ; a is absent or selected from the group consisting of hydrogen , alkyl , alkylcarbonyl , alkoxycarbonyl and aryl ; b is selected from the group consisting of hydrogen , alkyl and heterocycle ; and d and e are independently selected from the group consisting of hydrogen , alkyl and heterocycle ; and d and
the composition of claim 27 , wherein the citrus pectin is selected from the group consisting of li@@ mon@@ e , le@@ mon , grapefruit and orange .
gel-like therapeutic or dietary drug composition for administration to domestic animals
microparticles for the controlled release of biologically active molecules
recombinant live vaccine against gram-negative enteric pathogens .
oxiran@@ e-@@ pseudo@@ oligosaccharides , process for their preparation , their use and pharmaceutical compositions .
system for sampling and analyzing in vivo
a solution according to claim 6 , 7 or 8 , wherein the amount of the organic acid is from 0.005 to 2 % by weight , preferably from 0.01 to 1 % by weight of the solution .
therefore , the use of tra@@ vat@@ an is not recommended during breast-feeding .
composition according to claim 6 , characterized in that r is chosen from dodecyl , c 18 -c 26 -alkyl and phenyl ( c 8 -c 13 ) alkyl , m = 0 and n is an average value ranging from about 5 to 150 .
claims for the following contracting state : at a process for the preparation of a pharmaceutical combination for use in the augmentation of bone mass in a patient in need thereof , comprising combining a parathyroid hormone or a physiologically active fragment thereof with : a process according to claim 1 , wherein the composition is obtained so as to obtain an intimate mixture .
disintegrating particle and cleaner or detergent compositions
pressure sensitive hot melt adhesive composition based on polysiloxanes and methyl alkyl@@ polysiloxane waxes , methods and products .
the isolated dna fragment of claim 2 comprising the cla i fragment as shown in figure 5 which is downstream of the dna fragment shown in figure 7a ( 1 ) and is present between the cla i site present in the second line and the ala-@@ ala sequence present in the third line of figure 7a ( 1 ) .
method for operating medical devices , in particular of dialysis equipment , in which characteristic treatment data ( 22 ) with a touch screen surface ( 10 ) are displayed in a first display view ( 22 ) in a first image screen view ( 20 , 30 , 40 ) and their functional connection , and the contact of the symbols ( 20 , 30 , 40 ) generates the first image screen view .
compounds according to any one of claims 1 to 5 , wherein r 1 represents hydrogen .
tell your doctor if you have a history of helicobacter pylori infection , and therefore your doctor may decide to stop you on a helicobacter pylori infection , and your doctor may decide to stop you on a helicobacter pylori infection . • your doctor will want to determine whether you have a helicobacter pylori infection and your doctor will tell you that you are taking or have recently taken any other medicines , including medicines obtained without a prescription , or if you notice any serious effects or other effects not mentioned in this leaflet .
scientific conclusions and grounds for amendment of the summaries of product characteristics
the response rate in the 0.1 % tacrolimus group ( 7@@ 1.6 % )
an ultrasonic diagnostic apparatus comprising : a transfer means that comprises an ultrasonic probe , including an array ( 14 ) of piezoelectric elements , and is adapted to transmit a plurality of acoustic elements , including an array ( 14 ) of piezoelectric elements , and is adapted to transmit a plurality of acoustic beams with different acoustic elements , with a plurality of acoustic means ( 1 ) having a plurality of acoustic elements with different acoustic elements , and the second of said second and second groups of active signals ( 1 ) having a plurality of
agent according to claim 7 , characterized in that it contains nitroglycerin as anti@@ ang@@ inal agent .
the isolated receptor of claim 18 or claim 19 , wherein at least one of the soluble receptor subunits comprises a sequence of amino acid residues as shown in seq id no : 3 .
a method according to any one of claims 17 to 21 , wherein movement of the second wheel arrangement from the first position causes the third wheel arrangement to provide at least the rear portion of the stretcher .
glycopyrronium works by blocking the broncho@@ constri@@ ctive effect of acetylcholine on the smooth muscle cells of the airways , thereby widening the airways .
asymmetrically shaped intraocular lens insertion cassette
non-invasive apparatus and method for heart monitoring
the device of claim 1 , wherein the outer sleeve is configured to surround a leg of the patient .
the macromer of claim 1 , wherein the macromer is capable of thermo@@ reversible gelation in an aqueous solution of the macromer at a concentration of at least 2 % by weight , and wherein the gelling temperature is between about 0 ° c and about 65 ° c.
medical filter according to one of the preceding claims , characterized in that it is provided with wire elements ( 8 ) extending substantially diametrically over the base and are connected to one another in order to serve as extraction elements .
use of a compound of the formula : wherein a is nh ₂ or ; n is 1 to 12 and , if a is -nh ₂ , is only 7 to 12 ; r ₁ is hydrogen or lower alkyl and r ₂ is ch ₂ - ; d forms a fused ring , or a pharmaceutically acceptable salt thereof , for the manufacture of a medicament for treating hypertension .
an ultrasonic examination image display system comprising an ultrasound probe connected to an ultrasound system for transmitting and receiving ultrasound signals to a medium having a body with a body with a body with a body with a body having a mobile body with a body having a mobile body with a body having a mobile body , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems comprise , in order to transmit and
composition according to any one of claims 14 to 16 , which is in the form of a composition for caring for , cleaning or make-up of the skin or keratinous material , a hair treatment composition , a sunscreen composition .
a collimator for high-@@ energy radiation and program for ste@@ uri@@ sing the collimator
it is prepared using only pure ethyl alcohol as solvent and shellac in combination with benzoic oil and / or other tree resins and / or essential oils .
surgical system with distributed excimer laser
preparations according to claim 1 , characterized in that the total amount of one or more alcohols used in the final cosmetic or dermatological preparations is chosen from the range of 0.1 - 25.0 % by weight , preferably 0.5 - 15.0 % by weight , based on the total weight of the preparations .
the web of any preceding claim , further comprising the topical softening treatment prior to mechanical treatment .
based on this issue , the chmp is of the opinion that an additional 5-@@ year extension is required based on pharmacovigilance for reasons for pharmacovigilance .
arrangement according to one of claims 8 to 11 , characterised in that the connection device ( 5 ) is a welding device , preferably an ultrasonic welding device .
a kit of parts according to claim 11 , claim 12 or claim 13 including means ( 13 ) ( 14 ) for adjusting the retaining member to carry alternative leg lengths .
an il-7 fusion protein comprising an immunoglobulin chain and an il-7 molecule modified by a linker molecule , which is directly or via a linker molecule , wherein the modification in il-7 is as follows : ( i ) the amino acid residues at positions 70 and 91 , wherein the modification in il-7 is as follows : ( i ) the amino acid residues at positions 70 and cys@@ 141 , in the case that the modification in il-7 is excluded by a peptide hinge region functionally linked to an fc portion of a heavy igg chain .
the dental adhesive kit according to claim 2 , wherein component ( b ) is contained in an amount of 1-@@ 200 parts by weight based on 100 parts by weight of the total amount of components ( a ) and ( c ) to ( f ) .
device according to claim 1 or 2 , characterized in that the insertion tube ( 4 ) and the piston / cylinder device ( 3 ) are designed to form an integral unit ( 2 ) .
agent for the oxidation dyeing of keratin fibres , based on a developer substance coupler substance combination , characterized in that it comprises , as developer substance , at least one 1,4-di@@ amino@@ -2-@@ alkenyl-@@ benzene derivative of formula ( i ) according to any one of claims 1 to 5 .
composition according to any one of the preceding claims , characterized in that the conditioning agent is present in a concentration ranging from 0.001 % to 10 % , preferably from 0.005 % to 7 % by weight , and in particular from 0.01 % to 5 % by weight relative to the total weight of the composition .
cosmetic composition according to claim 9 , characterized in that the nanopigments of the coated metal oxide mixtures are composed of titanium dioxide and cerium oxide coated with silicon dioxide , or mixtures of titanium dioxide and zinc dioxide , which are coated with alumina , silicon dioxide and silicone or aluminium oxide , silicon dioxide and glycerol .
use of adam@@ t@@ s1 for the preparation of a test kit for the determination of an inhibitor for aggre@@ can@@ ase , characterized in that adam@@ t@@ s1 , a substrate and an inhibitor is incubated with one another and the neo@@ epitopes generated by aggre@@ can@@ ase activity .
the invention relates to a pricking device ( 1 ) , comprising a lancet ( 2 ) , an energy store ( 5 ) for transferring energy in the energy store ( 5 ) to the lancet ( 2 ) for carrying out a pricking movement , a charging device for carrying out the energy accumulator ( 5 ) and a control unit , such that the energy store ( 5 ) is automatically charged with energy for next puncturing movement of the lancet ( 2 ) .
site specific system for producing diverse protein sequences
a method according to claim 8 , wherein the rna replicase gene and the coat protein gene are located on different single stranded ( + ) rnas .
yeasts transformed with a modified vector according to any one of claims 1 to 8 and which are capable of synthesizing a polypeptide and having following induction of the expression of the insertion sequences , which are recognized on their surface and recognized by ligands recognized by the natural membrane receptor .
a w is selected from the group consisting of : a compound of claim 1 , wherein : d is selected from the group consisting of : a compound of claim 1 having the following formula : wherein : halo is selected from the group consisting of : br , f , cl and i ; and x is selected from the group consisting of c 1-8 alkyl and cycloalkyl .
the use of claim 7 , wherein the first and / or second therapeutic agents are an antiarrhythmic agent and the antiarrhythmic agent is selected from the group consisting of adenosine , quinidine , propranolol , digoxin , lidocaine , bre@@ ty@@ lium , amiodarone , and verapamil .
a personal urine collection device according to claim 27 , further comprising a frame ( 81 ) installed in the front chamber of the container , and an ultraviolet lamp ( 82 ) installed on one side of the frame of the collector member for radiating ultraviolet radiation against the interior of the collector part to carry out sterilization .
the method of claim 15 , wherein the osmotic pressure is from 200 to 600 mosm / kg water .
an inhibitor of helicobacter pylori colony formation , comprising as an active ingredient the glycoprotein of any one of claims 1-6 . a pharmaceutical composition for preventing and / or treating a mammalian disease , including human , or associated with helicobacter pylori , which comprises the glycoprotein of any one of claims 1-6 .
a process according to claim 1 , wherein the crystallization solvent is selected from the group consisting of : hex@@ anol , pentanol , 2-@@ penta@@ - and 3-@@ pentan@@ ol mixture , iso@@ pentanol .
composition according to any one of the preceding claims , characterized in that the feed@@ pellet ( s ) ( one or more compounds ) is / are chosen from the group n , n-diethyl-@@ 3-methyl@@ benzamide , 3- ( n-n-@@ butyl-@@ n-acetyl-@@ amino ) -propionic acid ethyl ester and dimethyl phthalate .
a method according to any one of the preceding claims , wherein the pro@@ tose sequence is the yeast -a-@@ factor pro@@ sequence .
adults adults should take the telzir oral suspension without food and on an empty stomach .
a method according to claim 1 , wherein the ligand is at least 99 % pure .
method for producing pretreated raw material
device according to claim 1 , characterized in that the coupling medium ( 11 ) is u-shaped , in which the u-shaped arms show away from the fluid path and show the part ( 4 ) to be re@@ used .
a peptide according to claim 1 for promoting re-@@ epitheli@@ alization of the colon .
an endoscope according to any one of claims 15-@@ 20 , wherein the thermal expansion coefficient of the glass range used for the chin members ( 86 , 85 ; 86 &apos; , 85 &apos; ) is approximately equal .
a pharmaceutical preparation according to claim 8 , wherein said visible light has a wavelength greater than or equal to 420 nm .
apparatus for generating an image of an object and in particular for observation of the rear portions of an eye , whose light is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the
the occurrence of thrombocytopenia and anaemia associated with myelo@@ suppressive chemotherapy cannot be prevented by treatment with filgrastim alone .
agent for improving and natural maintenance of so@@ ils and plant growth and corresponding method therefor .
what infanrix penta is and what it is used for 2 .
i &apos;ve never been in se@@ at@@ tle .
the method of claim 7 or 8 wherein the microorganism capable of selectively metaboli@@ sing ( r ) -3-chloro@@ -1,2-@@ propanediol is the microorganism of the genus selected from the group consisting of pichia , tricho@@ spo@@ one and corynebacterium .
the method of claim 9 , wherein the oligonucleotide has a 3 &apos; and a 5 &apos; end , the oligonucleotide being complexed to the antibody at the 5 &apos; end and the 3 &apos; end of the oligonucleotide is labelled with 32 p. the method of claim 9 wherein the labeled dna dendrimer is labelled with a first secondary reporter and the amount of the antigen is labeled with 32 p. the method of claim 9 , which is complementary to the first secondary reporter and is conjugated to a molecule selected from the group consisting of a fluoro@@
do not use pegasys after the expiry date which is stated on the label .
if other symptoms of systemic toxicity occur , the signs of systemic toxicity are expected to be similar to other routes of administration following administration of local anaesthetics .
a process for the preparation of a complex of macromolecular poly@@ galac@@ tans and a nitrogen-containing compound and use of said complex .
a single layered assembly ( 12 ) for use in a disposable absorbent article having a particulate material ( 5 ) , which is enclosed between enclosing layers ( 1 , 2 ) , wherein the enclosing layers ( 1 , 2 ) are enclosed in the form of two continuous strips ( 1 , 2 ) , wherein the enclosing layers ( 1 , 2 ) are enclosed in the form of two continuous strips ( 1 , 2 ) , which are enclosed in the form of two continuous strips ( 1 , 2 ) , wherein the
ze@@ pati@@ er should not be used in patients with moderate or severe hepatic impairment ( cirrhosis of the child-pugh class b or c ) .
until another aetiology has been identified , signs or symptoms of endo@@ c@@ rin@@ opa@@ thies should be considered as immuno@@ con@@ c@@ log@@ s .
a hybrid molecule comprising a fusion of a first ligand capable of binding to a first molecule of hepatocyte growth factor receptor , to a first molecule of hepatocyte growth factor receptor , to a first immunoglobulin constant domain and a fusion of a second ligand capable of binding to a second molecule of said receptor , wherein said ligand is not an antibody to hepatocyte growth factor receptor or a non-@@ covalent conjugate of an antibody and not a covalent conjugate of an antibody and an antigen for said antibody ; and wherein said first and second receptor molecules
a method for detecting or in vitro diagnosis of brain disease involving ph@@ f and tau protein , e.g. alzheimer &apos;s disease , e.g. alzheimer &apos;s disease comprising : contacting a sample of a brain homogenate , cerebrospinal fluid , or serum of a patient suspected to form an antigen-antibody complex ; and detecting the immunological binding of the antibody to the sample of the brain homogenate , cerebrospinal fluid or serum .
device according to one of claims 1 to 3 , characterised by an actuating mechanism which can be operated in response to an adjustment of an actuating member of the mechanism , a rotational movement of the rotatable part ( 5 ) relative to the base plate .
what ai@@ rex@@ ar spiromax is and what it is used for 2 .
system according to claim 5 or 6 , characterized in that the separator ( 40 ) and the receiving unit ( 10 ) are mounted movably relative to one another .
the negative pressure respirator of claim 1 , wherein the impac@@ tor element ( 50 ) is transparent .
the dental handpiece of claim 6 , wherein the annular sealing means comprises a magnetic fluid ( 84 , 184 ) and a permanent magnet ( 82 , 83 , 182 , 183 ) of annular shape retaining the magnetic fluid .
cardiac therapy system with controlled activity signals of the autonomic nervous system ( s ) ( 6 ) , especially in addition to a conventional pacemaker circuit ( 8 ) , in particular in addition to a conventional pacemaker circuit ( 8 ) , is triggered and / or synchronized in the patient &apos;s body by means of a nerve stimulation of the vascular resistance ( 5 ) to be modified and / or synchronized , or a pump system ( 10 ) is activated and / or synchroni@@ sed .
adapter according to claim 1 , characterized in that the adapter frame ( 30 ) for fixing to the skull bone is formed by means of screws .
liquid applicator according to claim 9 , wherein the distal end face ( 7 ) of the liquid applicator element ( 8 ) is rho@@ mbo@@ id shaped .
a pharmaceutical product in the form of a dosage unit comprising : a ) a multilayer capsule or a housing having two or more layers , the outer layer having hydrophilic properties and the inner layer having hydrophobic properties , in contact with the inner layer b ) one or more drug substances admixed with a hydrophobic carrier , dissolved , suspended or agglomerated in it .
hygiene article according to claims 1 to 5 , characterized in that the total amount of water of the separately or jointly added aqueous solutions is 0 0.75 to 5 % by weight , preferably 1 to 4 % by weight , based on the polymer .
a composition according to claim 1 in the form of a food , beverage or medicine .
the system of claim 7 , wherein the electrical tactile signaling current ( sr ) has alternating periods of different amplitude .
an immunogenic composition comprising recombinant retroviral or recombinant retro@@ vir@@ al-@@ like particles , comprising 1 ) a transgenic sequence encoding one or more epitopes ( s ) of carcinomas , leukemia or lymphoma , which is under the control of the transcription and expression of the transcription and expression of the same , and which is under the control of regulatory signals of the transcription and expression or regulatory signals , which is under the control of regulatory signals of the transcription and expression or regulatory signals , which is capable of inducing or stimulating a cell mediated response
cardboard box containing 1 , 6 or 12 colourless glass vial ( s ) of 250 ml .
use of ( a ) an analgesic inducing amount of tramadol and ( b ) an analgesic enhancing amount of at least one analgesic enhancer selected from dextromethorphan , dextro@@ ph@@ an and a pharmaceutically acceptable salt thereof for the manufacture of a medicament for alleviating arthritic pain .
a process for the preparation of the racemic or optically active compounds having the general formula ( vi ) : wherein the meaning of x halogen is - or the salts thereof , wherein the meaning of x halogen is : - or the salts thereof , wherein the meaning of x halogen is converted to the general formula ( vii ) , in its optically active isomers , in its optically active isomers , and / or to the salts thereof and / or to the salts thereof and / or to the racemic or optically active compounds of
the syringe assembly of claim 1 , further including sealing means ( 86 ) on said plunger plunger ( 56 ) disposed proximally relative to said distal end ( 58 ) of said plunger rod ( 56 ) and said plug ( 34 ) for sealing said chamber ( 20 ) against contamination .
a spacer member for a resilient fastener permanently anchored in the jaw , comprising a substantially sleeve-like spacer for attaching to the mounting member by means of a separate spacer screw having an elongated , thread@@ -free central region and a threaded portion for engagement into a threaded bore in the occlusive portion of the fastener , the sleeve shaped portion having a threaded thread ( 18 ) having an elongated threaded portion and a threaded portion for engaging a threaded bore in the occlusive portion of the fastener , characterized in that the sheath portion ( 13 ) of
process according to claim 20 , characterized in that the cells are t lymphocytes .
the method of claim 3 , wherein the step of generating a plurality of vertical image slices further comprises the step of reconstructing a plurality of parallel beams generated from a projection of data of the rectilinear web .
use of a composition according to any preceding claim in the manufacture of a medicament for treatment selected from the group consisting of dental brigh@@ tening , plaque , mouth odour , caries and tar@@ tar .
device according to claim 5 , characterized in that a collection container ( 24 ) for tissue liquid is connected to the transmission head ( 4 ) via the tube ( 22 ) .
the powder is packed in colourless vials of 5 ml with a coated stopper sealed with a li@@ la plastic cap over the aluminium seal .
process for the production of ligands specific for hormone receptors according to claim 1 , characterised in that they contain a radioactive halogen selected from the group of radioactive isotopes of fluorine , iodine , bromine and a@@ statin which is bonded to the double bond of the vinyl group which is bound to the double bond of the double bond in the α position of the c ₁ ₇ position .
a compound according to claim 1 which is 4- &#91; 4 &apos; - ( 2-benzyl-@@ benzofuran@@ -3-yl ) -biphenyl-4-@@ yloxy@@ sulfonyl &#93; -2-hydroxy-@@ benzoic acid or a pharmaceutically acceptable salt thereof .
interaction with other medicinal products and other forms of interaction : no information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product .
apparatus according to any one of the preceding claims , wherein the distal ends ( 24 ) of the basket wires ( 21 ) are connected to the end piece by lost .
at the end of treatment , the dose of nespo 500 μ g every 3 weeks was similar to that of the weekly dose .
device for cutting and coagulating tissue
a device as claimed in any one of the preceding claims , characterised in that the area to which the cassette is inserted below the chassis ( 370 ) of the main pump unit ; the sensor housing ( 800 , 8@@ 14 ) is mounted on the chassis ( 370 ) of the main pump unit ; the slit ( 80@@ 8 , 8@@ 14 ) is mounted on the chassis ( 370 ) of the main pump unit ; the slit ( 80@@ 8 , 8@@ 14 ) is mounted on the chassis ( 370 ) of the
- tiredness , swelling of the lymph nodes in the neck , axi@@ llary or groin area ,
the method of claim 12 , comprising a plurality of such altered cycles .
48 minimum particulars to appear on small immediate packaging units hbvaxpro 5 micrograms / 0.5 ml
a vector harboring a dna construct harboring the structure c-@@ m-@@ a-d , wherein a is a dna sequence which is homologous with a genomic dna fragment which is homologous with a genomic dna fragment which is homologous with a dna fragment that is homologous with a genomic dna fragment , which is a dna sequence to be amplified , d is a dna sequence which is homologous with a genomic dna fragment which is located distally with a genomic dna fragment which is located distally to b , compared to b , and wherein m denotes a dna sequence
the device or use of any one of claims 34 to 38 , wherein the matrix comprises dehydrated mammalian tissue .
the method of claim 28 , wherein insects which are exposed to the chimeric protein exhibit weight loss .
rotated anchor hook for a stent for abdominal aortic aneurysm ( aaa )
method and apparatus for detecting dental caries
a process according to claim 1 for the preparation of phosphatid@@ yl- ( l ) -@@ serine , wherein r 1 and r 2 acyl chains of the palmitic , stearic , palmit@@ ole@@ one , oleic , linoleic or arachidonic acid are in similar proportions such as egg lecithin .
use of a compound according to any one of claims 1 to 11 for the manufacture of a medicament for the treatment of a condition mediated by activation of the ade@@ on@@ sin-@@ a3 receptor .
compounds of the formula i wherein r 1 is selected from ( i ) phenyl ( ii ) pyridinyl ( iii ) thienyl ( iv ) imidazolyl ( v ) imidazolyl ( vi ) triazolo ( vii ) pyrrolyl ( viii ) thiazolyl and ( ix ) pyridyl-@@ n-oxide , each independently selected from the group consisting of straight and branched c 1 -c 6 alkyl , no 2 , cf 3 , c 1 -c 6 alkoxy , chloro , fluoro , bromo and iodine , and further salts thereof .
the absorbent article according to claim 1 , wherein the proximal edge ( 36 ) is connected to the bodyside liner ( 14 ) in the leg cuffs ( 22 ) in the crotch region ( 22 ) , i.e. , at a location disposed at the longitudinal center line ( 60 ) of the article relative to the leg cuffs ( 24 ) .
due to the high safety span ( 19-@@ fold of the corresponding no-@@ effect dose ) , these neoplastic changes will not be found in humans .
alternatively , silgard can be administered after a 3-@@ dose schedule ( 0.5 ml at 0 , 2 , 6 ) .
process of capillary dyeing by oxidation , characterized in that it consists in applying to the hair a dye composition comprising at least one compound of the formula ( i ) or one of its addition salts with an acid , in that the oxidizing agent is applied to the hair at a first time , with an acid containing at least one compound of the formula ( i ) or one of its addition salts with an acid , and in that the oxidizing agent is applied to the hair in the second time , and the hair is
use according to claim 6 , wherein the leg muscle cell is a front muscle cell .
the results of this survey indicate an image of the current level of lymph node endo@@ dissection and lymph@@ ad@@ ene@@ ctomy in bronchial carcinomas and could serve as a basis for the progress of a uniform document scheme .
treatment of inflammatory bowel disease with interferon gamma inhibitors
the method of any one of claims 22-@@ 25 , wherein when host microorganisms containing said plasmid are cultured under conditions which provide a constant , low number of copies of said plasmid , said plasmid having a copy number in the range of about 0.5-@@ 1 copy per cell and wherein when said host microorganisms lead to a substantially elevated number of copies of said plasmid , said plasmid having a copy number in the range of at least about 500@@ -@@ 1000 copies per cell .
a telemetry system according to any one of the preceding claims , further comprising : a further inducer for sending the information containing the information ; a further capacitor , which is parallel to the first inductor ; a switch parallel to the first inductor ; means for periodically sequential opening and closing the switch to modulate a voltage parallel to the first inductor and the first capacitor .
when deciding to prescribe io@@ a , consideration should be given to current risk factors of individual women , especially for venous thromboembolism ( vte ) , and the risk of vte with io@@ a should be compared with other chc ( see sections 4.3 and 4.4 ) .
syringe assembly according to claim 2 or 3 , characterised in that the stops ( 38@@ d , 38@@ p ) for the fixed connection are delimited by axial hooks ( 4@@ 2d , 4@@ 2p ) which can be inserted into the sleeve ( 20 ) and can be deformed by elastic radial deformation .
the invention relates to novel compounds of general formula ( i ) m - l , wherein m is a radioisotope of tc or re and l is a ligand of the general formula ( ii ) , in which r , r , r , r , r and r are different and are suitable for the coordinating binding of metal ions , on the other hand for coupling to selectively accumulating compounds .
use of a compound according to any one of claims 1 to 26 for the manufacture of a medicament for the treatment of obesity or obesity .
in order to increase life life and support comfort , the sole part ( 11 ) is designed as a hollow profile with substantially vertical supports for connecting the fully flat base and to the full-@@ area ( 12 ) adjacent to the foot bed ( 13 ) , the supports having at least in the middle axial direction an increasing diameter or an increasing horizontal cross-section .
the method of claim 15 , wherein the active substance-containing granules have an average size of about 15 mesh to about 30 mesh .
acoustic imaging and doppler catheters and guide wires
pregnancy and breast-feeding if you are pregnant or breast-feeding , think you may be pregnant or are planning to have a baby , ask your doctor for advice before taking this medicine .
further non-clinical studies are carried out with the aim that potential mechanisms for vascular occlu@@ sions are further characterised in treatment with pon@@ atinib .
massage device according to one of the preceding claims , characterized in that it comprises means for adjusting the force of the return spring ( 16 ) .
the european commission granted a marketing authorisation valid throughout the european union for nexobrid on 18 december 2012 .
the device ( 10 ) of claim 9 , wherein the first attachment ( 50 , 52 ) and the pad ( 30 ) are of cooperating hooks and loops for the manufacture of a fixture between and the second fasteners ( 48 , 54 ) and the gripper ( 44 ) are provided with cooperating hooks and loops for making a fixation therebetween .
a compound of the formula wherein r 1 is ch 3 and n is about 112 .
xo@@ fi@@ go contains sodium , depending on the volume given , this medicinal product may contain up to 54 mg sodium per dose .
treatment of adults , adolescents and children aged 6 years and above with diabetes mellitus , extra treatment with insulin .
antisera , their preparation and pharmaceutical compositions containing them .
diphenyl hetero@@ alkyl derivatives , their preparation and medicaments and cosmetics made therefrom .
mixing of the used and fresh dialysis fluid is not carried out in the container ( 1 ) .
a pharmaceutical composition for curing diseases caused by vasoconstriction , comprising an anti-@@ endothelin antibody as an effective component .
a process for the preparation of a sodium salt of a desired enantiomer of the 2- ( 4-isobutyl@@ phenyl ) propionic acid , wherein the sodium salt has an enantiomeric purity greater than 90 % , which comprises the steps : a ) dissolving the sodium 2- ( 4-isobutyl@@ phenyl ) propionate , which comprises 50 % or more of the desired enantiomer , in a solvent , separating the solid sodium salt from the solvent ; e ) repeating steps a ) to d ) until the desired degree of enantiomeric purity is achieved .
6.6 special precautions for disposal
a process for producing hardened fats comprising reacting a 1,3-@@ specific lipase with a mixture of an oil having a palmitic acid content of at least 30 % ; and free beh@@ enic acid or ester with a monovalent or di@@ hydric alcohol , said mixture having a monovalent or di@@ hydric alcohol , said mixture having a fatty acid composition of 6 to 25 % of lauric acid , 23 to 48 % palmitic acid and 0.5 to 5 % of beh@@ enic acid , based on the weight of the mixture , with respect to the weight of
a biopsy device comprising : a ) a housing ( 12 ) having a bore ( 12 ) extending along a longitudinal axis of the housing ( 12 ) and a drill ( 20 ) extending parallel to the longitudinal axis of the housing ( 12 ) and a drill ( 20 ) extending parallel to the bore , and a bar ( 20 ) extending parallel to the bore , and a latch ( 20 ) which extends in the guide ( 20 ) at a right angle to the longitudinal axis ( 16 ) at a right angle
the method of claim 3 , wherein the solvent is selected from the group consisting of methylene chloride , chloroform or carbon tetrachloride .
hold the valve is a mo@@ tiv@@ ated stu@@ den@@ tin .
a formulation for producing an open-cell polyurethane foam according to claim 15 , wherein the catalyst component ( d ) is contained in an amount of 0.1 to 1 % by weight .
the tampon ( 10 ) of claim 12 comprising elastic , multiple branched regenerated cellulosic fibers .
use according to any one of claims 1 to 16 , which is for the manufacture of a medicament for administration to various mucosal surfaces .
these ec50 values are far below the concentration range of 87 µm to &gt; 100 µm for 50 % cell toxicity .
the catheter ( 10 ) of any one of claims 1 to 8 , wherein the catheter body ( 12 ) has a single lumen ( 18 ) extending therethrough .
a device according to claim 1 , characterised in that it includes locking means ( 80 , 81 , 82 ) for relative rotational movement between the parts ( 3 , 4 ) of the housing ( 2 ) about the longitudinal axis ( k ) of the latter , the means ( 80 , 81 , 82 ) being provided on the two parts ( 3 , 4 ) of the device housing .
1 / cor@@ r ) &#91; guideline for the investigation of bioequivalence &#93; at the highest strength , unless the active substance is highly soluble or there is an indication for safety / tolerance reasons .
be@@ da@@ qu@@ iline and m2 are no substrates or inhibitors of p-glycoprotein .
at steady state doses and dosing regimens , steady state plasma concentrations are reached within 24-@@ 48 hours and are generally less than 1 μg / ml .
chimeric hepatitis c virus and bovine viral diarrhea virus chimeric chimera
a device ( 10 ) for embolic aneurysm according to claim 1 or a cathe@@ ter-@@ based system for embolic aneury@@ sms as claimed in claim 2 , wherein the closure element ( 38 ) is formed of a material so that the closure element ( 38 ) expands when the closure element ( 38 ) is released in the aneurysm to substantially add the aneurysm to the aneurysm .
organ@@ o ( poly ) siloxanes and such organ@@ o ( poly ) siloxanes , by irradiation with light crosslinkable materials
extract of ginkgo biloba leaves according to claim 11 , characterized in that it contains about 52 % by weight of flavone glycosides and about 13 % by weight of terpen@@ e-@@ lactones .
the composition of claim 9 , wherein the receptor is coupled to a macromolecular carrier .
fungal strains with reduced susceptibility in vitro to isa@@ vu@@ conazole have been reported and cross-resistance with voriconazole and other triazole antifungals cannot be excluded .
the vaccine of claim 1 , wherein the eimeria antigens comprise one or more engineered antigen / fusion polypeptides containing at least one eimeria epitope .
1 . hollow fibre of regenerated copper ammonium , having an axially disposed cylindrical bore extending over the fiber length and having a uniform circular cross-section , wherein the fiber length is at least 10 m and the bore is filled with gas and does not contain traces of a contaminating liquid .
